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Abstract 
 
This report focusses on the concept of lead-oriented synthesis in an attempt to synthesise 
diverse small molecule scaffolds that target lead-like chemical space. The ‘top-down’ approach 
was taken, which is a method used within the Marsden and Nelson group where polycyclic 
assemblies are prepared and then deconstructed to give a library of diverse lead-like molecules. 
Each lead-like scaffold was synthesised with good stereo/regio control, on a large scale from 
cheap starting materials, with appropriate molecular properties. Each compound was then 
investigated for its diversification at points of the scaffold, in the possibility of providing access 
to a variety of novel-like, sp3-riched compounds suitable for screening. The computational 
software LLAMA was used throughout the project to help analyse properties and guide the 
development of three-dimensional compounds.  
 
Chapter 1 discusses the overview of the drug discovery process, detailing the problems faced 
in the pharmaceutical industry, highlighting the high failure rates for drug candidates 
possessing certain molecular properties. The ideal molecular properties for drug, leads and 
fragment compounds is discussed, with the modern synthetic approaches to prepare such lead 
diverse screening compounds in an efficient manner. 
 
Chapter 2 – 4 details the synthesis of diverse novel scaffolds prepared from robust synthetic 
methodologies to access a library of compounds with appropriate molecular properties for 
biological screening. In total 14 scaffolds were synthesised from 28 synthetic operations and 
52 novel compounds from a total of 73 synthetic operations. Here the method has produced a 
library of complex and highly three-dimensional compounds with attention paid to 
physicochemical and functional group properties, whilst maintaining synthetic efficiency. The 
library was sent for biological evaluation against five different targets, of which 15 hits were 
observed. A follow-up library was then produced where 13 compounds were sent for a second 
round of biological evaluation against the Plasmodium falciparum cells. 
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1.0 Introduction  
 
1.1 An overview of the drug discovery and development process 
 
The drug discovery process is a highly complex and multidisciplinary process which arises 
from the requirement for medicinal products for the treatment of a disease or clinical 
condition.1 In very early development stages, a biological target can be found which causes or 
leads to a disease.2 A hypothesis is proposed that states inhibition or activation of the protein 
or pathway will result in a therapeutic effect in a disease state.1,3 Chemical or biological 
compounds are screened and tested against the target to find lead candidates for further 
investigation.4 Active compounds are usually identified through the widely available 
technology known as high throughput screening, whereby a hit is found from screening the 
compounds against the given biological target. A hit is a primary active compound with 
biological relevance and is a small molecule with non-promiscuous binding behaviour, 
exceeding a certain threshold value in a given assay.5 Once a high quality hit has been identified 
it is then further validated and developed into a lead, this process is known as hit-to-lead and 
is an early stage in drug development (as seen in Figure 1).5 The next step is lead optimisation, 
which involves the lead compound being improved for downstream development ADMET 
(absorption, distribution, metabolism, excretion, and toxicity) testing can be carried out to 
understand and optimise a candidate’s biological properties.6 Here in vivo and in vitro cell 
based studies are used to characterise the biological mechanism of action.7 Toxicological data 
is produced, which allows the lead compound to be developed into a safe and effective drug, 
with good affinity and selectivity.1,8 The development drug candidate will then progress 
through into pre-clinical/clinical trials and ultimately become a marketed medicine.5,9 An 
alternative method for small molecule drug discovery is fragment based drug discovery 
(FBBD),10 which involves screening fragments; this technique is further elaborated in Section 
1.6. 
 
Figure 1.  A schematic to outline the process by which drug discovery is undertaken. Adapted from ref.5 
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1.2 Problems in the pharmaceutical industry  
High attrition rates have been identified in clinical drug development and this has been an 
ongoing problem in the pharmaceutical industry.11 Monitoring the physicochemical properties 
of candidates in early phases of discovery may reduce the number of efficacy and safety related 
failures that the industry suffers, and may be beneficial in identifying compounds of candidate 
drug quality.12 
Drug candidates fail in clinical trials because of a variety of complications;13 often difficulties 
arise due to toxicological problems and poor bioavailability and pharmacokinetic properties.1,14 
Phase II/III attrition rates are increasing and evidence has demonstrated that improving 
research and development (R&D) efficiently and productively will help this. Overall attrition 
rates of 93-96% have been identified in clinical drug development,11 with 66% of compounds 
that enter phase II failing prior to phase III and a further 30% of candidates that enter phase III 
failing prior to the submission to launch phase.15 Efforts have been made to reduce failure rate 
and advances in cheminformatics reveal a clear link between drug candidate success and 
physicochemical properties relevant in small-molecule drug discovery.12 With judicious 
selection of lead compounds and constant monitoring of physical properties during 
optimisation, a medicinal chemist can be in control of the compound’s physicochemical 
properties and this hopefully will increase the success rate of drug candidates. An attrition 
percentage that decreases by 5% can in turn lead to an improvement of up to double the amount 
of new medicines brought to market.16 Recent studies have shown that lead-oriented synthesis 
(LOS) can increase the range and quality of molecules used to develop medicines, in the hope 
of reducing attrition in the drug discovery process.17,18,19 
 
The cost of drug discovery and developing new drugs has increased rapidly each year.20 The 
estimated cost of a new drug is ~ £1 billion (this also includes cost of failed campaigns) with a 
timescale of approximately 12-15 years for the drug to reach the marketplace.21,22 Due to these 
remarkably high numbers, it is becoming an important problem which needs addressing. A 
number of challenges face the pharmaceutical industry such as the loss of capital from expiring 
patents and the low number of new chemical entities11,23 
 
Reducing attrition rates of drug candidates during the early stages of drug discovery and 
development is critical in order to help solve these ongoing problems in the pharmaceutical 
industry.21 There are now numerous pieces of evidence to support the theory that the chance of 
a small molecule drug candidate being successful is highest when its physicochemical 
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properties lie within a certain range.24 Some of these properties, such as molecular weight and 
lipophilicity, have a significant effect on the drug’s ability to succeed. These desired properties 
can be targeted from an early stage by the use of a suitable synthetic strategy so that a lead 
compound can be developed without problematic characteristics and occupying the conceptual 
area known as lead-like space.25 
 
1.3 Drug likeness - properties of successful hits and drugs 
 
As described above, there is an apparent link between physicochemical properties and drug-
like properties for a drug candidate. An attempt to characterise these links was introduced by 
Lipinski and co-workers in 1997,26 who analysed the physicochemical properties of a large 
number of orally bioavailable drugs and concluded that a compound is more likely to be 
membrane permeable and easily absorbed by the body if it matches the following criteria 
(Table 1).27 These observations are referred to as the Lipinski rule of 5.  
 
Physicochemical Properties Ideal value 
Molecular Weight (Daltons) 500 
Hydrogen bond acceptors 10 
Hydrogen bond donors 5 
clogP 5 
Table 1. Outline of the ‘Lipinski rule of 5’, which predicts that poor absorption or permeation is more likely when these rules 
are breached. 26,27 
 
The majority of compounds which are orally bioavailable conform to these rules and Lipinski 
advises that an ideal drug will have a higher chance of being successful if it possess such 
characteristics. 26,28 (N.B. there are numerous successful drugs with characteristics that lie 
outside this range).  Ideally these should be a small molecule that is no larger than 500 Daltons, 
with a logP being no greater than 5. The property logP is the log of the ratio of concentrations 
of a solute between immiscible phases, water and octanol (Equation 1).27,31 The compound 
should also possess no more than 5 groups that can donate hydrogen bonds and no more than 
10 groups that can accept hydrogen bonds. These criteria have been widely applied by 
medicinal chemists to predict the overall drug-likeness of a molecule. However, recent studies 
have shown that compounds with significantly lower molecular weight and logP values are 
now being favoured, because compounds that are close to the Lipinski limits have a lower 
probability of success.24,29,30 
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Equation 1. Equation showing the calculation of logP.31  
 
Recent studies have highlighted the detrimental effect of excessive lipophilicity for numerous 
reasons.16,30 In order to deliver a drug molecule to its given target, the drug must be polar 
enough to be soluble in aqueous media (such as the blood) and yet lipophilic enough to pass 
through the lipid membrane to get into the cell without binding to unwanted proteins upon 
entry. If a drug is too lipophilic it may have undesirable absorption, distribution, metabolism 
and excretion (ADME) properties,32 as well as having issues with binding to serum proteins in 
the blood, thus leaving a low level of the unbound drug free to bind to the desired target. Lastly, 
it may have off-target effects.33 However, although lowering lipophilicity is important, if the 
logP value is below 1 this has been shown to increase problems with metabolic clearance, 
aqueous solubility and the drug may have difficulty in crossing cellular membranes.34,35,36 
 
During the lead optimisation process, the candidate molecule generally increases in molecular 
weight and lipophilicity downstream from the initial lead compound, as substituents are added 
to the molecule in order to enhance binding to and selectivity for the target.24,37 Therefore the 
lead molecule will ideally have a preferred set of physicochemical properties, which allow for 
further optimisation. This smaller area of physicochemical space is known as lead-like space 
and controlling the molecular properties of a lead molecule is crucial if the final compound is 
to remain in optimal drug-like space (Figure 2). 17,24,38   
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Figure 2. A graph demonstrating areas of chemical space. Fragment-like space (black circle), lead-like space (red-circle) 
optimal drug-like space (blue oval) and early combinatorial library space (green circle). It also indicates the molecular weight 
and clogP for each chemical space. Adapted from source.24 
1.4 Lead-likeness 
 
A molecule that has properties outside the lead-like parameters before optimisation will have 
a much reduced chance of succeeding at later stages in drug development and discovery.24  As 
stated in the previous section, optimisation will generally increase lipophilicity and logP, 
therefore possibly leading to off-target activity. A range of parameters for lead-likeness have 
been developed and are summarised below (Table 2).  
 
Physicochemical Properties Ideal Value 
Molecular Weight (Daltons) 200 – 350 
Heavy atoms (C, O, N, S etc.) 14 – 26 
Lipophilicity -1  clogP  3 
Shape More 3D shape 
Number of aromatic rings (nAr) 1 - 3 
Undesired sub-substructure filters Remove moieties containing chemically 
reactive, electrophilic or redox active 
groups 
Table 2. Outline of the preferred molecular properties and features for lead-like small molecules. 19,24  
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Although there has been extensive research into the influence of lipophilicity and molecular 
weight on drug candidate success rates, there has now been increased interest in the degree of 
three-dimensional (3D) shape and aromatic character of the lead compound.39,40 Increasing the 
complexity of a drug candidate by varying its chirality and shape has a good correlation with 
the success of a compound’s transition from discovery, through clinical testing, to market.39 
Compared with unsaturated molecules, saturated molecules have been shown to have higher 
aqueous solubility and lower lipophilicity, both of which are important physical properties for 
success in the drug discovery setting.39 One way of assessing the complexity and saturation of 
a 3D molecule is to look at the fraction of sp3 hybridized carbons (Fsp3), with highly complex 
3D molecules having a higher Fsp3 count; the Fsp3 count is calculated below (Equation 2). 
Furthermore, studies have suggested that complex 3D shapes have desirable aqueous solubility 
because of increased solvation and poorer solid state crystal lattice packing.39,41,42 In addition, 
more than three aromatic rings in a molecule correlates with poorer developability and 
decreased aqueous solubility, therefore increasing the risk of attrition in early drug 
development.40  
 
 
Equation 2. Equation showing how to calculate the degree of saturation of a compound.39 
 
Due to the industry’s focus on specific reaction types and the synthetic accessibility of 
molecules with high sp2 character (through e.g. biaryl couplings and amide bond formation), 
there is a large proportion of screening compounds that are relatively two-dimensional.43 The 
complexity of synthesising sp3 hybridised carbon centres has led to limited availability of 
complex chiral structures.44 As an illustration of the traditional focus on these molecules, one 
can examine their 3D structure by using a normalized principal moment of inertia (PMI) plot.  
PMI plots represent the three-dimensional shape of a molecule on a two-dimensional ternary 
plot. The vertices of the plot portray the three extremes of molecular geometry.45 The left-hand 
vertex represents the rod-like molecular shape which is symbolised by an sp-hybridised 2,4,6-
octatriyne. The right-hand vertex represents the sphere-like molecular shape which is 
symbolised by an sp3 hybridised adamantane. The bottom vertex represents the disk-like 
molecular shape which is symbolised by an sp2 hybridised benzene molecule. Compounds are 
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plotted between the three vertices and assessed on their three-dimensional shape. 
A PMI plot was produced for a random 1% (90911 compounds) of compounds from the ZINC 
database, showing the molecular shape of the compounds (Figure 3).46 The ZINC database 
consists of commercially available compounds for virtual screening, where over 35 million 
compounds can be purchased.47 It provides evidence of the lack of 3D shape of available 
compounds, and thus giving increased importance to produce molecular scaffolds with 3D 
shape and chirality. 
 
 
Figure 3. A PMI plot of 90911 virtual compounds from a random 1% the ZINC database of commercially available 
compounds. The compounds (green dots) are plotted based on their rod-like properties, disk-like properties and sphere-like 
properties.46 
A study by Shivanyuk and co- workers in 2010 performed an analysis of the lead-likeness of a 
library of 7.9×106 compounds, using a more relaxed early definition of lead like properties.*  
The study consisted of assembling and analysing 7.9×106 commercially available compounds 
from 29 suppliers, within which 5.2×106 structures were identified as unique. These 
compounds were then subjected to assessments of their physical and biological properties. A 
broader set of parameters* to Table 2 were applied to the compounds which revealed only 16% 
of them had potential to be leads.48   
 
 
* The corresponding values used to select lead-like compounds were taken from a paper by Hann and Oprea38: 
200 < molecular weight (Da) < 460, -4 < logP < 4.2, rotating bonds  10, polar surface area  170. 
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However, a more recent study reviewed 4.9×106 commercially available compounds from 104 
different sources, with the aim of finding the percentage of lead-like compounds. A much lower 
percentage of compounds were of lead-likeness. Using the GlaxoSmithKline (GSK) lead-
likeness guide, featured in Table 2, the compounds were then analysed for molecular weight, 
lipophilicity and undesired features. The results showed that 70% of compounds fell outside 
‘lead-like’ space because of their molecular weight and the remaining half then failed because 
of lipophilicity issues. The remaining compounds had undesired functional groups, leaving 
only 2.6% compounds (1.2×104 compounds) that had desirable lead-like properties.24  
 
A good starting point for a drug discovery programme is to follow simple molecular property 
guidelines. These guidelines in Table 2 broadly describe lead-like space and provide simple 
parameters to follow in order to increase chances of the derived drug candidate being 
successful; also with the help of readily available computational tools, synthetic approaches 
can be evaluated and prioritised to ensure the compounds stay in lead-like space. Software tools 
such as LLAMA can be freely accessed and used to monitor lead-like synthesis of 
compounds.45 
 
1.5 Diversity-oriented synthesis (DOS) 
 
Diversity-oriented synthesis, first introduced by Schreiber,49 aimed to scope chemical space by 
preparing a large number of skeletally diverse compounds for use in high-throughput 
screening, in the hope of finding hits with biological targets. This method aims to efficiently 
produce a collection of diverse complex molecules with a wide range of desirable physical and 
biological properties.50 This strategy has major advantages with its exploration of wider 
chemical space and its use as a tool for the discovery of novel biologically active molecules.51,52 
However, this method has been criticised for its lack of consideration of molecular properties.51 
 
A successful DOS strategy termed build/couple/pair (B/C/P) was described by Nielsen and 
Schreiber.53 A generation of stereochemically diverse compounds were prepared, from chiral 
building blocks containing orthogonal sets of functionality suitable for subsequent coupling. 
The B/C/P strategy involves the asymmetric syntheses of these chiral building blocks, that 
when coupled provides the basis for large stereochemical diversity (Figure 4a). The Couple 
phase (Figure 4b) involves intermolecular coupling reactions that join the building blocks, 
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with the aim of complete control of all possible stereochemical outcomes (or without 
stereochemical consequences). Finally, the Pair phase involves functional group pairing 
reactions, which involves intramolecular coupling reactions that provide the basis for skeletal 
diversity (Figure 4c).  
 
 
Figure 4. A general example of the B/C/P strategy in action. Step (a) showing the ‘build’ phase with the black dot representing 
coupling functional groups, the red dot and blue dot representing a pairing functional group. Step (b) represents the coupling 
phase and step (c) represents the pair stage. 
 
1.6 Fragment based drug discovery (FBDD) 
 
Fragment-based lead discovery is a discovery approach that involves the screening of smaller, 
lower molecular weight (140–230 Da) compounds, called fragments.54 Compared with HTS 
hits, these fragments-based hits are typically weak inhibitors (100 M–mM) of the biological 
target. Fragment-based compounds are much simpler, less functionalized compounds that have 
a lower affinity than typical commercially available compounds used in a HTS.55  
 
One of the earliest approaches to describe the building of fragment libraries, was the rule-of-
three guidelines which was first reported by Jhoti et al. in 2003.56 However, since the strategy 
has been more developed over the years, a more strict set of guidelines can be used for the 
construction of fragment libraries.54 Rees and Murray of Astex Pharmaceuticals have reported 
a more detailed set of properties, which is shown below (Table 3).  
 
 
 
 
 12 
Property Guideline 
Molecular recognition Diverse, usually polar groups for binding to a protein (a single 
pharmacophore) 
Synthetic vectors Multiple synthetically accessible vectors for fragment growth 
(allows access to a variety of new binding interactions in 3D 
space) 
Physicochemical 
properties 
Molecular weight: 140 – 230 (Daltons) 
Heavy atoms: 10 – 16 
Lipophilicity: 0  clogP  2 
Stability: >24 h in solution 
Number of rotatable bonds: 0 – 3 
Undesired sub-structure filters: Remove moieties known to be 
associated with high reactivity, aggregation in solution or false 
positives.57 
Properties commensurate with biophysical screening at high 
concentrations, e.g., aqueous solubility (preferably  5 mm in 
5% DMSO, or other screening co-solvents); 
Synthetic tractability ~ 50 – 100 mg and  4 steps from commercially available 
reagents 
Shape Variety of 3-dimensional shapes for each scaffold and 
pharmacophore; 
Number of chiral centres: 0 – 1, sometimes 2 
Table 3- Outline of the Astex guidelines for fragment-like molecules.54 
The principal disadvantage of FBDD is that because of the small nature of the fragment 
molecules, there are fewer protein-ligand interactions when compared with drug-like/lead-like 
compound that are more complex and hence binding affinities are much lower, meaning direct 
assay of bioactivity is not possible in many cases.58 The process requires sensitive biophysical 
detection techniques such as protein crystallography or NMR spectroscopy as the primary 
screening techniques, and preferably requires high quality structural data in-order to determine 
the binding of the fragment to a target.10 
 
Where structural information exists fragments can be grown to form new interactions using 
structure-based drug design, to form high affinity leads. These low potency fragments have 
high-quality interactions that can be readily optimized into potent lead molecules through 
linking similar proximal binding fragments of a protein site.59  
 
A typical fragment library can consist of 1,000 – 5,000 compounds, to provide a reasonable 
number of hits.60,61 An example of a fragment compound  is shown below, where a large 
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number of drugs derived from this widely practised strategy have entered clinical trials 
(Scheme 1).61  
 
Scheme 1 An example of a fragment which follows the guidelines in Table 3 and its corresponding drug candidate  
 
1.7 Lead-oriented synthesis (LOS) 
 
The objective of lead-oriented synthesis is to prepare diverse novel compounds that target lead-
like chemical space. Its major challenge is to identify and demonstrate the use of new synthetic 
methodologies to achieve these goals. Although very similar to DOS, LOS focuses on the 
physicochemical nature of the product molecules, rather than solely their skeletal diversity.25 
Another key aim is to be able to produce a wide range of lead-like chemical structures that are 
not susceptible to excessive LogP drift and also, can be synthesised in an efficient way with 
the use of cheap reagents and conditions.62 Syntheses must be tolerant to a wide range of polar 
functional groups, with the scaffolds also having no residual electrophilic or reactive centres. 
In order for a lead-like molecule to be successful it must be able to efficiently and effectively 
interact with biological systems.24 Scaffolds which are primarily synthesised are susceptible to 
further diversification and decoration to create a library of lead-like compounds for biological 
screening.  
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Scheme 2. A general schematic for ‘bottom-up’ approach. Step 1- functional group-tolerant bimolecular coupling, step 2 
monocyclisation to pairwaise coupling and step 3 bicyclisation by pairwaise coupling 
 
1.7.1 Bottom-up approach to lead-oriented synthesis 
 
The bottom-up approach is used within the Marsden and Nelson group, which involves the 
preparation of small polyfunctionalised precursors to synthesise diverse lead scaffolds;46 the 
approach shows similarities to Schreiber’s BCP approach. An example of this method in action 
was performed by Marsden, Nelson and co-workers.17 It involved a strategy for the efficient 
lead-oriented synthesis, by the preparation of twenty-two novel lead-like scaffolds from four 
-amino acid-derived building blocks and six connective reactions. The small building blocks 
contained multiple chemically-orthogonal functional groups, which were then coupled using a 
minimal toolkit of reactions. To then confirm the validity of the library analysis, exemplar 
decoration was performed. The compounds were then evaluated for lead-like assessment, 
finding the library targeted the broad regions of lead-like chemical space and followed the rules 
for lead-likeness (c.f. Table 2). Their novelty and diversity assessment found that the twenty-
two scaffolds synthesised were both novel and skeletally diverse. An example is shown below 
showing a few examples of successfully synthesised lead-like scaffolds (Scheme 3).  
 15 
 
 
Scheme 3. A general example of a ‘bottom-up’ approach, where four starting material compounds produce twenty-two  
scaffolds. 
 
Previous work has been carried out within the group by Marsden, Nelson and co-workers in 
2015, where 52 diverse lead-like molecular scaffolds were synthesized from a set of 13 
precursors, which targeted lead-like chemical space.18 They exploited a suite of robust, 
functional group-tolerant transformations, from commercially available compounds and  
synthesised cyclisation precursors from allylic carbonates and amines (Scheme 4). From there, 
a range of scaffolds were produced from cyclisation or functionalization (filled circles), with 
third building blocks labelled in red and new bonds marked bold, yielding a large number of 
novel compounds with lead-like molecular properties.18  
 16 
 
Scheme 4. A general outline of the formation of lead-like scaffolds from cyclisation precursors. Filled circles represent 
cyclisation functional groups and bold lines represent new bonds. 
 
With the use of ten amine substrates and an allylic carbonate (two alternatives), thirteen 
cyclisation precursors were successfully prepared via iridium catalysis in excellent yields (46-
82%) and with high enantio- or diastereoselectivity. A few examples are shown below. 
(Scheme 5). 
 
 
Scheme 5. Two examples of cyclisation precursors. 
 
Lead-like molecules were then synthesised from the thirteen cyclisation precursors, using a 
robust cyclisation toolkit.  The toolkit consisted of six cyclisation methods that were exploited 
to convert the precursors into novel scaffolds. An example of such is below (Scheme 6), 
showing a Pd-catalysed aminoarylation which enabled conversion of the cyclisation precursor 
19, into the pyrrolidines 20a and 20b. Each of the reactions proceeded efficiently and with high 
diastereoselectivity. 
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Scheme 6. A scheme showing the synthesis of two lead-like scaffolds 20a and 20b from a cyclisation precursor 19. 
 
The 52 scaffolds were assessed for their novelty, diversity and their Fsp3 character. They 
elaborated a virtual library based on these scaffolds and compared the properties of these to a 
selection of the ZINC database. The compounds were successively filtered by molecular size 
(14 ≤ number of heavy atoms (nHA) ≤ 26), lipophilicity (−1 ≤ AlogP ≤ 3) and undesirable 
structural features, with the result it was found each one of the 52 scaffolds allow significant 
regions within lead-like chemical space to be targeted (Table 4).  
 
Filter Random 1% of ZINC 
Database (90911) 
Virtual Library 
(19530) 
Fail 
14  nHA  26 
43971 
(48%) 
5104 
(26%) 
Fail 
-1  AlogP  3 
17828 
(20%) 
2905 
(14.8%) 
Fail Structural 8180 
(9%) 
53 
(0.2%) 
Pass All 20932 
(23%) 
11468 
(59%) 
Table 4. Lead-like assessment data of the a random 1% of the ZINC database and the virtual library. 
 
The compounds were compared with the ZINC database and CAS registry for novelty and were 
assessed using a hierarchical analysis for diversity (Table 4).63,64 Then finally, the fraction of 
sp3 was analysed by comparing to a random sample of compounds from the ZINC database, 
which showed on average the 52 scaffolds had significantly greater sp3 character than most 
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commercially available compounds (Figure 5). This shows that the unified lead-oriented 
synthetic approach yielded novel, diverse and lead-like molecular scaffolds.18,19 
 
 
Figure 5. A graph comparing the fraction of sp3 hybridized carbons from the ZINC database (red) and the 52 scaffolds 
(average in black and individual in green). 
 
1.7.2 Top-down approach to lead-oriented synthesis  
 
The top-down approach is a new method used within the Marsden and Nelson groups whereby 
complex polycycles are prepared and are then deconstructed by selectively cleaving and 
modifying chemical bonds to give a library of diverse lead-like molecules.46 A range of 
chemical methodologies are used to break apart the assemblies and generate lead compounds. 
The bottom-up approach differs from the top-down approach, in that complexity is added 
sequentially leading to a final complex molecule. However, each of the approaches have the 
same intention of synthesising lead-like molecules. 
 
This strategy requires a complex molecule that is capable of subsequent synthetic elaboration 
to further produce a library that possess the characteristics of lead-like molecules. Compound 
21 below (Figure 6) shows an example of such, were the molecule is susceptible to ring 
addition, expansion and cleavage. 
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Figure 6. An example of ‘top-down’ approach, where compound 21 is susceptible to ring expansion and bond cleavage, to 
synthesise lead-like molecules. 
 
Previous work has been carried out within the group using the top-down approach. Here, 
intramolecular [5+2] cycloadditions yielded four complex parent scaffolds, where the scaffolds 
were diversified at various points to synthesise a fragment library with controlled molecular 
properties. Each cycloadduct followed the top-down strategy, following the criteria of a short 
synthetic sequence (≤5 steps), scalable and synthetically tractable (Figure 7).46 Each 
cycloadduct was then investigated for its diversification at points of the scaffold, in the 
possibility of providing access to a variety of novel-like, natural product-like scaffolds for its 
use in the LOS/FOS programme.46 The scaffolds had a focus of natural product likeness, as it 
was important to synthesise a library of sp3-riched fragments.65  
21 
22 
23 
24 
25 
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Figure 7. An example of four compounds following the ‘top-down’ strategy. 
Once the cycloadducts had been synthesised, the scaffolds were then subjected to scaffold 
manipulation at various points of the scaffolds (Figure 8). A toolkit of chemical methodologies 
was applied to either generate a ring expanded product or used to break apart the assemblies to 
generate ring-cleaved compounds. Some examples are shown below (Figure 8), where the 
products were deprotected and in some cases, decorated with medicinally relevant capping 
groups. 
 
Figure 8. Some examples of manipulated compounds derived from the maltol 27, Kojic acid 26 and compound 28. 
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From the 4 complex bridged parent scaffolds, the unified-approach led to the synthesis of 26 
diverse sp3-rich scaffolds, from a total of 64 synthetic operations†. Each scaffold was produced 
with high step efficiency and with high ‘natural product likeness’ (Figure 9, Panel A). A set 
of 52 racemic fragments were then prepared, and all designed to have high shape diversity and 
controlled molecular properties (HAC: 13-19, AlogP 1.5<clogP<3). The library was identified 
as more 3D and natural product-like (Figure 9, Panel B), than commercially available 
fragments.  
 
 
Figure 9. The natural product-likeness assessment of (A) 26 scaffolds (black), 4,460 natural products (green) and acommercial 
screening collection (278,365 largely synthetic compounds, grey). (B) Naturalproduct likeness scores for the 52 fragments 
prepared (black), 1,236 commercially-available fragments(grey) and 128 natural product-inspired fragments (green). 
 
To assess the compound’s shape diversity and the relationship between the scaffolds, the 
frameworks were assessed using Waldmann’s hierarchical tree analysis.66 The comparison of 
the compounds framework was done by removal of rings until a parent monocyclic ring system 
was achieved. The 26 scaffolds were simplified to obtain nine parent monocycles (Figure 11), 
thus concluding this approach led to significant diversity.  
 
 
† Processes conducted in a single reaction vessel 
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Figure 10 Waldmanns’ hierarchical tree analysis for the 26 fragment scaffolds 
Each fragment was then screened against the protein targets, with the use of high-throughput 
crystallographic screens. The proteins were soaked with fragments and then subjected to 
automated X-ray diffraction. In total, the screening resulted in seven hits for the ATAD2 
bromodomain, eight hits for the BRD1 bromodomain and two hits for the JMJD2D. The 
approach hoped to serve as distinctive starting points for drug discovery, with the possibility 
of fragment growth to improve potency.  
 
1.7.3 Other studies 
 
When searching the literature, no study of the top-down approach to LOS has been conducted 
outside the group. However, a study of the bottom-up approach to LOS was performed by 
Ryabukhin and co-workers in 2014.67 They developed a method which fitted well in the 
concept of lead-oriented synthesis using the bottom-up approach, where they synthesised 132 
lead-like compounds from a one-pot variation of a Castagnoli condensation reaction, in high 
yields and diastereoselectivities. The one-pot multicomponent reaction involved aldehydes 75, 
alicyclic primary amines 74, and anhydrides 76, obtaining a range of 1,2-disubstituted 5-
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oxopyrrolidines (example 79) and 6-oxopiperidine-3-carboxylic acids (example 80 and 81)  
(Scheme 7).  
 
 
 
Scheme 7. A one-pot variation of a Castagnoli condensation reaction, showing three lead-like compounds, as an example of 
lead-oriented synthesis. 
 
The predicted physicochemical property values of the library were summarised and they 
conformed to the GSK lead-like guide.24 The calculated logP range of the scaffolds fell slightly 
outside the range of the desirable parameters, but the average was within range (logP average 
= 1.29). The multicomponent library showed 3D characteristics, with the Fsp3 count ranging 
from 0.25 − 0.82 (average Fsp3 = 0.51). According to the GSK guidelines this is seen as a 
positive because it defines a more 3D shape. 
 
Physicochemical property Lead-like library 
(132 compounds) 
GSK lead-like guide 
Molecular Weight (Daltons) 265 – 349 200 – 350 
Lipophilicity 1.25 – 3.32 -1  clogP  3 
Number of aromatic rings (nAr) 1 – 3 1 – 3 
Table 5. A comparison of their lead-like library with the GSK lead-like guide. 
 
By applying the multicomponent Castagnoli condensation reaction, 132 lead-like compounds 
were synthesised in two synthetic steps. Despite the high number of scaffolds produced using 
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this method no novelty or diversity assessment was applied, so the validity of this approach 
cannot be confirmed. If a Waldmann hierarchical tree analysis was performed on the library,66 
only two parent monocycles (83, 84) would be obtained (Figure 11). Therefore, it can be 
concluded that this approach lacks skeletal diversity. 
 
Figure 11. Waldmanns’ hierarchical tree analysis for the multicomponent Castagnoli series.  
 
When comparing this study to previous bottom-up approaches, this particular library requires 
the synthesis of a new set of starting material for each lead-like compound. This is a major 
disadvantage for its efficiency of producing a large library, as only a small number of 
compounds can be produced from each starting material. With the absence of cyclising and 
coupling functional groups, like those seen in previous bottom-up approaches, the diversity of 
the overall compounds is limited to two similar core structures, therefore limiting its 
exploration of chemical space.  
 
 
1.7.4 Summary of LOS 
 
For drug discovery to increase its productivity, new methodologies are needed to help prepare 
bioactive molecules to improve human health, with clear guidelines of what molecules that will 
have the biggest impact on the search for new medicines. New methods such as LOS, which is 
described above, will hopefully help solve these significant challenges in drug discovery.24 
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1.8 Aims and objectives  
 
1.8.1 General aims and objectives 
 
 
Figure 12. The general aims of the project, starting from the synthesis of a starting material scaffold, then decorating, 
screening for biological activity and performing structure-activity relationship.  
To address the ongoing issues in the drug discovery process, as described in Section 1.2, it was 
therefore proposed to synthesise a library of compounds with specific molecular properties 
(described in Section 1.3 & 1.4) that would be a good starting point in drug discovery. Thus, 
the overall aims of the project were to: (1) prepare a parent cycloadduct in an efficient and 
concise manner, from readily available starting materials, which can be diversified at each 
point of the scaffold; (2) manipulate the parent cycloadduct to prepare a variety of novel and 
diverse molecular scaffolds; (3) decorate scaffolds to create a library that covers broad regions 
of lead-like chemical space; (4) test these libraries against a range of biological targets; (5) 
perform structure-activity relationship (SAR) on active compounds, if any hits are observed. 
 
The synthesis of this lead-like library will hopefully expand the relevant chemical space 
accessible to drug discovery programmes. This further exploration of space may help address 
the challenges of increased productivity in the drug discovery industry. 18,68 
 
1.8.2 Objective 1 – parent cycloadduct synthesis 
 
The project will follow the top-down approach, where first the synthesis of a small, 3D, highly-
functionalised parent cycloadduct is required, which has different regions of the molecule that 
are open to manipulation. The rigid bicyclic system 89 was initially identified as possessing 
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numerous functional handles that are capable of subsequent synthetic elaboration and therefore 
being suitable for the top-down approach. (Scheme 8).   
 
 
Scheme 8. A scheme for the synthesis of compound 100 and its diversification points. 
1.8.3 Objective 2 – lead-like scaffold synthesis 
 
Once a parent cycloadduct has been successfully synthesised, the next objective is to prove the 
chosen scaffold can be diversified at a variety of positions of the scaffold. Using known 
chemistry within the Marsden and Nelson group, the chosen scaffold will undergo annulation 
(Figure 13, example 1), bond cleavage (Figure 13, example 2),  group addition (Figure 13, 
example 3) and ring expansion (Figure 13, example 4) to produce a variety of diverse 
molecular scaffolds. 
 
 
Figure 13. Manipulation reactions planned for the parent cycloadduct 89.. 
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1.8.4 Objective 3 – final compound synthesis  
 
Once objective 2 is achieved and a range of lead-like scaffolds have been synthesised, the next 
step is to select appropriate scaffolds for decoration to produce a final compound library for 
biological screening. The selected scaffolds will undergo various decoration reactions from a 
known organic toolkit, which involves well known reactions such as amide coupling, reductive 
amination and alcohol alkylation. The ability of a scaffold to access lead-like space will be 
assessed by creation of a virtual library using computational software such as LLAMA or 
PipelinePilot.45 Once a set of scaffolds (around 10) has been selected, these will be decorated 
with medicinally-relevant capping groups to yield the compound library.  
 
1.8.5 Objective 4 – biological evaluation 
 
Once the compound library is complete, it will be screened against a range of biological assays. 
Suitable biological targets will be selected upon completion of the compound library, and will 
be screened in Leeds or with collaborators at other universities which have specified screening 
facilities. 
 
1.8.6 Objective 5 – structure-activity relationship 
 
If any of the compounds result in positive biological data, the next objective will be to perform 
structure-activity relationship. The analysis of SAR enables the identification and 
determination of important chemical motifs that are responsible for activity. Each position of 
the scaffold will be examined by changing functional groups independently and identifying the 
important active chemical groups of the compounds. Observing and analysing the difference 
in potencies will gain a better understanding of which chemical groups are responsible for 
evoking a target biological effect in the organism.69 
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2.0 Results and discussion 1: Lead-like scaffold synthesis 
 
The top-down strategy for lead-oriented synthesis depended upon a complex molecule that was 
capable of subsequent synthetic elaboration to further produce a library that was both diverse 
and novel. To explore objectives 1 and 2 it was therefore proposed to prepare a library of 
diverse tropane-related scaffolds that were to be formed by addition of substituents to, 
cyclisation reactions of, and fusion of additional ring(s) to the key bicyclic intermediates.  
These key indeterminates would obtain various functional groups able to be decorated with 
medicinal relevant capping groups for screening. 
 
2.1 Development of potential parent scaffolds  
Tropane containing skeleton 94 was chosen as the parent scaffold due to the multitude of 
different functionalities present, as well as the potential for manipulation at multiple 
diversification points (Figure 14a). The scaffold’s diverse functionality could be exploited to 
form lead-like scaffolds and would be ideal for a ‘top-down’ approach. Embedded in this 
scaffold is the well-known, often medicinally active, [3.2.1]-bridged bicyclic tropane core. The 
tropane moiety is a frequently observed bicyclic nitrogen containing heterocycle among U.S. 
FDA approved drugs and natural products (Figure 14b).70  
 
 
Figure 14a). The parent scaffold chosen for the ‘top-down’ approach strategy and the diversification points. b) An example 
of three [3.2.1]-bridged bicyclic compounds 95-97. 
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The proposed route to the desired framework was centred around a one-pot two-step 
intermolecular [5+2] cycloaddition between an oxopyridinium salt 98 and a dipolarophile 99 
(Scheme 9). The advantage to this approach is that a variety of dipolarophiles could be utilised 
for the cycloaddition. This approach followed a similar synthetic route to a parent scaffold 
which was synthesised in the Marsden and Nelson group,65 where the scaffold formed contains 
a bridged heteroatom and an enone functional group. However, the below intramolecular 
approach required more steps for the synthesis and it lacked diversity. Each parent scaffold 
contains a fused pyrrolidine and no other functional group can be introduced easily. 
 
Scheme 9. An example of both the intramolecular and intermolecular approach for the ‘top-down’ approach strategy. 
2.2 [5+2] Cycloaddition chemistry to synthesise parent scaffolds  
 
In order to synthesise the chosen scaffold for the top-down approach, the N-substituted 
hydroxypyridinium salts (87 and 105) were obtained by N-alkylation of 3-hydroxypyridine 86 
with an appropriate alkyl halide (BnBr and MeI) (Scheme 10). This gave the pyridinium 
precursors required for the [5+2] cycloadditions in near quantitative yields, where no 
purification was required.71  
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Scheme 10. Formation of the benzyl and methyl substituted hydroxypyridinium salt 2.13 and 2.14. 
With the N-substituted pyridinium salts in hand, attention was focused on synthesising the 
potential parent scaffold 108. Initial efforts involved the [5+2] cycloaddition with benzyne as 
the dipolarophile. The scaffold was synthesised following a modified procedure by Shi et al.71 
which required pre-formation of the oxidopyridinium ylide 106. This was achieved by the 
deprotonation of pyridinium salt 87 using Amberlite IRA- 420 resin giving ylide 106 in a 92% 
yield (Scheme 11). Subsequent [5+2] cycloaddition between ylide 106 and benzyne, which 
was generated in situ from precursor 107 and a fluoride anion, gave the desired cycloadduct 
108 in a low 25% yield. However, despite success in the synthesis of cycloadduct 108, it was 
discontinued due to the expensive benzyne precursor starting material 107 and its overall poor 
yield of the product. Also, more functionalised reagents were more expensive and may have 
produced a mixture of regioisomers.  
 
Scheme 11. Scheme for formation of cycloadduct 108, from salt 87 and benzyne precursor 107. 
 
The pyridinium salt was then subjected to cycloaddition reactions with a range of dipolarophile 
alkenes via the in-situ generation of the ylide, a summary of which is shown below (Table 6).  
 
Entry R R’ Solvent No. of 
isomers 
Ratio of 
isomers  
Combined 
yield 
1 Bn CN Neat 4 4:4:2:1 109, 45% 
2 Bn SO2Ph THF 1 100:0:0:0 89, 70% 
 
 The ratio isomers were determined using integration of distinct peaks of the crude 1H NMR 
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3 Bn CO2Me Neat 4 6:4:1:2 110, 92% 
4 Bn SOPh THF 4 8:5:3:1 111, 24%  
5 Bn CO2
tBu 1,4-dioxane 4 8:3:3:2  112, 65% 
Table 6. Outcome of cycloaddition reactions involving pyridinium salt 98 and dipolarophile 99. 
 
Moderate to good yields were observed in the cycloaddition reactions, however, in most cases 
an inseparable mixture of diastereomers and regioisomers was obtained. These were seen by 
the 1H NMR of the crude mixture and isolated compounds. Interestingly, when phenyl vinyl 
sulfone was used as the dipolarophile a single isomer was formed in a good 70% yield (Table 
6, entry 2). The conditions were adapted from those detailed by Ducrot and Lallemand.72,73 The 
stereochemistry and regioselectivity of cycloadduct 89 were assigned according to the 1H NMR 
spectra data, where the key proton H coupling was predicted to show only coupling to proton 
H.+‡ The predicted coupling constants matched those of the 1H NMR data as shown in (Figure 
15) and the interpretation of data supports the literature precedent. 
 
 
Figure 15. The stereochemistry assignment for the parent cycloadduct 89, including its predicted coupling constants for the 
endo/exo isomer. 
 
Due to the high molecular weight of the phenyl sulfonyl substituent on the parent cycloadduct 
89, derivatisations were planned that would incorporate smaller or more chemically diverse 
sulfonyl substituents. These derivatives would allow for the synthesis of new scaffolds via ring 
addition reactions and for the addition of larger capping groups in the library synthesis, whilst 
remaining in lead-like space. The smaller scaffolds would also allow access to a larger fragment 
library. In the cases where removing the benzyl group was not feasible, smaller nitrogen 
substituents were introduced. The planned parent scaffold derivatives are shown below 
(Scheme 12). 
 
+‡ H of compound 89 had coupling at ~ 5 Hz and no coupling constant with H. The coupling constants were 
predicted using the software chem3D. 
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Scheme 12. A proposed set of sulfonyl derivatives to be synthesised using the [5+2] cycloaddition chemistry. 
 
It was envisioned that five vinyl sulfonyl derivatives would be used for the synthesis of the 
parent scaffold series (Figure 16). Methyl vinyl sulfone 118 was commercially available and 
the vinyl sulfonyl pyridine 122 was synthesised using chemistry reported by Carretero et al.74 
A vinyl sulfonamide/sulfonate series (118 – 122) was also synthesised using a modified 
synthesis by Caddick et al.75  
 
 
Figure 16. The five vinyl sulfonyl derivatives planned for parent scaffold derivative synthesis. 
 
Three vinyl sulfonyl derivatives 119 – 121 were obtained, using the conditions detailed by 
Caddick et al in 2009.75 Moderate to good yields were observed when a range of nucleophiles 
were added to compound 123 at -78 oC, as shown below (Table 2).  
 
 
 
 
 33 
 
 
Entry Nucleophile (Nu) Product Yield 
1 HNMe2 
 
121 
50% 
2 
 
124 
 
119 
33% 
3 
 
125 
 
 
120 
80% 
Table 7. Outcome of vinyl sulfonyl derivative reactions. 
 
A procedure by Carretero et al.74 was used for the synthesis of compound 122. Disulfide 126 
was subjected to a Grignard substitution with vinylmagnesium bromide followed by an 
oxidation with NaW7O4.2H2O/H2O2. However, no formation of compound 122 was observed, 
and only starting material 126 was recovered (Scheme 5).  The route was discontinued as the 
four sulfonyl derivatives (118 – 121) were considered enough to bring diversity at this stage.   
 
 
Scheme 13. The proposed synthetic route to compound 122 via i) Grignard addition and ii) oxidation. 
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In order to synthesise the cycloadducts, a range of N-substituted hydroxypyridinium salts were 
obtained by N-alkylation of 3-hydroxypyridine 85. Different alkyl halides were chosen and in 
each case the salts were obtained in near quantitative yields on a 12 – 24 mmol scale.76,77,78 
 
 
 
Conditions X R Outcome 
PhMe (0.5M) Cl 
 
128, 99% 
THF (0.5 M) Br 
 
129, 99% 
MeCN (0.5 M) Br 
 
130, 99% 
THF (0.5 M) Br 
 
131, 99% 
THF (0.5 M) Br 
 
132, 99% 
Table 8 Outcome of alyklation reactions involving 3-hydroxypyridine 86 and a range of electrophiles. 
With a new panel of compounds in hand, the newly synthesised pyridinium salts and vinyl 
sulfonyl derivatives were subjected to the [5+2] cycloaddition procedure.73 The results are 
shown below, where a range of cycloadducts were synthesised in poor to excellent yield (20-
89%) (Table 9). 
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Entry R R’ HAC No. of 
isomers 
Ratio of 
isomers  
Major 
product 
yield 
(%)§ 
 
1 Bn SO2Me 20 2 10:1 117, 57% 
2  
Bn 
 
 
25 
 
3 
 
20:2:1 
 
133, 36 % 
3 PMB SO2Me 22 2 10:1 134, 52
 % 
4 
 
 
SO2Ph 
 
26 
 
2 
 
10:1 
 
 
135, 41% 
5 Me SO2Me 14 3 10:2:1 116, 20%
 
6 Me SO2NMe2 16 3 20:4:1 114, 54% 
7 
 
 
SO2Me 
 
26 
 
2 
 
10:1 
 
136, 50 % 
8 Me SO2Ph 19 2 7:1 115, 20
 % 
9 
 
SO2Me 27 1 100:0 137, 89% 
Table 9. Outcome of cycloaddition reactions involving N-substituted hydroxypyridinium salts and vinyl sulfonyl derivatives.  
It was noticed that the yields were particularly low when the cycloaddition involved the methyl 
pyridinium salt 105 (Table 9, entry 5), with large quantities of the unreacted dipolarophile seen 
but no residual pyridinium salt observed. It was proposed that the iodide counterion could be 
interfering with the reaction by dealkylating the methylhydroxy pyridinium salt. The base was 
therefore changed to silver oxide, where the silver can act as an iodide scavenger and this 
increased the yield dramatically. Consequently, new conditions were identified and applied to 
the synthesis of cycloadduct 116 (Scheme 14). 
 
 
 The ratio isomers were determined using integration of distinct peaks of the crude 1H NMR field. 
§ Major isomer isolated as a single isomer. The yield recorded for the major isomer only. 
O
S
O
NO
Br
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Scheme 14. The formation of cycloadduct 116 using the alternative base silver oxide. 
 
In total 10 parent scaffolds were synthesised with different sulfonyl and nitrogen-bridged 
substituents. Each parent scaffold was synthesised with good stereo/regio control, on a large 
scale from cheap starting materials, therefore following the ‘top-down’ approach strategy rules. 
Objective one, a synthesis of a highly functionalised parent cycloadduct, was successfully 
achieved, therefore attention was turned to the exploitation of the present functionality to 
synthesise a range of lead-like scaffolds. 
 
 
2.3 Development of methods to enable exploration of each vector of the parent 
scaffold  
 
With a range of parent scaffolds in hand, the next step was to investigate the reactivity of 
functionality at the different positions of the scaffold (Scheme 15). Exploring each growth 
vector is necessary to prove the parent scaffold is worthy of the ‘top-down’ approach strategy. 
Therefore, a variety of molecular scaffolds were proposed, applying a toolkit of chemical 
methodologies to produce a library of novel and diverse lead-like scaffolds. 
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Scheme 15. A proposed set of manipulation reactions of the parent cycloadduct 2.46 at different points of the scaffold. 
 
 
2.3.1 Development of methods to enable exploration of growth vectors at the 3- 
and 4- positions  
The first vector of interest was the electron-deficient alkene of the enone. Similar enone 
containing scaffolds had been made previously in the Marsden and Nelson group,46 and success 
had occurred when producing lead-like compounds from ring and functional group addition 
strategies. Therefore, a range of annulation reactions were investigated at this position, as 
shown below (Scheme 16).  
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Scheme 16. A variety of annulation reactions at the 3- and 4-position of the parent cycloadduct 138. 
 
With the primary aim of synthesising medicinally relevant heterocycles at the 3- and 4-
positions, the first reaction attempted was the formation of pyrrole 151. The pyrrole was 
obtained using chemistry first introduced by van Leusen,79 using toluenesulfonylmethyl 
isocyanide (TosMIC) 150 and potassium tert-butoxide. This afforded the product in an 85% 
yield, introducing another point of diversification at the pyrrole nitrogen (Scheme 17). 
 
 
Scheme 17. Formation of pyrrole containing scaffold 151 using van Leusen chemistry. 
Interestingly when using the methyl sulfonyl derivative 117, the cyclocondensation reaction 
was unsuccessful. Several conditions were used in the attempt to synthesise the pyrrole 152 
(Table 10). It was proposed that the deprotonation of the methyl sulfone was competing with 
the TosMIC deprotonation; consequently TosMIC was first deprotonated and a solution of the 
scaffold was subsequently cannulated into the deprotonated TosMIC solution. However, still 
no product was obtained after purification and other routes involving stronger bases were also 
unsuccessful (Table 10). 
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Entry Conditions Outcome 
1 TosMIC (1.0 eq.), 
tBuOK (5.0 eq.), 
0oC - rt, THF 
Starting material 
117 
2 TosMIC (3.0 eq.), 
tBuOK (10.0 eq.),   
slow addition of compound 117 
LCMS analysis showed 
traces of product (152) but 
no material obtained from 
purification 
3 TosMIC (1.0 eq.), LiHMDS (5.0 eq.),  
 slow addition of compound 117 
Complex mixture of 
products, no observation of 
152 
Table 10. Outline of conditions used in an attempt to synthesise pyrrole scaffold 152. 
 
The next scaffold of interest was the dihydroisoxazole 153 – 154. The reaction conditions 
selected for this synthesis were adapted from the chemistry performed by Mukaiyama and 
Hoshino.80 The procedure involved the reaction of phenyl isocyanate and nitroethane to 
generate a nitrile oxide 155 in situ, with the subsequent 1,3-dipolar cycloaddition affording the 
dihydroisoxazole scaffold 153 – 154 in 18% yield (Scheme 18), as a 2:1 mixture of cis-
isoxazolines with endo and exo stereochemistry. Due to the next synthetic step being an 
oxidation reaction, both stereoisomers would afford the same product, therefore no separation 
of compounds 153 – 154 was necessary.  
 
 
Scheme 18. A general scheme for the synthesis of the fused dihydroisoxazole compound 153 and 154. 
 
With the substrate 153 – 154 now in hand, oxidation was attempted to form isoxazole 156. 
Several attempts were made and success occurred when using the oxidation reagent DDQ in 
toluene for 2 hours in a low yield of 12%; the conditions are shown below (Table 11). 
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Entry Conditions Outcome 
1 DBU (4 eq.), I2 (1.2 eq), THF, reflux, 16 h. Starting material 
2 DDQ (1.2 eq.), PhMe, reflux, 16 h. Complex mixture 
3 p-chloranil (1.04 eq.), o-xylene reflux, 16 h. Complex mixture 
4 DDQ (2.0 eq.), PhMe, reflux, 2 h. 156, 12% 
Table 11. Outcome of oxidation reactions of dihydroisoxazole 153– 154 to form isoxazole compound 156. 
 
The same reaction conditions (Scheme 18) that were used to synthesise compounds 153 – 154 
(Scheme 19) were then repeated on substrates 116 and 134, with varying N-substituents. 
Dihydroisoxazole 157 was then oxidised to form the isoxazole fused scaffold 159 albeit in poor 
yield (Scheme 19). It was also envisaged that when compound 158 was exposed to cerium 
ammonium nitrate (CAN), the para-methoxybenzyl (PMB) group might be removed alongside 
the scaffold undergoing oxidation giving rise to the unprotected isoxazole 160. However, a 
complex mixture of products was observed and this route was deprioritised (Scheme 19). 
 
 
Scheme 19. A scheme to show the synthesis of scaffolds 157, 158 and 159 . 
Synthetic efforts were next focused on the pyrrolidine-fused compound 162 and 163, formed 
via an azomethine ylide [3+2] cycloaddition, where the best conditions found were those 
described by Fray et al (Table 12, entry 2 and 3).81  When acidic conditions for the ylide 
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generation were applied, the desired product was not obtained (Table 12, entry 1), presumably 
because of problems with the presence of a basic nitrogen. Consequently, basic conditions were 
used to successfully synthesise compound 162 and 163 in good yields.  
 
 
Entry R Conditions Outcome  
1 Bn Ylide precursor 161 (1.7 eq.),  
TFA (2.6 eq.), DCM, 0oC - rt 
Starting material 
2 Bn Ylide precursor 161  (1.1 eq.),  
LiF (1.2 eq.), MeCN, rt 
162, 63% 
3 Me Ylide precursor 161  (1.1 eq.),  
LiF (1.2 eq.), MeCN, rt 
163, 67% 
Table 12. Outcome of cycloaddition reactions involving enone 89, 115 and ylide 161 to form compound 162 and 163. 
 
The stereochemistry was assigned according to the 1H NMR spectra and NOESY data (Figure 
17). The predicted coupling constants of H matched those of the 1H NMR data, and the key 
NOESY interactions helped confirm the structures configuration. The key proton H was 
predicted to show no coupling with protons H and H, and this was confirmed with a singlet 
present in the NMR data. The structure hypothesis was later confirmed by the acquisition of a 
crystal structure of a decorated analogue from this substrate (Section 2.5.2). 
 
 
Figure 17. Stereochemistry assignment of compound 162 – 163. with measured J values.. 
 
The next substrate explored was compound 166, which involved the use of a 
trimethylenemethane ylide using conditions highlighted by Trost and Chan,82 however, the 
desired [3+2] cycloaddition was unsuccessful in both attempts, using the conditions 
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summarised below (Table 13). Only the Arbuzov product 167 was observed (with unknown 
stereochemistry), when P(OEt)3 was used as the ligand (Table 13, entry 1). When the active 
palladium source was changed, no reaction was observed and only starting material was 
recovered. Consequently, efforts towards this target were discontinued. 
 
 
Entry Conditions Outcome 
1  
Enone 89 (1.0 eq.), Pd(OAc)2 
(20 mol%), P(OEt)3 (1.1 eq.), 
ylide (1.86 eq.), 
THF reflux 
 
 
2 Enone 89 (1.0 eq.), Pd(PPh3)4 
(4 mol%), dppe (1.5 mol%), 
ylide (1.0 eq.), THF reflux 
Starting material, 89 
Table 13. Conditions used in attempt to synthesise compound 166. 
 
The final compounds targeted at this vector were the fused dihydropyrazole scaffolds 168 - 
169. The conditions were adapted from those detailed by Shi et al. 71  The [3+2] cycloaddition 
of ethyl diazoacetate followed by a tautomerisation gave the desired compounds in moderate 
to high yields (58 - 77%) (Scheme 20). 
 
 
Scheme 20. The synthesis of pyrazole 168 and 169  from a [3+2] cycloaddition reaction. 
 
The stereochemistry of the compound was determined by the comparison with a similar 
compound reported by Shi et al.71 The NOESY data was used to confirm the stereochemistry 
of the dihydropyrazole scaffold 168, with the key interactions shown on the cycloadduct 
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compound (Figure 18). To further verify the stereochemistry, a comparison of key interactions 
was undertaken with a similar literature compound.71  
 
Figure 18. Stereochemistry assignment for pyrazole 2.76. 
 
The dihydropyrazole compound 169 was then aromatised by an oxidation with CAN at 0 oC 
for 4 hours (Scheme 21). However, due to difficulties in the purification, the crude material 
was subsequently hydrolysed to form the pyrazole carboxylate 170 in an overall yield of 4%. 
It was concluded that a new route should be devised to the desired compound because of the 
extremely low yield.  
 
Scheme 21. The new synthetic route towards the synthesis of pyrazole carboxylate 2.78. 
An alternate route was attempted using a one-pot procedure method, where both the 
aromatisation and hydrolysis occurred in one step (Scheme 22). This route involved 
aromatisation (presumably by an aerobic oxidation) to synthesise the desired scaffold 170. 
Unfortunately, the reaction also proceeded in a low yield 14%.  
 
Scheme 22. The new synthetic route for pyrazole carboxylate 170. 
 
In total for the exploration of growth vectors at the 3- and 4- positions, 10 scaffolds were 
synthesised from 4 core scaffolds. The results provided evidence that the parent scaffolds 
showed promising reactivity at the enone position, where the scaffolds were synthesised with 
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good stereo/regio control. Further exploitation of the present functionality was to be explored 
to synthesise a library of diverse scaffolds for biological testing. 
 
2.3.2 Development of methods to enable exploration of growth vectors at the 2- 
and 3-positions 
 
Scheme 23. A general scheme depicting an annulation reaction at the 2- and 3-position 
Having achieved success with the functionalisation at the 3- and 4- positions, which in turn 
gave rise to a diverse set of scaffolds, the next vectors to be explored were at the 2- and 3- 
positions. A simple two-step route to an -halogenated substrate 172 was suggested, using 
readily available starting materials. It was envisioned that the -halogenated ketone 172 could 
be converted to a range of heterocycles 173 by applying Hantzsch-type syntheses (Scheme 
24).83 
 
 
Scheme 24. Step (i) palladium on carbon reduction, step (ii) alpha halogenation and step (iii) hantzsch synthesis. 
 
To enable -halogenation, reduction of the olefin was required which was achieved by 
following hydrogenation conditions detailed in the literature,73 shown below (Table 14). The 
reactions proceeded overnight at room temperature, giving the reduced tropanones in excellent 
yields of 89 - 99%. 
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Starting 
material 
R R’ Conditions Outcome 
89 Ph Bn H2, Pd/C 10mol%, rt, 16 
h 
MeOH/(Me)2CO 
174, 97% 
117 Me Bn H2, Pd/C 10mol%, rt, 16 
h 
MeOH 
175, 96% 
116 Me Me H2, Pd/C 10mol%, rt, 16 
h 
MeOH/(Me)2CO 
176, 96% 
114 NMe2 Me H2, Pd/C 10mol%, rt, 16 
h 
MeOH/(Me)2CO 
177, 89% 
Table 14 Outcome of reductions reactions involving palladium on carbon and hydrogen with the sulfonyl derivatives. 
However, when synthesising compound 175 on a larger scale, the reaction was left for 4 days 
and as a result underwent secondary reactions to produce alcohol 178 in quantitative yield. The 
expected compound was not present in the 1H NMR with evidence suggesting no benzyl group 
was present. The HRMS matched the proposed structure, where the benzyl-protected nitrogen 
had been deprotected and a reductive amination occurred with acetone. The observed 
compound was produced on a large scale with a free OH available for decoration and final 
library synthesis. It should be noted that the benzyl group remained intact in some cases, which 
can be deemed an issue when the free nitrogen is required for decoration.  
 
 
Scheme 25. A scheme for the formation of the unexpected compound 178. 
 
With step (i) achieved in high yields, -halogenation was attempted using a wide range of 
procedures. The conditions attempted are highlighted below, where the conditions used by a 
modified procedure from Jørgensen et al in 2004,84 gave the only route to the compound of 
interest (Table 15, entry 4 and 5). No attempt to assign stereochemistry was made and only a 
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single isomer was observed from inspection of 1H NMR spectra.  When the nitrogen substituent 
was a methyl group, the same conditions were repeated but only a complex mixture was 
observed. No product was seen in the LCMS and it was suggested that the nitrogen may be 
reacting with the -chloro substituent, resulting in a tricyclo-quaternary nitrogen, although no 
evidence for this was observed. 
 
 
Entry SO2R NR’ Conditions Outcome 
1 SO2Ph NBn p-TsOH (0.1 eq), NBS (1.2 eq.), 
DCM, 
0 oC – 40 oC 
Complex 
mixture 
2 SO2Ph NBn Amberlyst - 15, NBS (1.1 eq.), 
EtOAc, 
0 oC –  rt stir 
Starting 
material 174 
3 SO2Ph NBn Trichloroiscyanuric acid (1.0 
eq.), 
MeOH (2.0 eq.), DCM 
 
Starting 
material 174 
4 SO2Ph NBn Proline (30 mol%), NCS (2.0 
eq.), DCM 
179, 40% 
5 SO2Me NBn Proline (1.0 eq.), NCS (1.3 eq.), 
DCM 
180, 57% 
6 SO2Me NMe Proline (1.0 eq.), NCS (1.3 eq.), 
DCM 
Complex 
mixture 
Table 15 Outcome of -halogenation reactions involving tropanone 174 - 175. 
Upon synthesising -chloro compounds 179 and 180, a range of heterocyclic fused scaffolds 
were then planned, which would exploit the -haloketone functionality. Firstly, a Hantzsch 
thiazole synthesis was carried out using the conditions reported by Donohoe et al. in 2012 and 
the results are shown below (Table 16).83 
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Entry Starting 
material 
R Conditions R’ Outcome  
1 179 Ph 
 
(3.0 eq.) 
DMF (0.15 M) 
Ph 181, 20% 
 
2 180 Me 
  
(4.0 eq.),   
DMF (0.15 M) 
Me 182, 3%  
Table 16. Outcome of Hantzsch thiazole synthesis reactions involving -chloro compounds 181 sand 182  
 
-Haloketone 179 was treated with 2-aminopyridine 183 using the procedure of Chen et al.85 
in an attempt to prepare the annulation product aza-indole 184. Unfortunately, the desired 
product was not obtained and only starting material was observed (Scheme 26). Due to 
difficulties synthesising azaindole 184, this scaffold was deprioritised.  
 
 
Scheme 26. Scheme for the attempted annulation reaction to form azaindole 184. 
 
Tropanone compounds 174-177 were subjected to indole synthesis using conditions detailed 
by Chen et al.86 The conditions involved the reaction of the ketone with an o-iodoaniline under 
palladium catalysis. A series of indole annulated analogues were synthesised with different 
sulfonyl groups and nitrogen substituents, all in moderate to poor yields (Table 17).  
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Entry Starting 
material 
R R’ Conditions Outcome 
1 174 Ph Bn Ketone (1.0 eq.), o-
iodoaniline (1.2 eq.), 
DABCO (1.0 eq.), Pd(OAc)2 
(10 mol%), DMF, 105 oC 
186, 40 % 
 
2 177 NMe2 Me Ketone (1.0 eq.), o-
iodoaniline (3.0 eq.), 
DABCO (3.0 eq.), Pd(OAc)2 
(10 mol%), DMF, 105 oC 
187, 29% 
3 175 Me Bn Ketone (1.0 eq.), o-
iodoaniline(3.0 eq.), DABCO 
(3.0 eq.), Pd(OAc)2 (10 
mol%), DMF, 120 oC 
188, 20% 
4 176 Me Me  Ketone (1.0 eq.), o-
iodoaniline(3.0 eq.), DABCO 
(3.0 eq.), Pd(OAc)2 (10 
mol%), DMF, 120 oC 
189, 17% 
Table 17. Outcome of indole synthesis reactions involving tropanone 174 – 177.  
The classical Fischer indole synthesis was also used to synthesise the indole scaffold 186 in a 
40% yield and can be used as an alternative approach to synthesise the fused heterocycle 
(Scheme 27).87, 88,89 
 
Scheme 27. Fischer indole conditions used to synthesise compound 186. 
 
Another annulation reaction was investigated based on conditions detailed by Wu et al. in 
2001,69 with the hope of producing a fused pyrazole scaffold 192 (Scheme 28). However, when 
the tropanone 175 was treated with diethyl oxalate 191 and sodium ethoxide, only starting 
material was recovered. Consequently, the scaffold was deprioritised. 
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Scheme 28. The attempted annulation reaction to synthesise scaffold 192 . 
 
To further explore the vectors about the ketone, a procedure by Bai et al in 2017 was executed 
for the synthesis of the fused pyrimidine compounds 194 and 195 (Scheme 29a). 23 Under these 
reaction conditions, the core scaffold underwent an enolisation, followed by an acid mediated 
Diels-Alder and retro-Diels-Alder sequence. The reaction resulted in a loss of water and 
trifluoroacetonitrile, affording the desired pyrimidines in low to moderate yields. The key 
intermediates are shown below (Scheme 29b). 
 
 
 
Scheme 29a) The scheme for the formation of pyrimidine 194 and 195. b) key intermediates in the formation. 
 
Synthetic efforts were then focused on the pyridine-fused scaffolds 202 - 206. By using the 
conditions detailed by Rossi et al in 2003, the pyridine core was synthesised by a one-pot gold 
catalysed process. This proceeded through the sequential amination of the carbonyl compounds 
175 – 177 followed by a regioselective cyclisation of the N-propargylenamine intermediate and 
aromatisation. The mechanism is shown below (Table 18) where the desired compounds were 
formed in low to good yields (20-63%).  
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Entry Starting 
material 
R  R’ R3 Outcome 
1 175 Me Bn H 202, 63% 
2 176 Me Me H 203, 43% 
3 177 NMe2 Me H 204, 40% 
4 176 Me Me Ph 205, 20% 
Table 18. Outcome of synthesis of pyridine scaffold derivatives. Above shows the key mechanistic steps and scheme. 
 
It was envisaged that by applying metal-catalysed reduction conditions to the pyridine scaffold 
203, another point of diversification would be introduced at the free NH of the piperidine 206. 
However, when attempting to isolate the piperidine 206, no product was obtained and only a 
complex mixture was observed. An alternative set of conditions were applied using a different 
catalyst, high pressure and temperature, and even these harsh conditions only resulted in 
starting material (Table 19).  
 
 
 
Entry Conditions Outcome 
1 PtO2 (20 mol%), H2, AcOH, 16 h Complex mixture 
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2 Pd/C, 10 bar, 50 oC, H2, 16 h Starting material 203 
recovered 
Table 19. Outcome of the conditions used in attempt to synthesise piperidine 206. 
 
2.3.3 Development of methods to enable exploration of growth vectors at the 4-
position  
Positon 4 was the next position of investigation, where known chemistry within the Marsden 
and Nelson group was used to introduce diversity to another point of the sulfone cycloadduct. 
A Rh(I)-catalysed conjugate addition of phenylboronic acid was used to add a phenyl group to 
the 4-position, by using conditions adapted from those detailed by Miyaura et al.90 The 
conditions were optimised upon scale up, however, modest yields were still observed as shown 
below (Table 20). Nevertheless, this would allow the 4-position to be diversified with a range 
of arylboronic acids.  
  
 
Entry mmol [Rh] 
eq. 
NEt3 
eq. 
PhB(OH)2 eq. Temp. 
(oC) 
Time Yield 
1 0.57 1 mol% 1.0 1.5 50 16 h 38% 
2 1.41 1 mol% 1.0 3.0 90 3 d 40% 
3 4.10 1 mol% 1.0 3.0 90 16 h 28% 
Table 20. Outcome of 1,4-addition reactions involving parent scaffold 89 
 
The last scaffold to be synthesised in this vector series was the tetracyclic scaffold 208 and 
209. Exposing the aryl bromide 135 and 137 to a range of Heck conditions, the novel 
compounds 208 and 209 were ultimately synthesised in poor yields (12- 24%) by following a 
literature procedure by Grigg et al (Table 21).91  
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Entry R R’ Conditions Outcome 
 
1 Ph H Pd(OAc)2  (20 mol%), PPh3 
(20 mol%), NEt3 (2.0 eq.), 
THF,  reflux 
 
Starting 
material 
135 
2 Ph H Pd(PPh3)4 (20 mol%), NEt3 
(2.0 eq.), THF, reflux 
 
Starting 
material 
135 
3 Ph H Pd(OAc)2 (10 mol%), PPh3 
(20 mol%), HCOONa 
(1.5 eq.), ZnCl2 (1.0 eq.), 
PhMe, reflux 
 
208, 24% 
4 Me F Pd(OAc)2 (10 mol%), PPh3 
(20 mol%), HCOONa 
(1.5 eq.), ZnCl2 (1.0 eq.), 
PhMe, reflux 
 
209, 12% 
Table 21. Outcome of intramolecular 1,4-addition reactions involving parent scaffold derivatives 135 and 137. 
To further elaborate the library, the carbonyl was reduced to the alcohol using DIBAL at 
 -78 oC, yielding only one diastereoisomer as observed via 1H NMR (Scheme 30). The desired 
scaffold 210 now had a free hydroxyl group for decoration, where a range of medicinally-
relevant capping groups could potentially be reacted to produce an array of screening 
compounds. The relative stereochemistry was predicted by analogy with to similar compounds 
synthesised (Comparison to a crystal structure (Section 2.5.2)). 
  
Scheme 30. The formation of alcohol 210 derived from tetracyclic scaffold 208. 
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2.3.4 Development of methods to enable exploration of growth vectors at the 3-
position 
 
Diversification at the 3-position was investigated by using the conditions detailed by Shi et al. 
in 2012, proceeding through a Baylis-Hillman reaction (Scheme 31).71 The reaction gave rise 
to primary alcohol 212 in moderate yield, with the alkene left available for further scaffold 
synthesis (e.g. annulation) and a primary alcohol to diversify. 
 
Scheme 31. The conditions used for the Baylis-Hillman reaction to synthesise compound 212. 
 
2.3.5 Development of methods to enable exploration of growth vectors at the 2-
position 
In an attempt to introduce diversity at the 2-position of cycloadduct 89, nucleophilic addition 
of a methyl group to the ketone was attempted (Scheme 32). The conditions using 
methyllithium were taken from within the group due to success with similar tropane scaffolds, 
however, the desired addition into the carbonyl at C-2 did not occur. Instead, the methyllithium 
apparently acted as a base, effecting deprotonation alpha to the sulfone followed by an 
intramolecular Michael addition into the enone afforded the cyclopropane exclusively in 20% 
yield. Analysis by LC-MS showed the correct mass, with the 1H-NMR spectrum showing the 
absence of the starting material alkene protons. The proposed mechanism is shown below 
(Scheme 32). 
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Scheme 32. The general scheme of the synthesis of cyclopropane 213 and its mechanism of formation. 
 
This unexpected reaction was intriguing and it also gave rise to a novel scaffold with potential 
points for further diversity. It was found that switching the base to the non-nucleophilic 
LiHMDS gave a higher selectivity for the cyclopropane 213, affording the desired compound 
in a 60% yield. However, when changing the R group of the sulfone, no analogous compounds 
were synthesised. The summary is shown below (Table 22). It was proposed that for entry 1, 
the deprotonation of the methyl sulfone was competing with the deprotonation of the proton 
adjacent to the sulfone, and a complex mixture was observed. When the reaction in entry 2 was 
attempted, a side product 219 occurred from dimerization of the starting material, which was 
confirmed by 1H-NMR and LCMS analysis.  In an attempt to solve this problem, a lower 
concentration of solvent was used to decrease the reaction rate (Table 22, entry 3), however, 
only starting material was observed. To our surprise, when the nitrogen substituent was 
changed to a methyl, no reaction occurred and only starting material was recovered.  
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Entry Starting 
material 
NR’ R Conditions Outcome 
1 117 NBn SO2Me THF (0.02M),  
3 h 
 
Complex mixture 
2 133 NBn 
 
THF (0.2M), 3 
h 
 
 
219 
3 133 NBn 
 
THF (0.02M),  
3 h 
dropwise 
addition of 133 
 
Starting material 
133 
4 115 NMe SO2Ph THF (0.02M),  
3 h 
dropwise 
addition of 115 
Starting material 
115 
 
Table 22. Outcome of the attempted conditions to synthesise cyclopropane derivatives. 
 
It was proposed that cyclopropane 213 was potentially unstable due to its ability to undergo a 
retro-Michael reaction. Three compounds were therefore proposed that eradicated the ketone 
functionality to remove this possibility (Scheme 33). The three reactions followed previous 
procedures but unfortunately were all unsuccessful, rendering this compound problematic and 
therefore it was to be deprioritised as a screening library set.  
 56 
 
Scheme 33. A scheme showing the routes to three compounds using previously described procedures. 
 
To accomplish the desired methyl addition at the 2-position, an alternative approach was 
undertaken using methylmagnesium iodide. Due to the less basic nature of the Grignard reagent 
the decorated product was obtained in a 52% yield with no trace of the cyclopropane-containing 
compound. A mixture of diastereoisomers were obtained in a 3:2 ratio, however no attempt 
was made to isolate the isomers. The relative stereochemistry of the major diastereomer was 
not determined due to the complexity of the crude 1H-NMR (Scheme 34).  
 
Scheme 34. A general scheme for the formation of compound 2.126 from a Grignard addition. 
 
Subsequent efforts to introduce different groups at the 2-position included a reductive 
amination, using the conditions detailed by Bhattacharyya et al.92 Compound 174 was 
susceptible to 1,4 addition, so the partially reduced substrate was used instead. The tropanone 
174 was treated with N-methylbenzylamine and titanium isopropoxide in ethanol at room 
temperature for 6 hours, then cooled to 0 oC and reduced via sodium borohydride. The reaction 
produced a separable 2:1 mixture of diastereomers, which was assigned according to the crude 
1H NMR in 52% yield. The stereochemistry of the two isomers was assigned according to key 
NOESY interactions (Scheme 35). 
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Scheme 35. A scheme for the synthesis of compound 223 and 224, with their stereochemistry assignment. 
 
 
2.3.6 Development of methods to enable exploration of growth vectors at the 6-
position 
2.3.6.1 Oxidative desulfonylation  
 
Two methods were proposed to lower the heavy atom count of the parent cycloadduct 89. The 
first was to change the sulfonyl substituent, which could be achieved by using smaller sulfonyl 
substituents on the dipolarophile in the cycloaddition (see Table 8, Section 2.2.2). However, a 
more challenging approach would be to change the functional group entirely, thereby also 
increasing the diversity. The proposed functional group interconversion was from a sulfone to 
a ketone, which in turn would also offer an extra vector to explore. This change would help 
further demonstrate the scaffold’s potential to be diversified at numerous positions, and would 
dramatically decrease the heavy atom count from 25 to 10 (Figure 19a, compounds 89 and 
225). This would allow the pursuit of a potential fragment library for testing. Also, the desired 
compound 89 would possess a similar core to the known natural products alstoniaphylline A 
and B (Figure 19b, compounds 226 - 227). 
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Figure 19a). The parent scaffold 89 and the planned smaller derivative compound 225. b) Two natural products 226 – 227 
which share similar framework to compound 89.. 
 
To further functionalise at the 6-position it was proposed that the functional group 
interconversion would occur through an oxidative desulfonylation.93-94 The suggested route 
was a four-step, three-pot synthesis involving a Luche reduction and an alcohol protecting step, 
therefore avoiding the complications from the reactive enone functionality. The final step 
involved the key oxidative desulfonylation step (Scheme 36).95 
 
Scheme 36 Step (i) Luche reduction, step (ii) alcohol protection and step (iii & iv) oxidative desulfonylation. 
 
A Luche reduction96 using cerium (III) chloride, sodium borohydride and methanol at -78 oC, 
with the parent cycloadduct 89 proceeded in an 80% yield and afforded the desired alcohol 228 
as an inseparable 3.5:1 mixture of stereoisomers. The major isomer was assigned according to 
key NOESY interactions (Scheme 37) 
 
  
Scheme 37. The Luche reduction conditions  and the stereochemistry assignment of compound 228. 
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Attempts were then made to protect the alcohol. First, tert-butyldiphenylsilyl (TBDPS) 
protection was trialled, however no desired product was obtained after two conditions were 
applied. It was proposed that this was due to steric interactions between the bulky OTBDPS 
group and the N-benzyl group, or the reactivity of the silyl electrophile. A third attempt 
involved tert-butyldimethylsilyl (TBS) protection via the silyl triflate, and silyl ether 232 – 233 
was obtained in a high 82% yield (Table 23). 
 
 
Entry Conditions Outcome (product) 
1 TBDPS-Cl (1.1 eq.), 
imdiazole (2.2 eq.), DMF 
(0.4 M), rt, 6h 
 
Starting material, 228 
2 TBDPS-Cl (1.1 eq.), 
imdiazole (2.2 eq.), DMF (4 
M), rt, 6h 
 
Starting material, 228 
3 TBS-OTf (1.1 eq.), 
imidazole (2.0 eq.), DMF 
(0.7 M), 0 oC – rt, 6h 
 
82% (232, 233) 
(3.5:1 mixture of isomers) 
Table 23. Outcome of the conditions used to synthesise a protected alcohol 232 and 233. 
 
The next aim was to successfully remove the phenylsulfonyl functional group using a method 
described by Tsuchihashi et al.94,95 The method involves a formal oxidation of the sulfone-
bearing carbon by lithiation and electrophilic sulfenylation then hydrolysis of the 
sulfenylsulfone. The intermediate -sulfenylsulfone 234 was observed by LC-MS analysis, but 
not isolated and the intermediate was subjected to two sets of conditions (Scheme 38). On first 
attempt, the crude product was refluxed in acid with Methanol and the only product observed 
by LC-MS analysis was the deprotected intermediate 235. Step (iv) was reattempted with 
dioxane as solvent, giving the desulfonylated compound 236 in a 98% yield (over two steps). 
The reaction mixture was able to be heated at reflux at high temperatures which not only 
enabled the desulfonylation, but also removal of the TBS group to afford the keto alcohol 236 
(Scheme 38). 
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Scheme 38. A scheme showing the two attempts of the oxidative desulfonylation step. Attempt 1 was unsuccessful and attempt 
2 was successful.  
The stereochemistry of compound 236 was assigned according to the 1H NMR spectra data, 
using the software Avogadro (Figure 20). The key proton H was predicted to show only 
coupling to proton H, where a doublet was observed. No coupling interaction was seen between 
H and H. 
 
Figure 20. The predicted coupling constants for both possible isomers of the desulfonylation product 2.141. 
 
An alternative route was suggested to a different desulfonylation product. It was proposed this 
route would avoid the product loss through the mixtures of diastereomers, which occurred 
using the route above (Table 23). It was envisaged that when reducing the ketone in the absence 
of the double bond, a single diastereomer would be produced, as this is a known product in the 
literature.97 When tropanone 174 was subjected to the reduction using DIBAL, the intermediate 
product was formed as a single diastereomer. The crude alcohol was protected with a silyl ether 
TBS protecting group and the desulfonylation conditions were applied. The desired product 
was achieved in an 82% yield. When comparing to the previous route, product 238 was 
obtained in a 76% yield over three steps, therefore the new route was more efficient and higher 
yielding. The alcohol stereochemistry was already determined in the first step by comparison 
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to known compounds and similar compounds in the literature.98,99 The major isomer is 
predominantly syn stereochemistry to the bridgehead nitrogen. 
 
Scheme 39. A scheme showing the new efficient route to a desulfonylated compound 238.  
2.3.7 Ring expansion 
 
To introduce more diversity to the lead-like scaffold set, ring expansion reactions were to be 
undertaken to synthesise 8-membered rings. The Beckman rearrangement was first 
investigated, where conditions to synthesise the desired scaffolds are shown below (
 
Scheme 40). Tropanone compounds 174 – 175 was first subjected to hydroxylamine to 
synthesise the oxime, which was then treated with tosyl chloride. In both cases the intermediate 
O-sulfonyl oxime 241 was observed by the LCMS. When acid was added the reaction was not 
successful. There were no traces detected by LCMS analysis, nor any product isolated upon 
purification. Due to time constraints, this scaffold was discontinued.  
 
Scheme 40. The attempted Beckman rearrangement on scaffolds 174 and 175. 
Having achieved no success with the above ring expansion, an alternative 8-membered scaffold 
was suggested. A two-step route via a fused cyclopropane 242 was proposed, using readily 
available starting materials. It was envisioned that the strained cyclopropane system would be 
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a pivotal intermediate that guides the ensuing reaction towards ring expansion.100 With the aid 
of palladium on carbon under a hydrogen atmosphere, a larger ring structure could be obtained.  
 
Scheme 41. The new proposed route to a novel ring expanded scaffold. Step (i) cyclopropanation and step(ii) reduction. 
A Corey-Chaykovsky reaction was carried out in an attempt to synthesise the desired scaffold 
242, with the reaction conditions shown below (Scheme 42).101,102 First a sulfur ylide is 
synthesised in-situ, following a 1,4-addition reaction and subsequent ring closure to produce 
the scaffold 242 as a single diastereomer.  
 
Scheme 42. The conditions used to synthesise the fused cyclopropane scaffold 242. 
 
The stereochemical assignment is shown below (Figure 21): proton Hb has no coupling 
between adjacent protons, therefore a singlet is only observed in the 1H NMR spectra. 
 
 
 
Figure 21. Shows the predicted coupling constants for each isomer and the proton NMR spectra 
 
With step (i) achieved in a moderate yield, the next step was to expand the ring system. When 
using palladium on carbon under hydrogen, no product was observed and, only the starting 
material was detected via LCMS analysis and this scaffold was deprioritised. Alternative routes 
would consist of SmI2-induced ring expansion reactions and radical expansion using AIBN and 
tributyltin hydride.103,104 
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Scheme 43. The reaction conditions attempted to break open the fused cyclopropane 242. 
2.4 Summary of lead-like scaffold synthesis 
 
In summary, 14 lead-like scaffolds were synthesised in a total of 24 steps from a single parent 
core scaffold 89.  This efficient process has demonstrated the feasibility of the top-down 
approach to LOS, where the chosen parent scaffold 89 was ideal for this approach. It should be 
noted that the sulfonyl group was initially chosen as a substituent that may be removed from 
the scaffolds. Even though this has proven possible with the oxidative desulfonylation reaction 
(Scheme 39), it suffered from a long synthetic sequence and this would be a synthetic challenge 
to undertake for every scaffold. Therefore, it was decided in the interests of efficiency that this 
substituent will remain in most lead-like and final compounds. Other sulfonyl groups were 
chosen to introduce diversity to the scaffold set, however again because of the lengthy process 
it was only attempted in a small number of compounds. Due to time constraints, the ring 
expansion chemistry was not explored thoroughly and there remain several reactivity pathways 
which could still be investigated to prepare new scaffolds. Nevertheless, the 14 lead-like 
scaffolds that were prepared were enough to complete the first objective. 
 
A summary of each scaffold is shown below (Figure 22). As explained previously (Section 
1.4), it was important that these scaffolds possessed certain properties in order to be good 
starting points in drug discovery. Prior to any laboratory work each scaffold was analysed for 
their molecular properties and a selection of particular scaffolds was done following a set of 
key criteria (c.f. Table 2). However, it was still necessary to analyse and compare each 
successfully synthesised scaffold using computationally analysis.  
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Figure 22. The collection of novel lead-like scaffolds produced from parent scaffold core 138. (colour coded according to 
step count) 
2.5 Computational assessment of the of lead-like scaffolds prepared  
2.5.1 Lead-likeness assessment of lead-like scaffolds 
 
To assess the scaffolds’ molecular weight and lipophilicity, the in-house open-access tool 
LLAMA was used.45 The properties of the 14 lead-like scaffolds were calculated and plotted 
on a scatter graph (Figure 23). In some cases,** the benzyl group was removed to minimalize 
molecular weight. Each compound was plotted against lipophilicity (AlogP) and molecular 
weight (mw), leading to 93% of the compounds occupying lead-like chemical space. 
Compound 248 fell just outside lead-like space, due to its larger molecular weight. To avoid 
this and reduce molecular weight, different dipolarophiles could be used in the cycloaddition, 
which could access the pyrimidine scaffold with a lower molecular weight or alternatively the 
sulfone could be removed.  Compound 178 had a lead-like penalty of 2 because of the absence 
of aromatic groups, where the other compounds all had a penalty of 0. The penalty is a measure 
of how far outside lead-like space a compound lies and the properties of which they are 
assessed against are shown in Table 2 in Section 1.4. The properties include heavy atom count, 
AlogP, number of aromatic rings and undesirable functional group filter, where the score is 
obtained from a sum of each penalty incurred. 
 
** Compounds marked with a ‘*’ in Figure 22. 
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Figure 23. The lipophilic and molecular weight assessment of the 14 lead-like scaffolds. Coloured according to lead-like 
penalty 
 
2.5.2 Fraction of sp3 hybridised carbon assessment of lead-like scaffolds 
 
As discussed in Section 1.4, studies have found that compounds with a higher Fsp3 value (and 
presence of chiral centres) have a better chance of succeeding through subsequent stages of 
drug discovery.24 To assess each scaffolds’ fraction of sp3 hybridised carbons, the software 
LLAMA was used to calculate each value and the results are plotted below (Figure 24).45 Each 
scaffolds value was analysed and compared with a random 1% of the ZINC database. The 
analysis of lead-like scaffolds showed that 93% of the library have a larger Fsp3 value, therefore 
achieving one of the objectives proposed. Compound 178 has a high Fsp3 score due to the 
compound consisting of only sp3 carbons. However, compound 249 has a low score, as it 
contains very few sp3 carbons and contains ‘flat’ sp2–rich groups, such as a fused pyrrole and 
a phenyl substituent. The four acyclic precursors used to synthesise the parent scaffolds have 
an average Fsp3 value of 0.14, showing a 4-fold increase when compared to the average 
scaffold value. It should also be noted that each compound has the presence of at least three 
chiral centres.   
Mw (Da) 
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Figure 24. A Fsp3 value comparison of lead-like scaffolds (average in green), average ZINC database(in red) and average 
acyclic precursor (in yellow). 
 
2.5.3 Three-dimensionality assessment of lead-like scaffolds 
To assess the lead-like scaffolds’ three-dimensional shape, each compound was plotted on a 
PMI plot using LLAMA (Figure 25).45 The lowest energy conformer for each compound was 
generated computationally and the system calculates the moments of inertia in the x, y and z 
axes. The system then calculates two plot coordinates (I1 and I2) by dividing inertia (x) and 
inertia (y) by inertia (z). Each two coordinates are plotted on a triangular scatter diagram to 
assess three-dimensionality, where each of the three vertices of the triangular plot represent the 
extremes of molecular geometry, as discussed in Section 1.4 (Figure 3). For comparison, a 
random 1% of the ZINC database was also plotted. As seen below, the scaffolds are now 
starting to move away from the heavily located area of chemical space (the ‘rod-like’ / ‘disc-
like’ area), and starting to populate the more unexplored area ‘sphere-like’ chemical space.  
Compound 239 (Figure 25, A) was located in the heavily explored region of chemical space 
due to the presence of the benzyl protecting group. However, due to the small nature of this 
compound the unprotected scaffold would lie outside lead-like chemical space, therefore this 
group was not removed. Nevertheless, if the methylated analogue was synthesised this would 
locate the compound in a more ‘sphere-like’ area of space (Figure 25, G) 
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Figure 25. PMI plot of lead-like scaffolds plotted in blue and random 1% of ZINC database compounds plotted in green.  
 
2.5.4 Diversity assessment of lead-like scaffolds 
To assess the diversity of the library, each compound’s framework was analysed. The method 
used was inspired by Waldmann’s ‘scaffold tree’ hierarchical analysis technique.66 The process 
involved ‘stripping’ away substituents, leaving the core-framework. Each core-framework was 
then analysed against a random 2% of the ZINC database using LLAMA. Frameworks 257 and 
254 had structures which were embedded as a substructure; this was expected for compound 
257 as the tropane-like moiety is frequently observed in many natural products. Framework 
254 only compared to 4 compounds in a possible ~180,000 compounds in the database. 
Therefore, in conclusion, these lead-like scaffolds possessed novel frameworks and 
experienced a diverse nature (which this strategy hoped to achieve). It should also be noted 
that a structure search in the literature was also performed for each scaffold to confirm their 
novelty.  
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Figure 26. Skeletal diversity assessment of lead-like scaffolds. The outer circle signifies synthesised scaffolds, where the inside 
circle displays the core-frameworks analysed against the ZINC database. 
 
 
With a total of 14 novel diverse lead-like scaffolds synthesised from one parent core scaffold, 
the second objective was now complete. These results set up the third objective well, where 
compounds which had been synthesised on a large scale can be decorated with medically 
relevant capping groups. A final library could be assembled for screening against a wide range 
of biological targets. 
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3.0 Results and discussion 2: decorating lead-like scaffolds 
for final library synthesis  
 
With a variety of scaffolds synthesised our third objective was to synthesise a compound library 
from each scaffold. This involved firstly synthesising each scaffold on a large scale in good 
yield, then changing functionality and finally decorating with medicinally relevant capping 
groups. 
In each case a change of functionality may occur: 
• If a carbonyl is present - reduce to a single diastereoisomer of the corresponding alcohol 
• If a protecting group is present - deprotect 
• If undesirable functionality is present - change functional group (e.g. ester to amide) 
 
Scheme 44 An example synthesis of a final decorated compound from parent scaffold 89. 
3.1.1. Manipulation of different scaffolds by a 1,4-addition  
The first scaffold selected for the library synthesis was the scaffold 207 that was produced 
from a 1,4-addition of an aryl boronic acid. A simple route was proposed involving the 
scaffold synthesis (step i), a deprotection if required (step ii) and finally a diastereoselective 
ketone reduction (step iii) (Scheme 45).  
 
 
Scheme 45.  Step (i) scaffold synthesis, step (ii) reduction, step (iii) deprotection, step (iv) reduction. 
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The initial step of the proposed route was a rhodium catalysed 1,4-conjugate addition with a 
range of arylboronic acids. In order to synthesise a diverse range of compounds for screening, 
the arylboronic acids selected ranged from electron-poor to electron-rich. The results are shown 
below (Scheme 46). Unfortunately, the more polar heterocyclic boronic acids (compounds 277 
and 278) were not successful, as no product was observed. While reactions with aryl and 
alkenylboronic acids are well-documented, there are few examples of heteroaryl residues.105 
The addition of the 4-fluorophenyl group however looked promising and the products 274 and 
275 were synthesised on a large scale (11.7 – 13.4 mmol). 
 
________________________________________________________________ 
 
Scheme 46. A scheme showing the general route to scaffolds 246, 262-277 and the derivatives synthesised. 
The next step in the synthesis was the diastereoselective reduction of the ketone. When 
compound 273 was reduced with sodium borohydride at 0 oC, an inseparable 1:1 mixture of 
diastereomers was obtained. Even upon decoration, in most cases the compounds remained a 
mixture of inseparable diastereoisomers after purification. To alleviate this problem compound 
273 was screened with a range of reducing agents in attempt to improve the diastereomeric 
ratio (d/r). The summary is shown below (Table 24). The conditions that generated the best 
selectivity were DIBAL at -78 oC in DCM. The diastereomeric ratio obtained was 3:1, which 
was determined by distinct proton integration ratios in the 1H NMR spectrum. 
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Entry Conditions Temp d/r 
1 NaBH4 (2.0 eq.), MeOH 0 
oC 1:1 
2 DIBAL (1M in cyclohexane) (3.0 eq.), DCM 
(278a, 71%) 
-78 oC 3:1 
3 DIBAL (1M in cyclohexane)  (3.0 eq.), THF -78 oC 3:2 
4 L-selectride (3.0 eq.), THF -78 oC 3:1 
5 LiAlH(OtBu)3 (3.0 eq.), THF -78 
oC 5:2 
Table 24. Outcome of reduction reactions involving the 1,4-addition product 273..  
The major isomer 278a was isolated via crystallisation from ethanol. A crystal structure was 
obtained to confirm the relative stereochemistry, where the alcohol and the para-fluorophenyl 
group display a syn-relationship to the sulfone and bridged nitrogen (Figure 27). 
 
Figure 27. Left - A crystal structure of compound 278a and right – compound 278a structure. 
 
 
In cases where the benzyl group was present, a deprotection was performed before the 
reduction step. The conditions used were those detailed below using palladium hydroxide on 
carbon as catalyst and pleasingly the desired product 279 was obtained in 67% yield. However, 
 
 Yield for the isolated major isomer. 
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a side product, dimethyl acetal 280, was also formed by a competing acid catalysed 
acetalisation reaction (Scheme 47). 
 
Scheme 47. A scheme showing the synthesis of deprotected 279 and side product 280. 
To alleviate this problem an alternative route was suggested. Instead, the compound was 
reduced prior to deprotection using the optimised reduction conditions. The major isomer 281 
of the alcohol was synthesised in an excellent yield of 85%. The deprotection of the benzyl 
group afforded the desired compound 282 in an 87% yield (Scheme 48). The acquired X-ray 
crystal structure revealed the same relative stereochemistry as for the N-methyl derivative. 
 
 
Scheme 48. A general scheme to compound 281 and the crystal structure of 281 with its structure. 
 
The para-fluorophenyl compounds 279a and 282 were then decorated with a range of 
medicinally-relevant capping groups and purified using a mass directed automated purification 
(MDAP) system. All the successful products were obtained in poor yields due to either 
problems with the MDAP system or due to issues with separating the diastereoisomers. The 
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results are shown below where 9 diverse novel compounds were synthesised ready for 
biological screening (Figure 28). All successful and failed reaction conditions can be seen in 
Appendix 6.1.1. 
 
Figure 28. A figure showing the 1,4-addition series of final compounds for screening. 
 
3.1.2 Manipulation of the pyrrolidine scaffold 
 
The next scaffold selected for library synthesis was the pyrrolidine series. The proposed route 
was a three-step synthesis involving preparation of the pyrrolidine scaffold (step i), a 
diastereoselective ketone reduction (step ii) and deprotection of the benzyl group (step iii). It 
was envisioned that once deprotected, the free NH could be decorated with a range of capping 
groups (Scheme 49). 
 
 74 
 
Scheme 49.  Step (i) Pyrollidine synthesis, (ii) Steroselective reduction of the ketone, (iii) Debenzlyation, then decoration with 
capping groups 
 
The first step of the proposed route was the synthesis of the pyrrolidine. It was hypothesised 
that this core scaffold could be synthesised by two sets of conditions, resulting in the nitrogen 
substituent being either a methyl or a benzyl group. The core scaffold could then contain either 
a fixed N-methyl group or a ‘removable’ group which could unmask a decoration position. 
Both conditions form an azomethine ylide in situ and the pyrrolidine is formed via a subsequent 
[3+2] cycloaddition. Method 1 forms an azomethine ylide by decarboxylative condensation of 
paraformaldehyde and sarcosine 298 and method 2 forms the ylide via compound 161 and LiF 
(Scheme 50).81,106 However, due to the polar nature of the compounds there was issues with 
the purification. Therefore, the N-methyl pyrrolidine scaffold was deprioritised and a range of 
N-benzyl substituted derivatives were synthesised on a large scale in good to excellent yields. 
 
 
 
____________________________________________________________________ 
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Scheme 50. a) The two routes to synthesise the fused pyrroldiine scaffolds 295 – 297, 288 – 301.  b) The results. 
 
With the pyrrolidine derivatives in hand, diastereoselective reduction using a range of reducing 
agents and conditions was attempted (Table 25). The d/r was determined by ratios of distinct 
protons in the 1H NMR spectrum and the best d/r was obtained when using the reducing agent 
DIBAL in THF at -78 oC. The best d/r’s were obtained from bulkier reducing agents and when 
the R group of the nitrogen bridgehead was a benzyl group (Table 25, entry 1, 3-4). The 
stereochemistry was later confirmed by the acquisition of a crystal structure of the decorated 
analogue 310 (Figure 29).  
 
Entry Conditions R Outcome 
1 DIBAL (1M cyclohexane), 
DCM (0.08M),  
-78 oC - rt, 16h 
 
Bn 
d/r -3:1, Single 
isomer isolated after purification,  
302, 57% 
2 DIBAL (1M cyclohexane), 
THF (0.08M), -78 oC - rt, 16h 
Me d/r - 3:2, Inseparable isomers  
303 (not isolated) 
3 DIBAL (1M cyclohexane), 
(3.0 eq.), 
para- 
fluorobenzyl 
d/r – 3:1 
 
 Yield for the isolated major isomer. 
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DCM (0.08M), -78 oC- rt, 16 h 304, 50% 
4 DIBAL (1M cyclohexane), 
THF (0.08M),  
-78 oC- rt, 16 h 
para- 
fluorobenzyl 
d/r – 4:1, 
Single isomer obtained  
304 
5 NaBH4,  
-78 oC - rt,  
MeOH, 16 h 
para- 
fluorobenzyl 
d/r – 1:1 
Inseparable isomers 
304 
6 CeCl3.7H2O,  
NaBH4, MeOH 
-78 oC –rt, 16 h 
para- 
fluorobenzyl 
d/r – 1:1 
Inseparable isomers 
304 
Table 25. Outcome of reduction reactions involving of the pyrollidine scaffolds 299 – 301. 
With step 2 of the synthesis complete, the debenzylation of both the bridged nitrogen and the 
pyrrolidine nitrogen was attempted. It was found that the bridged nitrogen could not to be 
deprotected with the conditions used and therefore the scaffold could not be decorated with 
capping groups at this position. However, the benzyl group on the pyrrolidine was removed 
using palladium(II) hydroxide in MeOH under hydrogen, affording a position for decoration 
(Table 26). Again, due to issues with polarity, (entry 3, Table 26), compound 307 was not 
isolated and instead telescoped through to the next step. 
 
 
Entry Conditions NR Outcome 
1 Pd(OH)2/C, H2, MeOH, 
conc.HCl (0.02 eq.) 
Bn  305 (92%) 
2 Pd(OH)2/C, H2, MeOH, 
 
para-fluorobenzyl 306 (92%) 
3 Pd(OH)2/C, H2, MeOH, Me 307, Not isolated 
Table 26. Outcome of deprotection conditions involving scaffolds 302 – 304. 
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With the third step of the scaffold synthesis achieved, the next aim was to decorate at the 
nitrogen of the pyrrolidine with a range of capping groups. The results are shown below where 
five diverse, novel compounds were synthesised (Scheme 51). A range of chemical reactions 
were performed at the free nitrogen, including amide synthesis, sulfonamide synthesis, 
reductive amination and urea formation All successful and failed reaction conditions can be 
seen in Appendix 6.1.2. 
 
________________________________________________________ 
 
 
Scheme 51. A general scheme for decoration and the resulting screening compounds. 
 
To confirm the stereochemistry of this series of compounds, a crystal structure was obtained 
of the decorated final compound 310 (Figure 29A). To our surprise, the alcohol substituent 
had the opposite configuration to the predicted structure, as the bulky reducing agent was 
expected to attack on the opposite face to the pyrrolidine ring. It was therefore postulated that 
there was a coordination between the pyrrolidine nitrogen atom and the aluminium, 
consequently delivering the hydride to the more hindered face (Figure 29B). 
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A)  
 
    
 
 
Figure 29.A) A figure showing the crystal structure and its related compound 2.187. B) The proposed coordination of DIBAL 
and compound 2.187. 
 
3.1.3 Manipulation of the alcohol scaffold 178 
 
As described in Section 2.3.2, when attempting to reduce the double bond of the enone, alcohol 
179 was synthesised in quantitative yield on a large scale. With the free hydroxyl group being 
available for decoration, the key scaffold was subjected to a range of medicinally relevent 
capping groups. Seven final compounds were obtained from the decoration process, with each 
compound shown below (Scheme 52). The conditions for each reaction are shown in the 
Appendix 6.1.3.  
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Scheme 52. A scheme showing the seven final screening compounds synthesised from decoration of alcohol 178. 
 
3.1.4 Manipulation of secondary amine 324 
The next scaffold selected for library synthesis was the tertiary amine series. The proposed 
route was a three-step synthesis: (step i) reduction, (step ii) diastereoselective reductive 
amination and (step iii) decoration (Scheme 53). 
 
 
Scheme 53. A general scheme to synthesise some decorated screening compounds. Step(i) enone reduction, step(ii) reductive 
amination, step (iii) decoration. 
 
 
The initial step was performed in quantitative yield as explained previously in Section 2.3.2 
(Table 14). The scaffold-synthesising step was performed using conditions detailed earlier 
(Section 2.3.5), where the nucleophile methylamine was used. The reductive amination with 
methylamine was successful where compound 324 was synthesised with high levels of 
selectivity, with only one isomer being produced in a 41% yield. This afforded a point of 
diversification at the NH for library synthesis. Due to the difficulties with ammonia causing a 
complex mixture, this nucleophile was deprioritised.  The stereochemistry was determined by 
comparison with similar compounds in the literature, where the amine shows a syn-relationship 
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to the bridged nitrogen and the sulfone group.107 When the nitrogen substituent was benzyl 
protected, a mix of inseparable isomers was formed, so compound 325 was discontinued. 
 
Scheme 54 A scheme for the synthesis of a secondary amine 324, and conditions in attempt to make compound 323 and 325. 
With compound 324 obtained in moderate yield on a large scale (4.46 mmol), a range of final 
compounds were obtained from the subsequent decoration reactions (Figure 30). The 
conditions are shown in Appendix 6.1.4. In total four of the five reactions obtained final 
compounds for screening, each with a diverse range of functional groups attained from 
decoration. 
 
 
Figure 30. Four decorated tertiary amines synthesised from compound 324. 
 
3.1.5 Manipulation of the indole scaffold 
 
The last of the series to undergo final compound synthesis were the indole fused scaffolds. The 
planned synthetic route required a scaffold synthesis step (step i), deprotection (step ii) and a 
decoration with capping groups at either the free NH of the indole or the bridge head nitrogen 
(Scheme 55).  
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Scheme 55. Step(i) scaffold synthesis, step(ii) deprotection, step(iii) decoration 
 
Due to difficulties with the Fischer indole conditions, the initial proposed step was to be 
undertaken using the palladium-mediated process (Table 17, Section 2.3.2). Different indole 
derivatives were planned which required a range of alternative halogenated-aniline reagents, 
which were purchased from readily available suppliers. The proposed substituted indole and 
azaindole compounds however were not obtained due to isolation issues: where some products 
were seen on the LCMS/1H NMR, but no compound was recovered after purification (Table 
27).  
 
 
Entry R  NR’ X,Y, R’’ Conditions Outcome 
 
1 
 
Ph 
 
NBn 
 
Br, N, H 
 (1.2 eq.),  
Ketone (1.0 eq.), DABCO (1.0 
eq.), Pd(OAc)2 (10 mol%),  
DMF, 105 oC, 2d 
Starting 
material 
(174) 
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2 
 
Me 
 
NMe 
 
I, C, F 
 (3.0 eq.) 
Ketone (1.0 eq.), DABCO (3.0 
eq.), Pd(OAc)2 (15 mol%),  
DMF, 120 oC, 2 d 
Complex 
mixture  
 
3 
 
Me 
 
NMe 
 
I,N,H 
 (3.0 eq.) 
Ketone (1.0 eq.), DABCO (3.0 
eq.), Pd(OAc)2 (15 mol%),  
DMF, 120 oC, 2 d 
Complex 
mixture 
 
4 
 
NMe2 
 
NMe 
 
I,C,CN 
 
(3.0 eq.) 
Ketone (1.0 eq.), DABCO (3.0 
eq.), Pd(OAc)2 (15 mol%),  
DMF, 120 oC, 2 d 
Complex 
mixture 
Table 27. Outcome of conditions used in attempt to synthesise azaindole and indole derivative. 
As discussed previously, four compounds had been successfully synthesised using this 
palladium method, compound 2.96 – 2.99 (Table 17). With these compounds in hand, our next 
proposed route involved the deprotection of the benzyl group on the nitrogen. However, after 
screening several sets of conditions, only starting material was observed (Table 28). 
 
 
 
Entry Conditions Outcome 
1 Pd(OH)2/C, H2, 16h, MeOH Starting material, 186 
2 Pd(OH)2/C, H2, 16h, MeOH,  
c. HCl 
Starting material, 186 
3 Pd/C, H2, 16h, MeOH Starting material, 186 
4 Pd/C, ammonium formate, 16h, MeOH Starting material, 186 
Table 28. Outcome of the conditions used in an attempted to deprotect compound 335. 
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Due to the synthetic difficulties of removing the protecting group we endeavoured to decorate 
with medicinal capping groups at the free nitrogen of the indole. Three reactions took place to 
bring diversity at this point and the conditions are detailed in Appendix 6.1.5. The five 
screening compounds from this series are shown below (Scheme 56), where only two final 
compounds were achieved after decoration. 
  
 
Scheme 56. The indole precursors 186 - 189 and decorated indoles 336 - 338. The compounds chosen for the screening 
collection marked with *. 
3.2 Computational assessment of 52 screening compounds 
Now a library of screening compounds had been synthesised, the compound properties such as 
lipophilicity and molecular weight were analysed. As discussed previously, lipophilicity is an 
important factor to monitor when a compound goes through the different stages of drug 
discovery, because if a compound is too lipophilic it may experience off-target biological 
activity. The ideal lipophilic values for optimal drug space are -1 − 5 AlogP.  Each compound 
fell in optimal drug like space, where the heavily decorated compounds 195 and 181 exceeded 
lead-like space. However, removal of protecting groups or the use of smaller substituents such 
as methyl groups could be used to alleviate this problem. 
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Figure 31. A) Mass distribution of screening compounds B) AlogP distribution of screening compounds with the two examples 
outside of lead-like space. 
3.2.1 Three-dimensionality assessment of screening compounds 
As stated previously, more three-dimensional compounds typically have lower attrition rates 
in drug discovery,39  therefore it was necessary to assess the 54 compounds on their three-
dimensionality. Each compound was plotted on a PMI plot using LLAMA (Figure 32). 
Evidence below suggests the compounds are moving away from the heavily populated region 
and now venturing into the more unpopulated ‘sphere-like’ region of chemical space. A random 
library was downloaded from the ZINC database consisting of 90,911 molecules and an 
average value was plotted (in yellow) for comparison. Examples D and E shown on the plot 
exhibit more 3D characteristics, whereas examples A an F are below the average value and 
populate the more explored area of chemical space. It is understandable that these are below 
the average value as they contain substituents of a ‘rod-like’ nature, whereas the better 
performers are smaller and have less linear characteristics.  Comparing the mean PMI 
coordinates below, it was clear that these compounds were more 3D then the random ZINC 
database library. It was therefore concluded that the objective of synthesising more 3D 
screening compounds was successfully achieved. 
195 181 
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Figure 32. A PMI plot showing the three-dimensionality of the screening compounds, with particular examples highlighted. 
The average value for the random ZINC library is shown in yellow and, the average coordinates for this library is shown by 
a red cross. 
 
3.2.2 Fsp3 value assessment of screening compounds 
 
Another objective of this project was to synthesise compounds that have a higher fraction of 
sp3 hybridised carbons. Each compound was again analysed in LLAMA and the Fsp3 value 
was calculated for the 52 screening compounds (Figure 33). A comparison to a random 1% of 
the ZINC database was shown, where it was clear the screening set experienced a higher Fsp3 
nature. As seen from the graph only two compounds (151, 337) (4%) have a lower value than 
the ZINC database score, where the average value has increased by 70%.  
327 
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Figure 33. A Fsp3 value comparison of the screening compounds. The average value 0.56 (in green) is also compared with 
the average ZINC database value 0.33 (in red).  
 
3.2.3 Conclusion and summary of screening compounds  
 
In summary, the careful selection of capping groups has facilitated the creation of a diverse 
and novel screening library for biological testing. The compounds have the correct molecular 
properties and all compounds fall in optimal drug-like space, with a heavy proportion still in 
lead-like chemical space. When compared to readily available screening compounds, this 
library has a larger average value of Fsp3 carbons and has a greater 3D nature.  
It should be noted that the removal of the benzyl protecting group posed a significant problem 
when synthesising final screening compounds. In many cases the deprotection step was 
essential as the free nitrogen was required for decoration with capping groups. A range of 
conditions were used in attempts to remove the protection group. In some cases the 
deprotection was achieved, which led to the conclusion that the correct conditions were 
scaffold dependent. Due to these issues, the benzyl group was present in some final compounds 
and resulted in a lower number of screening compounds than anticipated. 
Due to careful planning and searching of the literature, an ideal parent scaffold was selected 
that had a multitude of different functionalities present with various potential growth vectors 
available. This would be advantageous if any positive biological data was received, as there 
would be various vectors to explore when carrying out SAR. The parent scaffold was initially 
selected with the intension to remove the sulfone group or to use a variety of different sulfonyl 
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derivatives. However, due to problems with synthetic tractability 85% compounds contained 
the methyl sulfone group. Nevertheless, when comparing to previous ‘top-down’ approach 
strategies, this intermolecular approach is advantageous as the functionality can be changed 
prior to the cycloaddition. This allows for a diverse follow series to be synthesised rapidly and 
efficiently.  
Although each compound was novel and diverse, there are still issues with skeletal diversity. 
When assessing the relationship between the skeletal systems, using the ‘scaffold tree’ 
hierarchical analysis,66 it was found that the scaffolds were ultimately related to five similar 
parental frameworks. The analysis works by deconstruction of the scaffolds by iterative 
removal of rings, until a final parental core scaffold is observed. At each iteration step a ring 
is removed, retaining the central and complex rings (Figure 34). Due to the lack of ring 
expansion executed, 94% of compounds featured a [3.2.1]-bridged bicyclic core, explaining 
the reason for similar parental frameworks.   
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Figure 34. A waldmann ‘scaffold tree’ hierarchical analysis of the lead-like scaffolds. Compounds in blue are the five parental 
core frameworks found from ring deconstruction. 
 
As stated earlier, during discovery drug candidates tend to experience a shift in lipophilicity, 
known as ‘AlogP drift’. The graph below supports this theory and a comparison of four libraries 
is shown (Figure 35). The four libraries consist of: 
 
1) Lead-like scaffold library: initial scaffold library where no decoration has been 
undertaken. 
2) Screening library: 52 final compounds produced from the lead-like scaffold set. 
3) Virtual library: produced using LLAMA, where lead-like scaffolds were decorated using 
common medicinally relevant capping groups.  
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4) Failed library: the compounds which failed when synthesising the screening library (these 
compounds can be seen in the appendix) 
 
When comparing the first three libraries, there is a clear indication that the percentage of 
compounds in the more lipophilic regions is increasing. When comparing the lead-like library 
to the screening library, there is a 28% increase of compounds in the 2 – 5 regions of 
lipophilicity, and a decrease of 12% in the region of -1. When comparing to the virtual library 
it clearly shows without careful selection of capping groups it would be easy to synthesise 
compounds with a more lipophilic nature (AlogP = 3 – 5). It is also interesting to see the failed 
compound library heavily situates in the more polar areas of AlogP. This also supports the 
research carried out by Churcher et al, where a study found final compound libraries were often 
found to have a higher AlogP than intended. The reasoning behind this is due to the poor 
tolerance towards the polar functionalities, thereby, less polar compounds being isolated easier.  
 
Figure 35. Percentage of compounds y-axis. A comparison of lipophilic values from four different libraries. 1) lead-like 
scaffolds in green, 2) 52 screening compounds (in blue), 3) virtual library (in yellow) and 4) the failed library unsuccessfully 
synthesised (in red). 
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4.0 Biological evaluation of the 52 Screening compounds 
and SAR of active compounds 
 
4.1 Biological evaluation of the 52 screening compounds  
With a library of 52 screening compounds having been synthesised, and their molecular 
properties analysed, the next objective was to send each compound for biological evaluation 
against a wide range of biological targets. The compounds were screened against four different 
targets, at three different facilities (Table 29). A more detailed description of each assay and 
target will be given below.  
 
Entry Facility Target Assay type Number of 
compounds 
1 MPI Dortmund Autophagy phenotypic assay 52 
2 MPI Dortmund Hedgehog 
osteogenesis 
phenotypic assay 52 
3 University of East 
Anglia 
DNA i-motif 
binding 
phenotypic assay 52 
4 University of 
Cape Town 
Plasmodium 
falciparum 
phenotypic assay 52 
Table 29. A table showing each target the 52 screening compounds were tested against. 
 
4.1.1 Autophagy target; screening for autophagy modulators 
 
Autophagy is a highly conserved catabolic process that is regularly used by the cell as a 
mechanism for quality control and survival under nutrient stress conditions.108,109 It becomes 
activated under various conditions of cellular stress such as amino acid starvation and cytosolic 
Ca2+ upload.110 Autophagy modulation by targeting the pathway in cancer and 
neurodegenerative diseases has a  considerable potential as a therapeutic approach,108 therefore 
the compound collection was sent to MPI Dortmund, where they were screened for autophagy 
modulators. Each compound was tested for the ability to inhibit autophagy induced by amino 
acid starvation. Autophagy is required for removal of damaged proteins and clearance of 
pathogens.110,111  In cancer, it can promote tumour growth and there is a requirement for small 
molecules with a novel mode of action.111  
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The phenotypic assay for autophagy inhibition works by the process of MCF7 cells expressing 
eGFP-conjugated LC3 (MCF7-LC3 cells) that are treated under starved conditions using 
EarleQs balanced salt solution (EBSS), which induces the autophagy.111 If the compounds 
induce autophagy, LC3-I is lipidated with phosphatidylethanolamine to form LC3-II, which 
localizes to the autophagosomal membrane. Chloroquine inhibits autophagosome–lysosome 
fusion, of which will cause an accumulation of LC3-II. This will be visible as green puncta 
when tagged with eGFP. Autophagy inhibitors will reverse this accumulation (Figure 36).111 
A description of the assay can be found in Appendix 6.2.1 However, the 52 compounds 
unfortunately showed no activity.  
 
Figure 36. Outline of autophagy and the assay principle.  
 
4.1.2 Hedgehog Osteogenesis target; screening for inhibitors of the hedgehog 
signalling pathway 
 
To identify inhibitors of hedgehog signalling, an osteoblast differentiation assay was carried 
out on the 52 screening compounds.112 The hedgehog signalling pathway is essential for normal 
embryonic development and plays a critical role in tissue maintenance and regeneration.113,112 
The signalling pathway has been linked to cancers such as basal cell carcinoma and 
medulloblastoma.112,114 A transmembrane protein Smoothened (SMO) agonist called 
purmorphamine, was used to activate the signalling, where the pathway activity induces 
osteoblast differentiation. This leads to the expression of alkaline phosphatase enzyme that can 
serve as an indirect measure for hedgehog pathway induction.115 The screening for small 
molecule inhibitors of the hedgehog pathway was carried out by MPI Dortmund, where the 
compound collection was analysed for direct interaction with SMO. The compounds were 
analysed by monitoring the displacement of the BODIPY-labelled SMO antagonist 
cyclopamine. Cyclopamine binds to the heptahelical bundle of SMO,116 and treatment of these 
cells with BODIPY-labelled cyclopamine led to cellular fluorescence,  thus an indication of 
the binding to SMO.117 Of the 52 compounds screened, only two showed any activity. A 
detailed description of the assay can be found in Appendix 6.2.2.  
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The results of the two active compounds can be seen below, where the EC50 values were 
determined in dose-dependent mode (4.2 – 4.4 M) (Scheme 57). It was interesting to see that 
while the N-substituted indole derivatives showed activity and undecorated indole derivatives 
187 – 189 showed no activity. This SAR may suggest that the activity is induced by growing 
substituents from the free NH of the indole. However, the activity was deemed too weak to 
warrant follow-up with such limited time. 
 
 
Scheme 57. Active compounds 336 and 377, with inactive derivative 187 – 189. 
 
 
4.1.3 DNA binding motif; TO displacement 
 
I-motifs are four-stranded quadruplex DNA structures formed by sequences of cytosine-rich 
DNA, with building blocks consisting of cytosine–cytosine+ base pairs.118,119,120 These 
sequences may play a role in gene transcription, where targeting the structures with compounds 
may provide a way to target genetic diseases.119 A fluorescent intercalator displacement (FID)-
based method was used to screen the compounds against DNA secondary structures; here the 
screening compounds were monitored for binding with the i-motif DNA. This FID-based 
ligand screening uses thiazole orange (TO) against the i-motif forming sequence from the 
human telomere, to reveal new i-motif binding compounds.119  The 52 screening compounds 
were sent for screening to the University of East Anglia, where the compounds were examined 
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for change in fluorescence upon binding. The details of the assay can be found in Appendix 
6.2.3. 
 
The results are shown below, where the top 8 ligands showing ≥ 15% TO displacement (within 
error) are plotted (Figure 37). It should be noted that compound 170 with KCl shows enhanced 
displacement of TO from DAP over G4 or DS, but not when DAP is tested without KCl. Due 
to the nature of the project, structurally similar compounds are tested upon initial screening, 
therefore providing a clearer direction for performing structure activity relationship on the 
follow-up series. Compounds 314, 316 and 378 all share structural similarities, where aryl 
carbamates are observed at the 2-hydroxyl position. Compounds 314, 316 and 318 share the 
same structural ‘core’, as they were synthesised from the same precursor, compound 178. The 
results were interesting as the majority (though not all) of compounds which interact with i-
motifs are flat aromatics, which can intercalate the DNA base pair stacks.121,122,123 and the 
following examples below are highly 3D lead-like compounds.  
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Figure 37a) The top 8 TO displacement ligands for the DNA binding motif series, b) The results from the four screening 
conditions tested against from the 8 ligands. 1) DAP in sodium cacodylate, 2) DAP in sodium cacodylate in KCl, 3) h TeloG 
in sodium cacodylate in KCl and 4) DS in sodium cacodylate with KCl 
 
4.1.4 Plasmodium falciparum 
  
Malaria is the most common parasitic disease worldwide, where in 2017 it was reported that 
445,000 deaths occur annually.124 There are no specific symptoms for P. falciparum malaria 
infection, however illness with malaria occurs through complex interaction between the 
parasite, environment and human host.125,126,127 A recent challenge in the fight against malaria 
is that the species is affected by resistance to antimalarial drugs, therefore new drugs are 
required. 125, 128,129 
The 52 compounds were tested against the drug-sensitive strain of P. falciparum. The assay 
was carried out using activity of the parasite lactate dehydrogenase enzyme as a marker for 
parasite activity and thus survival.130 The compounds were biologically evaluated by testing 
the inhibition of the enzyme at various concentrations, where active compounds would inhibit 
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the enzyme activity. The assay details are provided in the Appendix 6.2.4. Of the 52 
compounds tested, none showed significant activity against the human malaria parasite in vitro. 
For 48 of the compounds, no growth inhibition was observed at the highest starting 
concentration of 6µM. The remaining 4 compounds (were weakly active, with mean IC50 
values from the two occasions of between 5µM and 6µM (highlighted in Figure 38). A follow-
up series was planned where each position of the scaffold was to be examined by changing 
functional groups independently and identifying the important active chemical groups of the 
compounds. 
 
Figure 38. The four active compounds against the target Plasmodium falciparum, with the data averages shown for each. 
 
In total, the 52 screening compounds were sent for biological evaluation against four targets at 
three different screening facilities. Weak activity was observed at most targets and there was 
potential to follow-up on each hit. Due to the time constraints, the promising compounds 
observing activity against P.falciparum was chosen to perform the synthesis of derivatives by 
exploration of structure activity relationship.  
 
4.2 SAR library of the active Cape Town compounds 
Most objectives of the project have been successfully achieved with 15 compounds showing 
promising activity in four different assays. The final objective was to carry out SAR and 
synthesise a new library based on the active compounds. This unified approach allowed for a 
fast follow-up series to be synthesised in an efficient manner. The synthetic efficiency is 
demonstrated below (Figure 39), where each scaffold can be synthesised in three or fewer 
steps. A range of derivatives of the active compounds were then synthesised in an attempt to 
improve the potency. The active compounds are shown below, four hits from the Plasmodium 
falciparum series (in blue), and two from the hedgehog osteogenesis series (in red).
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Figure 39. An overview of the synthetic route to the active compounds, Cape Town compounds in blue and Germany in red. 
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Owing to time constraints, the four hits produced from the Plasmodium falciparum series were 
selected as the scaffolds to pursue (Figure 39, in blue). The idea of this final series was to 
identify a chemical motif that possessed activity, with the primary aim to further increase the 
potency of the active compounds. Each position of the scaffold was to be examined by 
changing functional groups independently and identifying the groups within the compounds 
responsible for the activity. The library can then be analysed by observing the difference in 
potencies. A general plan for the follow-up SAR library is highlighted below (Figure 40). 
Methods for the scaffold elaboration involve the manipulation of the ketone (Figure 40, 
Method A and B), the amine (Figure 40, Method C), the sulfone (Figure 40, Method D) and 
the fused ring substituents (Figure 40, Method E). Each method will provide an insight into 
the important chemical groups responsible for the biological activity.  
 
Figure 40. A range of scaffold elaboration methods for the potential follow-up SAR library 
 
A range of novel cycloadducts were proposed, featuring different substituents at the bridged 
nitrogen. Applying the same conditions first described in Section 2.2 (Table 6), three novel 
cycloaddition precursors (351 - 353) were synthesised in near quantitative yields (Table 30). 
Each precursor was then subjected to the established cycloaddition conditions; however, only 
two were successful giving the desired compounds in low yields (Table 30, entry 2 and 3). The 
stereochemistry and regioselectivity of cycloadducts were assigned according to the 1H NMR 
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spectral data.†† It was envisaged that the ester group at the bridged nitrogen would feature as a 
synthetic handle for decoration, however, the cycloadduct was not observed in the crude LCMS 
and the scaffold was deprioritised (Table 30, entry 1).  
 
Entry R Conditions for salt formation Outcome for 
cycloaddition‡‡ 
 
1 
 
MeCN (0.5 M), 16h, 
351, 99% 
No reaction 
 
 
2 
 
 
IPA (0.5 M), 16 h, 
352, 99% 
 
354, 29% 
 
 
3 
 
IPA (0.5 M), 16 h, 
353, 99% 
355, 22% 
 
Table 30. Outcome of cycloaddition conditions involving three salts 351 – 353, and with dipolarphile 118. 
 
4.3 Manipulation of the active pyrazole scaffold 170 
 
A collection of cycloadducts containing different nitrogen substituents were subjected to a 
[3+2] cycloaddition with ethyl diazoacetate (method first detailed in section 2.3.1). It was 
determined previously that the procedure to prepare the fused pyrazoles could be done via 
telescoping the dihydropyrazole intermediates, so no isolation was necessary. However, due to 
polarity issues, the isolation of each product was found challenging and the overall yields for 
this compound series was poor (Table 31). 
 
†† The coupling constants matched the predicted coupling and the data was validated by comparison to 
previously synthesised cycloadducts.  
‡‡
 Yield for the major isomer only, only this isomer was isolated. 
  99 
 
 
 
  
Entry R R’ Intermediate 
yield 
Product 
Outcome 
 
1 
 
Me 
 
Me 
 
356, 84% 
 
357, 3% 
 
 
2 
 
 
Me 
 
 
 
358, 62% 
 
Complex 
mixture 
(isolation issues) 
 
3 
 
Me 
 
 
N/A 
Complex 
mixture 
(stability issues) 
4 Me PMB N/A 134, Starting 
material 
5  
Me 
 
 
N/A 
 
359, 8% 
6 Ph Bn 168, 58% 360, 11% 
Table 31. Outcome of the synthesis of pyrazole compounds 357 – 360 involving ethyl diazoacetate and subsequent aerobic 
oxidation. 
The next transformation of interest was a series of amide coupling reactions at the free 
carboxylic acid (Table 32). It was envisaged that a range of amides could be introduced as a 
point of diversification, which would be ideal for this SAR library. However, when changing 
the amines, conditions and starting materials, no desired product was observed or isolated in 
all cases. Consequently this route was discontinued as only the acid was recovered. 
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Entry R Nu (Amine) Conditions Outcome 
1 
2 
3 
Me 1) Methylamine 
2) Morpholine 
3) Dimethylamime 
DIPEA (2.5 eq.), amine 
(1.5 eq.), DMA, TBTU 
(1.6 eq.) 
Starting 
material 
360 
4 
5 
6 
Me 4) Methylamine 
5) Morpholine 
6) Dimethylamime 
EDC (2.0 eq.), DMAP 
(10 mol%), DMF 
Starting 
material 
360 
7 Ph Morpholine EDC (2.0 eq.), DMAP 
(10 mol%), DMF 
Starting 
material 
360 
Table 32. Outcome of amide formation conditions used in attempt to synthesise a range of amide derivatives of the pyrazole 
scaffold 170 and 360. 
 
Synthetic efforts were then focused on a range of alkylation reactions that would deliver diverse 
capping groups at the free nitrogen of the pyrazole. With the pyrazole unprotected, there was 
a possibility of forming regioisomers. This was exemplified in the cases of alkylated pyrazoles 
362 – 364 (Table 33, entry 1 and 2) where regioisomers were formed in a 3:2 mixture.§§ 
Unfortunately, the regioisomers were inseparable by column chromatography and the alkylated 
pyrazoles were all isolated in moderate yields (33 – 52%) (Table 33). It was unclear on the 
clarification of the major regioisomer, however, literature precedence for pyrazole alkylation 
mainly reported observation of pyrazole type 362 – 264a as the major product. 131,132 
 
Entry Conditions R Outcome 
1 KOH (2.3 eq.), MeI (1.3 eq.), 
DMF 
Me 362, 52% 
3:2 Mixture of 
regioisomers 
2 KOH (2.3 eq.), DMF,  
4-(bromomethyl) benzonitrile  
 
363, 41% 
 
§§
 The isomeric ratios were determined by ratios of distinct protons in the 
1
H NMR spectrum. 
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(1.3 eq.) 3:2 Mixture of 
regioisomers 
3 KOH (2.3 eq.), MOM-Cl (3.0 eq.), 
DMF 
 
364a, 33% major 
only 
4 KOH (2.3 eq.), NCCH2Br (3.0 
eq.), DMF 
 
170, Starting 
material 
Table 33. Outcome of alkylation reactions involving the free NH of pyrazole scaffold 170 and a range of alkyl electrophiles.  
 
4.4 Manipulation of the active compound 283 via 1,4-addition and decoration 
 
To fully investigate the important features of the active compound 283, it was proposed that a 
range of different boronic acids could be used to synthesise a diverse second round of screening 
compounds via the 1,4 addition to the enone. The 1,4-additions were performed on 
cycloadducts with varying sulfones, using conditions previously described (Table 20, section 
2.3.3). As predicted, boronic acids substituted at the para and meta positions furnished the 
desired 1,4 adducts in good to high yields (Table 34, entries 1-3, 5). However, when the 
boronic acid was ortho substituted, no desired 1,4-adduct was formed (Table 34, entry 4). It 
was believed that this was due to increased steric interactions, hindering the addition to the 
enone.  The stereochemistry of each was assigned according to the 1H NMR spectra data and 
comparison to the active compound 283. In each case, a singlet or doublet of a low coupling 
constant was observed for proton H5 (as opposed to the opposite stereochemistry being a large 
coupling constant of 11 Hz). 
 
Entry Ar SO2R Outcome 
1 
 
Ph 365, Telescoped*** 
 
***
 The product was not isolated and telescoped through to the next step. 
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2 
 
NMe2 366, Telescoped 
3 
 
Me 367, 94% 
4 
 
Me 116, Starting 
material only 
5 
 
Me 368, 73% 
Table 34. Outcome of  a series of 1,4 addition reactions with a range of aryl boronic acids. 
A series of alcohol intermediates were synthesised by applying the established conditions used 
to synthesise the hit compound precursor 278a (Table 35). In each case, the alcohol was not 
purified but rather the crude material was decorated directly with 4-(bromomethyl)benzonitrile 
373. Compounds 374 and 375 were isolated in moderate yields of 33% and 29% respectively 
(Table 35, entry 1 and 4). The stereochemistry of each stereocentre was determined by 
comparison of 1H NMR data with the active compound. However, there was purification 
problems and no product was isolated (Table 35, entry 2, 3 and 5). 
 
Entry Ar SO2R NR’ Outcome 
1 
 
Ph Me 374, 33% 
2 
 
NMe2 Me Purification 
problems 
3 
 
Me Me Purification 
problems 
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4 
 
Me Bn 375, 29% 
5 
 
Me Me Purification 
problems 
Table 35. Outcome of a series of reduction and decoration with compound 373 involving scaffolds 365 - 368. 
For this SAR follow-up library, it was proposed to synthesise a range of substituted benzyl 
derivatives at the alcohol with para, meta and ortho substituted aromatics. Using conditions 
previously identified, ethers 376 – 381 were isolated in moderate yields (Table 36, entry 1-6). 
For entry 7, only starting material was observed by LCMS analysis and this compound was 
discontinued. 
  
Entry R Outcome 
1 
 
376, 19% 
2 
 
377, 21% 
3 
 
378, 37% 
4 
 
379, 32% 
5 
 
380, 24% 
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6 
 
381, 25% 
7 
 
278a, starting 
material 
Table 36. Outcome of a series of alkylation reactions involving scaffold 278a and a range of aryl derivatives.  
 
4.5 Manipulation of the active compound 327 via reductive amination and 
decoration 
The last compounds to be synthesised for the SAR follow-up series were tertiary amine 
compounds produced from the key reductive amination reaction. Synthetic efforts were 
focused on three routes to produce a diverse library. Route one involved the synthesis of the 
secondary amine 327 (Figure 41, route 1). The idea was to decorate amine 327 with a range of 
capping groups to produce compounds with different functional groups. The second route 
featured the synthesis of the tertiary amine 382, with a different sulfone substituent or the 
bridged nitrogen substituent (Figure 41, route 2). Finally, in route 3 the amine 383 was to be 
decorated with a range of different benzyl derivatives (Figure 41, route 3). 
 
Figure 41. The planned SAR route for the tertiary amine compounds produced from a reductive amination. 
 
The amine containing scaffold 325 and 384 were produced using the reductive amination 
conditions discussed previously by Bhattacharyya et al.92 The summary is shown below, where 
each compound was synthesised with high levels of selectivity, with only one isomer being 
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produced in both cases (Table 37). The stereochemistry was determined by 1H-NMR 
comparison to the minor and major compounds in Section 2.3.5 (Scheme 35). 
 
 
Entry R R’ R’’ Outcome 
1 Me Me 
 
384, 11% 
2 Ph Me 
 
Starting 
material 
3 Me Bn Me 325, 94% 
4 Ph Me Me Starting 
material 
Table 37. Outline of reductive amination reactions involving tropanone 174-176 and a range of amine nucleophiles. 
With compound 384 in hand, it was proposed to decorate the free amine with a range of capping 
groups. However, due to problems with synthetic tractability and poor yielding reactions, only 
two reactions were carried out (Table 38). The reactions were unsuccessful due to problems 
with isolation and purification. Consequently, this route to the follow-up compounds this way 
was deprioritised because of difficulty synthesising the starting material in large quantities. 
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Entry R Outcome 
1 
 
Complex mixture  
2 
 
Complex mixture 
Table 38. Outcome of amide formation reactions involving free amine scaffold 384. 
It was envisaged that the follow-up series would include a range of different benzyl derivatives 
of the active compound 327. Therefore, compound 245 was subjected to two different sets of 
conditions; a reductive amination or an alkylation reaction. The alkylation reactions gave some 
success, where two compounds with different aromatic substituents were synthesised in low 
yields (Table 39, entry 1 and 2). Unfortunately, none of the reductive amination reactions were 
successful due to failure to isolate pure.  (Table 39, entry 3 - 6) 
 
 
 
Entry Method R Outcome 
1 1 
 
386, 9% 
2 1 
 
387, 20% 
3 2 
 
Failed to isolate  
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4 2 
 
Failed to isolate 
5 2 
 
Failed to isolate 
6 2 
 
Failed to isolate 
Table 39. Outcome of alkylation or reductive amination reactions involving of amine 245 to produce a library of benzyl 
derivatives 
The last route to be investigated involved synthesising variants of the active compound 327 
with different sulfonyl or nitrogen bridgehead substituents. Since the reductive amination 
reaction was unsuccessful with the different sulfonyl groups (Table 37, entry 4), the only 
modification of the chemical motif was the bridgehead nitrogen substituent. Amine 325, was 
consequently subjected to alkylation reactions, where compounds 392 and 393 were 
synthesised in low to moderate yields (9 - 49%) (Scheme 58). 
 
Scheme 58. Outcome of alkylation reactions involving amine 325 and two aryl electrophiles 373 and 391. 
4.6 Computational assessment of the SAR scaffold series  
 
In total, 22 final compounds were synthesised in 36 synthetic operations from 5 scaffolds. The 
chemical structure of the active scaffolds were modified by either the addition of different 
chemical groups, or the synthesis of different derivatives; all with the aim to increase potency 
and explore SAR. Since only one position was changed for each compound, the follow-up data 
should indicate the most important features. 
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To assess the molecular properties, the follow-up series were plotted on a scatter graph to 
analyse their molecular weight and AlogP properties (Figure 42). It should be noted that the 
compounds are now drifting into more lipophilic and high molecular weight areas of chemical 
space. When comparing to the previous screening library, there is a decrease of 20% of 
compounds in the polar regions of 0 – 1 AlogP, and a 19% increase of compounds in the more 
lipophilic areas of chemical space (3 – 5 AlogP). Therefore, this evidence further supports the 
hypothesis that compounds AlogP tends to increase through the discovery process.24  
 
Figure 42. A graph showing the relationship between lipophilicity and molecular weight of each screening compound. 
 
It is also important to monitor the relative three-dimensionality and diversity of the SAR 
library, so the compounds were plotted on a PMI plot using LLAMA.45 The plot can be seen 
below (Figure 43), where the library still shows a high level of diversity and three-
dimensionality. Compound 375 showed higher levels of three-dimensionality as it explored the 
more unpopulated region of chemical space. However, compounds 393 and 384 are situated in 
the more populated area of chemical space; the ‘rod-like’ region of chemical space. This is 
understandable as the negative impact of the ‘OCF3’ substituent deems the compounds as ‘rod-
like’. In conclusion, when comparing to the random 1% of ZINC database (90,911 
compounds), it is clear from the plot hat this objective has successfully been achieved. 
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Figure 43 A PMI plot showing the three-dimensionality of the screening compounds, with particular examples highlighted 
Each compound was then analysed for their fraction of sp3 hybridised carbons (Figure 44). It 
was found that 14% of the compounds experienced a lower Fsp3 value than a random 1% of 
the ZINC database. It was concluded that the compounds experienced high Fsp3 character and 
were therefore still to be considered as ‘complex’. Again, an original aim of the project was 
successfully achieved.   
 
357 
387 384 
393 
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Figure 44. A Fsp3 value comparison of the screening compounds. The average value (in green) is also compared with the 
average ZINC database value (in red). 
 
In total, 13 compounds were sent for biological evaluation against the Plasmodium falciparum 
cells. Due to problems with stability and synthetic tractability, several compounds were not 
sent for screening. Because of time constraints, the remaining compounds were therefore not 
re-synthesised. However, this follow-up library was synthesised in a rapid and efficient manner 
(in under 2 months), using minimal steps. Again, because of time restrictions, SAR for the 
other active compounds were not carried out and there remains several follow-up compounds 
to be investigated. 
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5.0 Conclusions and future work 
 
5.1 Summary and conclusions  
In the search for clinical candidates, thousands of compounds are synthesised and screened for 
biological activity. SAR must then be carried out and the candidate produced on a multi-kg 
scale. Therefore, the candidate must be scalable and produced from readily available starting 
materials. When carrying out SAR, various accessible points of the compound must be 
available for modification. The advantage of the LOS method in general is its ability to produce 
a large number of small, diverse molecules in an efficient manner. In doing so this method 
produced 14 lead-like scaffolds from 28 synthetic operations and 52 novel compounds from a 
total of 73 synthetic operations. Each had the potential to be produced on a large scale, with 
various accessible points available for SAR.  
 
In comparison to other methods such as combinatorial synthesis, this method relies on capping 
groups to bring diversity to the library set and often results in synthesising compounds outside 
of lead-like space.24 With efforts to increase the library size, multiple points available on the 
molecules are subjected to a wide range of capping groups, therefore producing compounds 
with no focus on molecular properties. A comparison of the method vs LOS is shown below 
(Figure 45). A combinatorial approach aims at similar structures, therefore lacking in diversity. 
The LOS approach has diverse target structures and produces a library of complex diverse 
compounds, with a focus on molecular properties. 
 
  
Figure 45. A) an example of a combinatorial library approach to synthesising screening compounds vs B) a LOS approach to 
synthesising screening compounds 
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Other methods such as DOS, also have issues with molecular properties as many libraries are 
often produced using cascades, with a heavy focus on producing a diverse library. When 
comparing to a DOS library by Spring et al in 2015,133 only 4 novel scaffolds were synthesised 
from 22 synthetic operations, and with no focus on molecular properties. In comparison to the 
LOS library, the DOS library is averaging 1 scaffold per 5.5 steps, whereas the LOS library is 
averaging 1 scaffold per 2 steps, showing a greater efficiency. When comparing another a DOS 
library, this time within the group,134 96 molecules were synthesised (from no more than five 
discrete steps). The library however, only produced 65% novel compounds and again with no 
focus on molecular properties. Comparatively, the LOS library produced only novel 
compounds with controlled molecular and the compounds were sent for biological evaluation.  
 
Here our method has produced a library of diverse novel compounds with attention paid to 
physicochemical and functional group properties, whilst maintaining synthetic efficiency. This 
method is advantageous as it is a combination of each method described. The drug discovery 
process seeks to identify molecules able that efficiently interact with biological systems, 
therefore the library has specifically been designed to contain various groups that do interact. 
Interactions with biological systems frequently occur through polar or hydrogen bonding 
interactions, normally from acidic groups, Brønsted bases and heterocycles.24 With this in 
mind, strategic planning enabled the synthesis of each final compound possessing these 
characteristics. It should be noted that the presence of such groups is known to be troublesome 
in synthetic operations, therefore making this a challenging task. However, each final 
compound has various relevant functional groups available for interactions and these 
compounds were sent for biological evaluation against a wide range of biological targets.  
 
From 5 different assay targets, 15 number of compounds showed promising activity, where 
SAR was performed on 3 compounds of the Cape Town malaria series. In total 13 compounds 
were sent for a second round of biological evaluation against the Plasmodium falciparum cells, 
where unfortunately no activity was observed. Due to time constraints no further synthesis was 
carried out.  
 
Overall, the method has demonstrated a successful LOS strategy, where a large number of 
scaffolds were produced in an efficient and rapid manner. The novel and diverse compound set 
experienced high levels of three-dimensionality and complexity. A number of hits from 
different targets was observed with each compound possessing the correct physicochemical 
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properties for screening. However, the method cannot be truly verified as no evidence can be 
provided for the reducing of attrition rates in drug discovery. 
 
5.2 Future work  
5.2.1 Synthesising a more diverse set of scaffolds for screening  
As briefly discussed, 85% of the screening compounds contained the methyl sulfone group. In 
order for a more diverse set of compounds a focus should have been on producing compounds 
with different functionality. However, this would have consequently led to a lower number of 
compounds for the screening library. Also, there remains several reactive pathways available 
for ring expansion, that would synthesise a more structurally diverse set of scaffolds for 
screening. With only the decoration of the [3.2.1] cycloadduct being explored, the core 
diversity is limited. In future, a focus should be to try to manipulate the chosen scaffold by a 
range of cleaving and ring expansion reactions to produce a more skeletally diverse library, 
thus, so that the scaffolds are not simple derivatives of each other. Below shows a range of 
ideas to produce a skeletally diverse collection of future lead-like and screening compounds 
(Scheme 59). 
 
 
Scheme 59. A proposed route to five new molecular scaffolds with different core structures. 
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5.2.2 SAR with indole compounds 336 – 337 
Due to time constraints, there remain a number of compounds to synthesise for a follow-up 
SAR library. In particular the compounds from the hedgehog osteogenesis assay from 
Dortmund, Germany. An example of a few synthetic strategies for an SAR library are shown 
below (Scheme 60). More work could have been undertaken in an attempt to increase the 
potency of such compounds.  
 
Scheme 60. Suggested SAR library follow up series for the Hedgehog osteogenesis target 
5.3 Using machine learning to predict biological activity 
Machine learning is currently one of the most discussed and rapidly evolving topics in drug 
discovery.135,136,137,138 Owing to the high demand of exploring and analysing big data, this has 
encouraged the use of machine learning algorithms to predict biological effect of chemical 
compounds based on mathematical and statistical relations.138 Quantitative structure-activity 
realtionships (QSARs) are predictive statistical models that correlate big data and analyse the 
response, chemical data and their relationship. It is therefore proposed that computational 
future work could be undertaken that would involve machine learning algorithms comparing 
the 52 screening compounds with known active compounds in the literature. This strategy 
would compare the structures to a large data set of known compounds with activity and would 
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indicate certain compounds that may show activity. This process would have huge advantages 
such as prevention of material loss, increasing the chances of hits and less manual labour. Also, 
less money would be spent on screening and re-synthesising screening compounds. In terms of 
SAR, machine learning programs could be used to accurately predict in silico how structure 
modifications influence biological behaviour.139 To conclude, these suggestions with the use 
of machine learning could potentially increase activity and efficiency, there it could play 
crucial part in future LOS strategies.  
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6.0 Experimental 
 
6.1 General experimental 
 
All reactions were carried out under an atmosphere of nitrogen. Solvents were removed under 
reduced pressure using a Büchi rotary evaporator and a Vacuubrand PC2001 Vario diaphragm 
pump.  
 
All other solvents and reagents were of analytical grade and dried using a solvent Pure Solv 
MD solvent purification system (Innovative Technology Inc.) Commercially available starting 
materials were obtained from Sigma–Aldrich, Fluorochem Ltd and Alfa Aesar.  
 
Flash column chromatography was carried out using silica (35-70 μm particles). Thin layer 
chromatography was carried out on commercially available pre-coated glass or aluminium 
plates (Merck silica 2 8 8 0 Kieselgel 60F254).  
 
Analytical LC-MS was performed using a system comprising of a Bruker HCT Ultra ion trap 
mass spectrometer equipped with electrospray ionization and an Agilent 1200 series LC made 
up of, a high vacuum degasser, a binary pump, a high performance autosampler, an autosampler 
thermostat, a thermostated column compartment and diode array detector.  
 
Proton and carbon NMR spectra were recorded on a Bruker Avance DPX 300, Avance 500, 
AV-3 400 or DRX 500 or JEOL ECA600II spectrometer using an internal deuterium lock. 
Carbon NMR spectra were recorded with composite pulse decoupling using the watts 16 pulse 
sequence. DEPT, COSY, HMQC and HMBC pulse sequences were routinely used to aid the 
assignment of spectra. Chemical shifts are quoted in parts per million downfield of 
tetramethylsilane, and coupling constants (J) are given in Hz. NMR spectra were recorded at 
300 K unless otherwise stated.  
 
Melting points were determined on a Reichert hot stage microscope and are uncorrected.  
 
Infrared spectra were recorded on a Bruker alpha FT-IR spectrometer using a “platinum ATR” 
accessory and are reported in wavenumbers (cm–1).  
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High resolution mass spectrometry was routinely performed on a Bruker HCT Ultra 
spectrometer using electrospray (+) ionization. Nominal and accurate mass spectrometry using 
electrospray ionisation was carried in the School of Chemistry at the University of Leeds, using 
a Bruker MaXis Impact spectrometer. 
 
6.2 General procedures  
 
General Procedure A: 3-Hydroxypyridinium salt 
To a solution of 3-hydroxypyridine (1.0 eq.) in solvent (0.2-1.8M) at rt was added alkyl halide 
(1.0 eq.). The reaction mixture was heated at reflux for 16 h, then cooled and concentrated in 
vacuo.  
General Procedure B: Cycloaddition with pyridinium salt 
To a solution of compound salt 87 (1.3 eq.) in anhydrous THF (0.2 M) at rt was added 
vinylsulfone (1.0 eq.) and triethylamine (2.0 eq.). The reaction mixture was heated at reflux for 
16 h – 2.5 d then cooled to rt and filtered. The crude mixture was taken up in water, and the 
aqueous phase was extracted with EtOAc (× 3) and the combined organic extracts were dried 
over MgSO4 and concentrated in vacuo.  
 
General Procedure C: Cycloaddition with methylhydroxypyridinium salt 
To a solution of compound methyl salt 105 (1.3 eq.) in anhydrous THF (0.2 M) at rt was added 
vinyl compound (1.0 eq.), and silver oxide (1.8 eq.). The reaction mixture was covered from 
light and heated at reflux for 16 h - 2.5 d. The reaction was then cooled to rt and silver iodide 
was filtered off. The crude mixture was taken up in water, and the aqueous phase was extracted 
with EtOAc (× 3) and the combined organic extracts were dried over MgSO4 and concentrated 
in vacuo.  
 
General procedure D: Vinyl sulfonyl derivatives 
To a stirred solution of amine (1.0 eq.) and NEt3 (2.2 eq.) in DCM (0.2M) at −78 °C was added 
dropwise of 2-chloroethanesulfonyl chloride 123 (1.1 eq.) in DCM (0.2M) over 4 h. The 
mixture was allowed to warm to rt. The crude mixture was taken up in water, and the aqueous 
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phase was extracted with DCM (× 3) and the combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. 
 
General procedure E: Strong cation exchange solid phase extraction (SCX SPE)  
TfOH (0.5 M in MeOH, 10 mL / 5 g SCX SPE) was dripped through the SCX SPE cartridge 
prior to use. MeOH (20 mL) was then flushed through using pressurised air. The crude residue 
was loaded (3.5 mmol / 5 g SCX SPE silica) in the minimum amount of MeOH. The cartridge 
was flushed with MeOH and the fractions were collected and monitored by TLC. The cartridge 
was then flushed with sat. NH3/MeOH and the fractions were collected and monitored by TLC. 
Fractions containing product were combined and concentrated.  
General Procedure F: Hydrogenation using Pd/C or Pd(OH2)/C  
The substrate (1.0 eq.) was dissolved in MeOH or EtOH (~20 mL g-1) and added via syringe 
to a round-bottomed flask containing 10 wt% Pd/C (% w/w as specified) or 20 wt% Pd(OH)2/C 
(% w/w as specified) submerged in minimal solvent (MeOH or EtOH) under N2. If required, 
conc. HCl (~12 M) was added as specified. The head space of the flask was exposed to a 
sequence of vacuum/H2 flushes (×3), then exposed to an atmosphere of H2 (balloon). The 
reaction was monitored by TLC until complete. At this point the balloon was removed and the 
reaction mixture was purged with a vacuum then with N2 (with a gas outlet) for 5 minutes. The 
reaction mixture was filtered through Celite eluting with MeOH, then concentrated in vacuo. 
The product was typically used in the next step without further purification.  
General procedure G: Alcohol TBS protection  
 
To a stirred solution of alcohol (1.0 eq.) in anhydrous DMF (0.5M) at 0 oC, was added tert-
butyldimethylsilyl trifluoromethanesulfonate (1.1 eq.), imidazole (2.0 eq.). The reaction 
mixture was left to stir for 16 h at rt. The crude mixture was taken up in water, and the aqueous 
phase was extracted with EtOAc (3 ×) and the combined organic extracts were washed with 
brine, dried over MgSO4 and concentrated in vacuo. 
 
General procedure H: Oxidative desulfonylation  
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To a stirred solution of protected alcohol (1.0 eq.) in THF (0.2 M) at −78 °C was added 
LiHMDS (1 M solution in THF, 10 eq.) dropwise. After 10 min, dimethyl disulfide (20 eq.) 
was added and stirred for 16 h at rt. The crude mixture was taken up in water, and the aqueous 
phase was extracted with DCM (3 ×) and the combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The reaction mixture was taken up in 1,4-dioxane (0.2M) 
and followed by an addition of conc.HCl (60 eq.). The reaction mixture was heated at reflux 
for 16 h, cooled to rt and concentrated in vacuo 
 
General Procedure I: DIBAL reduction 
To a solution of ketone (1.0 eq.) in anhydrous solvent (0.08 M) at -78 oC was added DIBAL 
(1M cyclohexane) (3.0 eq.) dropwise over 0.5 h. The reaction mixture was stirred for 4 h at -
78 oC and then allowed to warm to rt. The residue was taken up in saturated potassium sodium 
tartrate tetrahydrate solution and stirred for 1 h. The aqueous phase was extracted with DCM 
(×3) and the combined organic extracts were dried over MgSO4 and concentrated in vacuo. 
 
General procedure J: thiazole Thiazole formation 
To a stirred solution of alpha-chlorinated ketone (1.0 eq.) in DMF (0.15 M) at rt was added 
thiobenzamide (4.5 eq.). The reaction mixture was heated at reflux for 16h, then cooled and 
concentrated in vacuo.  
 
General procedure K: Pyrimidine formation 
To a solution of ketone (1.0 eq.) in EtOH (0.5 M) at rt was added 2,4,6-tris(trifluoromethyl)-
1,3,5-triazine (2.0 eq.) and TFA (10 mol%). The reaction mixture was heated at reflux for 16 
h, quenched with NaHCO3. The crude mixture was was taken up in EtOAc, and aqueous phase 
was extracted with EtOAC (3 ×) and the combined organic extracts were washed with water 
(3 ×), dried over MgSO4 and concentrated in vacuo. 
 
General procedure L: Isoxazole formation 
To a solution of enone (1.0 eq.) in THF/Et2O (1:1) (0.1M) at 0 
oC was added nitroethane (2.0 
eq.), phenylisocyanate (4.1 eq.) and triethylamine (0.08 eq.). The reaction was left to stir for 
16 h at room temperature and then filtered. The crude mixture was taken up in water, and the 
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aqueous phase was extracted with Et2O (3 ×) and the combined organic extracts were dried 
over MgSO4 and concentrated in vacuo.  
 
General procedure M: Dihydropyrazole formation 
To a solution of enone (1.0 eq.) in anhydrous THF (0.2M) at 0 oC was added ethyl diazoacetate 
(contains ≥13 wt. % dichloromethane) (2.0 eq.). The reaction mixture was stirred for 3 d at rt. 
The crude mixture was taken up in water, and the aqueous phase was extracted with EtOAc (3 
×) and the combined organic extracts were dried over MgSO4 and concentrated in vacuo.  
 
General procedure N: Pyrazole formation 
To a solution of dihydropyrazole (1.0 eq.) in MeOH (0.2M), was added NaOH (2M, 10 eq.). 
The reaction was stirred at rt and monitored by LC-MS, where more NaOH (2M) was added 
until the reaction went to completion. The crude mixture was neutralised to pH 7 and taken up 
in DCM, and the aqueous phase was extracted with DCM. The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo. 
 
General procedure O: Pyridine formation 
To a solution of ketone (1.0 eq.) in EtOH (0.2 M) at rt was added propylamine (2.0 eq.) and 
sodium tetrachloroaurate(III) dihydrate (2.5 mol%). The reaction mixture was heated at 80 oC 
for 16 h. The crude mixture was concentrated in vacuo.  
 
General procedure P: Indole synthesis  
To a solution of ketone (1.0 eq.) in anhydrous DMF (0.2M) at rt was added 2-iodoaniline (1.2 
eq.), Pd(OAc)2 (10 mol%) and DABCO (1.0 eq.). The reaction was stirred for 48 h at 105 
oC 
and then cooled to rt. The crude mixture was taken up in water, and the aqueous phase was 
extracted with EtOAc (3 ×) and the combined organic extracts were washed with brine, dried 
over MgSO4 and concentrated in vacuo.  
 
General procedure Q: Sulfonamide formation 
To a stirred solution of nucleophile (1.0 eq.) in anhydrous DMF (0.2M) at rt was added base 
(4 eq.) and sulfonyl chloride (8.0 eq.). The reaction was left to stir for 16 h at rt. If the reaction 
had not gone to completion, then heated until completion. The reaction mixture was 
concentrated in vacuo.  
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General procedure R: SNAr/Alkylation formation 
To a stirred solution of nucleophile (1.0 eq.) in anhydrous DMF (0.2M) at rt was added base 
(1.5 eq.). The reaction was left to stir for 0.5 h at 0 oC, then electrophile (3.0 eq.) was added 
and the reaction left to stir for 16 h at rt. If the reaction had not gone to completion, then heat 
at 80 oC until completion.  
 
General procedure S: Intramolecular Heck reactions 
To a stirred solution of enone (1.0 eq.) in PhMe (0.2 M) at rt was added sodium formate (1.5 
eq.), Pd(OAc)2 (10 mol%), PPh3 (20 mol%) and ZnCl2 (1.0 eq.). The reaction mixture was 
heated at reflux for 16h, then cooled and concentrated in vacuo.  
 
General Procedure T: 1,4-addition series 
To a solution of enone (1.0 eq.) in degassed dioxane:H2O (6:1) (0.3 M) at rt was added boronic 
acid (4 eq.), chloro(1,5-cyclooctadiene)rhodium(I) dimer (2.5 mol%) and triethylamine 
(1.0 eq.). The reaction mixture was left to stir for 16 h at 80 oC. Once cooled to rt the crude 
mixture was concentrated in vacuo.  
 
General procedure U: Pyrrolidine formation 
To a solution of enone (1.0 eq.) in anhydrous MeCN (0.2M) at rt was added N-
(Methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (2.2 eq.) and lithium fluoride (2.5 
eq.). The reaction mixture was heated at reflux for 16 h. The crude mixture was concentrated 
in vacuo.  
 
General procedure V: Amide formation 
To a solution of amine or amine hydrochloride salt (1.0 eq.) in anhydrous DCM (3 mL) at rt 
was added acid chloride (8.0 eq.) and pyridine (4.0 eq.). The reaction was left to stir for 16 h 
at room temperature, then NaOH (5.0 eq.) in MeOH/water (1:1) was added and stirred at rt for 
16 hours. The crude mixture was neutralised to pH 7 and taken up in DCM, and the aqueous 
phase was extracted with DCM. The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo. 
 
General procedure W: Reductive amination decoration with amine-containing scaffold 
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To a solution of amine or amine hydrochloride salt (1.0 eq.) in anhydrous DMF (0.2M) in 4A 
MS at rt was added aldehyde/ketone (5.0 eq.). The reaction was left to stir for 16 h at rt, then 
the reaction mixture was cooled to 0 oC and NaBH4 (3.0 eq.) was added and the reaction left to 
stir for 3 h at rt. If the reaction had not gone to completion, then heat at 80 oC until completion. 
The reaction mixture is concentrated in vacuo.  
 
General procedure X: Reductive amination with ketone –containing scaffold 
 
To a stirred solution of ketone (1.0 eq.) in MeOH (0.2 M) at rt was added amine (10 eq.) and 
Ti(OiPr)4 (2.0 eq.). After 6 h the reaction mixture was cooled to 0 
oC and NaBH4 (1.5 eq.) was 
added portionwise. The reaction mixture was warmed to rt, stirred for 3 h, then concentrated 
in vacuo. The residue was taken up in EtOAc and ammonium hydroxide (2 M, 6.0 eq.) was 
added. The resulting mixture was dried over MgSO4, and then filtered through celite. The 
resulting solution was concentrated in vacuo. 
 
General procedure Y: Urea/carbamate synthesis 
To a solution of alcohol (1.0 eq.) in anhydrous DMF (0.2 M) at rt was added base (6.0 eq.). 
The reaction mixture was stirred for 30 min and isocyanate (2.5 eq.) was added and the reaction 
was stirred overnight. Water was added and the reaction was stirred for 2 h, then the crude 
mixture was taken up in EtOAc, and aqueous phase was extracted with EtOAC (3 ×) and the 
combined organic extracts were washed with water (5 ×), dried over MgSO4 and concentrated 
in vacuo.  
 
General procedure Z: Amine alkylation  
 
To a stirred solution of nucleophile (1.0 eq.) in anhydrous DMF (0.2M) at rt was added 
NaHCO3 (6.0 eq.) and electrophile (4.0 eq.) was added and the reaction left to stir for 16 h at 
rt. If the reaction had not gone to completion, it was heated at 80 oC until completion.  
 
General procedure : Pyrazole alkylation  
 
To a stirred solution of pyrazole (1.0 eq.) in anhydrous DMF (0.2M) at rt was added KOH (2.3 
eq.) and electrophile (3.0 eq.), then the reaction left to stir for 16 h. The reaction mixture was 
concentrated in vacuo.  
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6.3 Experimental  
1-Benzyl-3-hydroxypyridin-1-ium bromide (87)98 
 
 
 
General procedure A was followed using 3-hydroxypyridine (3.00 g, 32.0 mmol, 1.0 eq.), 
benzyl bromide (3.80 mL, 32.0 mmol, 1.0 eq.) and 2-propanol (20 mL). Title compound 87 
(8.43 g, 32.0 mmol, 99%) was isolated as a yellow solid. The NMR data is in accordance with 
the literature.98 1H NMR (400 MHz, DMSO-d6): δ 11.97 (1H, s, OH), 8.81 – 8.66 (2H, m, 
ArH), 8.01 – 7.93 (2H, m, ArH), 7.59 – 7.52 (2H, m, ArH), 7.52 – 7.38 (3H, m, ArH), 5.80 
(2H, s, NCH2). 13C NMR (101 MHz, DMSO-d6): δ 157.6 (Ar), 136.2 (ArH), 134.8 (Ar), 133.1 
(ArH), 132.3 (ArH), 129.8 (ArH), 129.7 (ArH), 129.4 (ArH), 129.2 (ArH), 63.6 (CH2). IR νmax 
(neat)/cm-1: 3339 (OH), 3031, 2991 (C-H), 2867, 2736, 2632, 1494, 1454 (C=C); HRMS 
(ESI): C12H11NO [M-H]: calculated 186.0913, found 186.0913.  
 
N-Benzyl-3-oxypyridinium betaine (106)71 
 
A solution of pyridinium salt 87 (8.43 g, 32.0 mmol, 1.0 eq.) was taken up in 3:1 THF/water 
and Amberlite IRA-420 resin was added. The reaction was stirred for 0.5 h, then the reaction 
mixture was filtered and concentrated in vacuo. Purification by flash chromatography on silica 
gel, eluting with 10% MeOH in DCM with 1 vol% NH4OH afforded the title compound 106 
(5.39 g, 29.1 mmol, 92%) as a yellow solid; Rf = 0.30, (10% MeOH in DCM 1 vol% NH4OH). 
The NMR Data is in accordance with the literature.71 1H NMR
 
(400 MHz, CDCl3) δ 8.59 (1H, 
s, ArH), 7.90 (1H, d, J 5.8, ArH), 7.77 (1H, dd, J 8.8, 2.3, ArH), 7.54 (1H, dd, J 8.8, 5.8, ArH), 
7.45 – 7.37 (5H, m, ArH), 5.70 (2H, s, NCH2); 13C NMR (101 MHz, CDCl3) δ 162.9 (Ar), 
133.8 (ArH), 133.2 (Ar), 132.4 (ArH), 130.0 (ArH), 129.7 (ArH), 129.5(ArH), 129.0 (ArH), 
127.7 (ArH), 64.9 (NCH2). IR νmax (neat)/cm-1: 3339 (O-H), 3035, 2992, 2864, 2751, 1495, 
1454 (C=C), 1412; HRMS (ESI): C12H11NO [M
+]: calculated 186.0913, found 186.0916. 
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3-Hydroxy-1-methylpyridin-1-ium iodide (105)140 
 
 
 
General procedure A was followed using 3-hydroxypyridine (3.00 g, 32 mmol, 1.0 eq.), 
iodomethane (2.00 mL, 32 mmol, 1.0 eq.) in 2-propanol (20 mL). Title compound 105 (7.50 g, 
31.6 mmol, 99%) as an orange solid. The NMR data is in accordance with the literature.140 1H 
NMR (400 MHz, DMSO-d6): 11.83 (1H, s, OH), 8.52 – 8.43 (2H, m, ArH), 7.97 – 7.87 (2H, 
m, ArH), 4.28 (3H, s, CH3); 13C NMR (126 MHz, DMSO-d6): 157.2 (Ar), 136.8 (ArH), 134.2 
(ArH), 131.3 (ArH), 128.7 (ArH), 26.0 (CH3); IR νmax (neat)/cm-1: 3023, 2967 (C-H), 1789, 
1720 (C=O), 1635, 1553, 1510, 1495 (C=C); HRMS (ESI): C6H7NO [M-H]: calculated 
110.0597, found 110.0600. 
 
 
1-(2-Bromo-4-fluorobenzyl)-3-hydroxypyridin-1-ium bromide (132) 
 
 
General procedure A was followed using 3-hydroxypyridine (1.50 g, 15.75 mmol) and 2-
bromo-4-fluorobenzyl bromide (4.23 g, 15.75 mmol) in THF (25 mL). Title compound 132 
(5.28 g, 14.5 mmol, 99%) as a colourless solid; δH (400 MHz, DMSO-d6): 11.98 (1H, s, OH), 
8.61 – 8.56 (2H, m, ArH), 8.08 – 7.98 (2H, m, ArH), 7.78 (1H, dd, J 8.5, 2.7, ArH), 7.58 (1H, 
dd, J 8.7, 5.9, ArH), 7.42 (1H, td, J 8.5, 2.7, ArH), 5.93 (2H, s, NCH2); δC (101 MHz, DMSO-
d6): 162.8 (d, J 251.2, Ar-F), 157.5 (Ar), 136.5 (ArH), 133.9 (d, J 9.0, ArH), 133.3 (ArH), 132.8 
(ArH), 129.9 (d, J 3.1, Ar), 129.3 (ArH), 124.9 (d, J 10.2, Ar), 121.2 (d, J 25.2, ArH), 116.2 (d, 
J 21.3, ArH), 62.9 (CH2); IR νmax (neat)/cm-1: 3024 (CH), 2915, 2826, 2749, 1558 (C=C), 1479, 
1456, 1433; HRMS (ESI): C12H10Br
79FNO [M-H]: calculated 282.9997, found 282.9954 
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3-Hydroxy-1-(4-methoxybenzyl)pyridin-1-ium chloride (128) 
 
 
 
General procedure A was followed using 3-hydroxypyridine (2.00 g, 21.0 mmol) and 4-
methoxybenzyl chloride (2.80 mL, 21.0 mmol) in toluene (10 mL). Title compound 128 
(5.21 g, 20.7 mmol, 99%) as a colourless solid. The NMR data is in accordance with the 
literature. 76 δH(400 MHz, DMSO-d6); 8.78 (1H, m, ArH), 8.68 (1H, m, ArH), 8.12 – 8.02 
(1H, m, ArH), 7.94 (1H, m, ArH), 7.64 – 7.45 (2H, m, ArH), 7.04 – 6.97 (2H, m, ArH), 5.71 
(2H, s, CH2), 3.76 (3H, s, OMe); δC(101 MHz, DMSO-d6); 160.5 (Ar), 157.8 (Ar), 135.6 
(ArH), 132.9 (ArH), 131.1 (ArH), 129.4 (ArH), 129.2 (ArH), 126.7 (Ar), 115.0 (ArH), 63.3 
(CH2), 55.7 (OMe); IR νmax (neat)/cm-1: 3040, 2992, 2904 (CH), 2446, 1571 (C=C), 1504, 
1546, 1438; HRMS (ESI): C13H13NO2 [M-H]: calculated 216.1019, found 216.1011.  
 
1-(2-Bromobenzyl)-3-hydroxypyridin-1-ium bromide (131) 
 
 
 
General procedure A was followed using 3-hydroxypyridine (1.15 g, 12.0 mmol) and 2-
bromobenzyl bromide (3.00 g, 12.0 mmol) in THF (19 mL). Title compound 131 (4.10 g, 
11.9 mmol, 99%) as a colourless solid. The NMR data is in accordance with the literature.141 
δH(400 MHz, DMSO-d6); 12.03 (1H, s, OH), 8.83 – 8.41 (2H, m, ArH), 8.13 – 7.91 (2H, m, 
ArH), 7.78 (1H, d, J 8.0, 1.2, ArH), 7.54 – 7.46 (1H, m, ArH), 7.43 (1H, td, J 7.7, 1.8, ArH), 
7.35 (1H, dd, J 7.6, 1.7, ArH), 5.91 (2H, s, CH2); δC(101 MHz, DMSO-d6); 157.6 (Ar), 136.7 
(ArH), 133.9 (ArH), 133.5 (Ar), 133.5 (ArH), 132.8 (ArH), 131.9 (ArH), 131.7 (ArH), 129.4 
(ArH), 129.2 (ArH), 123.9 (Ar), 63.7 (CH2); IR νmax (neat)/cm-1: 3404 (OH), 3008 (CH), 2993, 
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2947, 1584, 1508 (C=C), 1459, 1416; HRMS (ESI): C12H10Br
79NO [M-H]: calculated 
264.0019, found. 263.7976.  
 
1-(4-Fluorobenzyl)-3-hydroxypyridin-1-ium bromide (129) 
 
 
 
General procedure A was followed using 3-hydroxypyridine (2.28 mL, 24.1 mmol) and 4-
fluorobenzyl bromide (3.00 mL, 24.1 mmol) in THF (14 mL). Title compound 129 (6.80 g, 
23.9 mmol, 99%) as a white solid; δH(400 MHz, DMSO-d6); 11.97 (1H, s, OH), 8.92 – 8.59 
(2H, m, ArH), 8.26 – 7.90 (2H, m, ArH), 7.82 – 7.54 (2H, m, ArH), 7.43 – 7.05 (2H, m, ArH), 
5.81 (2H, s, CH2); δC(101 MHz, DMSO-d6); 163.0 (d, J 246.2, ArF), 157.6 (Ar), 136.1 (ArH), 
133.1 (ArH), 132.3 (ArH), 131.9 (d, J 8.7, ArH), 131.1 (d, J 3.1, Ar), 129.4 (ArH), 116.6 (d, J 
21.7, ArH), 62.7 (CH2); IR νmax (neat)/cm-1: 3061, 2872, 2830 (CH), 2510, 1604, 1578 (C=C), 
1506, 1487; HRMS (ESI): C12H10FNO [M-H]: calculated 204.0819, found 204.0816. 
 
4-(Vinylsulfonyl)morpholine (119) 
 
General procedure C was followed using morpholine (1.75 mL, 20.1 mmol), 2-
chloroethanesulfonyl chloride 30 (1.9 mL, 18.4 mmol), and NEt3 (2.90 mL, 20.1 mmol) in 
DCM (40 mL). Purification by flash chromatography on silica gel, eluting with a gradient of 
70% EtOAc in hexane afforded the title compound 119 (1.00 g, 5.64 mmol, 31%) as a 
colourless oil; Rf = 0.28, (40% EtOAc in hexane); δH(400 MHz, Chloroform-d): 6.44 (1H, 
dd, J 16.6, 9.9, CH), 6.26 (1H, d, J 16.6, CH2), 6.10 (1H, d, J 9.9, CH2), 3.81 – 3.72 (4H, m, 
OCH2CH2), 3.18 – 3.09 (4H, m, NCH2CH2); δC(101 MHz, Chloroform-d): 131.8 (CH), 129.5 
(CH2), 66.2 (OCH2CH2), 45.6 (NCH2CH2); IR νmax (neat)/cm-1: 3105 (CH), 3057, 2972, 2899, 
1610 (C=C), 1455, 1343 (S=O); HRMS (ESI): C6H12NO3S [M+H
+]: calculated 178.0532, 
found 178.0530. 
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N,N-Dimethylethenesulfonamide (121) 
 
General procedure C was followed using dimethylamine (2M in THF) (24.0 mL, 48.0 mmol), 
2-chloroethanesulfonyl chloride (3.00 mL, 28.7 mmol), NEt3 (6.00 mL, 43.0 mmol) in DCM 
(90 mL). Purification by flash chromatography on silica gel, eluting with a gradient of 70% 
EtOAc in hexane afforded the title compound 121 (2.59 g, 19.1 mmol, 67%) as a yellow oil; 
Rf 0.57, (70% EtOAc in hexane); δH(300 MHz, Chloroform-d): 6.45 (1H, dd, J 16.6, 9.9, 
CH), 6.25 (1H, d, J 16.6, CH2), 6.06 (1H, d, J 9.9, CH2), 2.80 (6H, s, NMe2); δC(101 MHz, 
Chloroform-d): 131.4 (CH), 128.6 (CH2), 37.5 (NMe2); IR νmax (neat)/cm-1: 3105, 3058 (C-
H), 3019, 2967, 2885, 2813, 1461 (C=C), 1333 (S=O); HRMS (ESI): C4H10NO2S [M+H
+]: 
calculated 136.0427, found 136.0635; 
 
 
2,4,6-Trichlorophenyl ethenesulfonate (120)75 
 
General procedure C was followed using 2,4,6-trichlorophenol (1.99 g, 10.0 mmol, 1.0 eq.), 
NEt3 (31 mL, 22 mmol, 2.2 eq.), and 2-chloroethanesulfonyl chloride (11.5 mL, 11.0 mmol, 
1.1 eq.) in DCM (250 mL). Purification through a plug of 10% K2CO3/silica with DCM (250 
mL). Title compound 120 (7.70 g, 21.8 mmol, 70%) as a colourless solid; Rf = 0.40, (30% 
EtOAc in hexane). The data is in accordance with the literature.75 1H NMR
 
(400 MHz, CDCl3) 
7.40 (2H, s, ArH), 6.94 (1H, dd, J 16.5, 9.9, CH), 6.56 (1H, dd, J 16.5, 0.9, CH2), 6.26 (1H, 
dd, J 9.9, 0.9, CH2). 
13C NMR (101 MHz, CDCl3): 142.0 (Ar), 133.9 (ArH), 133.1 (2-CH), 
131.3 (Ar), 130.8 (Ar), 129.2 (1-CH2); IR νmax (neat)/cm-1: 3114, 3073, 2980 (C-H), 2498 
(C=C), 1613, 1561, 1441 (C=C), 1374 (S=O); HRMS (ESI): C8H6Cl3O3S [M+H
+]: calculated 
285.9025, found 285.9025. 
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8-Benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-carbonitrile and 
8-Benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-7-carbonitrile (109) 
 
 
To a solution of compound 87 (1.00 g, 3.76 mmol, 1.0 eq.) was added acrylonitrile (7.30 mL, 
113 mmol, 30 eq.), hydroquinone (10 mg, 0.08 mmol, 0.02 eq.) and triethylamine (1.05 mL, 
7.52 mmol, 2.0 eq.). The reaction mixture was heated at reflux for 16 h, cooled to rt and 
concentrated in vacuo. Purification by flash chromatography on silica gel, eluting with 40% 
EtOAc in hexane, to give in order of elution, compound 109a (242 mg, 1.02 mmol, 27%) as a 
brown oil; Rf = 0.28 (40% EtOAc in hexane), followed by compound 109b (161 mg, 0.68 mmol, 
18%) as a brown oil; Rf = 0.29 (40% EtOAc in hexane). The product was a mix of inseparable 
isomers and the major diagnostic peaks were used to report the ratio of isomers, 4:4:2:1. The 
NMR data is in accordance with the literature142 and the major peaks are reported: 
 
(1S*,5S*,6R*)-8-Benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-carbonitrile (109a) 
 
1H NMR
 
(400 MHz, CDCl3): 7.40 – 7.20 (5H, m, ArH), 6.91 (1H, dd, J 9.8, 5.0, 4-CH), 6.15 
(1H, dd, J 9.8, 1.6, 3-CH), 4.02 (1H, d, J 5.0, 5-CH), 3.92 (1H, d, J 13.3, NCH2), 3.81 (1H, d, 
J 13.3, NCH2), 3.78 – 3.70 (1H, m, 1-CH), 2.99 (1H, dd, J 9.3, 3.4, 6-CH ), 2.76 (1H, ddd, J 
14.0, 7.9, 3.4, 7-CH2), 2.15 (1H, ddd, J 14.0, 9.3, 0.9, 7-CH2). 13C NMR (101 MHz, CDCl3): 
194.6 (C=O), 150.1 (4-CH), 136.8 (Ar), 129.0 (3-CH), 128.7 (ArH), 128.6 (ArH), 127.8 (ArH), 
119.1 (CN), 71.4 (1-CH), 57.4 (5-CH), 53.4 (NCH2), 34.3 (6-CH), 26.3 (7-CH2); IR νmax 
(neat)/cm-1: 3027, 2953 (C-H), 2843, 1733 (C=O), 1683, 1495, 1454 (C=C), 1435; HRMS 
(ESI): C15H15N2O [M+H
+]: calculated 239.1180, found 239.1179. 
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(1S*,5S*,6S*)-8-Benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-carbonitrile (109b) 
 
1H NMR
 
(501 MHz, CDCl3): 7.41 – 7.18 (5H, m, ArH), 7.07 (1H, dd, J 9.9, 5.0, 4-CH), 6.33 
(1H, dd, J 9.9, 1.5, 3-CH), 3.99 – 3.96 (1H, m, 5-CH), 3.73 (1H, d, J 13.0, NCH2), 3.70 (1H, 
d, J 13.0, NCH2), 3.65 (1H, ddt, J 7.9, 1.9, 1.0, 1-CH), 3.38 (1H, dt, J 10.4, 6.0, 6-CH), 2.86 
(1H, ddd, J 13.9, 10.4, 7.9, 7-CH2), 1.96 (1H, ddd, J 13.9, 6.0, 1.1, 7-CH2); 13C NMR (126 
MHz, CDCl3): 197.2 (C=O), 145.7 (4-CH), 136.8 (Ar), 130.0 (3-CH), 128.7 (ArH), 128.6 
(ArH), 127.9 (ArH), 119.4 (CN), 68.2 (1-CH), 58.9 (5-CH), 53.1 (NCH2), 30.8 (6-CH), 30.1 
(7-CH2); IR νmax (neat)/cm-1: 3063, 3030, 2958 (C-H), 2844, 1759, 1683 (C=O), 1495, 1435 
(C=C); HRMS (ESI): C15H15N2O [M+H
+]: calculated 239.1180, found 239.1179. 
 
tert-Butyl 8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-carboxylate and 
tert-Butyl 8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-7-carboxylate (112)97 
 
 
To a solution of compound 87 (250 mg, 1.35 mmol, 1.2 eq.) in anhydrous 1,4-dioxane (3 mL) 
was added tert-butyl acrylate (0.46 mL, 3.13 mmol, 1.0 eq.) and triethylamine (1.30 mL, 
9.40 mmol, 3.0 eq.). The reaction mixture was heated at reflux for 16 h, cooled to rt and 
concentrated in vacuo. Purification by flash chromatography on silica gel, eluting with 30% 
EtOAc in hexane to give compound 112a (640 mg, 2.04 mmol, 65%) as a brown oil; Rf = 0.50, 
(30% EtOAc in hexane). The product was a mix of inseparable isomers and the major 
diagnostic peaks were used to report the ratio of isomers, 8:3:3:2. Data for the major isomer is 
reported: 
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(1S*,5S*,6R*)-tert-Butyl 8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-carboxylate 
(112a)97 
 
1H NMR (501 MHz, CDCl3): 7.36 – 7.21 (5H, m, ArH), 6.95 (1H, dd, J 9.8, 5.0, 4-CH), 6.08 
(1H, dd, J 9.8, 1.6, 3-CH), 3.97 (1H, d, J 5.0, 5-CH), 3.85 (1H, d, J 13.4, NCH2), 3.73 – 3.65 
(1H, m, NCH2), 3.47 (1H, dt, J 10.3, 6.1, 6-CH), 2.91 (1H, ddd, J 13.8, 8.0, 3.5, 7-CH), 2.84 
(1H, dd, J 9.2, 3.4, 1-CH2), 1.84 (1H, ddd, J 13.8, 9.2, 0.9, 7-CH2), 1.44 (9H, s, 
tBu); 13C NMR 
(126 MHz, CDCl3): 199.3 (C=O), 171.7 (C=O), 147.7 (4-CH), 138.2 (Ar), 128.4 (ArH), 128.4 
(ArH), 128.3 (ArH), 128.3 (3-CH), 81.2 (C), 69.0 (1-CH), 60.1 (5-CH), 51.9 (NCH2), 48.2 (6-
CH), 28.1 (tBu), 27.5 (7-CH2); IR νmax (neat)/cm-1: 3029, 2976 (C-H), 1722 (C=O), 1682, 1604, 
1585, 1495, 1453 (C=C); HRMS (ESI): C19H23NNaO3 [M+Na]: calculated 336.1571, found 
336.1570. 
 
 
Methyl 8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-carboxylate and 
Methyl 8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-7-carboxylate(110)73  
 
To a solution of compound 87 (1.00 g, 3.76 mmol, 1.0 eq.) was added methyl acrylate 
(3.30 mL, 37.6 mmol, 10 eq.), hydroquinone (10 mg, 0.07 mmol, 0.02 eq.) and triethylamine 
(1.05 mL, 7.52 mmol, 2.0 eq.). The reaction mixture was heated neat at reflux for 16 h, cooled 
to rt and concentrated in vacuo. Purification by flash chromatography on silica gel, eluting with 
20% EtOAc in hexane to give compound 110 (939 mg, 3.46 mmol, 92%) as a brown oil; Rf = 
0.16, (20% EtOAc in hexane). The product was a mix of inseparable stereo/regioisomers and 
the major diagnostic peaks were used to report the ratio of isomers, 6:4:1:2. Only major listed, 
1H NMR data was in accordance with the literature:73  
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(1S*,5S*,6R*)-Methyl 8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-carboxylate (110a)73 
 
1H NMR
 
(400 MHz, CDCl3): 7.40 – 7.19 (5H, m, ArH), 6.98 (1H, dd, J 9.8, 5.0, 4-CH ), 6.15 
– 6.08 (1H, m, 3-CH), 4.08 (1H, d, J 5.0, 5-CH), 3.84 (1H, d, J 13.5, NCH2), 3.79 – 3.51 (5H, 
m, NCH2, OCH3, 1-CH), 3.01 – 2.88 (2H, m, 6-CH, 7-CH2), 1.98 – 1.90 (1H, m, 7-CH2). 13C 
NMR (101 MHz, CDCl3) 198.8 (C=O), 173.1 (C=O), 147.5 (4-CH), 137.9 (Ar), 128.6 (ArH), 
128.6 (ArH), 128.5 (3-CH), 128.4 (ArH), 68.5 (1-CH), 60.0 (5-CH), 52.3 (OCH3), 52.0 
(NCH2), 47.0 (6-CH), 27.9 (7-CH2). IR νmax (neat)/cm-1: 3029, 2976 (C-H), 1722, 1683 (C=O), 
1604, 1585, 1495, 1454 (C=C); HRMS (ESI): C16H18NO3 [M+H
+]: calculated 272.1289, found 
272.1289. 
 
(5S*,9S*)-Dihydro-10-(phenylmethyl)-6H-benzocycloheptene-5,9-imin-6-one (108) 71 
 
To a stirred solution of compound 106 (478 mg, 3.35 mmol, 1.0 eq.), in anhydrous MeCN 
(13 mL) was added 2-(trimethylsilyl)phenyltrifluoromethanesulfonate (1.00 g, 3.35 mmol, 1.3 
eq.) and caesium fluoride (3.90 g, 8.56 mmol, 9.9 eq.). The reaction mixture was stirred for 
24 h, then concentrated in vacuo. The resulting mixture was diluted with water (10 mL) and 
EtOAc (10 mL). The phases were separated and the aqueous phase was extracted with EtOAc 
(2 × 10 mL). The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. Purification by flash chromatography on silica gel, eluting with 20% EtOAc in hexane 
afforded the title compound 108 (17 mg, 0.07 mmol, 20%) as a yellow oil; Rf = 0.33, (10% 
EtOAc in hexane). NMR Data is in accordance with the literature.71 1H NMR
 
(400 MHz, 
CDCl3): 7.69 – 6.94 (10H, m, ArH, 8-CH), 5.58 (1H, dd, J 9.7, 1.4, 7-CH), 4.46 (1H, s, 5-CH), 
4.45 (1H, d, J 5.5, 9-CH), 3.78 (2H, s, NCH2); 13C NMR (101 MHz, CDCl3) 194.6 (C=O), 
151.1(8-CH), 145.9 (C), 138.6 (C), 137.4 (C), 129.1 (ArH), 128.6 (ArH), 127.7 (ArH), 127.6 
(ArH), 127.3 (ArH), 126.0 (ArH), 123.1 (7-CH), 123.0 (ArH), 76.8 (5-CH), 64.7 (9-CH), 56.1 
(NCH2); IR νmax (neat)/cm-1: 3063, 3028, 2965 (C-H), 2836, 1756, 1681 (C=O), 1495, 1454 
(C=C); HRMS (ESI): C18H16NO [M+H
+]: calculated 261.1154, found 262.1241. 
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8-Benzyl-6-(phenylsulfinyl)-8-azabicyclo[3.2.1]oct-3-en-2-one and 
8-benzyl-7-(phenylsulfinyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (111)72 
 
To a solution of compound 87 (250 mg, 1.35 mmol, 1.0 eq.) in anhydrous THF (4 mL) was 
added phenylvinylsulfoxide (0.18 mL, 1.35 mmol, 1.0 eq.), hydroquinone (3.00 mg, 0.03 
mmol, 0.02 eq.) and triethylamine (0.34 mL, 2.70 mmol, 2.0 eq.). The reaction mixture was 
heated at reflux for 4 d, cooled to rt and concentrated in vacuo. Purification by flash 
chromatography on silica gel, eluting with 20 % EtOAc in hexane. To give in order of elution, 
compound 108a (81 mg, 0.24 mmol, 18%) as a yellow solid; Rf = 0.40 (20% EtOAc in Hexane), 
followed by compound 108b (25 mg, 0.07 mmol, 6%) as a yellow solid; Rf = 0.45 (20% EtOAc 
in Hexane). The product was a mix of inseparable stereo/regioisomers and the major diagnostic 
peaks were used to report the data and the ratio of isomers, 8:5:3:1:  
 
 (1S*,5S*,6R*)-8-Benzyl-6-phenylsulfinyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (108) 72 
 
1H NMR (400 MHz, CDCl3) δ 7.80 – 7.73 (1H, m, ArH), 7.65 – 7.39 (4H, m, ArH), 7.40 – 
7.22 (5H, m, ArH), 6.98 (1H, dd, J 9.8, 5.0, 4-CH), 6.15 (1H, dd, J 9.8, 1.5, 3-CH) ,4.39 (1H, 
d, J 5.0, 5-CH), 3.96 – 3.83 (1H, m, NCH2), 3.81 – 3.65 (1H, m, NCH2), 3.61 (1H, d, J 7.5, 6-
CH), 3.25 (1H, dd, J 8.5, 3.2, 1-CH), 2.12 (1H, ddd, J 14.6, 7.5, 3.2, 7-CH2), 1.58 (1H, dd, J 
14.6, 8.5, 7-CH2); 13C NMR (101 MHz, CDCl3) 198.0 (C=O), 145.9 (4-CH), 143.0 (C), 137.6 
(C), 132.0 (3-CH), 129.5 (ArH), 128.6 (ArH), 128.5 (ArH), 127.6 (ArH), 125.4 (ArH), 124.7 
(ArH), 69.1 (6-CH), 67.6 (5-CH), 57.7 (1-CH), 51.7 (NCH2), 26.3 (7-CH2). IR νmax (neat)/cm-
1: 3065, 2981 (C-H), 2954, 2926, 1682 (C=O), 1605, 1465 (C=C), 1380 (S=O). 
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(1S*,5S*,6S*)-8-Benzyl-6-phenylsulfinyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (108b) 72 
 
1H NMR (400 MHz, CDCl3) 7.75 – 7.66 (2H, m, ArH), 7.70 – 7.43 (3H, m, ArH), 7.39 – 7.16 
(6H, m, ArH, 4-CH), 6.41 (1H, dd, J 9.8, 1.5, 3-CH), 4.27 – 4.12 (1H, m, 5-CH), 3.93 – 3.66 
(3H, m, NCH2, 6-CH, 1-CH), 3.59 (1H, dd, J 8.0, 1.4, NCH2), 2.17 (1H, ddd, J 14.2, 9.8, 7.7, 
7-CH2), 1.53 – 1.40 (1H, m, 7-CH2). 13C NMR (101 MHz, CDCl3) 197.9 (C=O), 146.6 (4-
CH), 143.0 (C), 137.1 (C), 130.5 (3-CH), 129.6 (ArH), 129.4 (ArH), 128.6 (ArH), 127.7 (ArH), 
125.1 (ArH), 124.8 (ArH), 69.7 (6-CH), 68.7 (5-CH), 59.5 (1-CH), 52.9 (NCH2), 25.7 (7-CH2). 
IR νmax (neat)/cm-1: 3065, 2981 (C-H), 2954, 2926, 1682 (C=O), 1605, 1465 (C=C), 1380 
(S=O). 
 
(1S*,5S*,6R*)-2,4,6-Trichlorophenyl-8-benzyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-
sulfonate (138) 
 
To a solution of compound 87 (250 mg, 1.35 mmol, 1.0 eq.) in anhydrous THF (4 mL) was 
added 2,4,6-trichlorophenyl ethenesulfonate (227 mg, 1.35 mmol, 1.0 eq.), hydroquinone 
(3 mg, 0.03 mmol, 0.02 eq.) and triethylamine (0.34 mL, 2.70 mmol, 2.0 eq.). The reaction 
mixture was heated at reflux for 16 h then cooled to rt and concentrated in vacuo. Purification 
by flash chromatography on silica gel, eluting with 5% EtOAc in hexane. Crystallization from 
EtOAc afforded the title compound 138 (207 mg, 0.59 mmol, 43%) as a yellow solid; Rf = 0.40 
(20% EtOAc in hexane); 1H NMR
 
(500 MHz, CDCl3) 7.41 (2H, s, ArH), 7.37 – 7.23 (5H, m, 
ArH), 6.98 (1H, dd, J 9.8, 5.0, 4-CH), 6.23 (1H, dd, J 9.8, 1.5, 3-CH), 4.40 (1H, d, J 5.0, 5-
CH), 4.16 (1H, dd, J 9.1, 4.6, 6-CH), 3.95 (1H, d, J 13.5, NCH2), 3.84 (1H, d, J 13.5, NCH2), 
3.81 (1H, d, J 7.6, 1-CH), 3.13 (1H, ddd, J 14.6, 7.6, 4.2, 7-CH2), 2.31 (1H, dd, J 14.6, 9.1, 7-
CH2); 
13C NMR (101 MHz, CDCl3) 197.5 (C=O), 144.5 (4-CH), 141.8 (Ar), 137.0 (Ar), 133.2 
(Ar), 130.5 (Ar), 129.6 (3-CH), 129.3 (ArH), 128.6 (ArH), 128.3 (ArH), 127.6 (ArH), 67.8 (1-
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CH), 66.0 (6-CH), 58.6 (5-CH), 51.5 (NCH2), 28.5 (7-CH2); IR νmax (neat)/cm-1: 3087, 3032, 
2945 (CH), 2890, 2833, 1688 (C=O), 1441 (C=C) 1323 (S=O); HRMS (ESI): 
C20H16
35Cl3NO4S [M+]: calculated 471.9944, found 471.9938.  
 
 (1S*,5S*,6R*)-8-Benzyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (89)73 
 
General procedure B was followed using compound 87 (8.30 g, 31.2 mmol, 1.0 eq.), phenyl 
vinyl sulfone (5.24 g, 31.2 mmol, 1.0 eq.), hydroquinone (0.07 g, 0.62 mmol, 0.02 eq.) and 
triethylamine (8.60 mL, 62.3 mmol, 2.0 eq.) in anhydrous THF (154 mL). Crystallization from 
EtOAc twice afforded the title compound 89 (7.70 g, 21.8 mmol, 70%) as a yellow solid; Rf = 
0.40 (30% EtOAc in hexane). The NMR data is in accordance with the literature.73 1H NMR
 
(400 MHz, CDCl3) 7.91 – 7.83 (2H, m, ArH), 7.73 – 7.64 (1H, m, ArH), 7.61 – 7.51 (2H, m, 
ArH), 7.33 – 7.21 (3H, m, ArH), 7.11 – 7.04 (2H, m, ArH), 6.92 (1H, dd, J 9.8, 5.0, 4-CH), 
6.13 (1H, dd, J 9.8, 1.5, 3-CH), 4.17 (1H, d, J 5.0, 5-CH), 3.79 (1H, d, J 13.2, NCH2), 3.68 
(1H, d, J13.2, NCH2), 3.64 – 3.55 (2H, m, 6-CH, 1-CH), 2.80 (1H, ddd, J 14.4, 7.7, 4.6, 7-CH2 
), 2.01 (1H, dd, J 14.4, 9.3, 7-CH2); 
13C NMR (101 MHz, CDCl3): 197.6 (C=O), 145.6 (C), 
138.1 (C), 137.0 (4-CH), 133.9 (ArH), 129.4 (ArH), 129.0 (3-CH), 129.0 (ArH), 128.5 (ArH), 
128.5 (ArH), 127.5 (ArH), 77.2 (6-CH), 68.0 (5-CH), 58.1 (1-CH), 51.6 (NCH2), 27.3 (7-CH2); 
IR νmax (neat)/cm-1: 3169, 3036, 2967 (C=H), 2927, 1672 (C=O), 1477, 1448 (C=C), 1315 
(S=O); HRMS (ESI): C20H20NO3S [M+H
+]: calculated 354.1155, found 354.1158. 
 
(1S*,5S*,6R*)-8-Methyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (115)  
 
General procedure B was followed using compound 105 (780 mg, 5.94 mmol, 1.0 eq.), phenyl 
vinyl sulfone (1.00 g, 5.95 mmol, 1.0 eq.), hydroquinone (10 mg, 0.62 mmol, 0.02 eq.) and 
triethylamine (1.70 mL, 11.9 mmol, 2.0 eq.) in anhydrous THF (2.3 mL). Purification by flash 
chromatography on silica gel, eluting with 30% EtOAc in hexane. Crystallization from EtOAc 
afforded the title compound 115 (330 mg, 1.19 mmol, 20%) as a yellow solid; Rf = 0.40, (30% 
EtOAc in hexane.). The NMR data is in accordance with the literature. 73,143 1H NMR
 
(400 
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MHz, CDCl3) 7.88 – 7.81 (2H, m, ArH), 7.65 – 7.56 (1H, m, ArH), 7.56 – 7.46 (2H, m, ArH), 
6.86 (1H, dd, J 9.8, 5.0, 4-CH), 5.99 (1H, dd, J 9.8, 1.5, 3-CH), 4.16 (1H, d, J 4.9, 5-CH), 3.54 
– 3.43 (2H, m, 6-CH, 1-CH), 2.70 (1H, ddd, J 14.3, 7.7, 4.4, 7-CH2), 2.31 (3H, s, CH3), 1.85 
(1H, dd, J 14.3, 9.1, 7-CH2). 
13C NMR (101 MHz, CDCl3): 197.7 (C=O), 145.4 (4-CH), 138.2 
(Ar), 134.0 (Ar), 129.3 (Ar), 128.7 (Ar), 128.5 (3-CH), 69.9 (6-CH), 67.7 (1-CH), 60.2 (5-CH), 
34.5 (NMe), 27.8 (7-CH2). IR νmax (neat)/cm-1: 3060, 3029, 2945 (C-H), 2899, 1721 (C=O), 
1496, 1448 (C=C), 1369 (S=O); HRMS (ESI): C14H16NO3S [M+H
+]: calculated 278.0845, 
found 278.0845. 
 
 
(1S*,5S*,6R*)-8-Benzyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (117) 
 
 
 
General procedure B was followed using methyl vinyl sulfone (3.4 mL, 38.8 mmol) and benzyl 
salt 87 (14.0 g, 52.4 mmol), triethylamine (11 mL, 77.6 mmol). Purification by crystallization 
from EtOAc afforded the title compound 117 (6.40 g, 22.0 mmol, 57%) as a yellow solid; Rf = 
0.57, (100% EtOAc in hexane); M.Pt. 132.1 – 133.0 oC; δH(400 MHz, Chloroform-d) 7.36 – 
7.20 (3H, m, ArH), 7.12 (2H, dd, J 7.6, 1.8, ArH), 6.93 (1H, dd, J 9.8, 5.0, 4-CH), 6.16 (1H, 
dd, J 9.8, 1.5, 3-CH), 4.02 (1H, d, J 5.0, 5-CH), 3.77 (1H, d, J 12.7, NBn), 3.71 (1H, d, J 12.7, 
NBn), 3.65 (1H, d, J 7.9, 6-CH), 3.34 (1H, dd, J 9.5, 4.1, 1-CH), 2.80 (3H, s, Me), 2.63 (1H, 
ddd, J 15.0, 7.9, 4.1, 7-CH2), 2.16 (1H, dd, J 15.0, 9.5, 7-CH2); δC(75 MHz, Chloroform-d): 
197.0 (C=O), 144.7 (4-C), 136.7 (Ar), 129.1 (ArH), 128.8 (ArH), 128.7 (ArH), 128.0 (3-C), 
67.7 (1-C), 66.5 (1-C), 58.0 (5-C), 51.7 (NBn), 38.1 (Me), 27.8 (7-CH2); IR νmax (neat)/cm-1: 
3032, 3003 (CH), 2934, 2847, 1675 (C=O), 1497 (C=C), 1451, 1292 (S=O); HRMS (ESI): 
C15H18NO3S [M+H
+]: calculated 292.1002, found 292.1003. 
 
 
 
 
 
  136 
 
 
(1S*,5S*,6R*)-8-Methyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (116a) 
. 
 
General procedure C was followed using methyl vinyl sulfone (4.2 mL, 47.6 mmol) and salt 
105 (14.7 g, 61.9 mmol), silver oxide (20 g, 85.7 mmol). Purification by flash chromatography 
on silica gel, eluting with a gradient of 60 - 100% EtOAc in hexane afforded the major title 
compound 20a (6.40 g, 29.7 mmol, 67%) as a yellow solid; Rf = 0.22, (60% EtOAc in hexane). 
Recrystallisation from EtOAc afforded the title compound 116; M.Pt. 110.0 – 111.7 oC; δH(400 
MHz, Methanol-d4): δ 6.98 (1H, dd, J 9.8, 5.0, 4-CH), 5.98 (1H, dd, J 9.8, 1.6, 3-CH), 4.10 
(1H, d, J 5.0, 5-CH), 3.54 (1H, dd, J 9.3, 4.1, 6-CH), 3.48 (1H, d, J 7.7, 1-CH), 2.89 (3H, s, 
NMe), 2.68 (1H, ddd, J 14.7, 7.7, 4.1, 7-CH), 2.37 (3H, s, Me), 2.03 (1H, d, J 14.7, 9.3, 7-CH); 
δC(101 MHz, Methanol-d4): δ 197.3 (C=O), 146.0 (4-CH), 127.4 (3-CH), 69.5 (6-CH), 66.0 
(1-CH), 60.3 (5-CH), 37.4 (Me), 33.1 (NMe), 27.2 (7-CH2); IR νmax (neat)/cm-1: 3052, 2980 
(C-H), 2919, 2847, 1681 (C=O), 1468 (C=C), 1453, 1291 (S=O); HRMS (ESI): C9H14NO3S 
[M+H+]: calculated 216.0689, found 216.0692. 
 
(1S*,5S*,6S*)-8-Methyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (116b) 
 
 
Purification by flash chromatography on silica gel, eluting with a gradient of 60 - 100% EtOAc 
in hexane afforded the minor title compound 20b (500 mg, 2.32 mmol, 67%) as a yellow solid; 
Rf = 0.14, (60% EtOAc in hexane); δH(400 MHz, Chloroform-d): 6.97 (1H, dd, J 9.5, 5.0, 4-
CH), 5.98 (1H, dd, J 9.9, 1.5, 3-CH), 3.82 (1H, t, J 5.0, 5-CH), 3.77 (1H, d, J 1.5, 6-CH), 3.25 
(1H, J 8.0, at, 1-CH), 2.92 (3H, s, NMe), 2.58 (1H, dt, J 13.0, 6.3, 7-CH2), 2.44 (3H, s, Me), 
2.23 (1H, dd, J 13.0, 9.5, 7-CH2). δC(101 MHz, Chloroform-d): 194.5 (C=O), 149.1 (4-CH), 
126.8 (3-CH), 71.6 (6-CH), 63.0 (1-CH), 59.8 (5-CH), 39.4 (Me), 35.5 (NMe), 31.2 (7-CH2); 
IR νmax (neat)/cm-1: 3023, 2958 (C-H), 2939, 2895, 1679 (C=O), 1453 (C=C), 1408, 1321 
(S=O); HRMS (ESI): C9H14NO3S [M+H
+]: calculated 216.0689, found 216.0691. 
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(1S*,5S*,6R*)-8-Benzyl-6-(morpholinosulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one (133) 
 
 
General procedure B was followed using sulfone 119 (999 mg, 5.64 mmol) and 
benzylpyridinium salt 87 (1.95 g, 7.33 mmol), trimethylamine (2.00 mL, 11.3 mmol). 
Purification by flash chromatography on silica gel, eluting with a gradient of 30% EtOAc in 
hexane afforded the title compound 133 (700 mg, 1.93 mmol, 57%) as a yellow solid; Rf = 0.16, 
(40% EtOAc in hexane); δH(400 MHz, Chloroform-d): 7.32 – 7.16 (5H, m, ArH), 6.93 (1H, 
dd, J 9.8, 5.0, 4-CH), 6.12 (1H, dd, J 9.8, 1.5, 3-CH), 4.08 (1H, d, J 5.0, 5-CH), 3.81 (1H, d, J 
13.0, NBn), 3.74 (1H, d, J 13.0, NBn), 3.69 – 3.58 (5H, m, OCH2CH2, 6-CH), 3.48 (1H, dd, J 
9.3, 4.5, 1-CH), 3.27 – 3.20 (4H, m, NCH2CH2), 2.67 (1H, ddd, J 14.3, 7.7, 4.5, 7-CH), 2.00 
(1H, dd, J 14.3, 9.3, 7-CH); δC(101 MHz, Chloroform-d): 197.5 (C=O), 145.7 (4-CH), 137.0 
(Ar), 129.0 (3-CH), 128.9 (ArH), 128.7 (ArH), 127.7 (ArH), 68.3 (6-CH), 66.9 (OCH2CH2), 
63.9 (1-CH), 58.5 (5-CH), 51.9 (NBn), 46.4 (NCH2CH2), 27.6 (7-CH2); IR νmax (neat)/cm-1: 
3035, 2972 (C-H), 2919, 2864, 1682 (C=O), 1495 (C=C), 1451, 1367 (S=O); HRMS (ESI): 
C18H23N2O4S [M+H
+]: calculated 363.1373, found 363.1382. 
 
(1S*,5S*,6R*)-8-(2-Bromobenzyl)-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one 
(131) 
 
 
 
General procedure B was followed using phenyl vinyl sulfone (1.21 g, 7.20 mmol) and bromo 
salt 131 (1.91 g, 7.20 mmol) and triethylamine (2.00 mL, 14.4 mmol). Purification by flash 
chromatography on silica gel, eluting with a gradient of 30% EtOAc in hexane. Crystallization 
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from EtOAc afforded the title compound 131 (1.26 g, 2.91 mmol, 41%) as a green solid; Rf = 
0.25, (30% EtOAc in hexane); δH(400 MHz, Chloroform-d): 7.87 – 7.71 (2H, m, ArH), 7.67 
– 7.55 (1H, m, ArH), 7.53 – 7.40 (3H, m, ArH), 7.31 – 7.13 (2H, m, ArH), 7.13 – 7.01 (1H, m, 
ArH), 6.94 (1H, dd, J 9.8, 5.0, 4-CH), 6.09 (1H, dd, J 9.8, 1.5, 3-CH), 4.19 (1H, d, J 5.0, 5-
CH), 3.83 (1H, d, J 14.8, NCH2), 3.78 (1H, d, J 14.8, NCH2), 3.64 (1H, d, J 7.7, 6-CH), 3.55 
(1H, dd, J 9.5, 4.6, 1-CH), 2.77 (1H, ddd, J 14.5, 7.7, 4.6, 7-CH2), 1.94 (1H, dd, J 14.5, 9.5, 7-
CH2); δC(101 MHz, Chloroform-d): 197.2 (C=O), 146.4 (4-C), 138.1 (Ar), 136.5 (Ar), 134.1 
(ArH), 134.0 (ArH), 132.7 (ArH), 130.2 (3-C), 129.5 (ArH), 128.8 (ArH), 128.6 (ArH), 127.6 
(ArH), 123.8 (Ar), 68.6 (6-C), 67.5 (1-C), 58.3 (5-C), 51.1 (N-C), 27.3 (7-C); IR νmax (neat)/cm-
1: 3062 (C-H), 3020, 2955, 2868, 1684 (C=O), 1479 (C=C), 1446, 1304 (S=O); HRMS (ESI): 
C20H19
79BrNO3S [M+H
+]: calculated 434.0244, found 434.0258. 
 
 (1S*,5S*,6R*)-N,N,8-Trimethyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-sulfonamide (114a) 
 
 
General procedure B2 was followed using sulfone compound 121 (581 mg, 4.30 mmol) and 
salt 105 (1.20 g, 6.45 mmol), triethylamine (1.2 mL, 8.6 mmol). Purification by flash 
chromatography on silica gel, eluting with a gradient of 50% EtOAc in hexane afforded the 
major title compound 114a (494 mg, 2.02 mmol, 54%) as a yellow solid; Rf = 0.31, (60% 
EtOAc in hexane); δH(400 MHz, Chloroform-d): 6.90 (1H, dd, J 9.8, 5.0, 4-CH), 6.03 (1H, 
dd, J 9.8, 1.5, 3-CH), 4.08 (1H, d, J 5.0, 5-CH), 3.58 (1H, d, J 8.0, 6-CH), 3.50 (1H, dd, J 9.3, 
4.2, 1-CH), 2.89 (6H, s, NMe2), 2.71 (1H, ddd, J 14.4, 8.0, 4.2, 7-CH2), 2.45 (3H, s, NMe), 
1.96 (1H, dd, J 14.4, 9.3, 7-CH2). δC(101 MHz, Chloroform-d): 197.8 (C=O), 45.4 (4-CH), 
128.2 (3-CH), 70.0 (6-CH), 64.2 (1-CH), 61.0 (5-CH), 38.2 (NMe2), 34.7 (NMe), 27.8 (7-CH2); 
IR νmax (neat)/cm-1: 3019, 2960 (CH), 2914, 2878, 2805, 1674 (C=O), 1487 (C=C), 1319 
(S=O); HRMS (ESI): C10H17N2O3S [M+H
+]: calculated 245.0954, found 245.0961. 
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Minor (1S*,5S*,6S*)-N,N,8-trimethyl-2-oxo-8-azabicyclo[3.2.1]oct-3-ene-6-sulfonamide 
(114b) 
 
 
Purification by flash chromatography on silica gel, eluting with a gradient of 50% EtOAc in 
hexane afforded the minor title compound 114b (71 mg, 0.29 mmol, 54%) as a yellow solid; 
Rf = 0.16, (60% EtOAc in hexane); δH(400 MHz, Chloroform-d): 7.04 (1H, dd, J 9.9, 5.3, 4-
CH), 6.02 (1H, dd, J 9.9, 1.5, 3-CH), 3.88 (1H, at, J 5.3, 5-CH), 3.82 (1H, as, 1-CH), 3.40 (1H, 
t, J 6.9, 6-CH), 2.96 (6H, s, NMe2), 2.69 (1H, dt, J 12.7, 6.9, 7-CH2), 2.52 (3H, s, NMe), 2.21 
(1H, dd, J 12.7, 8.9, 7-CH2); δC(101 MHz, Chloroform-d): 195.5 (C=O), 149.6 (4-CH), 126.7 
(3-CH), 72.1 (6-CH), 60.2 (1-CH), 59.2 (5-CH), 38.0 (NMe2), 36.3 (NMe), 31.6 (7-CH2); IR 
νmax (neat)/cm-1: 3009 (CH), 2959, 2928, 2893, 2809, 1603 (C=O), 1454, 1294 (S=O); HRMS 
(ESI): C10H17N2O3S [M+H
+]: calculated 245.0954, found 245.0961. 
 
(1S*,5S*,6R*)-8-(4-Methoxybenzyl)-6-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one 
(134) 
 
 
General procedure B was followed using methyl vinyl sulfone (500 l, 5.65 mmol) and salt 
128 (2.14 g, 8.48 mmol), triethylamine (1.60 mL, 11.3 mmol). Recrystallisation from EtOAc 
afforded the title compound 134 (700 mg, 1.93 mmol, 52%) as a green solid, Mpt 139.9 – 
140.8 oC; δH (400 MHz, Chloroform-d): 7.03 (2H, d, J 8.5, ArH), 6.91 (1H, dd, J 9.8, 4.9, 4-
CH), 6.78 (2H, d, J 8.5, ArH), 6.15 (1H, dd, J 9.8, 1.5, 3-CH), 4.00 (1H, d, J 4.9, 5-CH), 3.75 
– 3.69 (4H, m, OMe, NCH2), 3.67 – 3.62 (2H, m, 6-CH, NCH2), 3.33 (1H, dd, J 9.6, 4.1, 1-
CH), 2.79 (3H, s, SO2Me), 2.62 (1H, ddd, J 15.0, 7.8, 4.1, 7-CH2), 2.15 (1H, dd, J 15.0, 9.6, 7-
CH2); δC(101 MHz, Chloroform-d): 197.2 (C=O), 159.3 (Ar), 144.6 (4-C), 130.0 (Ar), 129.1 
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(ArH), 128.8 (3-C), 114.2 (ArH), 67.6 (6-C), 66.5 (1-C), 57.8 (5-C), 55.3 (OMe), 51.0 (NCH2), 
38.0 (SO2Me), 27.8 (7-CH2); IR νmax (neat)/cm-1: 3025 (OH), 3023, 2993 (CH), 2947, 2893, 
1730 (C=O), 1512 (C=C), 1459, 1296 (S=O); HRMS (ESI): C16H20NO4S [M+H
+]: calculated 
322.1108, found 322.1035 
 
(1S*,5S*,6R*)-8-(4-Fluorobenzyl)-6-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one 
(136) 
 
 
General procedure B was followed using methyl vinyl sulfone (2.0 mL, 22.7 mmol) and salt 
129 (5.52 g, 27.2 mmol, 1.2 eq.), triethylamine (6.3 mL, 45.3 mmol). Purification by 
crystallization from EtOAc afforded the title compound 136 (3.26 g, 10.5 mmol, 46%) as a 
yellow solid; Rf = 0.57, (100% EtOAc in hexane). M.Pt. 142.1 – 143.0 oC; δH(400 MHz, 
Chloroform-d): 7.23 – 7.15 (2H, m, ArH), 7.07 – 6.99 (3H, m, ArH, 4-CH), 6.24 (1H, dd, J 
9.8, 1.5, 3-CH), 4.14 (1H, d, J 4.9, 5-CH), 3.83 (1H, d, J 12.9, NCH2), 3.78 (1H, d, J 12.9, 
NCH2), 3.72 (1H, d, J 6.5, 6-CH), 3.45 (1H, dd, J 9.5, 4.1, 1-CH), 2.90 (3H, s, SO2Me), 2.73 
(1H, ddd, J 14.9, 7.7, 4.1, 7-CH2), 2.24 (1H, dd, J 14.9, 9.5, 7-CH2); δC(101 MHz, 
Chloroform-d): 196.9 (C=O), 162.4 (d, J 246.8, Ar-F), 144.7 (4-C), 132.5 (d, J 3.3, Ar), 130.4 
(d, J 8.1, ArH), 129.1 (3-C), 115.7 (d, J 21.5, ArH), 67.6 (6-C), 66.4 (1-C), 58.0 (5-C), 51.0 
(NCH2), 38.3 (SO2Me), 27.7 (7-C); IR νmax (neat)/cm-1: 3021 (C-H), 2992, 2947, 2903, 1690 
(C=O), 1508 (C=C), 1462, 1317 (S=O); HRMS (ESI): C15H17FNO3S [M+H
+]: calculated 
310.0908, found 310.0916. 
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(1S*,5S*,6R*)-8-(2-Bromo-4-fluorobenzyl)-6-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-
2-one (137) 
 
 
General procedure B was followed using methyl vinyl sulfone (1 mL, 11.2 mmol) and methyl 
salt 132 (5.28 g, 14.54 mmol, 1.3 eq.), triethylamine (3.2 mL, 22.4 mmol) in THF (56 mL). 
Purification by crystallization from EtOAc afforded the title compound 137 (3.89 g, 10.0 mmol, 
89%) as a yellow solid; M.Pt. 132.1 – 133.0 oC; δH (400 MHz, Chloroform-d): 7.33 (1H, dd, 
J 8.2, 2.6, ArH), 7.24 (1H, dd, J 8.5, 5.9, ArH), 7.10 (1H, dd, J 9.8, 4.9, 4-CH), 7.04 (1H, td, J 
8.2, 2.6, ArH), 6.25 (1H, dd, J 9.8, 1.4, 3-CH), 4.16 (1H, d, J 4.9, 5-CH), 3.94 (1H, d, J 13.3, 
NBn), 3.86 (1H, d, J 13.3, NBn), 3.77 (1H, d, J 8.0, 6-CH), 3.44 (1H, dd, J 9.6, 4.1, 1-CH), 
2.85 (3H, s, Me), 2.70 (1H, ddd, J 14.9, 8.0, 4.1, 7-CH2), 2.24 (1H, dd, J 14.9, 9.6, 7-CH2); δC 
(101 MHz, Chloroform-d): 196.7 (C=O), 161.9 (d, J 251.8, Ar-F), 132.3 (d, J 3.6, Ar), 132.0 
(d, J 8.4, ArH), 124.8 (d, J 9.5, Ar), 120.6 (d, J 24.3, ArH), 115.0 (d, J 21.1, ArH), 68.0 (1-C), 
66.5 (1-C), 58.2 (5-C), 50.7 (NBn), 38.1 (Me), 27.7 (7-C); IR νmax (neat)/cm-1: 3065 (CH), 
3031, 2994, 2944, 1677 (C=O), 1465 (C=C), 1453, 1227 (S=O); HRMS (ESI): 
C15H16
79BrFNO3S [M+H
+]: calculated 388.0013, found 388.0009. 
 
(1S*,5S*,6R*)-8-Methyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-one (176) 
 
General procedure F was followed using compound 116 (6.40 g, 29.45 mmol) in 
MeOH/Acetone (60 mL) was added 10% Pd/C (600 mg, 10% weight) at rt. Title compound 
176 (6.27 g, 28.89 mmol, 98%) as a colourless solid; δH (400 MHz, DMSO-d6) 3.91 (1H, dd, 
J 9.5, 6.4, 1-CH), 3.68 (1H, s, 5-CH), 3.24 (1H, d, J 7.0, 6-CH), 2.97 (3H, s, SO2Me), 2.64 – 
2.51 (1H, m, 3-CH2), 2.41 (1H, dt, J 14.0, 6.4, 7-CH2), 2.36 (3H, s, NMe), 2.30 (1H, ddd, J 
13.4, 7.2, 3.6, 4-CH2), 2.23 (1H, dd, J 14.0, 9.5, 7-CH2), 2.13 (1H, dd, J 16.7, 7.2, 3-CH2), 1.85 
(1H, dd, J 13.4, 8.7, 4-CH2); δC (101 MHz, DMSO-d6) 210.0 (C=O), 70.7 (1-C), 65.5 (6-C), 
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59.2 (5-C), 38.6 (Me), 35.5 (NMe), 33.2 (3-C), 29.4 (7-C), 27.5 (4-C); IR νmax (neat)/cm-1: 
3004 (CH), 2965, 2923, 2879, 2853, 1707 (C=O), 1274 (S=O), 1157; HRMS (ESI): 
C9H16NO3S [M+H
+]: calculated 218.0845, found 218.0845. 
 
(1S*,5S*,6R*)-8-Benzyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]octan-2-one (174) 
 
General procedure F was followed using compound 89 (1.10 g, 3.11 mmol, 1.0 eq.) in 
MeOH/Acetone (20 mL) was added 10% Pd/C (100 mg, 10% weight) at rt. Title compound 
174 (1.07 g, 3.01 mmol, 97%) as a colourless solid, Rf = 0.40 (30% EtOAc in hexane); 1H 
NMR
 
(400 MHz, CDCl3) 7.89 – 7.80 (2H, m, ArH), 7.68 – 7.56 (1H, m, ArH), 7.60 – 7.45 
(2H, m, ArH), 7.28 – 7.13 (3H, m, ArH), 7.16 – 7.06 (2H, m, ArH), 3.82 (1H, br s, 5-CH), 3.79 
(1H, d, J 13.5, NCH2), 3.65 (1H, d, J 13.5, NCH2), 3.59 (1H, dd, J 9.3, 6.7, 6-CH), 3.37 (1H, 
d, J 7.1, 1-CH), 2.59 (1H, dt, J 14.1, 7.1, 7-CH2), 2.44 – 2.15 (3H, m, 4-CH, 3-CH2), 2.04 (1H, 
dd, J 14.1, 9.3, 7-CH2), 1.78 – 1.64 (1H, m, 4-CH). 13C NMR (101 MHz, CDCl3): 207.9 (C=O), 
138.3 (Ar), 137.4 (Ar), 133.9 (Ar), 129.4 (Ar), 128.8 (Ar), 128.5 (Ar), 128.4 (Ar), 127.4 (Ar), 
67.8 (6-CH), 60.4 (1-CH), 58.0 (5-CH), 53.0 (NCH2), 33.1 (7-CH2), 30.0 (4-CH2), 28.8 (3-
CH2); IR νmax (neat)/cm-1: 2948 (C-H), 2927, 2839, 2811, 1772 (C=O), 1582, 1448 (C=C), 
1316 (S=O); HRMS (ESI): C20H22NO3S [M+H
+]: calculated 356.1315, found. 356.1313 
 
(1S*,5S*,6R*)-N,N,8-Trimethyl-2-oxo-8-azabicyclo[3.2.1]octane-6-sulfonamide (177) 
 
General procedure F was followed using compound 114 (1.30 g, 5.32 mmol) in 
MeOH/Acetone (20 mL) was added 10% Pd/C (60 mg, 10% weight) at rt. Purification by flash 
chromatography on silica gel, eluting with a gradient of 60% EtOAc in hexane afforded the 
title compound 177 (1.17 g, 4.75 mmol, 89%) as a colourless solid; Rf = 0.10, (60% EtOAc); 
δH(400 MHz, Chloroform-d): 3.74 (1H, s, 5-CH), 3.56 (1H, dd, J 9.1, 6.2, 6-CH), 3.37 (1H, 
d, J 7.0, 1-CH), 2.89 (6H, s, SO2NMe2), 2.56 (1H, dt, J 14.1, 7.0, 7-CH2), 2.45 (3H, s, NMe), 
2.39 – 2.26 (3H, m, 4-CH2, 3-CH2), 2.09 (1H, dd, J 14.1, 9.1, 7-CH2), 1.93 – 1.79 (1H, m, 4-
CH2); δC(101 MHz, Chloroform-d): 209.1 (C=O), 71.1 (1-C), 64.0 (6-C), 60.3 (5-C), 38.2 
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(NMe2), 36.1 (NMe), 32.8 (3-C), 30.3 (7-C), 27.7 (4-C); IR νmax (neat)/cm-1: 3189, 3001, 2935 
(CH), 2879, 2818, 1644 (C=O), 1296 (S=O), 1157; HRMS (ESI): C10H18N2O3S [M+H
+]: 
calculated 247.1111, found 249.1265. 
 
 
(1S*,5S*,6R*)-8-Benzyl-3-chloro-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]octan-2-one (179) 
 
To a solution of ketone 174 (200 mg, 0.56 mmol, 1.0 eq.) in DCM (4 mL) at rt was added NCS 
(150 mg, 1.13 mmol, 2.0 eq.) and L-proline (21 mg, 0.34 mmol, 30 mol%). The reaction was 
stirred for 16 h at rt. The crude mixture was taken up in water (10 mL), and the aqueous phase 
was extracted with DCM (3 × 10 mL) and the combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. Purification by flash chromatography on silica gel, eluting 
with a gradient of 20% EtOAc in hexane. Crystallisation from EtOAc afforded the title 
compound 179 (88 mg, 0.23 mmol, 40%) as a white solid as a single isomer of undetermined 
stereochemistry; Rf = 0.16 (30% EtOAc in hexane); δH(300 MHz, Chloroform-d): 7.97 – 7.83 
(2H, m, ArH), 7.77 – 7.64 (1H, m, ArH), 7.65 – 7.53 (2H, m, ArH), 7.36 – 7.23 (3H, m, ArH), 
7.19 – 7.08 (2H, m, ArH), 4.53 (1H, t, J 9.8, 3-CH), 3.91 (1H, s, 5-CH), 3.82 – 3.61 (4H, m, 
NCH2, 6-CH, 1-CH), 2.70 (1H, dt, J 14.8, 6.7, 7-CH2), 2.58 (2H, dd, J 9.8, 3.0, 4-CH2), 2.22 
(1H, dd, J 14.8, 9.4, 7-CH2); δC(101 MHz, Chloroform-d): 199.3 (C=O), 137.7 (Ar), 136.5 
(Ar), 134.1 (ArH), 129.5 (ArH), 128.9 (ArH), 128.5 (ArH), 128.5 (ArH), 127.6 (ArH), 68.2 (6-
CH), 66.7 (1-CH), 58.4 (3-CH), 57.2 (5-CH), 52.0 (2-CH2), 42.3 (4-CH2), 29.1 (7-CH2); IR 
νmax (neat)/cm-1: 3061, 3030, 3005 (CH), 2964, 2927, 1730 (C=O), 1602 (C=C), 1291 (S=O); 
HRMS (ESI): C20H21
35ClNO3S [M+H
+]: calculated 390.0925, found 390.1668. 
 
(1S*,5S*,6R*)-8-Benzyl-3-chloro-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-one (180) 
 
To a solution of ketone 175 (200 mg, 0.68 mmol, 1.0 eq.) in DCM (6 mL) at rt was added NCS 
(119 mg, 0.88 mmol, 1.3 eq.) and L-proline (50 mg, 0.68 mmol, 1.0 eq.). The reaction was 
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stirred for 16 h at rt. The crude mixture was taken up in water (10 mL), and the aqueous phase 
was extracted with DCM (3 × 10 mL) and the combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. Purification by flash chromatography on silica gel, eluting 
with a gradient of 20% EtOAc in hexane. Crystallisation from EtOAc afforded the title 
compound 180 (88 mg, 0.23 mmol, 57%) as a white solid a single isomer of undetermined 
stereochemistry; Rf = 0.17 (40% EtOAc in hexane); δH(400 MHz, DMSO-d6) 7.42 – 7.16 (5H, 
m, ArH), 5.25 (1H, dd, J 11.3, 8.2, 3-CH), 4.06 – 3.99 (1H, m, 6-CH), 3.87 (1H, d, J 13.7, 
NBn), 3.83 (1H, s, 5-CH), 3.59 (1H, d, J 13.7 NBn), 3.50 (1H, d, J 6.0, 1-CH), 2.98 (3H, s, 
Me), 2.76 – 2.65 (1H, m, 7-CH2), 2.60 – 2.38 (2H, m, 4-CH2), 2.41 – 2.26 (1H, m, 7-CH2); IR 
νmax (neat)/cm-1: 3054, 3020, 3005 (CH), 2960, 2900, 1720 (C=O), 1658 (C=C), 1298 (S=O); 
HRMS (ESI): C15H19
35ClNO3S [M+H
+]: calculated 328.0769, found 328.1376. 
 
(1S*,5S*,6R*)-8-Benzyl-2-methyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-ol (214) 
 
To a stirred solution of enone 89 (100 mg, 0.28 mmol, 1.0 eq.) in THF (1.4 mL) at −78 °C was 
added methylmagnesium iodide (3 M solution in THF) (0.12 mL, 0.37 mmol, 1.3 eq.) 
dropwise. The reaction mixture was stirred for 1 h, then warmed up to rt and stirred for 16 h. 
The crude mixture was taken up in water (5 mL), and the aqueous phase was extracted with 
EtOAc (3 × 5 mL) and the combined organic extracts were dried over MgSO4 and concentrated 
in vacuo to afford compound 214 as a 3:2 mixture of diastereoisomers. Purification by flash 
chromatography on silica gel, eluting with a gradient of 30% EtOAc in hexane afforded only 
the major isomer, title compound 214 (54 mg, 0.15 mmol, 52%) as a colourless oil; Rf = 0.33, 
(30% EtOAc in hexane). 1H NMR
 
(400 MHz, CDCl3) 7.82 – 7.77 (2H, m, ArH), 7.62 – 7.42 
(4H, m, ArH), 7.41 – 7.30 (2H, m, ArH), 7.27 (1H, s, OH), 7.26 – 7.13 (2H, m, ArH), 5.93 
(1H, dd, J 9.5, 5.9, 4-CH), 5.26 (1H, d, J 9.4, 3-CH), 3.98 – 3.87 (2H, m, NCH2, 5-CH), 3.74 
(1H, d, J 13.7, NCH2), 3.61 (1H, dd, J 9.2, 6.5, 6-CH), 3.22 (1H, d, J 6.6, 1-CH), 2.51 (1H, dd, 
J 13.8, 9.2, 7-CH), 2.34 (1H, dt, J 13.8, 6.6, 7-CH), 1.37 (3H, s, Me); 13C NMR (101 MHz, 
CDCl3): 138.9 (Ar), 138.2 (Ar), 133.5 (ArH), 132.5 (ArH), 129.4 (ArH), 129.3 (ArH), 129.2 (4-
CH), 128.2 (3-CH), 128.1 (ArH), 128.1 (ArH), 71.4 (1-CH), 70.4 (6-CH), 69.6 (C), 59.0 (5-
CH), 55.9 (NCH2), 27.8 (Me), 24.2 (7-CH2); IR νmax (neat)/cm-1: ; HRMS (ESI): C21H24NO3S 
[M+H+]: calculated 370.1465, found 370.1571. 
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6-Benzyl-1-(phenylsulfonyl)-6-azatricyclo[3.2.1.02,7]octan-4-one (213) 
 
To a stirred solution of enone 89 (100 mg, 0.28 mmol, 1.0 eq.) in THF (1.4 mL) at −78 °C was 
added LiHMDS (1 M solution in THF, 0.34 mL, 0.34 mmol, 1.2 eq.) dropwise. The reaction 
was stirred for 16 h at rt. The crude mixture was taken up in water (5 mL), and the aqueous 
phase was extracted with EtOAc (3 × 5 mL) and the combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. Purification by flash chromatography on silica gel, eluting 
with a gradient of 30% EtOAc in hexane afforded the title compound 213 (170 mg, 0.17 mmol, 
60%) as a colourless oil; Rf = 0.48 (30% EtOAc in hexane). 1H NMR
 
(300 MHz, CDCl3) 7.95 
– 7.84 (2H, m, ArH), 7.76 – 7.53 (3H, m, ArH), 7.40 – 7.21 (5H, m, ArH), 3.72 – 3.63 (2H, m, 
NCH2), 3.61 (1H, dd, J 7.1, 0.9, 7-CH), 3.38 (1H, d, J 5.9, 5-CH), 2.76 – 2.53 (3H, m, 8-CH2, 
3-CH2), 2.36 (1H, dt, J 7.1, 2.1, 2-CH), 1.85 (1H, d, J 12.7, 8-CH2).
 13C NMR (101 MHz, 
CDCl3): 202.2 (C=O), 139.2 (Ar), 136.5 (Ar), 133.8 (ArH), 129.4 (ArH), 128.7 (ArH), 128.6 
(ArH), 127.9 (ArH), 127.8 (ArH), 68.4 (5-CH), 56.4 (NCH2), 47.9 (7-CH), 46.3 (1-C), 32.1 (3-
CH2), 26.8 (8-CH2), 19.8 (2-CH); IR νmax (neat)/cm-1: 3028, 2927 (CH), 2897, 1730 (C=O), 
1684, 1638, 1445 (C=C), 1379 (S=O); LCMS (ESI): C20H20O3S [M+H
+]: calculated 354.1158, 
found 354.20 
 
(1S*,2S*,4R*,6S*,8R*)-9-Benzyl-8-(phenylsulfonyl)-9-azatricyclo[4.2.1.02,4]nonan-5-one 
(242) 
 
To a stirred solution of trimethylsulfoxonium chloride (60 mg, 0.46 mmol, 1.1 eq.) in 
anhydrous THF (3 mL) was added sodium hydride (in 60% mineral oil) (19 mg, 0.46 mmol, 
1.1 eq.) at 0 oC and the mixture left to stir at rt for 1h. Enone 89 (150 mg, 0.42 mmol, 1.0 eq.) 
was added to the reaction mixture and stirred for 3 h. The resulting mixture was diluted with 
water (10 mL) and DCM (10 mL). The phases were separated and the aqueous phase was 
extracted with DCM (2 × 10 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. Purification by flash chromatography on silica gel, eluting with 40% 
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EtOAc in hexane afforded the title compound 242 (56 mg, 0.15 mmol, 36%) as a brown oil; Rf 
= 0.28, (40% EtOAc in hexane). δH (400 MHz, Chloroform-d): 7.90 – 7.84 (2H, m, ArH), 
7.63 – 7.58 (1H, m, ArH), 7.56 – 7.49 (2H, m, ArH), 7.33 – 7.17 (5H, m, ArH), 4.16 (1H, s, 1-
CH), 3.88 (1H, d, J 13.4, NBn), 3.63 (1H, d, J 13.4, NBn), 3.56 (1H, t, J 8.6, 1.3, 8-CH), 3.52 
(1H, d, J 7.3, 6-CH), 2.56 (1H, dt, J 13.8, 7.8, 7-CH2), 1.98 – 1.93 (1H, m, cyp), 1.86 (1H, dd, 
J 13.8, 8.9, 7-CH2), 1.51 – 1.39 (2H, m, cyp), 1.01 (1H, ddd, J 10.9, 7.1, 4.2, cyp); δc (126 
MHz, Chloroform-d): 204.5 (C=O), 139.4 (Ar), 138.2 (Ar), 133.9 (ArH), 129.6 (ArH), 129.2 
(ArH), 128.5 (ArH), 128.1 (ArH), 127.4 (ArH), 71.7 (6-C), 71.3 (5-CH), 60.3 (1-C), 55.8 
(NBn), 31.2 (cyp), 23.4 (cyp), 22.2 (7-C), 13.2 (cyp); IR νmax (neat)/cm-1: 3018, 2943, 2880 
(CH), 2806, 1709 (C=O), 1515 (C=C), 1496, 1291 (S=O); LCMS (ESI): C21H22NO3S [M+H
+]: 
calculated 368.1315, found 368.10. 
 
 
(1S*,5S*,6R*)-8-Benzyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-ol (228) 
 
3.5:1 
To a solution of enone 89 (2.40 g, 6.98 mmol, 1.0 eq.) in MeOH (70 mL) at rt was added 
CeCl3.7H2O (5.20 g, 14.0 mmol, 2.0 eq.) and the mixture stirred for 10 min. The reaction 
mixture was cooled to 0 oC followed by a portionwise addition of NaBH4 (370 mg, 9.77 mmol, 
1.4 eq.). The reaction mixture was stirred for 16 h at rt and concentrated in vacuo. The crude 
mixture was taken up in water (10 mL) and DMF (5 mL), and the aqueous phase was extracted 
with Et2O (3 × 10 mL) and the combined organic extracts were dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography on silica gel, eluting with a 
gradient of 40% EtOAc in hexane afforded a 1:3.5 mixture of inseparable diastereoisomers. 
Major isomer reported: Compound 228 (1.92 g, 5.42 mmol, 80%) as a colourless solid; Rf = 
0.15 (40% EtOAc in Hexane). 1H NMR
 
(501 MHz, CDCl3): 7.94 – 7.76 (2H, m, ArH), 7.73 – 
7.61 (1H, m, ArH), 7.59 – 7.48 (2H, m, ArH), 7.36 – 7.21 (3H, m, ArH), 7.19 – 7.06 (2H, m, 
ArH), 5.88 (1H, ddd, J 9.7, 4.8, 1.6, 4-CH), 5.71 (1H, ddd, J 9.7, 2.3, 1.7, 3-CH), 4.69 – 4.50 
(1H, m, 2-CH), 3.88 (1H, d, J 13.4, NCH2), 3.78 (1H, d, J 13.4, NCH2), 3.75 (1H, d, J 4.8, 5-
CH), 3.59 (1H, dd, J 9.4, 4.1, 1-CH) 3.36 (1H, t, J 6.2, 6-CH), 2.65 – 2.56 (1H, m, 7-CH2), 
2.40 (1H, dd, J 7.2, 4.1, 7-CH2). 
13C NMR (101 MHz, DMSO-d6) 139.2 (Ar), 139.0 (Ar), 134.1 
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(ArH), 131.3 (4-CH), 129.7 (ArH), 129.1 (ArH), 128.5 (ArH), 128.5 (3-CH), 128.4 (ArH), 
127.2 (ArH), 69.4 (1-CH), 63.4 (5-CH), 59.9 (6-CH), 57.2 (2-CH), 50.8 (NCH2), 24.9 (7-CH2); 
IR νmax (neat)/cm-1: 3537 (OH), 3055, 3028, 3002, 2934 (CH), 2885, 1445 (C=C), 1312 (S=O); 
HRMS (ESI): C20H22NO3S [M+H
+]: calculated, 356.1319 found 356.1313. 
 
 (1S*,2S*,5S*,6R*)-8-Benzyl-2-((tert-butyldimethylsilyl)oxy)-6-(phenylsulfonyl)-8-
azabicyclo[3.2.1]oct-3-ene (232 Major).  
 (1S*,2R*,5S*,6R*)-8-Benzyl-2-((tert-butyldimethylsilyl)oxy)-6-(phenylsulfonyl)-8-
azabicyclo[3.2.1]oct-3-ene (233 Minor). 
Major      Minor 
 
General procedure G was followed using alcohol 228 (890 mg, 2.51 mmol, 1.0 eq.), tert-
butyldimethylsilyl trifluoromethanesulfonate (0.64 mL, 2.76 mmol, 1.1 eq.), imidazole (341 
mg, 5.01 mmol, 2.0 eq.) in anhydrous DMF (4 mL). Purification by flash chromatography on 
silica gel, eluting with a gradient of 5% EtOAc in hexane afforded the title compound 130a 
(585 mg, 1.25 mmol, 50%) as a colourless oil; Rf = 0.16, (5% EtOAc in hexane), followed by 
the title compound 130b (350 mg, 0.75 mmol, 30%) as a colourless oil; Rf = 0.20 (5% EtOAc 
in hexane).  
Compound 232: 
1H NMR
 
(400 MHz, CDCl3) 7.94 – 7.84 (2H, m, ArH), 7.70 – 7.60 (1H, m, ArH), 7.60 – 7.49 
(2H, m, ArH), 7.36 – 7.20 (3H, m, ArH), 7.19 – 7.09 (2H, m, ArH), 5.81 (1H, ddd, J 9.8, 4.6, 
1.5, 3-CH), 5.65 (1H, dt, J 9.8, 2.1, 4-CH), 4.50 (1H, s, 5-CH), 3.89 (1H, d, J 13.1, NCH2), 
3.79 (1H, d, J 13.1, NCH2), 3.74 (1H, d, J 4.6, 2-CH), 3.63 (1H, dd, J 9.5, 3.8, 1-CH), 3.20 
(1H, t, J 7.0, 6-CH), 2.73 (1H, dd, J 14.4, 9.5, 7-CH2), 2.35 (1H, ddd, J 14.4, 7.0, 3.8, 7-CH2), 
0.86 (9H, s, tBu), 0.00 (3H, s, SiMe), − 0.05 (3H, s, SiMe). 13C NMR (101 MHz, CDCl3): 138.9 
(Ar), 138.4 (Ar), 133.3 (ArH), 130.8 (4-CH), 129.1 (ArH), 128.9 (ArH), 128.6 (3-CH), 128.5 
(ArH), 128.2 (ArH), 127.1 (ArH), 70.0 (2-CH), 65.5 (5-CH), 60.4 (6-CH), 57.4 (1-CH), 51.4 
(NCH2), 25.8 (SiC(CH3)3), 24.9 (7-CH2), 18.1 (C), − 4.7 (Si(CH3)2); IR νmax (neat)/cm-1: 3086, 
3019, 2985 (C-H), 2905, 1706 (C=O), 1493, 1445 (C=C), 1310 (S=O); HRMS (ESI): 
C26H36NO3SSi [M+H
+]: calculated 470.2180, found 470.2208. 
Compound 233: 
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1H NMR
 
(400 MHz, CDCl3) 7.88 – 7.78 (2H, m, ArH), 7.67 – 7.58 (1H, m, ArH), 7.57 – 7.43 
(2H, m, ArH), 7.40 – 7.17 (3H, m, ArH), 7.19 – 7.11 (2H, m, ArH), 5.83 (1H, s, 3-CH), 5.82 
(1H, s, 4-CH), 3.99 (1H, d, J 14.0, NCH2), 3.83 – 3.73 (2H, m, NCH2, 5-CH), 3.52 (1H, s, 2-
CH), 3.45 (1H, d, J 7.7, 1-CH), 3.41 (1H, dd, J 9.3, 4.4, 6-CH), 2.60 (1H, ddd, J 14.0, 7.7, 4.4, 
7-CH), 1.77 (1H, dd, J 14.0, 9.3, 7-CH), 0.85 (9H, s, tBu), 0.05 (3H, s, SiMe), 0.00 (3H, s, 
SiMe). 13C NMR (101 MHz, CDCl3): 139.3 (Ar), 138.4 (Ar), 133.4 (ArH), 129.1 (ArH), 129.0 
(ArH), 128.9 (ArH), 128.5 (4-CH), 128.0 (3-CH), 127.9 (ArH), 126.6 (ArH), 69.3 (6-CH), 67.6 
(2-CH), 61.8 (1-CH), 56.2 (5-CH), 51.5 (NCH2), 28.8 (7-CH2), 25.8 (SiC(CH3)3), 18.0 (C), − 
4.7 (SiCH3), − 4.9 (SiCH3); IR νmax (neat)/cm-1: 3086, 3019, 2985 (C-H), 2905, 1706 (C=O), 
1493, 1445 (C=C), 1310 (S=O); HRMS (ESI): C26H36NO3SSi [M+H
+]: calculated 470.2180, 
found 470.2208. 
 
(1S*,2R*,5S*)-8-Benzyl-2-hydroxy-8-azabicyclo[3.2.1]oct-3-en-6-one (236) 
 
General procedure H was followed using protected alcohol 232 (357 mg, 0.76 mmol, 1.0 eq.), 
LiHMDS (1 M solution in THF, 7.6 mL, 7.6 mmol, 10 eq.), dimethyl disulfide (1.4 mL, 15 
mmol, 20 eq.) anhydrous THF (4 mL). The reaction mixture was taken up in 1,4-dioxane (3.5 
mL), conc.HCl (1.4 mL, 46 mmol, 60 eq.) and heated at reflux for 2 h. Purification by flash 
chromatography on silica gel, eluting with a gradient of 30% EtOAc in hexane afforded the 
title compound 236 (170 mg, 0.74 mmol, 98%) as a brown oil; Rf = 0.10, (40% EtOAc in 
hexane). 1H NMR
 
(400 MHz, CDCl3) 7.33 – 7.15 (5H, m, ArH), 5.87 – 5.73 (2H, m, 3-CH, 4-
CH), 4.63 (1H, d, J 5.0, 2-CH), 3.70 (2H, s, NCH2), 3.62 – 3.55 (2H, m, OH, 1-CH), 3.31 – 
3.24 (1H, m, 5-CH), 2.81 (1H, dt, J 18.7, 1.0, 7-CH2), 2.35 (1H, ddd, J 18.7, 7.4, 1.2, 7-CH2). 
13C NMR (101 MHz, CDCl3): 210.3 (C=O), 137.5 (Ar), 132.4 (4-CH), 128.7 (ArH), 128.5 
(ArH), 127.5 (ArH), 125.7 (3-CH), 66.1 (2-CH), 65.0 (5-CH), 59.5 (1-CH), 55.4 (NCH2), 32.8 
(7-CH2); IR νmax (neat)/cm-1: 3399 (OH), 3031, 2930 (CH), 2870, 1742 (C=O), 1495, 1454 
(C=C) 1360 (S=O); HRMS (ESI): C14H16NO2 [M+H
+]: calculated 230.1178, found 230.1176. 
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(1S*,2R*,5S*)-8-Benzyl-2-hydroxy-8-azabicyclo[3.2.1]octan-6-one (238) 
 
General procedure I was followed using ketone 174 (1.00 g, 2.81 mmol), DIBAL (1M 
cyclohexane) (8.4 mL,8.4 mmol) in anhydrous DCM (35 mL) to give crude compound as a 
colourless oil. General procedure G was followed using alcohol (1.00 g, 2.81 mmol), tert-
butyldimethylsilyl trifluoromethanesulfonate (1.9 mL, 8.43 mmol, 3.0 eq.), imidazole (600 mg, 
8.43 mmol, 3.0 eq.) in anhydrous DMF (4 mL); the compound was taken through crude to the 
next step. General procedure H was followed using crude protected alcohol (161 mg, 0.34 
mmol, 1.0 eq.), LiHMDS (1 M solution in THF, 7.6 mL, 7.6 mmol, 10 eq.), dimethyl disulfide 
(1 mL, 6.82 mmol, 20 eq.) in THF (2 mL). The reaction mixture was taken up in 1,4-dioxane 
(2.0 mL), conc.HCl (0.7 mL, 23 mmol, 60 eq.) and heated at reflux for 2 h. Purification by 
reverse phase biotage MeCN/H2O 1% formic acid gave title compound 238 (64 mg, 0.28 mmol, 
82%); δH (400 MHz, Methanol-d4): 7.33 – 7.29 (2H, m, ArH), 7.25 – 7.19 (2H, m, ArH), 7.18 
– 7.12 (1H, m, ArH), 3.63 – 3.58 (2H, m, NBn, 2-CH), 3.55 (1H, d, J 13.1, NBn), 3.47 – 3.37 
(1H, m, 1-CH), 2.84 – 2.77 (1H, m, 5-CH), 2.57 (1H, ddd, J 19.0, 7.8, 1.4, 7-CH2), 2.01 – 1.92 
(1H, m, 4-CH2), 1.89 (1H, d, J 19.0, 7-CH2), 1.73 – 1.43 (3H, m, 4-CH2, 3-CH2); δC (126 MHz, 
Methanol-d4): 220.3 (C=O), 138.2 (Ar), 128.6 (ArH), 128.1 (ArH), 127.0 (ArH), 68.0 (2-C), 
66.8 (5-C), 62.0 (1-C), 57.5 (NBn), 35.8 (7-C), 24.5 (3-C), 24.4 (4-C); IR νmax (neat)/cm-1: 
3420 (OH), 3061, 3029 (CH), 2945, 2853, 1742 (C=O), 1455 (C=C), 1438; HRMS (ESI): 
C14H18NO2 [M+H
+]: calculated 232.1332, found 232.1334. 
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(4S*,6R*,7S*)-9-Benzyl-2-phenyl-6-(phenylsulfonyl)-5,6,7,8-tetrahydro-4H-4,7-
epiminocyclohepta[d]thiazole (181) 
 
 
 
General procedure J was followed using chloroketone 179 (60 mg, 0.15 mmol) and 
thiobenzamide (94 mg, 0.69 mmol). Purification by flash chromatography on silica gel, eluting 
with a gradient of 40% EtOAc in hexane afforded the title compound 181 (20 mg, 0.04 mmol, 
30%) as a colourless oil; Rf = 0.56, (40% EtOAc); δH (400 MHz, Chloroform-d): 7.99 – 7.69 
(5H, m, ArH), 7.54 – 7.40 (2H, m, ArH), 7.38 – 7.31 (3H, m, ArH), 7.25 – 7.11 (5H, m, ArH), 
4.24 (1H, d, J 6.0, 6-CH), 4.04 (1H, d, J 4.4, 7-CH), 3.72 (1H, d, J 13.6, NBn), 3.57 (1H, d, J 
13.6, NBn), 3.47 (1H, t, J 8.3, 4-CH), 3.21 (1H, dd, J 16.9, 4.4, 8-CH2), 2.58 (1H, dt, J 12.7, 
6.0, 5-CH2), 2.47 (1H, d, J 16.9, 8-CH2), 2.23 (1H, dd, J 12.7, 8.3, 5-CH2); δC (151 MHz, 
DMSO-d6): 165.7 (Ar), 153.9 (Ar), 138 .9 (Ar), 138.6 (Ar), 133.7 (Ar), 134.4 (ArH), 133.7 
(Ar), 130.5 (ArH), 129.9 (ArH), 129.8 (ArH), 129.0 (ArH), 128.7 (ArH), 128.6 (ArH), 127.4 
(ArH), 126.3 (ArH), 67.7 (6-C), 59.3 (7-C), 56.9 (4-C), 51.1 (NBn), 37.0 (8-C), 27.8 (5-C); IR 
νmax (neat)/cm-1: 3010, 2967 (CH), 2918, 2880, 2848, 1597 (C=C), 1436, 1237 (S=O); HRMS 
(ESI): [M+H+]: C27H25N2O2S2 calculated 473.1352, found 473.1345 
 
(4S*,6R*,7S*)-9-Benzyl-2-methyl-6-(methylsulfonyl)-5,6,7,8-tetrahydro-4H-4,7-
epiminocyclohepta[d]thiazole (182) 
 
 
General procedure J was followed using chloroketone 180 (164 mg, 0.50 mmol) and 
thioacetamide (150 mg, 2.00 mmol) in DMF (2.5 mL). Purification by reverse phase biotage 
MeCN/H2O 1% formic acid gave title compound 182 (6 mg, 0,02 mmol, 3%) as a colourless 
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oil; δH (600 MHz, DMSO-d6): 7.33 – 7.17 (5H, m, ArH), 4.24 (1H, d, J 5.6, 4-CH), 3.83 (1H, 
d, J 4.6, 7-CH), 3.63 (1H, d, J 13.8, NBn), 3.58 (1H, t, J 8.0, 6-CH), 3.52 (1H, d, J 13.8, NBn), 
3.09 (1H, dd, J 16.9, 4.7, 8-CH2), 2.91 (3H, s, Me), 2.58 (3H, s, Me), 2.53 – 2.45 (1H, m, 8-
CH2) 2.43 – 2.33 (1H, m, 5-CH2), 2.20 (1H, dd, J 12.4, 9.0, 5-CH2); δC (151 MHz, DMSO-
d6): 163.2(Ar), 145.5(Ar), 139.1(Ar), 130.3 (Ar), 128.8 (ArH), 128.8 (ArH), 127.5 (ArH), 66.7 
(6-C), 56.5 (7-C), 56.1 (4-C), 50.7 (NBn), 38.5 (Me), 38.4 (8-C), 30.7 (5-C), 19.4 (Me); IR νmax 
(neat)/cm-1: 3026, 3012 (CH), 2980, 2922, 1594, 1521 (C=C), 1304, 1122 (S=O); HRMS 
(ESI): C17H21N2O2S2 [M+H
+]: calculated 349.1039, found 349.1053. 
 
(1S*,5S*,6R*)-8-Benzyl-3-(hydroxymethyl)-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-
2-one (212) 
 
To a solution of enone 89 (70 mg, 0.20 mmol, 1.0 eq.) in anhydrous THF (1.0 mL) was added 
formaldehyde (36% in water) (0.03 mL, 0.4 mmol 2.0 eq.) and DMAP (2.5 mg, 10 mol%). The 
reaction was stirred for 16 h at rt and the reaction mixture was acidified with the addition of 
one drop of HCl (2M), and aqueous phase was extracted with DCM (3 x 5 mL). The combined 
organic extracts were washed with NaHCO3 (5 mL) and brine (5 mL), dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography on silica gel, eluting with a 
gradient of 30% EtOAc in hexane afforded the title compound 212 (41 mg, 0.12 mmol, 54%) 
as a yellow oil; Rf = 0.10, (30% EtOAc in hexane). 1H NMR
 
(400 MHz, CDCl3) 7.90 – 7.82 
(2H, m, ArH), 7.72 – 7.62 (1H, m, ArH), 7.60 – 7.50 (2H, m, ArH), 7.33 – 7.22 (2H, m, ArH), 
7.26 (1H, s, ArH), 7.09 (2H, dd, J 7.5, 2.0, ArH), 6.85 (1H, dt, J 5.2, 1.5, 4-CH), 4.36 – 4.23 
(2H, m, CH2-OH), 4.22 (1H, d, J 5.2, 5-CH), 3.78 (1H, d, J 13.3, NCH2), 3.69 (1H, d, J 13.3, 
NCH2), 3.64 – 3.57 (2H, m, 6-CH, 1-CH), 2.80 (1H, ddd, J 14.3, 7.7, 4.5, 7-CH2), 2.34 (1H, s, 
OH), 1.97 (1H, dd, J 14.3, 9.2, 7-CH2). 
13C NMR (101 MHz, CDCl3): 198.5 (C=O), 140.3 (4-
CH), 138.4 (Ar), 138.2 (C), 137.0 (Ar), 133.9 (ArH), 129.4 (ArH), 128.8 (ArH), 128.5 (ArH), 
127.5 (ArH), 127.5 (ArH), 67.7 (6-CH), 67.3 (5-CH), 59.6 (CH2-OH), 58.3 (1-CH), 51.6 
(NCH2), 27.1 (7-CH2); IR νmax (neat)/cm-1: 3492 (OH), 3062, 3028, 2949 (CH), 2843, 1677 
(C=O), 1446 (C=C), 1367 (S=O); HRMS (ESI): C21H22NO4S [M+H
+]: calculated 384.1271, 
found 384.1276. 
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(5S*,7R*,8S*)-10-Methyl-7-(methylsulfonyl)-2,4-bis(trifluoromethyl)-6,7,8,9-tetrahydro-5H-
5,8-epiminocyclohepta[d]pyrimidine (194) 
 
 
General procedure K was followed using ketone 176 (250 mg, 1.15 mmol), 2,4,6-
tris(trifluoromethyl)-1,3,5-triazine (0.2 mL, 2.29 mmol, 2.0 eq.) and TFA (9 L, 10 mol%) in 
EtOH (2.5 mL). Purification by flash chromatography on silica gel, eluting with a gradient of 
100% EtOAc in hexane afforded the title compound 194 (171 mg, 0,44 mmol, 54%) as a brown 
oil; δH (400 MHz, DMSO-d6): 4.30 (1H, d, J 6.9, 6-CH), 4.03 (1H, d, J 5.0, 5-CH), 3.78 (1H, 
t, J 8.6, 1-CH), 3.43 (1H, dd, J 18.4, 5.0, 4-CH2), 3.01 (3H, s, Me), 2.86 (1H, d, J 18.4, 4-CH2), 
2.62 (1H, dt, J 13.4, 6.9, 7-CH2), 2.38 (3H, s, Me), 2.32 (1H, dd, J 13.4, 8.6, 7-CH2); δc (101 
MHz, DMSO): 172.7 (Ar), 153.0 (q, J 37.0, Ar), 152.8 (q, J 35.0, Ar), 128.6 (Ar), 121.1 (q, J 
277.1, CF3), 119.6 (q, J 275.3, CF3), 66.3 (1-C), 65.5 (6-C), 58.2 (5-C), 39.2 (Me), 35.7 (Me), 
27.7 (4-C), 27.7 (7-C); IR νmax (neat)/cm-1: 3023, 2953(CH), 2882, 2807, 1569 (C=C), 1419, 
1202 (S=O) 1123; HRMS (ESI): C13H14F6N3O2S [M+H
+]: calculated 390.0705, found 
390.0707. 
 
 (5S*,7R*,8S*)-10-Benzyl-7-(methylsulfonyl)-2,4-bis(trifluoromethyl)-6,7,8,9-tetrahydro-
5H-5,8-epiminocyclohepta[d]pyrimidine (195) 
 
 
General procedure K was followed using ketone 175 (200 mg, 0.68 mmol), 2,4,6-
Tris(trifluoromethyl)-1,3,5-triazine (0.25 mL, 1.36 mmol, 2.0 eq.) and TFA (6 L, 10 mol%) 
in EtOH (6 mL). Purification by flash chromatography on silica gel, eluting with a gradient of 
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100% EtOAc in hexane afforded the title compound 195 (45.4 mg, 0,43 mmol, 32%) as a 
brown oil; δH (400 MHz, DMSO-d6): 7.36 – 6.92 (5H, m, ArH), 4.23 (1H, d, J 6.7, 6-CH), 
3.95 (1H, d, J 5.0, 5-CH), 3.80 – 3.72 (2H, m, 1-CH, NBn), 3.68 (1H, d, J 13.7, NBn), 3.36 – 
3.26 (1H, m, 4-CH2), 2.93 (3H, s, Me), 2.83 (1H, d, J 18.4, 4-CH2), 2.61 (1H, dt, J 13.5, 6.7, 
7-CH2), 2.28 (1H, dd, J 13.5, 9.2, 7-CH2); δC (101 MHz, DMSO-d6): 172.6 (Ar), 172.6 (Ar), 
153.1 (q, J 36.8, Ar), 152.9 (q, J 35.8, Ar), 138.6 (ArH) , 128.8 (ArH), 128.8 (ArH), 127.6 
(Ar), 121.1 (q, J 277.1, CF3), 119.6 (q, J 275.3, CF3), 66.1 (1-C), 63.8 (6-C), 56.7 (5-C), 51.8 
(NBn), 39.1 (Me), 35.5 (4-C), 28.5 (7-C); IR νmax (neat)/cm-1: 3000 (CH), 2951, 2916, 2847, 
1589, 1530 (C=C), 1454, 1290 (S=O); HRMS (ESI): C19H18F6N3O2S [M+H
+]: calculated 
466.1018, found 446.1021. 
 
(4S*,5R*,7S*)-9-Benzyl-5-(phenylsulfonyl)-4,5,6,7-tetrahydro-4,7-
epiminocyclohepta[c]pyrrol-8(2H)-one (151) 
 
To a solution of enone 89 (100 mg, 0.29 mmol, 1.0 eq.) in anhydrous THF (1.5 mL) at 0 oC 
was added t-BuOK (159 mg, 1.42 mmol, 5.0 eq.) and TosMIC (55 mg, 0.29 mmol, 1.0 eq.). 
The reaction mixture was stirred for 16 h at room temperature. The crude mixture was taken 
up in water (5 mL), and the aqueous phase was extracted with DCM (3 × 5 mL) and dried over 
MgSO4 and concentrated in vacuo. Crystallization from EtOAc afforded the title compound 
151 (94 mg, 0.24 mmol, 85%) as a colourless solid; 1H NMR
 
(400 MHz, DMSO-d6) 11.63 
(1H, s, NH), 7.93 (2H, d, J 7.8, ArH), 7.78 (1H, t, J 7.8, ArH), 7.65 (2H, t, J 7.8, ArH), 7.43 
(1H, s, 1-CH), 7.29 – 7.16 (3H, m, ArH), 6.92 (2H, d, J 6.0, ArH), 6.67 (1H, s, 3-CH), 4.53 
(1H, s, 4-CH), 3.74 (1H, dd, J 9.4, 4.6, 7-CH), 3.48 (1H, d, J 15.0, NCH2), 3.47 (1H, d, J 15.0, 
NCH2), 3.30 – 3.28 (1H, m, 5-CH), 2.62 (1H, ddd, J 13.4, 8.0, 4.6, 6-CH2), 2.04 – 1.93 (1H, 
m, 6-CH2); 
13C NMR (101 MHz, DMSO-d6) 194.2 (C=O), 138.7 (ArH), 138.5 (ArH), 134.3 
(ArH), 129.9 (ArH), 129.1 (ArH), 128.5 (ArH), 128.4 (ArH), 127.3 (ArH), 123.8 (1-CH), 121.0 
(3-CH), 117.4 (8a-C), 114.3 (3a-C), 69.7 (5-CH), 67.3 (7-CH), 56.7 (4-CH), 51.3 (NCH2), 28.4 
(6-CH2); IR νmax (neat)/cm-1: 3172, 3122, 2896 (C-H), 1658 (C=O), 1494, 1460 (C=C), 1445, 
1324 (S=O); HRMS (ESI): C22H21N2O3S [M+H
+]: calculated 393.1267, found 393.1267. 
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(3aR*,5S*,7R*,8S*,8aS*)-3,9-Dimethyl-7-(methylsulfonyl)-6,7,8,8a-tetrahydro-3aH-5,8-
epiminocyclohepta[d]isoxazol-4(5H)-one (157) 
 
General procedure L was followed using cycloadduct 116 (1.00 g, 4.65 mmol), nitroethane 
(0.67 mL, 9.29 mmol), phenylisocyanate (2.20 mL, 18.6 mmol) and triethylamine (33 L, 0.23 
mmol). Purification by flash chromatography on silica gel, eluting with a gradient of 40 - 100% 
EtOAc in hexane afforded the title compound 157 (358 mg, 1.31 mmol, 28%) as a colourless 
solid; Rf = 0.09, (100% in EtOAc); δH(400 MHz, DMSO-d6): 4.61 (1H, dd, J 10.5, 1.6, 8a-
CH), 4.05 (1H, d, J 10.5, 3a-CH), 3.93 – 3.81 (2H, m, 8-CH, 7-CH), 3.62 (1H, d, J 7.5, 5-CH), 
3.07 (3H, s, NMe), 2.50 – 2.44 (1H, m, 6-CH2), 2.37 (3H, s, SO2Me), 2.14 (1H, dd, J 13.9, 9.1, 
6-CH2), 1.92 (3H, s, Me); δC(101 MHz, DMSO-d6): 201.5 (C=O), 152.0 (3-C), 81.4 (8a-C), 
71.7 (5-C), 64.3 (8-C), 63.4 (7-C), 58.8 (3a-C), 40.2 (SO2Me) 39.1 (NMe), 28.3 (6-CH2), 12.7 
(Me); IR νmax (neat)/cm-1: 3025, 2985 (CH), 2944, 2918, 1715 (C=O), 1459 (C=C), 1432, 1272 
(S=O); HRMS (ESI): [M+H+]: C11H17N2O4S calculated 273.0904, found 273.0566. 
 
(3aR*,5S*,7R*,8S*,8aS*)-9-(4-Methoxybenzyl)-3-methyl-7-(methylsulfonyl)-6,7,8,8a-
tetrahydro-3aH-5,8-epiminocyclohepta[d]isoxazol-4(5H)-one (158) 
 
General procedure L was followed using cycloadduct 134 (391 mg, 1.22 mmol), nitroethane 
(0.22 mL, 3.04 mmol), phenylisocyanate (0.6 mL, 5.49 mmol) and triethylamine (15 L, 0.10 
mmol). Purification by flash chromatography on silica gel, eluting with a gradient of 40 - 100% 
EtOAc in hexane afforded the title compound 158 (130 mg, 0.34 mmol, 28%) as a colourless 
solid; Rf = 0.14, (60% EtOAc in hexane); δH (400 MHz, Chloroform-d): 7.15 (2H, d, J 8.7, 
ArH), 6.77 (2H, d, J 8.7, ArH), 4.57 (1H, dd, J 10.5, 1.7, 8a-CH), 4.08 (1H, s, 8-CH), 3.83 – 
3.68 (3H, m, NCH2, 3a-CH), 3.63 (1H, d, J 7.6, 5-CH), 3.26 (1H, t, 7-CH), 2.87 (3H, s, OMe), 
2.59 (1H, dt, J 14.5, 7.6, 6-CH2), 2.54 (3H, s, SO2Me), 2.16 (1H, dd, J 14.5, 9.2, 6-CH2), 1.97 
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(3H, s, Me); δC(101 MHz, Chloroform-d): 200.4 (C=O), 159.1 (Ar), 151.3 (3-C), 130.1 (ArH), 
129.3 (ArH), 113.8 (Ar), 81.5 (8a-C), 69.5 (5-C), 64.2 (8-C), 62.6 (7-C), 60.0 (3a-C), 55.2 
(OMe), 54.3 (NCH2), 39.9 (SO2Me), 29.6 (6-CH2), 12.3 (Me); IR νmax (neat)/cm-1: 3034 (CH), 
3008, 2951, 2932, 1716 (C=O), 1510 (C=C), 1455, 1316 (S=O); LCMS: C18H23N2O5S 
[M+H+]: calculated 379.1322, found 379.35. 
 
(5S*,7R*,8S*)-9-benzyl-3-methyl-7-(phenylsulfonyl)-6,7,8,8a-tetrahydro-3aH-5,8-
epiminocyclohepta[d]isoxazol-4(5H)-one (152 – 153) 
 
2:1 
General procedure L was followed using cycloadduct 87 (600 mg, 0.29 mmol, 1.0 eq.), 
nitroethane (0.3 mL, 3.4 mmol, 2.0 eq.), phenylisocyanate (0.8 mL, 6.93 mmol, 4.1 eq.), 
triethylamine (6 drops) in THF/Et2O (1:1) (8 mL). Purification by flash chromatography on 
silica gel, eluting with a gradient of 25% EtOAc in hexane afforded the title compound 152 – 
153 (142 mg, 0.35 mmol, 18%) as yellow solid; Rf = 0.15, (25% EtOAc in hexane). Major 
isomer was determined by protons on the crude 1H-NMR spectra. 1H NMR
 
(400 MHz, CDCl3) 
8.01 – 7.14 (10H, m ArH), 4.51 (1H, d, J 10.9, 8-CH), 4.02 (1H, d, J 1.5, 3a-CH) 3.95 (1H, d, 
J 12.7, NCH2), 3.83 – 3.78 (1H, m, 7-CH), 3.64 (1H, d, J 12.7, NCH2), 3.44 (1H, td, J 8.7, 2.0, 
5-CH), 3.23 (1H, dt, J 10.9, 1.5, 8a-CH), 2.70 – 2.55 (1H, m, 6-CH), 1.97 – 1.83 (1H, m, 6-
CH), 1.28 (3H, s, CH3); 
13C NMR (101 MHz, CDCl3): 199.4 (C=O), 138.5 (Ar), 137.3 (Ar), 
134.4 (ArH), 129.8 (ArH), 129.8 (ArH), 128.6 (ArH), 128.1 (ArH), 127.8 (ArH), 79.1(8-CH), 
71.6 (7-CH), 69.5 (5-CH), 59.1 (8a-CH), 59.0 (3a-CH), 55.5 (NCH2) 30.7 (6-CH2), 10.5 (CH3); 
IR νmax (neat)/cm-1: 3096, 3019, 2995 (C-H), 2906, 1706 (C=O), 1470, 1445 (C=C), 1310 
(S=O); HRMS (ESI): C22H23N2O4S [M+H
+]: calculated 411.1373, found 411.1377. 
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(5S*,7R*,8S*)-3,9-Dimethyl-7-(methylsulfonyl)-5,6,7,8-tetrahydro-4H-5,8-
epiminocyclohepta[d]isoxazol-4-one (159) 
 
To a stirred solution of dihydroisoxazole 157 (255 mg, 0.83 mmol) in PhMe (4 mL) was added 
DDQ (258 mg, 1.25 mmol, 1.5 eq.) and the mixture refluxed for 2h. The cooled crude mixture 
was concentrated in vacuo. Purification by reverse phase biotage MeCN/H2O 1% formic acid 
gave title compound 159 (36 mg, 0.13 mmol, 16%) as a white solid; δH (300 MHz, DMSO-
d6) 5.08 (1H, s, 8-CH), 3.96 (1H, dd, J 9.4, 4.2, 7-CH), 3.65 (1H, d, J 7.8, 5-CH), 3.06 (3H, s, 
Me), 2.71 (1H, ddd, J 14.5, 7.8, 4.3, 6-CH2), 2.40 (3H, s, Me), 2.32 (3H, s, Me), 2.04 (1H, dd, 
J 14.5, 9.4, 6-CH2); δC (75 MHz, DMSO): 217.0 (C=O), 197.3 (Ar), 174.3 (Ar), 123.0 (Ar), 
75.0 (5-C), 70.9 (8-C), 64.4 (7-C), 41.0 (Me), 35.6 (Me), 28.5 (6-C), 9.0 (Me); IR νmax 
(neat)/cm-1: 3015, 3006 (CH), 2984, 2908, 1720 (C=O), 1469 (C=C), 1432, 1271 (S=O); 
HRMS (ESI): [M+H+]: C11H15N2O4S calculated 271.0747, found 271.0747.  
 
(5S*,7R*,8S8)-9-Benzyl-3-methyl-7-(phenylsulfonyl)-5,6,7,8-tetrahydro-4H-5,8-
epiminocyclohepta[d]isoxazol-4-one (156) 
 
 
To a stirred solution of dihydroisoxazole 152 – 153 (2.00 g, 4.88 mmol) in PhMe (24 mL) was 
added DDQ (2.76 g, 7.32 mmol, 1.5 eq.) and the mixture refluxed for 2h. The cooled crude 
mixture was concentrated in vacuo. Purification by reverse phase biotage MeCN/H2O 1% 
formic acid gave title compound 156 (125 mg, 0.31 mmol, 6%); δH (400 MHz, Chloroform-
d) 7.80 – 7.75 (2H, m, ArH), 7.62 (1H, ddt, J 8.7, 7.0, 1.2, ArH), 7.52 – 7.46 (2H, m, ArH), 
7.24 – 7.20 (3H, m, ArH), 7.02 (2H, dd, J 7.3, 2.2, ArH), 4.72 (1H, s, 8-CH), 3.73 – 3.63 (2H, 
m, 5-CH, NBn), 3.56 (1H, dd, J 9.2, 4.4, 7-CH), 3.49 (1H, d, J 13.3, NBn), 2.84 (1H, ddd, J 
14.6, 7.9, 4.4, 6-CH2), 2.40 (3H, s, Me), 2.01 – 1.93 (1H, m, 6-CH2 ); δC (101 MHz, 
Chloroform-d) 193.7 (C=O), 176.5 (Ar), 157.2 (Ar), 136.0 (Ar), 134.3 (Ar), 129.6 (ArH), 
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128.8 (ArH), 128.7 (ArH), 128.5 (ArH), 127.9 (ArH), 119.2 (ArH), 112.1 (Ar), 67.6 (8-CH), 
66.8 (6-CH), 58.0 (7-CH), 51.7 (NCH2), 27.7 (6-CH2), 10.6 (Me); IR νmax (neat)/cm-1: 3025, 
2982 (CH), 2957, 2937, 1697 (C=O), 1494 (C=C), 1457, 1150 (S=O); HRMS (ESI): 
C22H21N2O4S [M+H
+]: calculated 409.1217, found 409.1218. 
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 (3S*,3aS*,4S*,5R*,7S*)-Ethyl-9-benzyl-8-oxo-5-(phenylsulfonyl)-2,3,3a,4,5,6,7,8-
octahydro-4,7-epiminocyclohepta[c]pyrazole-3-carboxylate (168) 
 
General procedure M was followed using cycloadduct 89 (200 mg, 0.56 mmol, 1.0 eq.), and 
ethyl diazoacetate (0.90 mL, 1.12 mmol, 2.0 eq.) in anhydrous THF (1.4 mL). Purification by 
flash chromatography on silica gel, eluting with a gradient of 50% EtOAc in hexane afforded 
the title compound 168 (150 mg, 0.32 mmol, 58%) as yellow oil; Rf = 0.79 (40% EtOAc in 
hexane). 1H NMR
 
(400 MHz, CDCl3) 8.01 – 7.94 (2H, m, ArH), 7.75 – 7.64 (1H, m, ArH), 
7.61 (2H, dd, J 8.3, 7.0, ArH), 7.36 – 7.22 (5H, m, ArH), 6.74 (1H, s, NH), 4.74 (1H, s, 4-CH), 
4.18 – 3.86 (4H, m, 3-CH, NCH2, OCH2), 3.77 (1H, d, J 13.3, NCH2), 3.72 (1H, d, J 7.5, 5-
CH), 3.66 (1H, t, J 7.6, 7-CH), 3.36 (1H, dd, J 11.3, 1.9, 3a-CH), 2.83 (1H, dt, J 14.5, 7.6, 6-
CH2), 2.16 (1H, dd, J 14.5, 9.2, 6-CH2), 1.19 (3H, t, J 7.6, CH3); 
13C NMR (101 MHz, CDCl3): 
201.7 (C=O), 161.1 (C=O), 142.6 (Ar), 138.8 (Ar), 137.6 (8a-C), 134.2 (ArH), 129.7 (ArH), 
129.0 (ArH), 128.4 (ArH), 128.3 (ArH), 127.4 (ArH), 69.7 (7-CH), 69.7 (3-CH), 63.6 (5-CH), 
61.1 (CH2), 60.3 (4-CH), 55.5 (NCH2), 53.2 (3a-CH), 28.6 (6-CH2), 14.0 (CH3); IR νmax 
(neat)/cm-1:3067, 2903 (C-H), 2870, 1715 (C=O), 1627, 1494, 1445 (C=C), 1331 (S=O); 
HRMS (ESI): C24H26N3O5S [M+H
+]: calculated 468.1588, found 468.1578. 
 
(3S*,3aS*,4S*,5R*,7S*)-Ethyl 9-benzyl-5-(methylsulfonyl)-8-oxo-2,3,3a,4,5,6,7,8-
octahydro-4,7-epiminocyclohepta[c]pyrazole-3-carboxylate (169) 
 
General procedure M was followed using cycloadduct 117 (3.19 g, 10.94 mmol) and ethyl 
diazoacetate (2.3 mL, 21.9 mmol) in anhydrous THF (54 mL). Purification by flash 
chromatography on silica gel, eluting with a gradient of 80 - 100% EtOAc in hexane afforded 
the title compound 169 (3.44 g, 8.52 mmol, 78%) as a colourless solid; Rf = 0.38, (100% 
EtOAc); δH (400 MHz, Chloroform-d): 7.33 – 7.20 (5H, m, ArH), 6.85 (1H, s, NH), 4.72 (1H, 
s, 4-CH), 4.27 (1H, d, J 11.6, 3-CH), 4.06 – 4.02 (2H, m, OCH2), 3.94 (1H, d, J 13.2, NBn), 
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3.80 – 3.72 (2H, m, NBn, 5-CH), 3.68 – 3.57 (2H, m, 7-CH, 3a-CH), 3.04 (3H, s, SO2Me), 2.80 
(1H, dt, J 14.6, 7.4, 6-CH2), 2.37 (1H, dd, J 14.6, 9.3, 6-CH2 ), 1.24 (3H, t, J 7.1, CH3); δC(101 
MHz, Chloroform-d): 201.8 (C=O), 161.4 (C=O), 142.4 (Ar), 137.3 (C), 129.0 (ArH), 128.5 
(ArH), 127.5 (ArH), 69.3 (5-C), 67.9 (7-C), 63.7 (3-C), 61.3 (OCH2), 60.0 (4-C), 55.0 (NCH2), 
53.1 (3a-C), 40.3 (SO2Me), 28.2 (6-CH2), 14.0 (CH3); IR νmax (neat)/cm-1: 3286 (NH), 3003 
(CH), 2981, 2931, 1716 (C=O), 1565 (C=C), 1494, 1292 (S=O); HRMS (ESI): C19H24N3O5S 
[M+H+]: calculated 406.1431, found 406.1427. 
 
(4S*,5R*,7S*)-9-Benzyl-5-(methylsulfonyl)-8-oxo-2,4,5,6,7,8-hexahydro-4,7-
epiminocyclohepta[c]pyrazole-3-carboxylic acid (170) 
 
 
General procedure M was followed using cycloadduct 19 (3.19 g, 10.94 mmol) and ethyl 
diazoacetate (contains  13 wt. % DCM) (2.3 mL, 21.9 mmol) in THF (55 mL). The reaction 
mixture was filtered through silica. General procedure N was followed using compound 169, 
NaOH (4M) (20 mL) and MeOH (15 mL). The reaction mixture was concentrated in vacuo and 
purification by reverse phase biotage MeCN/H2O 1% formic acid gave the title compound 170 
(322 mg, 0.86 mmol, 8%) as a colourless oil; δH (300 MHz, DMSO-d6): 7.34 – 7.16 (5H, m, 
ArH), 5.00 (1H, s, 4-CH), 3.75 – 3.62 (4H, m NBn, 5-CH, 7-CH), 2.99 (3H, s, Me), 2.83 – 2.71 
(1H, m, 6-CH2), 2.09 (1H, dd, J 14.9, 9.6, 6-CH2); δc (126 MHz, DMSO): 190.0 (C=O), 172.5 
(C=O), 163.6 (Ar), 162.8 (Ar), 162.7 (Ar), 137.3(Ar), 128.5 (ArH), 128.1 (ArH), 127.2 (Ar), 
67.6 (7-C), 66.8(5-C), 56.5 (4-C), 51.3, (NBn), 39.0 (Me), 26.5. (6-C); IR νmax (neat)/cm-1: 
3466 (OH), 3047, 3023, 2995 (CH), 1699 (C=O), 1557 (C=C), 1455, 1296 (S=O); HRMS 
(ESI): C17H18N3O5S [M+H
+]: calculated 376.0962, found 376.0971. 
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(6S*,7R*,9S*)-10-Benzyl-7-(methylsulfonyl)-6,7,8,9-tetrahydro-5H-6,9-
epiminocyclohepta[b]pyridine (202) 
 
General procedure O was followed using compound 175 (111 mg, 0.38 mmol), propylamine 
(50 l, 0.76 mmol) and sodium tetrachloroaurate(III) dihydrate (4 mg, 2.5 mol%) in EtOH (1.9 
mL). Purification by flash chromatography on silica gel, eluting with a gradient of 100% 
EtOAc in hexane afforded the title compound 202 (79 mg, 0,24 mmol, 63%) as a brown oil; Rf 
= 0.44 (1% MeOH in DCM); δH (300 MHz, Chloroform-d): 8.32 (1H, dd, J 4.8, 1.5, ArH), 
7.37 (1H, d, J 7.7, ArH), 7.30 – 7.16 (5H, m, ArH), 7.10 (1H, dd, J 7.7, 4.8, ArH), 4.18 (1H, 
d, J 6.2, 6-CH) 3.82 (1H, d, J 5.0, 5-CH), 3.71 (1H, d, J 13.1, NBn), 3.57 (1H, d, J 13.1, NBn), 
3.37 – 3.18 (2H, m, 1-CH, 4-CH2), 2.81 (3H, s, Me), 2.65 – 2.43 (2H, m, 7-CH2, 4-CH2), 2.33 
(1H, dd, J 13.3, 9.2, 7-CH2); 13C NMR (75 MHz, Chloroform-d): 157.7 (Ar), 147.9 (ArH), 
137.9 (ArH), 137.2 (ArH), 128.7 (ArH), 128.5 (ArH), 127.5 (Ar), 126.8 (ArH), 122.8 (ArH), 
68.1 (6-C), 64.2 (1-C), 56.7 (5-C), 52.2 (NBn), 37.4 (Me), 36.9 (4-C), 30.7 (7-C); IR νmax 
(neat)/cm-1: 3061, 3028 (CH), 3007, 2928, 2845, 1495 (C=C), 1444, 1292 (S=O); HRMS 
(ESI): C18H21N2O2S [M+H
+]: calculated 329.1318, found 329.1324. 
 
(6S*,7R*,9S*)-10-Methyl-7-(methylsulfonyl)-6,7,8,9-tetrahydro-5H-6,9-
epiminocyclohepta[b]pyridine (205) 
 
 
General procedure O was followed using compound 176 (1.00 g, 4.60 mmol), propylamine 
(2.1 mL, 9.2 mmol) and sodium tetrachloroaurate(III) dihydrate (37 mg, 2.5 mol%) in EtOH 
(23 mL). Purification by reverse phase biotage MeCN/H2O 1% formic acid gave title 
compound 205 (500 mg, 1.98 mmol, 43%) as a brown oil; δH (400 MHz, DMSO-d6): 8.31 
(1H, dd, J 4.9, 1.5, ArH), 7.52 (1H, dd, J 7.7, 1.5, ArH), 7.21 (1H, dd, J 7.7, 4.9, ArH), 3.99 
(1H, d, J 6.1, 6-CH), 3.87 – 3.82 (1H, m, 5-CH), 3.60 (1H, t, J 8.2, 1-CH), 3.29 – 3.15 (1H, m, 
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4-CH2), 2.97 (3H, s, Me), 2.61 – 2.39 (2H, m, 4-CH2, 7-CH2), 2.31 (3H, s, Me), 2.11 (1H, dd, 
J 12.8, 9.1, 7-CH2); δc (101 MHz, DMSO-d6): 158.3 (Ar), 147.5 (ArH), 137.4 (ArH), 127.7 
(Ar), 122.9 (ArH), 66.8 (1-C), 65.9 (6-C), 58.9 (5-C), 39.0 (Me), 36.1 (4-C), 35.9 (Me), 30.9 
(7-C); IR νmax (neat)/cm-1: 3050, 3026 (CH), 2967, 2880, 1558, 1540 (C=C), 1430, 1202 
(S=O); HRMS (ESI): C12H17N2O2S
 [M+H+]: calculated 253.1005, found 253.1002. 
 
(6S*,7R*,9S*)-N,N,10-Trimethyl-6,7,8,9-tetrahydro-5H-6,9-epiminocyclohepta[b]pyridine-7-
sulfonamide (204) 
 
 
General procedure O was followed using compound 177 (89 mg, 0.36 mmol), propylamine (47 
l, 0.72) and sodium tetrachloroaurate(III) dihydrate (4 mg, 2.5 mol%) in EtOH (1.8 mL). 
Purification by reverse phase biotage MeCN/H2O 1% formic acid gave title compound 204 
(40.1 mg, 0.14 mmol, 40%) as a brown oil; δH (400 MHz, Chloroform-d): 8.40 (1H, d, J 4.5, 
ArH), 7.45 (1H, dd, J 7.9, 1.5, ArH), 7.18 (1H, dd, J 7.9, 4.5, ArH), 4.21 (1H, d, J 6.2, 6-CH), 
4.04 – 3.95 (1H, m, 5-CH), 3.45 – 3.31 (2H, m, 1-CH, 4-CH2), 2.92 (6H, s, NMe2), 2.72 (1H, 
ddd, J 12.7, 7.8, 6.2, 7-CH2), 2.58 (1H, d, J 17.1, 4-CH2), 2.52 (3H, s, Me), 2.29 (1H, dd, J 
12.7, 8.8, 7-CH2); δC (101 MHz, Chloroform-d): 158.0 (Ar), 147.2 (ArH), 137.5 (ArH), 127.1 
(Ar), 122.7 (ArH), 66.2 (6-C), 64.6(1-C), 60.5 (5-C), 38.0 (Me), 36.7 (Me), 36.5 (4-C), 32.2 (7-
C); IR νmax (neat)/cm-1: 3062 (CH), 2994, 2849, 2801, 1577 (C=C), 1446, 1429, 1280 (S=O); 
HRMS (ESI): C13H20N3O2S [M+H
+]: calculated 282.1271, found 282.1278. 
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(6S*,7R*,9S*)-10-Methyl-7-(methylsulfonyl)-4-phenyl-6,7,8,9-tetrahydro-5H-6,9-
epiminocyclohepta[b]pyridine (205) 
 
 
General procedure O was followed using compound 176 (250 mg, 1.15 mmol), 3-Phenyl-2-
propyn-1-ol (386 mg, 2.30 mmol) and sodium tetrachloroaurate(III) dihydrate (10 mg, 2.5 
mol%). in EtOH (6 mL). Purification by reverse phase biotage MeCN/H2O 1% formic acid 
gave title compound afforded the title compound 205 (75 mg, 0,23 mmol, 20%) as a brown oil; 
δH (400 MHz, Chloroform-d): 8.37 (1H, d, J 5.0, ArH), 7.49 – 7.28 (3H, m, ArH), 7.23 – 7.18 
(2H, m, ArH), 7.02 (1H, d, J 5.0, ArH), 4.19 (1H, d, J 6.1, 6-CH), 3.85 (1H, dd, J 5.2, 1.3, 5-
CH), 3.22 – 3.11 (2H, m, 1-CH, 4-CH2), 2.84 (3H, s, Me), 2.59 (1H, ddd, J 13.2, 7.2, 6.2, 7-
CH2), 2.46 – 2.31 (5H, m, Me, 7-CH2, 4-CH2); δC (101 MHz, Chloroform-d): 157.7 (Ar), 150.4 
(Ar), 147.8 (ArH), 137.9 (Ar), 128.7 (ArH), 128.4 (ArH), 128.1 (ArH), 124.2 (Ar), 123.6 
(ArH), 68.1 (1-C), 66.4 (6-C), 59.4 (5-C), 38.1 (Me), 36.8 (4-C), 35.8 (Me), 30.1 (7-C); IR νmax 
(neat)/cm-1: 3024 (CH), 2953, 2883, 2855, 1508 (C=C), 1420, 1270 (S=O), 1123; HRMS 
(ESI): C18H21N2O2S [M+H
+]: calculated 329.1318, found 329.1313. 
 
(6S*,8R*,9S*)-11-Benzyl-8-(phenylsulfonyl)-5,6,7,8,9,10-hexahydro-6,9-
epiminocyclohepta[b]indole (186) 
 
General procedure P was followed using ketone 174 (100 mg, 0.29 mmol, 1.0 eq.), 2-
iodoaniline (74 mg, 0.34 mmol, 1.2 eq.), Pd(OAc)2 (4 mg, 10 mol%) and DABCO (32 mg, 
0.34 mmol, 1.0 eq.) in anhydrous DMF (0.3 mL). Purification by flash chromatography on 
silica gel, eluting with a gradient of 60% EtOAc in hexane. Crystallization from EtOAc 
afforded the title compound 186 (48 mg, 0.11 mmol, 40%) as a brown solid; Rf = 0.80, (60% 
EtOAc in hexane). 1H NMR
 
(400 MHz, CDCl3) 8.00 – 7.86 (2H, m, ArH), 7.79 (1H, s, NH), 
  163 
 
 
7.74 – 7.59 (1H, m, ArH), 7.66 – 7.47 (2H, m, ArH), 7.52 – 7.37 (1H, m, ArH), 7.35 – 7.21 
(4H, m, ArH), 7.27 – 7.02 (4H, m, ArH), 4.10 (1H, s, 9-CH), 3.98 (1H, d, J 5.5, 8-CH), 3.70 
(1H, d, J 13.6, NCH2), 3.64 (1H, d, J 13.6, NCH2), 3.55 (1H, t, J 7.8, 6-CH), 3.18 (1H, dd, J 
16.2, 4.4, 10-CH2), 2.63 (1H, ddd, J 12.4, 7.4, 5.6, 7-CH2), 2.40 (1H, dd, J 16.2, 1.2, 10-CH2), 
2.24 (1H, dd, J 12.4, 8.7, 7-CH2). 
13C NMR (101 MHz, CDCl3): 138.5 (Ar), 138.4 (Ar), 135.5 
(ArH), 135.3 (Ar), 133.6 (ArH), 129.2 (ArH), 128.9 (ArH),  128.9 (Ar), 128.4 (ArH), 128.3 
(ArH), 127.0 (Ar), 121.8 (ArH), 119.9 (ArH), 118.2 (ArH), 111.2 (ArH), 103.7 (Ar), 69.4 (8-
CH), 57.1 (9-CH), 56.2 (6-CH), 51.2 (NCH2), 37.9 (7-CH2), 25.7 (10-CH2); IR νmax (neat)/cm-
1: 3381, 3026 (C-H), 2800, 2685, 2615, 1495 (C=C), 1445, 1337 (S=O); HRMS (ESI): 
C26H25N2O2S [M+H
+]: calculated 429.1631, found 429.1650. 
 
 (6S*,8R*,9S*)-11-Benzyl-8-(methylsulfonyl)-5,6,7,8,9,10-hexahydro-6,9-
epiminocyclohepta[b]indole (186) 
 
General procedure P was followed using ketone 175 (100 mg, 0.34 mmol), 2-iodoaniline (150 
mg, 0.68 mmol), Pd(OAc)2 (6 mg, 10 mol%) and DABCO (77 mg, 0.68 mmol). Purification 
by flash chromatography on silica gel, eluting with a gradient of 50% EtOAc in hexane 
afforded the title compound 186 (25 mg, 0.07 mmol, 20%) as a colourless solid; Rf = 0.23, 
(50% EtOAc); δH(400 MHz, Chloroform-d): 7.92 (1H, s, NH), 7.53 – 7.37 (3H, m, ArH), 
7.34 – 6.95 (6H, m, ArH), 4.05 (1H, d, J 5.4, 9-CH), 3.90 (1H, d, J 4.6, 8-CH), 3.67 (1H, d, J 
13.2 NBn), 3.62 (1H, d, J 13.2, NBn), 3.32 – 3.19 (2H, m, 6-CH, 10-CH2), 2.85 (3H, s, NMe), 
2.54 – 2.33 (3H, m, 10-CH2, 7-CH2); δC(101 MHz, Chloroform-d): 138.4 (Ar), 135.6 (Ar), 
134.9 (Ar), 129.8 (ArH), 128.6 (ArH), 127.2 (Ar), 121.9 (ArH), 120.0 (ArH), 118.9 (ArH), 
118.3 (ArH), 111.3 (ArH), 103.3 (Ar), 68.5 (8-C), 57.3 (9-C), 56.2 (6-C), 51.2 (NBn), 38.4 
(Me), 37.0 (7-C), 25.1(10-C); IR νmax (neat)/cm-1: 3285 (NH), 3003 (CH), 2995, 2922, 2876, 
1510 (C=C), 1498, 1298 (S=O); HRMS (ESI): [M+H+]: C21H23N2O2S calculated 367.1475, 
found 367.2178. 
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(6S*,8R*,9S*)-N,N,11-Trimethyl-5,6,7,8,9,10-hexahydro-6,9-epiminocyclohepta[b]indole-8-
sulfonamide (187) 
 
 
General procedure P was followed using compound 177 (105 g, 0.43 mmol) and 2-iodoaniline 
(280 mg, 1.29 mmol), Pd(OAc)2 (20 mg, 15 mol%) and DABCO (143 mg, 1.29 mmol) in DMF 
(1 mL). Purification by flash chromatography on silica gel, eluting with a gradient of 90% 
EtOAc in hexane affording the title compound 187 (40 mg, 0.12 mmol, 29%) as a colourless 
solid; Rf = 0.34, (90% EtOAc in hexane); δH (400 MHz, Chloroform-d): 8.13 (1H, s, NH), 
7.43 – 7.35 (1H, m, ArH), 7.27 (1H, dd, J 7.8, 1.2, ArH), 7.13 – 6.97 (2H, m, ArH), 4.04 (1H, 
d, J 5.3, 8-CH), 3.94 (1H, d, J 4.1, 9-CH), 3.47 – 3.33 (1H, m, 6-CH), 3.17 (1H, dd, J 16.0, 
4.3, 10-CH2), 2.82 (6H, s, NMe2), 2.58 (1H, ddd, J 12.3, 7.6, 5.5, 7-CH2), 2.43 (1H, dd, J 16.0, 
1.2, 10-CH2), 2.37 (3H, s, Me), 2.22 (1H, dd, J 12.3, 8.7, 7-CH2); δC (101 MHz, Chloroform-
d): 135.7 (Ar), 135.2 (Ar), 127.2 (Ar), 121.7 (ArH), 119.8 (ArH), 118.1 (ArH), 111.3 (ArH) 
103.2 (Ar), 64.8 (6-C), 59.6 (9-C), 58.8 (8-C), 38.4 (NMe), 38.0 (7-C), 34.8 (Me), 25.5 (10-
C);IR νmax (neat)/cm-1: 3385(NH), 3102 (CH), 3058, 2943, 2849, 1541 (C=C), 1453, 1291 
(S=O); HRMS (ESI): C16H22N3O2S [M+H+]: calculated 320.1427, found 320.1428. 
 
(6S*,8R*,9S*)-11-Methyl-8-(methylsulfonyl)-5,6,7,8,9,10-hexahydro-6,9-
epiminocyclohepta[b]indole (189) 
 
General procedure P was followed using compound 176 (200 mg, 0.92 mmol) and 2-
iodoaniline (633 mg, 2.76 mmol), Pd(OAc)2 (31 mg, 15 mol%) and DABCO (310 mg, 2.76 
mmol) in DMF (4.6 mL) at 120 oC for 2 d. Purification by reverse phase biotage MeCN/H2O 
1% formic acid gave title compound 189 (45 mg, 0,16 mmol, 17%) as a brown oil; δH (400 
MHz, DMSO-d6): 10.83 (1H, s, NH), 7.36 (1H, d, J 8.0, ArH), 7.30 (1H, d, J 8.0, ArH), 7.03 
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(1H, t, J 7.4, ArH), 6.96 (1H, t, J 7.4, ArH), 4.08 (1H, d, J 5.4, 8-CH2), 3.86 (1H, d, J 4.2, 9-
CH2), 3.50 (1H, t, J 8.0, 6-CH2), 3.16 – 3.04 (1H, m, 10-CH2), 2.97 (3H, s, Me), 2.28 (3H, s, 
Me), 2.54 – 2.39 (2H, m, 10-CH2, 7-CH2) 2.24 (1H, dd, J 12.0, 8.9, 7-CH2); δC (101 MHz, 
DMSO-d6): 136.4 (Ar), 136.0 (Ar), 127.4 (Ar), 120.8 (ArH), 119.0 (ArH), 118.1 (ArH), 111.7 
(ArH), 101.9 (Ar), 67.5 (6-C), 58.4 (8-C), 58.4 (9-C), 38.6 (Me), 37.7 (7-C), 34.4 (Me), 25.0 
(10-C); IR νmax (neat)/cm-1: 3216 (NH), 3100, 2990 (CH), 2923, 2877, 1507 (C=C), 1418, 1285 
(S=O); HRMS (ESI): C15H19N2O2S [M+H
+]: calculated 291.1162, found 291.1158. 
 
 
(6S*,8R*,9S*)-11-Benzyl-5,8-bis(methylsulfonyl)-5,6,7,8,9,10-hexahydro-6,9-
epiminocyclohepta[b]indole (336) 
 
 
General procedure Q was followed using compound 188 (71 mg, 0.19 mmol) in DMF (0.4 
mL), NaH (12 mg, 0.29 mmol, 1.5 eq.) and methanesulfonyl chloride (90 L, 1.14 mmol, 6.0 
eq.) at 60 oC for 3 d. The reaction mixture was concentrated in vacuo and purification by reverse 
phase biotage MeCN/H2O 1% formic acid gave the title compound 336 (9.6 mg, 0.02 mmol, 
11%) as a brown oil; δH (400 MHz, Methanol-d4) 7.98 – 7.92 (1H, m, ArH), 7.63 – 7.51 (1H, 
m, ArH), 7.45 – 7.23 (7H, m, ArH), 4.75 (1H, d, J 5.4, 9-CH), 4.06 (1H, s, 8-CH), 3.86 (1H, 
d, J 13.3, NBn), 3.75 (1H, d, J 13.3, NBn), 3.62 (1H, t, J 8.2, 6-CH), 3.42 – 3.27 (1H, m, 7-
CH2) 3.06 (3H, s, Me), 3.01 (3H, s, Me), 2.76 – 2.48 (3H, m, 7-CH2, 10-CH2); δC (101 MHz, 
Methanol-d4) 135.9 (Ar), 135.9 (Ar), 129.3 (Ar), 128.4 (ArH), 128.2 (ArH),  128.2 (ArH), 
127.1 (Ar), 124.3, (ArH) 123.4 (ArH), 118.5 (ArH), 113.4 (ArH), 112.4 (Ar), 67.4 (6-C), 56.5 
(8-C), 56.5 (9-C), 50.9 (NBn), 39.6 (Me), 37.4 (7-C), 36.7 (Me), 24.7 (10-C); IR νmax (neat)/cm-
1: 3062 (CH), 3026, 2928, 2848, 1605, 1584, 1541 (C=C),1300 (S=O); HRMS (ESI): 
C22H25N2O4S2 [M+H
+]: calculated 445.1250, found 445.1244. 
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2-((6S*,8R*,9S*)-11-Benzyl-8-(methylsulfonyl)-7,8,9,10-tetrahydro-6,9-
epiminocyclohepta[b]indol-5(6H)-yl)acetonitrile (337) 
 
General procedure R was followed using compound 188 (71 mg, 0.19 mmol) in DMF (0.4 
mL), NaH (12 mg, 0.29 mmol, 1.5 eq.), bromoacetonitrile (93 L, 1.33 mmol, 7.0 eq.) at 90 
oC for 3 d. The reaction mixture was concentrated in vacuo and purification by reverse phase 
biotage MeCN/H2O 1% formic acid gave the title compound 337 (15 mg, 0.04 mmol, 19%) as 
a brown oil; δH (400 MHz, Methanol-d4) 7.56 – 7.45 (6H, m, ArH), 7.42 – 7.22 (7H, m, ArH), 
7.18 (1H, td, J 7.5, 1.0, ArH), 5.30 (1H, d, J 18.5, NCH2), 5.22 (1H, d, J 18.5, NCH2), 4.43 
(1H, d, J 5.5, 9-CH), 4.05 (1H, d, J 4.0, 8-CH), 3.81 (1H, d, J 13.2, NBn), 3.73 (1H, d, J 13.2, 
NBn), 3.56 (1H, t, J 8.0, 6-CH), 3.36 – 3.22 (1H, m, 7-CH2) 3.00 (3H, s, Me), 2.75 – 2.43 (3H, 
m, 7-CH2, 10-CH2); δC (101 MHz, Methanol-d4) 136.4 (Ar), 135.8 (Ar), 128.6 (ArH), 128.4 
(Ar) 128.1 (ArH), 127.6 (Ar), 127.0 (ArH), 122.0 (ArH), 120.3 (ArH), 118.2 (ArH), 115.2 (Ar), 
108.9 (ArH), 105.3 (CN), 67.6 (6-C), 56.9 (8-C), 54.6 (9-C), 51.0 (NBn), 37.3(7-C), 36.7 (Me), 
30.1 (N-C), 24.5 (10-C); IR νmax (neat)/cm-1: 3034 (CH), 2963, 2873, 2828, 2106 (CN), 1557 
(C=C), 1459, 1300 (S=O); HRMS (ESI): C23H24N3O2S [M+H
+]: calculated 406.1584, found 
406.1578. 
(1R*,3R*,4R*,10R*,10aS*)-1-(Phenylsulfonyl)-1,2,3,5,10,10a-hexahydro-3,10-
ethanopyrrolo[1,2-b]isoquinolin-12-one (208) 
 
 
General procedure S was followed using enone 135 (105 mg, 0.25 mmol), sodium formate 
(19 mg, 0.28 mmol), Pd(OAc)2 (6 mg), PPh3 (14 mg) and ZnCl2 (34 mg, 0.25 mmol) in 
anhydrous THF (1.2 mL). Purification by flash chromatography on silica gel, eluting with a 
gradient of 30% EtOAc in hexane afforded the title compound 208 (21 mg, 0.06 mmol, 24%) 
as a colourless solid; Rf = 0.19, (30% EtOAc), δH(400 MHz, Chloroform-d): 8.00 – 7.83 (2H, 
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m, ArH), 7.72 – 7.57 (1H, m, ArH), 7.57 – 7.49 (2H, m, ArH), 7.16 – 7.04 (2H, m, ArH), 6.96 
– 6.82 (2H, m, ArH), 4.28 (1H, d, J 18.0, 5-CH2), 4.02 – 3.93 (2H, m, 5-CH2, 10a-CH), 3.87 
(1H, dd, J 9.3, 6.1, 3-CH), 3.49 (1H, dd, J 7.0, 1.9, 1-CH), 3.25 (1H, d, J 6.6. 10-CH), 2.76 – 
2.60 (2H, m, 2-CH2, 11-CH2 ), 2.17 (1H, dd, J 15.8, 1.8, 11-CH2 ), 2.07 (1H, dd, J 14.3, 9.3, 
2-CH2); δC(101 MHz, Chloroform-d): 209.4 (C=O), 137.7 (Ar), 137.3 (Ar), 134.1 (ArH), 
131.8 (Ar), 129.4 (ArH), 128.9 (ArH), 128.0 (ArH), 127.8 (ArH), 127.0 (ArH), 125.9 (ArH), 
71.4 (10a-C), 66.0 (3-C), 56.5 (1-C), 48.4 (5-C), 42.7 (11-C), 42.4 (10-C), 29.8 (2-C); IR νmax 
(neat)/cm-1: 3104, 3060 (CH), 3024, 2928, 1603 (C=O), 1510 (C=C), 1478, 1316 (S=O); 
HRMS (ESI): [M+H+]: C20H20NO3S
 calculated 354.1158, found 354.1150. 
 
(1R*,3R*,4R*,10R*,10aS*)-7-Fluoro-1-(methylsulfonyl)-1,2,3,5,10,10a-hexahydro-3,10-
ethanopyrrolo[1,2-b]isoquinolin-12-one (209) 
 
 
General procedure S was followed using enone 137 (50 mg, 0.13 mmol), sodium formate 
(13 mg, 0.19 mmol), Pd(OAc)2 (1 mg, 15 mol%), PPh3 (7 mg, 0.05 mmol) and ZnCl2 (18 mg, 
0.19 mmol). Purification by reverse phase biotage MeCN/H2O 1% formic acid gave title 
compound 209 (4.9 mg, 0.16 mmol, 12 %) as a colourless solid. δH (400 MHz, DMSO-d6): 
7.23 – 7.15 (1H, m, ArH), 7.10 – 7.04 (2H, m, ArH), 4.59 (1H, d, J 18.4, 5-CH2), 4.41 (1H, d, 
J 18.4, 5-CH2), 4.00 (1H, d, J 8.6, 5-CH2), 3.85 (1H, d, J 8.1, 10a-CH), 3.61 (1H, dd, J 9.4, 
5.9, 3-CH), 3.50 (1H, d, J 7.5, 1-CH), 2.94 (3H, s, Me), 2.24 (1H, dd, J 14.3, 7.7, 2-CH2), 2.09 
(1H, dd, J 13.6, 9.4, 2-CH2); δC(101 MHz, DMSO-d6): 208.3 (C=O), 160.1 (d, J 252.5, ArF), 
139.2 (d, J 7.1, Ar), 130.0 (d, J 8.3, Ar), 129.3 (d, J 34.1, ArH), 115.2 (d, J 21.5, ArH), 114.7 
(d, J 20.9, ArH), 68.4 (10a-C), 67.0 (3-C), 56.0 (1-C), 51.6 (5-C), 51.4 (11-C), 38.1 (Me), 36.4 
(10-C), 30.8 (2-C), IR νmax (neat)/cm-1: 3062, 3013, 2929 (CH), 2881, 1722 (C=O), 1543 
(C=C), 1499, 1297 (S=O); HRMS (ESI): C15H17FNO3S [M+H
+]: calculated 310.0908, found 
310.0904. 
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(1R*,3R*,4R*,10R*,10aS*,12R*)-1-(Phenylsulfonyl)-1,2,3,5,10,10a-hexahydro-3,10-
ethanopyrrolo[1,2-b]isoquinolin-12-ol (210) 
 
 
General procedure I was followed using ketone 208 (10 mg, 0.03 mmol) and DIBAL (1M 
cyclohexane) (0.1 mL, 0.1 mmol) in anhydrous DCM (1 mL). Purification by flash 
chromatography on silica gel, eluting with a gradient of 35-60% EtOAc in hexane afforded the 
title compound 210 (7.4 mg, 0,02 mmol, 74%) as a colourless oil; δH (400 MHz, Methanol-
d4): 7.87 – 7.80 (2H, m, ArH), 7.67 – 7.60 (1H, m, ArH), 7.57 – 7.50 (2H, m, ArH), 7.03 – 
6.80 (5H, m, ArH), 4.35 (1H, d, J 17.8, NBn), 4.05 (1H, d, J 17.8, NBn), 3.86 (1H, dd, J 9.3, 
6.0, 3-CH), 3.52 (1H, s, 10a-CH), 3.48 – 3.34 (2H, m, 12-CH, 1-CH), 2.44 – 2.38 (1H, m, 10-
CH2), 2.37 – 2.25 (1H, m, 2-CH2), 2.16 (1H, dt, J 15.2, 5.2, 11-CH2), 1.80 (1H, dd, J 13.6, 9.3, 
2-CH2), 1.56 (1H, dt, J 15.2, 1.7, 11-CH2); δC (101 MHz, Methanol-d4): 139.8 (Ar), 138.1 
(Ar), 136.3 (ArH), 133.6 (Ar), 129.0 (ArH), 128.5 (ArH), 128.5 (ArH), 127.5 (ArH), 125.9 
(ArH), 124.2 (ArH), 67.6 (12), 64.9 (10), 63.9 (10a), 56.8 (NBn), 48.8 (Me), 34.2 (1-C), 31.8 
(2-C), 28.9 (11-C); IR νmax (neat)/cm-1: 3368 (OH), 3061 (CH), 3002, 2922, 2872, 1490 (C=C), 
1445, 1290 (S=O); HRMS (ESI): C20H22NO3S [M+H
+]: calculated 356.1315, found 356.1323 
 
(1S*,4R*,5S*,6R*)-8-Benzyl-4-phenyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]octan-2-one 
(207) 
 
General procedure T was followed using cycloadduct 89 (200 mg, 0.57 mmol, 1.0 eq.), 
phenylboronic acid (104 mg, 0.85 mmol, 1.5 eq.), chloro(1,5-cyclooctadiene)rhodium(I) dimer 
(3 mg, 2.5 mol%) and triethylamine (0.08 mL, 0.6 mmol, 1.0 eq.) in degassed dioxane:H2O 
(6:1) (2 mL). Purification by flash chromatography on silica gel, eluting with a gradient of 30% 
EtOAc in hexane gave title compoound. Crystallization from EtOAc afforded the title 
compound 207 (244 mg, 0.577 mmol, 40%) as a colourless solid; Rf = 0.30, (30% EtOAc in 
hexane). M.Pt. 1H NMR
 
(400 MHz, CDCl3) 8.00 – 7.88 (2H, m, ArH), 7.79 – 7.63 (1H, m, 
  169 
 
 
ArH), 7.66 – 7.55 (2H, m, ArH), 7.34 – 7.21 (3H, m, ArH), 7.19 – 6.98 (7H, m, ArH), 3.93 
(1H, s, 5-CH), 3.87 (1H, d, J 13.3, NCH2), 3.76 – 3.66 (3H, m, NCH2, 1-CH, 6-CH), 3.05 (1H, 
dt, J 8.6, 2.5, 4-CH), 2.83 – 2.65 (2H, m, 7-CH2, 3-CH2), 2.55 (1H, dd, J 17.6, 8.5, 3-CH2), 
2.11 (1H, dd, J 13.9, 8.9, 7-CH2). 
13C NMR (101 MHz, CDCl3): 205.6 (C=O), 143.0 (C), 139.2 
(C), 137.6 (C), 134.0 (ArH), 129.6 (ArH), 128.9 (ArH), 128.3 (ArH), 128.2 (ArH), 128.1 (ArH), 
127.8 (ArH), 127.0 (ArH), 126.8 (ArH), 72.2 (1-CH), 70.4 (5-CH), 67.6 (6-CH), 56.2 (NCH2), 
47.4 (4-C), 39.0 (3-CH2), 29.9 (7-CH2). IR νmax (neat)/cm-1: 2977 (CH), 2966, 2965, 2890, 
1718 (C=O), 1496 (C=C), 1444, 1331 (S=O); HRMS (ESI): C26H26NO3S [M+H
+]: calculated 
432.1628 found 432.1628. 
 
(1S*,4R*,5S*,6R*)-8-Benzyl-6-(methylsulfonyl)-4-phenyl-8-azabicyclo[3.2.1]octan-2-one 
(246) 
 
General procedure T was followed using cycloadduct 116 (1.5 g, 5.2 mmol), phenylboronic 
acid (2.4 g, 15.6 mmol) chloro(1,5-cyclooctadiene)rhodium(I) dimer (30 mg, 2.5 mol%) and 
triethylamine (0.80 mL, 6.0 mmol, 1.0 eq.) in degassed dioxane:H2O (6:1) (20 mL). 
Purification by flash chromatography on silica gel, eluting with a gradient of 50 - 100% EtOAc 
in hexane affording the title compound 246 (542 mg, 1.47 mmol, 29%) as a colourless solid; 
Rf = 0.14, (100% EtOAc in hexane); δH(400 MHz, DMSO-d6): 7.47 – 7.19 (3H, m, ArH), 7.20 
– 6.97 (5H, m, ArH), 6.87 – 6.77 (2H, m, ArH), 4.30 (1H, t, J 8.5, 6-CH), 3.71 – 3.61 (3H, m, 
1-CH, NBn, 5-CH), 3.56 (1H, d, J 13.8, NBn), 3.32 (1H, s, 4-CH), 3.13 (3H, s, SO2Me), 3.05 
– 2.87 (1H, m, 3-CH2), 2.60 (1H, dt, J 14.3, 7.2, 7-CH2), 2.51 – 2.34 (2H, m, 3-CH2, 7-CH2); 
δC(101 MHz, DMSO-d6): 205.4 (C=O), 144.2 (Ar), 138.7 (Ar), 134.5 (ArH), 130.4 (Ar), 128.8 
(ArH), 128.4 (ArH), 128.3 (ArH), 127.0 (ArH), 126.8 (ArH), 72.8 (1-C), 66.9 (5-C), 66.7 (6-
C), 55.7 (NBn), 46.8 (4-C), 40.9 (Me), 38.8 (3-C), 29.2 (7-C); IR νmax (neat)/cm-1: 3027, 2985, 
2955 (CH), 2902, 1716 (C=O), 1459 (C=C), 1432, 1292 (S=O); HRMS (ESI): C21H24NO3S 
[M+H+]: calculated 369.1399, found 369.1396. 
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(1S*,4R*,5S*,6R*)-8-Benzyl-4-(4-methoxyphenyl)-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-one (272) 
 
General procedure T was followed using cycloadduct 116 (150 mg, 0.52 mmol) and 4-
methoxyphenylboronic acid (240 mg, 1.54 mmol), chloro(1,5-cyclooctadiene)rhodium(I) 
dimer (3 mg, 2.5 mol%) and triethylamine (0.08 mL, 6.0 mmol, 1.0 eq.) in degassed 
dioxane:H2O (6:1) (4 mL).  Purification by flash chromatography on silica gel, eluting with a 
gradient of 40% EtOAc in hexane afforded the title compound 272 (92 mg, 0.23 mmol, 44%) 
as a colourless solid; Rf = 0.25, (40% EtOAc in hexane); δH(400 MHz, Chloroform-d): 7.26 
– 7.18 (1H, m, ArH), 7.11 – 7.00 (4H, m, ArH), 6.98 – 6.91 (2H, m, ArH), 6.77 – 6.70 (2H, m, 
ArH), 3.88 (1H, s, 5-CH), 3.78 – 3.64 (5H, m, OMe, NBn, 6-CH), 3.62 – 3.54 (2H, m, NBn, 1-
CH), 3.11 (1H, dt, J 8.4, 2.5, 4-CH), 2.93 (3H, s, SO2Me), 2.76 – 2.52 (3H, m, 3-CH2, 7-CH2), 
2.28 (1H, dd, J 13.7, 8.9, 7-CH2). δC(101 MHz, Chloroform-d): 205.2 (C=O), 163.0 (Ar), 
160.6 (Ar), 138.7 (Ar), 129.0 (ArH), 128.8 (ArH), 128.1 (ArH), 127.1 (ArH), 113.7 (ArH), 77.2 
(6-C), 72.5 (1-C), 68.3 (5-C), 66.4 (OMe), 55.9 (NBn), 46.7 (4-C), 40.7 (3-C), 39.3 (SO2Me), 
30.2 (7-C); IR νmax (neat)/cm-1: 3062 (CH), 3029, 2955, 29255, 1716 (C=O), 1495 (C=C), 
1454, 1336 (S=O); HRMS (ESI): C22H26NO4S [M+H
+]: calculated 400.1504, found 400.2338. 
 
 
3-((1S*,2R*,5S*,7R*)-8-Methyl-7-(methylsulfonyl)-4-oxo-8-azabicyclo[3.2.1]octan-2-
yl)benzonitrile (275) 
 
General procedure T was followed using cycloadduct 117 (3.70 g, 17.2 mmol), 3-
cyanophenylboronic acid (7.58 g, 51.6 mmol), chloro(1,5-cyclooctadiene)rhodium(I) dimer 
(60 mg, 2.5 mol%) and triethylamine (1.60 mL, 12.0 mmol, 1.0 eq.) in degassed dioxane:H2O 
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(6:1) (40 mL). Purification by flash chromatography on silica gel, eluting with a gradient of 80 
- 100% EtOAc in hexane afforded the title compound 275 (1.00 g, 3.14 mmol, 18%) as a yellow 
oil; Rf = 0.33, (100% EtOAc in hexane); δH(400 MHz, Chloroform-d): 7.93 – 7.84 (1H, m, 
ArH), 7.73 – 7.58 (1H, m, ArH), 7.58 – 7.42 (2H, m, ArH), 4.13 (1H, t, J 8.5, 6-CH), 3.79 (1H, 
s, 5-CH), 3.69 (1H, d, J 6.9, 1-CH), 3.67 – 3.56 (1H, m, 4-CH), 3.33 (3H, s, SO2Me), 2.88(1H, 
dd, J 17.9, 8.8, 3-CH2), 2.68 (1H, dt, J 14.5, 7.4, 7-CH2), 2.55 – 2.44 (1H, m, 3-CH2), 2.43 – 
2.27 (4H, m NMe, 7-CH2); δC(101 MHz, Chloroform-d): 209.4 (C=O), 149.9 (Ar), 136.5 
(ArH), 135.2 (ArH), 134.1 (ArH), 133.0 (ArH), 122.3 (CN), 115.8 (Ar), 78.2 (1-CH), 72.5 (5-
C), 71.3 (6-C), 50.3 (SO2Me), 43.6 (4-C), 43.4 (NMe), 42.4 (3-C) 32.8 (7-C); IR νmax (neat)/cm-
1: 3097 (CH), 2959, 2872, 2830, 2509 (CN) 1631 (C=O), 1578 (C=C), 1305 (S=O); HRMS 
(ESI): [M+H+]: C16H19N2O3S calculated 319.1111, found 319.0338. 
(1S*,4R*,5S*,6R*)-8-Benzyl-4-(4-fluorophenyl)-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-one (274) 
 
 
 
General procedure T was followed using cycloadduct 116 (5.00 g, 17.2 mmol) and 4-
fluorophenylboronic acid (7.2 g, 51.6 mmol, 3.0 eq.) chloro(1,5-cyclooctadiene)rhodium(I) 
dimer (250 mg, 2.5 mol%) and triethylamine (17 mL, 17.2 mmol, 1.0 eq.) in degassed 
dioxane:H2O (6:1) (57 mL). Purification was by flash chromatography on silica gel, eluting 
with a gradient of 80 - 100% EtOAc in hexane. Crystallization of the resulting material from 
EtOAc afforded the title compound 274 (5.20 g, 13.4 mmol, 78%) as a colourless solid; Rf = 
0.50, (100% EtOAc in hexane). M.Pt.:152.4 – 153.1 oC; δH(400 MHz, Chloroform-d): 7.10 
– 6.99 (5H, m, ArH), 6.99 – 6.90 (2H, m, ArH), 6.87 – 6.79 (2H, m, ArH), 3.91 – 3.77 (1H, s, 
5-CH), 3.71 (1H, dd, J 6.7, 1.6, 6-CH), 3.67 (1H, d, J 13.1, NBn), 3.64 – 3.56 (1H, m, 1-CH), 
3.53 (1H, d, J 13.1, NBn), 3.13 (1H, dt, J 8.4, 2.6, 4-CH), 2.93 (3H, s, SO2Me), 2.71 – 2.51 
(3H, m 3-CH2, 7-CH2), 2.29 (1H, dd, J 13.8, 9.0, 7-CH2). δC(101 MHz, Chloroform-d) 205.2 
(C=O), 161.8 (d, J 245.1, Ar-F), 138.7 (d, J 3.5, Ar), 137.3 (Ar), 129.4 (d, J 8.0, ArH), 129.0 
(ArH), 128.1 (ArH), 127.2 (ArH), 115.1 (d, J 21.3, ArH), 72.5 (6-CH), 68.3 (1-CH), 66.4 (5-
CH), 55.9 (NBn), 46.7 (4-CH), 40.7 (SO2Me), 39.3 (3-CH2), 30.2 (7-CH2). IR νmax (neat)/cm-
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1: 3003 (CH), 2926, 2897, 2885, 1717 (C=O), 1510 (C=C), 1430, 1330 (S=O); HRMS (ESI): 
C21H23FNO3S [M+H
+]: calculated 388.1304, found 388.0436. 
 
(1S*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-one 
(279) 
 
 
General procedure F was followed using ketone 274 (160 mg, 0.41 mmol), Pd(OH)2/C (6 mg, 
10 w/w%) and conc. HCl (0.1 mL) in MeOH (10 mL) over 18 h. Purification by flash 
chromatography on silica gel, eluting with a gradient of 70% EtOAc in hexane afforded the 
title compound 279 (82 mg, 0.27 mmol, 67%) as a colourless oil; Rf = 0.16, (50% EtOAc in 
hexane); δH(400 MHz, Chloroform-d): 7.31 – 7.18 (2H, m, ArH), 7.14 – 6.99 (2H, m, ArH), 
4.06 (1H, s, 5-CH), 3.93 (1H, d, J 6.8 6-CH), 3.66 (1H, dd, J 8.7, 5.9, 1-CH), 3.36 (1H, d, J 
7.5, 4-CH), 2.95 (3H, s, SO2Me), 2.77 – 2.60 (2H, m, 3-CH2), 2.58 – 2.36 (2H, m. 7-CH2); 
δC(101 MHz, Chloroform-d): 206.5 (C=O), 162.0 (d, J 246.3, ArF), 138.4 (d, J 3.1, Ar), 129.1 
(d, J 7.9, ArH), 115.7 (d, J 21.3, ArH), 66.5 (6-CH), 66.2 (1-CH), 62.2 (5-CH), 46.5 (4-CH), 
39.1 (3-CH2), 38.7 (SO2Me), 31.7 (7-CH2); IR νmax (neat)/cm-1: 3054, 2997 (CH), 2981, 2950, 
1716 (C=O), 1510 (C=C), 1456, 1314 (S=O); LCMS: C14H17FNO3S [M+H
+]: calculated 
298.0908, found 298.14. 
 
(1S*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-one (273) 
 
General procedure T was followed using cycloadduct 117 (4.40 g, 20.4 mmol) and 4-
fluorophenylboronic acid (8.5 g, 61.2 mmol, 3.0 eq.) chloro(1,5-cyclooctadiene)rhodium(I) 
dimer (300 mg, 2.5 mol%) and triethylamine (20 mL, 20.4 mmol, 1.0 eq.) in degassed 
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dioxane:H2O (6:1) (68 mL). Purification by flash chromatography on silica gel, eluting with a 
gradient of 60 - 100% EtOAc in hexane afforded the title compound 273 (3.65 g, 11.7 mmol, 
57%) as a colourless solid; Rf = 0.05, (60% EtOAc in hexane). M.Pt. 141.9 – 142.7 oC; δH(400 
MHz, Chloroform-d): 7.35 – 7.19 (2H, m), 7.05 – 6.81 (2H, m), 3.81 (1H, s, 5-CH), 3.62 (1H, 
d, J 6.6, 1.6, 6-CH), 3.47 (1H, td, J 8.7, 1.8, 1-CH), 3.05 (1H, dd, J 8.3, 4.0, 4-CH), 2.92 (3H, 
s, SO2Me), 2.67 – 2.51 (3H, m, 3-CH2 7-CH2), 2.32 (3H, s, NMe), 2.23 (1H, dd, J 13.6, 8.7, 7-
CH2). δC(101 MHz, Chloroform-d): 206.3 (C=O), 161.9 (d, J 245.7, ArF), 139.5 (d, J 3.1, 
Ar), 129.1 (d, J 8.0, ArH), 115.3 (d, J 21.2, ArH), 74.0 (6-C), 68.9 (1-C), 68.7 (5-C), 46.7 (4-
C), 40.6 (NMe), 40.2 (SO2Me), 40.0 (3-C), 30.0 (7-C); IR νmax (neat)/cm-1: 3075, 2998 (CH), 
2939, 2897, 1716 (C=O), 1510 (C=C), 1455, 1222 (S=O); HRMS (ESI): C15H19FNO3S 
[M+H+]: calculated 312.1064, found 312.1656. 
 
 
(1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-ol (278a) 
 
 
General procedure I was followed using ketone 273 (1.96 g, 6.30 mmol) DIBAL (1M 
cyclohexane, 12.0 mL, 12.0 mmol) in anhydrous DCM (50 mL) to give a crude mixture of 
diastereomers 5:1. Crystallization from ethanol gave the major title compound 278a (1.40 g, 
4.47 mmol, 71%) as a colourless solid; 
M.Pt. 162.8 – 163.4 oC; δH(400 MHz, Chloroform-d): 7.47 – 7.32 (2H, m, ArH), 6.98 – 6.87 
(2H, m, ArH), 4.09 (1H, s, 5-CH), 3.62 – 3.54 (1H, m, 2-CH), 3.52 (1H, at, J 7.1, 6-CH), 3.31 
– 3.26 (1H, m, 1-CH), 2.91 (3H, s, SO2Me), 2.84 (1H, d, J 7.8, 4-CH), 2.66 (1H, d, J 11.5, 
OH), 2.50 (1H, dt, J 14.1, 7.1, 7-CH2), 2.42 (3H, s, NMe), 2.13 – 1.96 (2H, m, 7-CH2, 3-CH2), 
1.88 (1H, ddd, J 15.7, 7.8, 4.2, 3-CH2); δC(101 MHz, Chloroform-d): 162.4 (d, J 241.0, Ar-
F), 139.3 (Ar), 129.0 (d, J 7.8, Ar-H), 115.1 (d, J 21.1, Ar-H), 69.7 (1-C), 69.0 (2-C), 68.6 (6-
C), 67.1 (5-C), 44.1 (4-C), 42.1 (NMe), 40.8 (SO2Me), 29.9 (3-C), 28.1 (7-C); IR νmax 
(neat)/cm-1: 3497 (O-H), 3043, 3001 (C-H), 2998, 2937, 2943, 1509 (C=C), 1295 (S=O); 
HRMS (ESI): [M+H+]: C15H21FNO3S calculated 314.1221, found 314.1815. 
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(1S*,2R*,4R*,5S*,6R*)-8-Benzyl-4-(4-fluorophenyl)-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-ol (281) 
 
General procedure I was followed using ketone 274 (1.50 g, 3.95 mmol), DIBAL (1M 
cyclohexane, 12.0 mL, 12.0 mmol) in anhydrous DCM (50 mL) to give a crude mixture of 
diastereomers 10:1. Crystallization from ethanol gave the major title compound 281 (1.30 g, 
3.34 mmol, 85%) as a colourless solid; M.pt. 139.9 – 140.8 oC; δH(400 MHz, DMSO-d6): 
7.73 – 7.59 (2H, m, ArH), 7.18 – 6.91 (7H, m, ArH), 4.51 (1H, d, J 4.8, 5-CH), 4.03 (1H, at, J 
8.4, 6-CH), 3.67 – 3.57 (2H, m, 4-CH, NBn), 3.55 – 3.46 (2H, m, 2-CH, NBn), 3.34 (1H, s, 1-
CH), 3.06 (3H, s, SO2Me), 2.91 (1H, d, J 8.0, OH), 2.36 (1H, dt, J 14.1, 7.2, 7-CH2), 2.25 – 
2.01 (2H, m. 3-CH2, 7-CH2), 1.72 (1H, d, J 15.7, 3-CH2); δC(101 MHz, DMSO-d6): 161.1 (d, 
J 241.0, Ar-F), 141.6 (d, J 2.9, Ar), 139.8 (Ar), 131.4 (d, J 7.7, ArH), 128.9 (ArH), 128.0 (ArH), 
126.8 (ArH), 114.3 (d, J 20.6, ArH), 68.4 (2-C), 68.4 (6-C), 67.4 (5-C), 66.3 (1-C), 56.9 (NBn), 
46.3 (4-C), 40.8 (Me), 29.4 (7-C), 28.4 (3-C); IR νmax (neat)/cm-1: 3473 (OH), 3002 (CH), 
2960, 2930, 2885, 1512 (C=C), 1431, 1326 (S=O); HRMS (ESI): C21H25FNO3S [M+H
+]: 
calculated 390.1534, found 390.1537. 
 
(1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-
ol (282) 
 
 
General procedure F was followed using alcohol 281 (300 mg, 0.77 mmol), Pd(OH)2/C (15 
mg, 10 w/w%) and conc. HCl (0.2 mL) in MeOH (10 mL) over 18 h. Purification by general 
procedure D (SCX SPE) afforded the title compound 282 (200 mg, 0.67 mmol, 87%) as a 
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colourless oil; δH(400 MHz, Methanol-d4): 7.80 – 7.61 (2H, m, ArH), 7.20 – 6.88 (2H, m, 
ArH), 4.00 (1H, s, 5-CH), 3.86 (1H, dd, J 9.0, 5.5, 6-CH), 3.80 – 3.67 (1H, m, 2-CH), 3.63 – 
3.49 (1H, m, 1-CH), 3.03 (3H, s, SO2Me), 2.98 (1H, d, J 8.2, 4-CH), 2.41 – 2.11 (3H, m, 7-
CH2, 3-CH2), 1.97 (1H, d, J 15.8, 3-CH2); δC (101 MHz, Methanol-d4): 161.4 (d, J 243.2, 
ArF), 139.6 (d, J 3.1, Ar), 130.1 (d, J 7.7, ArH), 114.4 (d, J 21.1, ArH), 67.0 (2-C), 65.6 (6-C), 
61.3 (5-C), 60.7 (1-C), 42.6 (4-C), 37.7 (Me), 28.8 (7-C), 27.8 (3-C); IR νmax (neat)/cm-1: 3499 
(O-H), 3319 (N-H), 3059, 3004 (C-H), 3028, 2937, 1508 (C=C), 1288 (S=O); HRMS (ESI): 
C14H19FNO3S [M+H
+]: calculated 300.1064, found 300.1071. 
 
 
(3aR*,4S*,5R*,7S*,8aS*)-2-Benzyl-9-methyl-5-(phenylsulfonyl)-octahydro-4,7-
epiminocyclohepta[c]pyrrol-8(2H)-one (162) 
 
General procedure U was followed using enone 89 (162 mg, 0.58 mmol, 1.0 eq.), N-
(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (0.16 mL, 0.64 mmol, 1.1 eq.) and 
lithium fluoride (18 mg, 0.70 mmol, 1.2 eq.) in anhydrous MeCN (1.2 mL). Purification by 
flash chromatography on silica gel, eluting with a gradient of 40% EtOAc in hexane. 
Crystallization from EtOAc afforded the title compound 162 (158 mg, 0.38 mmol, 67%) as a 
white solid; Rf = 0.20 (40% EtOAc in hexane); 1H NMR
 
(400 MHz, CDCl3) 7.87 – 7.79 (2H, 
m, ArH), 7.64 – 7.53 (1H, m, ArH), 7.55 – 7.45 (2H, m, ArH), 7.29 – 7.12 (5H, m, ArH), 3.67 
(1H, s, 4-CH), 3.51 (2H, s, NCH2), 3.49 (1H, s, 7-CH), 3.34 (1H, td, J 8.8, 1.9, 5-CH), 3.00 – 
2.92 (2H, m, 1-CH2), 2.65 (1H, q, J 8.7, 8a-CH), 2.55 (1H, dt, J 14.0, 7.9, 6-CH2), 2.46 (3H, s, 
NMe), 2.41 (2H, dt, J 17.5, 8.8, 3-CH2), 2.36 – 2.23 (1H, m, 3a-CH), 1.81 (1H, dd, J 13.9, 8.8, 
6-CH2). 
13C NMR (101 MHz, CDCl3): 207.6 (C=O), 139.2 (Ar), 138.5 (Ar), 133.9 (ArH), 129.5 
(ArH), 128.7 (ArH), 128.3 (ArH), 128.1 (ArH), 127.1(ArH), 73.4 (5-CH), 70.2 (7-CH), 65.3 
(4-CH), 59.8 (NCH2), 58.5 (1-CH2), 57.4 (3-CH2), 45.9 (8a-CH), 45.2 (3a-CH), 40.5 (NMe), 
29.7 (6-CH2); IR νmax (neat)/cm-1: 3062, 3026, 2939 (CH), 2795, 1711 (C=O), 1585, 1446 
(C=C), 1319 (S=O); HRMS (ESI): C23H27N2O3S [M+H
+]: calculated 411.1737, found 
411.1765. 
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 (3aR*,4S*,5R*,7S*,8aS*)-2,9-Dibenzyl-5-(phenylsulfonyl)octahydro-4,7-
epiminocyclohepta[c]pyrrol-8(2H)-one (163) 
 
General procedure U was followed using enone 115 (100 mg, 0.29 mmol, 1.0 eq.), N-
(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (80 L, 0.31 mmol, 1.1 eq.) and 
lithium fluoride (9.00 mg, 0.34 mmol, 1.2 eq.) in anhydrous MeCN (0.6 mL). Purification by 
flash chromatography on silica gel, eluting with a gradient of 80% EtOAc in hexane afforded 
the title compound 163 (88 mg, 0.18 mmol, 63%) as a yellow oil; Rf = 0.10 (60% EtOAc in 
hexane). 1H NMR
 
(400 MHz, CDCl3) 7.89 – 7.76 (2H, m, ArH), 7.63 – 7.54 (1H, m, ArH), 
7.54 – 7.43 (2H, m, ArH), 7.37 – 7.29 (2H, m, ArH), 7.32 – 7.10 (8H, m, ArH), 3.91 (1H, d, J 
13.2, 9-NCH2), 3.73 (1H, s, 4-CH), 3.70 (1H, d, J 13.2, 9-NCH2), 3.62 (1H, dd, J 7.1, 1.5, 5-
CH), 3.54 (1H, d, J 12.7, 2-NCH2), 3.47 (1H, d, J 12.7, 2-NCH2), 3.41 (1H, td, J 8.8, 1.8, 7-
CH), 3.00 – 2.85 (1H, m, 1-CH2), 2.74 – 2.51 (4H, m, 6-CH2, 8a-CH, 1-CH2, 3-CH2), 2.41 – 
2.28 (1H, m, 3-CH2), 2.25 (1H, dtd, J 9.4, 7.7, 1.6, 3a-CH), 1.88 (1H, dd, J 13.8, 8.8, 6-CH2); 
13C NMR (101 MHz, CDCl3): 207.5 (C=O), 139.1 (Ar), 138.3 (Ar), 138.2 (Ar), 134.0 (ArH), 
129.6 (ArH), 129.4 (ArH), 128.9 (ArH), 128.9 (ArH), 128.4 (ArH), 128.1 (ArH), 127.4 (ArH), 
127.2 (ArH), 71.7 (5-CH), 70.1 (7-CH), 63.0 (4-CH), 59.8 (2-NCH2), 58.0 (9-NCH2), 57.6 (3-
CH2), 55.9 (1-CH2), 46.4 (8a-CH), 44.9 (3a-CH), 30.3 (6-CH2); IR νmax (neat)/cm-1: 3061, 
3028, 2940, 2795 (C-H), 1714 (C=O), 1672, 1446 (C=C), 1321 (S=O); HRMS (ESI): 
C29H31N2O3S [M+H
+]: calculated 487.2050, found 487.2073. 
 
(3aR*,4S*,5R*,7S*,8aS*)-9-Benzyl-2-methyl-5-(phenylsulfonyl)octahydro-4,7-
epiminocyclohepta[c]pyrrol-8(2H)-one (295) 
 
 
To a solution of enone 89 (100 mg, 0.28 mmol, 1.0 eq.) in anhydrous PhMe (3 mL) at rt was 
added paraformaldehyde (86 mg, 1.8 mmol, 10 eq.) and sarcosine (100 mg, 1.12 mmol, 4 eq.). 
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The reaction was refluxed for 16 h. The crude mixture was cooled to rt and concentrated in 
vacuo. Purification by flash chromatography on silica gel, eluting with a gradient of 60 - 100% 
EtOAc in hexane afforded the title compound 295 (83 mg, 0.20 mmol, 72%) as a white solid; 
δH(400 MHz, Chloroform-d): 7.91 – 7.80 (2H, m, ArH), 7.65 – 7.56 (1H, m, ArH), 7.56 – 
7.45 (3H, m, ArH), 7.41 – 7.34 (2H, m, ArH), 7.32 – 7.17 (2H, m, ArH), 3.92 (1H, d, J 13.0, 
NCH2), 3.77 (1H, s, 4-CH), 3.73 – 3.61 (2H, m, NCH2, 5-CH), 3.46 – 3.36 (1H, m, 7-CH), 2.97 
(1H, t, J 8.7, 1-CH2), 2.81 – 2.67 (2H, m, 3-CH2, 8a-CH), 2.66 – 2.54 (1H, m, 6-CH2), 2.54 – 
2.41 (2H, m, 3-CH2,1-CH2), 2.37 – 2.17 (4H, m, NMe, 3a-CH), 1.86 (1H, dd, J 13.8, 8.9, 6-
CH2);
 δC(101 MHz, Chloroform-d): 207.3 (C=O), 139.1 (Ar), 138.0 (Ar), 134.0 (ArH), 129.6 
(ArH), 129.3 (ArH), 128.4 (ArH), 128.1 (ArH), 127.5 (ArH), 71.9 (5-C), 70.0 (7-C), 62.5 (4-
C), 60.3 (1-CH2), 59.6 (3-CH2), 56.0 (NCH2), 47.0 (8a-C), 45.4 (3a-C), 41.7 (NCH3), 30.6 (6-
CH2); IR νmax (neat)/cm-1: 3029, 2939 (CH), 2844, 2787, 1715 (C=O), 1476 (C=C), 1446, 1381 
(S=O); HRMS (ESI): C23H27N2O3S [M+H
+]: calculated 411.1737, found 411.2529. 
 
(3aR*,4S*,5R*,7S*,8aS*)-2-Benzyl-9-methyl-5-(methylsulfonyl)octahydro-4,7-
epiminocyclohepta[c]pyrrol-8(2H)-one (299) 
 
General procedure U was followed using cycloadduct 117 (3.60 g, 16.7 mmol), N-
(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (8.9 mL, 36.8 mmol) and lithium 
fluoride (1.10 g, 41.8 mmol). Purification was by flash chromatography on silica gel, eluting 
with a gradient of 80 - 100% EtOAc in hexane. Crystallization from ethanol afforded the title 
compound 299 (2.85 g, 8.19 mmol, 49%) as a colourless solid; Rf = 0.11, (100% EtOAc); δH 
(400 MHz, DMSO-d6) 7.36 – 7.19 (5H, m, ArH), 3.87 (1H, t, J 8.9, 5-CH), 3.62 (1H, s, 4-
CH), 3.56 (1H, d, J 13.0, NBn), 3.53 – 3.47 (2H, m, NBn, 7-CH), 3.03 (3H, s, SO2Me), 2.84 – 
2.71 (2H, m, 3-CH2, 1-CH2), 2.58 – 2.52 (4H, m, 3-CH2, 1-CH2, 8a-CH, 3a-CH), 2.44 (1H, dd, 
J 14.4, 7.2, 6-CH2,), 2.38 (3H, s, NMe), 2.11 (1H, dd, J 13.9, 9.2, 6-CH2); δC(101 MHz, 
DMSO) δ 207.6 (C=O), 139.4 (Ar), 128.9 (ArH), 128.6 (ArH), 127.3 (ArH), 72.9 (7-C), 67.3 
(5-C), 64.4 (4-C), 59.5 (NBn), 57.8 (3-CH2), 56.7 (1-CH2), 45.5 (SO2Me), 45.0 (Me), 40.5 (8a-
C), 39.9 (3a-C), 28.2 (6-CH2); IR νmax (neat)/cm-1: 3084, 3030 (CH), 2951, 2907, 1659 (C=O), 
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1510 (C=C), 1440, 1275 (S=O); HRMS (ESI): C18H25N2O3S [M+H
+]: calculated 349.1580, 
found 349.1599. 
 
(3aR*,4S*,5R*,7S*,8aS*)-2-Benzyl-9-(4-fluorobenzyl)-5-(methylsulfonyl)octahydro-4,7-
epiminocyclohepta[c]pyrrol-8(2H)-one (301) 
 
 
 
General procedure U was followed using cycloadduct 136 (2.50 g, 8.08 mmol), N-
(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (4.5 mL, 17.3 mmol) and lithium 
fluoride (525 mg, 20.2 mmol). Purification by flash chromatography on silica gel, eluting with 
a gradient of 70 - 100% EtOAc in hexane. Crystallization from ethanol afforded the title 
compound 301 (6.31 g, 14.3 mmol, 88%) as a colourless solid; Rf = 0.14, (100% EtOAc). 
δH(400 MHz, DMSO-d6): 7.42 – 7.23 (7H, m, ArH), 7.08 (2H, t, J 8.9, ArH), 3.95 (1H, t, J 
8.9, 5-CH), 3.76 (1H, d, J 13.4, NBn), 3.7 (1H, d, J 13.4, NBn), 3.63 – 3.56 (3H, m, NBn, 4-
CH, 7-CH), 3.45 (1H, d, J 12.8, NBn), 3.05 (3H, s, SO2Me), 2.83 (1H, td, J 7.7, 5.0, 8a-CH), 
2.75 (1H, dd, J 8.5, 5.0, 1-CH2), 2.66 (1H, t, J 8.5, 1-CH2), 2.58 – 2.44 (3H, m, 6-CH2, 3-CH2, 
3a-CH), 2.37 (1H, dd, J 7.5, 5.6, 3-CH2), 2.17 (1H, dd, J 13.9, 9.2, 6-CH2);
 δC(101 MHz, 
DMSO-d6): 207.3 (C=O), 161.7 (d, J 242.4, ArF), 139.3 (Ar), 135.6 (Ar), 131.2 (d, J 8.1, ArH), 
129.0 (ArH), 128.6 (ArH), 127.3 (ArH), 115.3 (d, J 21.1, ArH), 71.4 (7-C), 67.0 (5-C), 62.5 (4-
C), 59.6 (NCH2), 57.4 (3-CH2), 57.1 (1-CH2), 54.2 (NCH2), 46.0 (8a-C), 44.7 (3a-C), 40.5 
(SO2Me), 28.9 (6-CH2); IR νmax (neat)/cm-1: 3000 (CH), 2936, 2906, 2863, 1705 (C=O), 1505 
(C=C), 1474, 1288 (S=O); HRMS (ESI): [M+H+]: C24H28FN2O3S calculated 443.1799, found 
442.8340. 
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(3aR*,4S*,5R*,7S*,8aS*)-2,9-Dibenzyl-5-(methylsulfonyl)octahydro-4,7-
epiminocyclohepta[c]pyrrol-8(2H)-one (300) 
 
 
General procedure U was followed using cycloadduct 116 (1.05 g, 3.60 mmol), N-
(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (<80% purity) (1.6 mL, 6.40 mmol) 
and lithium fluoride (226 mg, 8.71 mmol). Purification by flash chromatography on silica gel, 
eluting with a gradient of 70 - 100% EtOAc in hexane afforded the title compound 300 (863 
mg, 2.03 mmol, 57%) as a colourless solid; Rf = 0.14, (100% EtOAc); Compound had 
impurities so was telescoped to subsequent reactions without full characterisation.  
 
 
(3aR*,4S*,5R*,7S*,8S*,8aS*)-2,9-Dibenzyl-5-(methylsulfonyl)decahydro-4,7-
epiminocyclohepta[c]pyrrol-8-ol (302) 
 
 
 
General procedure I was followed using impure compound 300 (863 mg, 2.04 mmol) in DCM 
(25 mL) and DIBAL (6.10 mL, 6.10 mmol). Crystallization from ethanol afforded the title 
compound 302 (500 mg, 1.17 mmol, 57%) as a colourless solid; M.Pt. 175.8 – 176.8 oC; δH 
(400 MHz, Chloroform-d): 7.47 – 7.22 (8H, m, ArH), 7.11 – 6.99 (2H, m, ArH), 3.86 – 3.70 
(2H, m, NBn, NBn), 3.62 – 3.47 (2H, m, NBn, 4-CH), 3.46 – 3.38 (2H, m, 5-CH, 8-CH), 3.36 
– 3.24 (2H, m, 7-CH, NBn), 3.05 (1H, d, J 8.7, 3-CH), 2.83 (3H, s, Me), 2.58 (1H, dd, J 9.4, 
3.7, 1-CH2), 2.41 (1H, dt, J 13.3, 7.4, 6-CH2), 2.25 – 2.10 (3H, m, 3a-CH, 3-CH2, 8a-CH), 2.05 
– 1.92 (2H, m, 1-CH2, 6-CH2); δC(101 MHz, Chloroform-d): 139.3 (Ar), 138.3 (Ar), 129.5 
(ArH), 128.6 (ArH), 128.5 (ArH), 128.0 (ArH), 127.3 (ArH), 126.8 (ArH), 70.1 (4-C), 69.8 (7-
C), 68.7 (5-C), 61.2 (8-C), 59.6 (NCH2), 56.9 (3-C), 56.7 (NCH2), 54.6 (1-C), 46.4 (8a-C), 40.5 
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(Me), 34.6 (3a-C), 27.9 (6-C); IR νmax (neat)/cm-1: 3349 (OH), 3028, 2928 (CH), 2868, 2870, 
1494 (C=C), 1472, 1288 (S=O); HRMS (ESI): [M+H+]: C24H31N2O3S calculated 427.2050, 
found 427.2074. 
 
(3aR*,4S*,5R*,7S*,SR*,8aS*)-2-Benzyl-9-(4-fluorobenzyl)-5-(methylsulfonyl)decahydro-
4,7-epiminocyclohepta[c]pyrrol-8-ol (304) 
 
General procedure I was followed using compound 301 (2.70 g, 6.10 mmol) in THF (80 mL) 
and DIBAL (18.3 mL, 18.3 mmol). Recrystallization from ethanol afforded the title compound 
304 (1.24 g, 2.79 mmol, 50%) as a colourless solid; M.Pt. 173.2 – 174.0 oC; δH(400 MHz, 
DMSO-d6): 7.45 – 7.20 (7H, m, ArH), 7.15 – 7.03 (2H, m, ArH), 4.80 (1H, d, J 4.6, OH), 3.79 
(1H, d, J 13.3, NBn), 3.73 (1H, t, J 8.3, 7-CH), 3.70 – 3.58 (3H, m, 4-CH, NBn), 3.47 (1H, d, 
J 13.3, NBn), 3.41 (1H, s, 8-CH), 3.13 (1H, t, J 5.8, 5-CH), 3.00 (3H, s, Me), 2.75 (1H, d, J 
8.7, 3-CH), 2.70 (1H, dd, J 8.2, 5.7, 1-CH ), 2.38 (1H, dd, J 8.7, 4.7, 3-CH), 2.31 – 2.23 (1H, 
m, 6-CH), 2.23 – 2.16 (1H, m, 8a-CH), 2.17 – 2.03 (2H, m, 1-CH, 6-CH), 1.78 (1H, td, J 7.7, 
4.7, 3a-CH). δC(101 MHz, DMSO-d6) δ 161.5 (d, J 242.0, ArF), 140.4 (Ar), 137.1 (d, J 2.9, 
Ar), 130.6 (d, J 8.0, ArH), 128.6 (ArH), 128.6 (ArH), 127.1 (ArH), 115.1 (d, J 20.9, ArH), 71.9 
(4-C), 68.2 (7-C), 66.0 (5-C), 62.4 (8-C), 59.7 (NCH2), 58.8 (3-CH2), 55.8 (NCH2), 55.1 (1-
CH2), 46.2 (8a-C), 41.3 (Me), 40.4 (3a-C), 24.0 (6-CH2); IR νmax (neat)/cm-1: 3119 (OH), 2968 
(CH), 2927, 2882, 1506, 1482 (C=C), 1445, 1321 (S=O); HRMS (ESI): C24H30FN2O3S 
[M+H+]: calculated 445.1956, found 445.1960. 
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(3aR*,4S*,5R*,7S*,8R*,8aS*)-2-Benzyl-9-methyl-5-(methylsulfonyl)decahydro-4,7-
epiminocyclohepta[c]pyrrol-8-ol (303a) 
(3aR*,4S*,5R*,7S*,8S*,8aS*)-2-Benzyl-9-methyl-5-(methylsulfonyl)decahydro-4,7-
epiminocyclohepta[c]pyrrol-8-ol (303b) 
 
 
3:2 Mixture of diasteroisomers 
General procedure I was followed using compound 299 (2.60 g, 7.46 mmol) in THF (94 mL) 
and DIBAL (22 mL, 22.4 mmol). Title compound 303 (1.20 g, 3.43 mmol, 46%) as a colourless 
solid; 1H NMR (400 MHz, DMSO-d6): 7.40 – 7.18 (10H, m, ArH), 4.78 (1H, d, J 4.7, OH), 
3.78 (1H, t, J 8.3, 7-CH), 3.70 – 3.65 (1H, m, 7-CH minor), 3.66 – 3.50 (4H, m, 4-CH minor NBn, 
NBn minor), 3.39 – 3.35 (2H, m, 4-CH, 8-CH, 8-CH minor), 3.10 – 3.04 (2H, m, 5-CH, 5-CH 
Minor), 2.98 (3H, s, Me), 2.97 (3H, s, Me Minor) 2.87 – 2.73 (4H, m, 1-CH2 minor, 3-CH2, 1-CH2), 
2.68 (1H, d, J 8.7, 3-CH2 minor), 2.40 – 2.31 (3H, m, 3-CH2, 1-CH2, 3-CH2 minor,), 2.29 (3H, s, 
NMe), 2.26 (3H, s, NMe), 2.25 – 2.12 (5H, m, 8a-CH, 6-CH2, 3a-CH, 8a-CH minor, 6-CH2 minor), 
2.01 (1H, dt, J 13.6, 6.8, 6-CH2 minor), 1.90 (1H, dd, J 13.7, 9.3, 6-CH2), 1.72 (1H, td, J 7.9, 4.8, 
3a-CHminor); δC(101 MHz, DMSO-d6): 140.1 (Ar minor), 138.9 (Ar), 129.0 (ArH), 128.8 (ArH 
minor),128.8 (ArH), 128.6 (ArH minor), 127.5 (ArH), 127.1 (ArH minor), 71.5 (4-C minor), 70.5 (4-
C), 69.6 (7-C), 68.4 (7-C minor), 68.1 (5-C minor), 67.6 (5-C), 64.2 (8-C minor), 64.1 (8-C), 60.1 
(NCH2 minor), 59.5 (NCH2), 58.3 (3-CH2 minor), 56.1 (3-CH2), 55.4 (1-CH2), 55.3 (1-CH2 minor), 
46.2 (8a-C minor), 45.8 (8a-C), 41.5 (Me minor), 41.0 (3a-C minor), 40.8 (Me), 40.7 (Me minor), 40.5 
(3a-C), 34.1 (Me), 26.2 (6-CH2) 23.5 (6-CH2 minor); IR νmax (neat)/cm-1: 3283 (OH), 3026 (CH), 
2976, 2938, 2896, 2972, 1444 (C=C), 1329 (S=O); HRMS (ESI): C18H27N2O3S [M+H
+]: 
calculated 351.1737, found 351.1736. 
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(3aR*,4S*,5R*,7S*,8S*,8aS*)-9-(4-Fluorobenzyl)-5-(methylsulfonyl)decahydro-4,7-
epiminocyclohepta[c]pyrrol-8-ol (306) 
 
 
 
 General procedure F was followed using compound 304 (1.2 g, 6.10 mmol) in MeOH (20 mL) 
and Pd(OH)2 (120 mg, 20% w/w) at rt. The title compound 306 (880 mg, 2.48 mmol, 92%) as 
a colourless solid; M.Pt. 167.1 – 168.0 oC; δH(400 MHz, Chloroform-d) 7.27 (2H, dd, J 8.5, 
5.6, ArH), 6.91 (2H, t, J 8.5, ArH), 3.70 (1H, d, J 13.4, NBn), 3.64 (1H, s, 8-CH), 3.59 (1H, d, 
J 13.4, NBn), 3.51 (1H, dd, J 8.6, 4.5, 4-CH), 3.40 (1H, t, J 8.4, 7-CH), 3.26 (1H, t, J 5.7, 5-
CH), 2.97 – 2.85 (5H, m, 1-CH2, 3-CH2, Me), 2.83 – 2.75 (2H, m, 3-CH2, 1-CH2 ), 2.39 (1H, 
dd, J 13.7, 9.2, 6-CH2), 2.24 (1H, dt, J 13.7, 6.8, 6-CH2), 2.18 – 2.09 (1H, m, 8a-CH), 1.76 
(1H, td, J 7.9, 5.1, 3a-CH); δC (101 MHz, Chloroform-d) 162.0 (d, J 244.9, ArF), 135.2 (Ar), 
130.6 (d, J 7.9, ArH), 115.1 (d, J 21.1, ArH), 71.6 (4-C), 69.9 (7-C), 66.7 (5-C), 61.4 (8-C), 
56.2 (N-CH2), 51.4 (3-CH2), 48.8 (8a-C), 48.2 (1-CH2), 42.7 (3a-C), 40.5 (Me), 24.6 (6-CH2); 
IR νmax (neat)/cm-1: 3340 (OH), 3006 (CH), 2993, 2895, 1632 (C=O), 1508 (C=C), 1459, 1270 
(S=O); HRMS (ESI): C17H24FN2O3S [M+H
+]: calculated 355.1486, found 355.1488. 
 
(3aR*,4S*,5R*,7S*,8S*,8aS*)-9-Benzyl-5-(methylsulfonyl)decahydro-4,7-
epiminocyclohepta[c]pyrrol-8-ol (305) 
 
 
 
General procedure F was followed using compound 302 (205 mg, 0.48 mmol) in MeOH (10 
mL), 10% Pd(OH)2/C (20 mg, 20% w/w) and conc. HCl (0.1 mL) at rt. Purification by SCX 
SPE (strong cation exchange solid phase extraction) afforded the title compound 305 (150 mg, 
0.45 mmol, 92%) as a colourless oil; δH(501 MHz, Methanol-d4): 7.35 – 7.12 (5H, m), 3.83 
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(1H, d, J 12.8, NBn), 3.72 (1H, d, J 12.8, NBn), 3.70 (1H, s, 4-CH), 3.58 (1H, dd, J 9.1, 4.9, 5-
CH), 3.49 – 3.45 (1H, m, 8-CH), 3.42 (1H, dd, J 7.8, 3.3, 7-CH), 3.09 (1H, dd, J 9.9, 6.4, 1-
CH2), 2.94 (1H, d, J 9.9, 1-CH2), 2.89 (3H, s, SO2Me), 2.64 (1H, t, J 9.9, 3-CH2), 2.55 (1H, dd, 
J 9.9, 4.5, 3-CH2), 2.36 – 2.22 (2H, m, 3a-CH, 8a-CH), 2.15 (1H, ddd, J 14.5, 7.8, 4.9, 6-CH2), 
2.02 (1H, ddd, J 14.5, 9.1, 1.1, 6-CH2); δC(126 MHz, Methanol-d4) δ 137.7 (Ar), 130.2 (ArH), 
129.7 (ArH), 128.9 (ArH), 69.5 (4-C), 67.0 (7-C), 62.1 (8-C), 60.2 (NBn), 57.9 (8-C), 56.9 (3-
C), 55.7 (1-C), 43.2 (8a-C), 39.0 (Me), 35.5 (3a-C), 28.6 (6-C); IR νmax (neat)/cm-1: 3376 (O-
H), 3330 (N-H), 3027, 2928 (C-H), 2825, 1550 (C=C), 1453, 1286(S=O); HRMS (ESI): 
[M+H+]: C17H25N2O3S calculated 337.1580, found 337.1584. 
 
 
 (1S*,2R*,5S*,7R*)-2-(4-Fluorophenyl)-8-((1-methyl-1H-imidazol-2-yl)sulfonyl)-7-
(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-ene (287) 
 
 
General procedure Q was followed using amine 282 (125 mg, 0,37 mmol), 1-methylimidazole-
2- sulfonyl chloride (330 mg, 5.0 eq.) and pyridine (120 L, 1.49 mmol). Purification by 
MDAP afforded title compound 287 (6 mg, 0.14 mmol, 4%) as a colourless oil; δH (400 MHz, 
Methanol-d4) 7.65 – 7.49 (1H, m, ArH), 7.26 – 7.09 (2H, m, ArH), 7.11 – 6.97 (3H, m, ArH), 
6.35 (1H, ddd, J 9.7, 5.5, 1.7, 2-CH), 5.68 (1H, ddd, J 9.7, 4.3, 1.5, 3-CH), 4.95 (1H, td, J 5.6, 
1.5, 1-CH), 4.77 (1H, q, J 1.7, 5-CH), 4.02 (1H, td, J 8.1, 1.8, 6-CH), 3.68 – 3.63 (1H, m, 4-
CH), 3.50 (3H, s, SO2Me), 3.01 (3H, s, NMe), 2.59 – 2.50 (1H, m, 7-CH2), 2.29 (1H, ddd, J 
12.1, 8.1, 5.6, 7-CH2); δC (101 MHz, Methanol-d4) 162.2 (d, J 244.4, Ar-F), 135.5 (Ar), 135.5 
(d, J 3.2 Ar), 131.1 (4-CH), 130.1 (d, J 8.2, ArH), 127.4 (ArH), 125.8 (3-CH), 125.3 (ArH), 
114.7 (d, J 21.7, ArH), 66.3 (6-C), 63.2 (5-C), 57.6 (1-C), 50.4 (4-C), 38.6 (Me), 37.5 (7-CH2), 
34.5 (SO2Me); IR νmax (neat)/cm-1: 3063 (CH), 3033, 2975, 2922, 2821, 1604, 1540 (C=C), 
1509; HRMS (ESI): [M+H+]: C18H21FN3O4S2 calculated 426.0952, found 426.1082. 
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Cyclopropyl((1S*,2R*,4R*,5S*,6R*)-4-(4-fluorophenyl)-2-hydroxy-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-8-yl)methanone (285) 
 
 
General procedure V was followed using amine 282 (127 mg, 0.38 mmol) and 
cyclopropanecarbonyl chloride (350 l, 3.80 mmol, 10.0 eq.) and pyridine (125 l, 1.52 mmol, 
4.0 eq.). Purification by MDAP gave title compound 285 (22 mg, 0.06 mmol, 16%) as a 
colourless oil with 1:1 ratio of rotamers; δH(501 MHz, DMSO-d6): 7.90 – 7.72 (2H, m, ArH), 
7.73 – 7.52 (2H, m, ArH), 7.07 (2H, t, J 8.9, ArH), 6.99 (2H, t, J 8.9, ArH), 5.35 (1H, s, OH), 
5.20 (1H, s, OH), 4.88 (1H, s, 5-CH), 4.72 (1H, s, 2-CH), 4.67 (1H, s, 5-CH), 4.62 (1H, d, J 
6.3, 2-CH), 4.08 (1H, t, J 7.5, 6-CH), 3.91 (1H, dd, J 9.4, 5.3, 6-CH), 3.82 (1H, s, 1-CH), 3.78 
(1H, s, 1-CH), 3.20 (1H, d, J 6.2, 4-CH), 3.10 – 2.99 (4H, m, SO2Me, 4-CH), 2.79 (3H, s, 
SO2Me), 2.40 – 2.28 (3H, m, 7-CH2, 7-CH2 ), 2.24 (1H, dd, J 14.2, 9.4, 3-CH2), 2.15 – 2.05 
(2H, m, 7-CH2, 3-CH2), 1.99 – 1.84 (1H, m, cyp.), 1.68 (1H, d, J 16.0, 3-CH2), 1.62 (1H, d, J 
15.9, 3-CH2), 0.86 – 0.78 (1H, m, cyp.), 0.64 – 0.57 (3H, m, cyp), 0.50 – 0.42 (2H, m, cyp, 
cyp), 0.41 – 0.34 (1H, m, cyp.), 0.34 – 0.26 (1H, m, cyp.), 0.06 – -0.09 (1H, m, cyp.) δC (126 
MHz, DMSO-d6): 170.0 (C=O), 169.6 (C=O), 161.0 (d, J 241.8, ArF), 160.7 (d, J 241.2, ArF), 
139.7 (d, J 3.1, Ar), 139.2 (d, J 3.1, Ar), 131.4 (d, J 7.8, ArH), 130.7 (d, J 7.8, ArH), 114.4 (d, 
J 20.7, ArH), 114.1 (d, J 20.7, ArH), 67.1 (1-C), 67.0 (1-C), 64.2 (6-C), 64.2 (6-C), 60.6 (2-C), 
59.9 (2-C), 57.2 (5-C), 57.2 (5-C), 44.6 (4-C), 44.1 (4-C), 38.6 (SO2Me), 36.7 (SO2Me), 28.6 
(3-C), 28.4 (7-C), 27.8 (3-C), 26.6 (7-C) , 11.0 (cyp), 10.7 (cyp), 6.6 (cyp), 6.5 (cyp), 6.4 (cyp), 
6.2 (cyp); IR νmax (neat)/cm-1: 3369 (OH), 3009 (CH), 2928, 2893, 1603 (C=O), 1510 (C=C), 
1439, 1296 (S=O); HRMS (ESI): [M+H+]: C18H23FNO4S calculated 368.1326, found 
368.2022. 
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 (1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-2-(pyrazin-2-
yloxy)-8-azabicyclo[3.2.1]octane (288) 
 
General procedure R was followed using alcohol 279a (147 mg, 0.47 mmol), NaH (17 mg, 
0.71 mmol) and 2-chloropyrazine (85 L, 0.94 mmol, 2.0 eq.). Purification by MDAP afforded 
title compound 288 (2.4 mg, 0.01 mmol, 2%) as a colourless oil. 
δH(400 MHz, Chloroform-d): 8.11 (1H, d, J 1.5, ArH), 8.06 (1H, d, J 2.8, ArH), 8.01 (1H, 
dd, J 2.8, 1.5, ArH), 7.42 – 7.32 (2H, m, ArH), 7.05 – 6.85 (2H, m, ArH), 5.55 – 5.30 (1H, m, 
2-CH), 3.82 (1H, s, 5-CH), 3.65 (1H, t, J 5.5, 1-CH), 3.52 (1H, t, J 8.2, 6-CH), 3.05 – 2.96 (1H, 
m, 4-CH), 2.92 (3H, s, SO2Me), 2.53 – 2.36 (1H, m, 7-CH2), 2.38 – 2.16 (5H, m, NMe, 3-CH2, 
7-CH2), 1.74 (1H, ddd, J 14.7, 11.0, 7.8, 3-CH2); δC(101 MHz, Chloroform-d): 161.4 (d, J 
242.9, ArF), 159.2 (Ar), 140.6 (Py-H), 139.1 (d, J 3.0, Ar), 137.0 (Py-H), 136.0 (Py-H), 129.7 
(d, J 7.8, ArH), 115.0 (d, J 21.0, ArH), 70.6 (2-C), 69.2 (6-C), 67.9 (5-C), 65.7 (1-C), 46.4 (4-
C), 41.5 (NMe), 40.6 (SO2Me), 28.0 (3-C), 25.7 (7-C); IR νmax (neat)/cm-1: 2952 (CH), 2926, 
2876, 2867, 1510 (C=C), 1457, 1409, 1298 (S=O); HRMS (ESI): [M+H+]: C19H23FN3O3S 
calculated 392.1439, found 392.1435. 
 
1-((1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-2-hydroxy-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-8-yl)-2-methoxyethanone (289) 
 
General procedure V was followed using amine hydrochloride 282 (127 mg, 0.38 mmol) and 
methoxyacetyl chloride (0.2 mL, 2.9 mmol) and pyridine (250 l, 3.04 mmol). Purification by 
MDAP afforded title compound 289 (2 mg, 0.57 mol, 1%) as a colourless oil with a ratio of 
1:1 rotamers; δH(400 MHz, Methanol-d4): 7.96 – 7.80 (2H, m, ArH), 7.78 – 7.63 (2H, m, 
ArH), 7.15 – 7.00 (2H, m, ArH), 7.02 – 6.87 (2H, m, ArH), 5.12 (1H, s, 5-CH), 4.93 (1H, d, J 
7.5, 2-CH), 4.50 (1H, s, 5-CH), 4.48 – 4.43 (1H, m, 2-CH), 4.24 (1H, d, J 14.7, CH2OMe), 
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4.15 (1H, d, J 14.7, CH2OMe), 4.07 (1H, dd, J 9.1, 5.6, 1-CH), 3.98 (1H, dd, J 5.0, 2.6, 2-CH), 
3.97 – 3.89 (2H, m, 2-CH, 1-CH,), 3.72 (1H, d, J 15.0, CH2OMe), 3.33 (3H, s, Me), 3.28 – 3.20 
(2H, m, 4-CH, 4-CH), 3.07 (3H, s, Me), 3.05 (3H, s, Me), 2.95 (3H, s, Me), 2.83 (1H, d, J 15.0, 
CH2OMe), 2.59 – 2.12 (6H, m, 7-CH2, 7-CH2, 3-CH2, 3-CH2 ), 1.96 – 1.91 (1H, m, 3-CH2), 
1.91 – 1.86 (1H, m, 3-CH2); δC (101 MHz, Methanol-d4): 168.4 (C=O), 167.8 (C=O), 165.8 
(d, J 242.4, ArF), 165.4 (d, J 242.4, ArF), 138.9 (d, J 3.0 Ar), 138.7 (d, J 3.0, Ar), 131.1 (d, J 
7.8, ArH), 130.5 (d, J 7.8, ArH), 114.6 (d, J 21.3, ArH), 114.1 (d, J 21.2, ArH), 69.7 (1-C), 69.0 
(1-C), 67.9 (6-C), 67.8 (6-C), 64.2 (2-C), 63.9 (2-C), 60.2 (CH2), 59.6 (CH2), 58.3 (5-C), 58.0 
(5-C), 57.8 (OMe), 57. 8 (OMe), 45.3 (4-C), 44.9 (4-C), 37.7 (SO2Me), 36.5 (SO2Me), 27.9 (3-
C), 27.9 (3-C), 27.1 (7-C), 26.5 (7-C); IR νmax (neat)/cm-1: 3429 (OH), 2994 (CH), 2955, 2929, 
1684 (C=O), 1511 (C=C), 1457, 1329 (S=O); LCMS: [M+H+]: C17H23FNO5 calculated 
372.1275, found 372.40. 
 
2-(((1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-yl)oxy)thiazole (286) 
 
General procedure R was followed using alcohol 279a (147 mg, 0.47 mmol), NaH (17 mg, 
0.71 mmol) and 2-bromothiazole (85 L, 0.94 mmol, 2.0 eq.). Purification by MDAP afforded 
title compound 286 (19 mg, 0.05 mmol, 11%) as a brown oil. 
δH(400 MHz, Chloroform-d): 7.45 – 7.33 (2H, m, ArH), 7.07 – 6.93 (2H, m, ArH), 6.60 (1H, 
d, J 5.2, ArH), 6.17 (1H, d, J 5.2, ArH), 4.27 – 4.14 (1H, m, 2-CH), 3.85 (1H, s, 5-CH), 3.51 
(1H, t, J 8.0, 6-CH), 3.39 (1H, t, J 5.4, 1-CH), 2.99 (3H, s, SO2Me), 3.14 – 2.86 (1H, m, 4-CH), 
2.57 – 2.21 (5H, m, 7-CH2, NMe), 2.15 (1H, dd, J 14.5, 6.5, 3-CH2), 1.61 (1H, ddd, J 14.5, 
10.7, 7.7, 3-CH2). δC(101 MHz, Chloroform-d): 175.8 (Ar), 161.4 (d, J 244.7, ArF), 139.4 (d, 
J 3.3, Ar), 129.6 (d, J 7.6, ArH), 114.9 (d, J 21.0, Ar), 120.6 (Ar-H), 103.8 (Ar-H), 69.3 (6-C), 
68.9 (1-C), 67.3 (5-C), 66.9 (2-C), 46.1 (4-C), 41.5 (NMe), 40.6 (SO2Me), 31.3 (3-C), 24.6 (7-
C); IR νmax (neat)/cm-1: 2975 (C-H), 2938, 2908, 2877, 1656, 1510 (C=C), 1459, 1224 (S=O); 
HRMS (ESI): [M+H+]: C18H22FN2O3S2 calculated 397.1050, found 397.1082. 
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(3aR*,4S*,5R*,7S*,8S*,8aS*)-9-(4-Fluorobenzyl)-5-(methylsulfonyl)-2-(pyridin-3-
ylmethyl)decahydro-4,7-epiminocyclohepta[c]pyrrol-8-ol (312) 
  
General procedure W was followed using amine hydrochloride 306 (140 mg, 0.36 mmol) and 
isonicotinaldehyde (170 L, 1.8 mmol), NaBH4 (40 mg, 3.0 eq.). Purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave title 
compound 312 (66 mg, 0.15 mmol, 41%) as a colourless oil; δH (400 MHz, Methanol-d4) 8.72 
(1H, s, ArH), 8.63 (1H, d, J 4.9, ArH), 8.08 – 7.97 (1H, m, ArH), 7.55 (1H, dd, J 7.9, 4.8, ArH), 
7.42 – 7.37 (2H, m, ArH), 7.05 – 6.98 (2H, m, ArH), 4.36 (2H, s, NCH2), 3.88 – 3.78 (3H, m, 
N-CH2, 7-CH), 3.78 – 3.71 (1H, m, 4-CH), 3.71 – 3.64 (2H, m, 8-CH, N-CH2), 3.50 – 3.34 (3H, 
m, 1-CH2, 5-CH, 3-CH2), 3.10 (1H, dd, J 10.8, 8.6, 1-CH2), 3.04 (3H, s, Me), 2.63 – 2.50 (1H, 
m, 8a-CH), 2.46 (1H, dd, J 13.8, 9.9, 6-CH2), 2.33 (1H, dt, J 13.8, 6.9, 6-CH2), 2.22 – 2.12 
(1H, m, 3a-CH); δC(101 MHz, Methanol-d4) δ 167.0 (ArH), 162.1 (d, J 243.7, Ar-F), 150.4 
(ArH), 138.8 (ArH), 135.4 (d, J 3.0, Ar), 130.6 (d, J 7.9, ArH), 129.3 (Ar), 124.1 (ArH), 114.5 
(d, J 21.4, ArH), 70.8 (4-C), 68.3 (7-C), 66.7 (5-C), 59.7 (8-C), 57.6 (N-CH2), 56.3 (N-CH2), 
55.4 (3-CH2), 54.6 (1-CH2), 45.5 (8a-C), 40.8 (3a-C), 39.2 (Me), 23.8 (6-CH2); IR νmax 
(neat)/cm-1: 3203 (OH), 3015 (CH), 2943, 2922, 1577, 1508 (C=C), 1421, 1297 (S=O); HRMS 
(ESI): C23H29FN3O3S [M+H
+]: calculated 446.1908, found 446.1908. 
 
(3aR*,4S*,5R*,7S*,8S*,8aS*)-9-(4-Fluorobenzyl)-2-isopropyl-5-(methylsulfonyl)decahydro-
4,7-epiminocyclohepta[c]pyrrol-8-ol (308) 
 
General procedure W was followed using amine hydrochloride 306 (140 mg, 0.36 mmol) and 
acetone (300 L, 3.6 mmol, 10 eq.) NaBH4 (40 mg, 3.0 eq.).. Purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O 1% formic acid gave title 
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compound 308 (44 mg, 0.11 mmol, 31%) as a colourless oil; δH (400 MHz, DMSO-d6): 7.45 
– 7.30 (2H, m, ArH), 7.22 – 7.04 (2H, m, ArH), 3.85 (1H, t, J 8.2, 7-CH), 3.69 – 3.60 (2H, m, 
NBn), 3.60 – 3.50 (2H, m, 8-CH, 4-CH), 3.24 – 3.04 (4H, m, 1-CH2, 3-CH2, CH(Me)2, 5-CH), 
3.03 (3H, s, SO2Me), 2.99 – 2.89 (2H, m, 1-CH2, 3-CH2), 2.36 – 2.21 (2H, m, 8a-CH, 6-CH2), 
2.11 (1H, dt, J 13.6, 6.9, 6-CH2), 1.94 (1H, q, J 7.6, 3a-CH2), 1.19 – 1.14 (6H, m, Me, Me); δC 
(101 MHz, DMSO-d6): 161.7 (d, J 242.1, Ar-F), 136.6 (d, J 2.9, Ar), 130.8 (d, J 8.0, ArH), 
115.3 (d, J 21.0, ArH), 70.6 (4-C), 68.2 (7-C), 66.4 (5-C), 60.8 (8-C), 55.8 (CH(Me)2), 55.8 
(N-CH2), 54.6 (3-CH2), 52.1 (1-CH2), 45.6 (8a-C), 40.8 (3a-C), 40.5 (SO2Me), 23.9 (6-CH2), 
19.5 (Me), 19.5 (Me); IR νmax (neat)/cm-1: 3454 (OH), 3009 (CH), 2929, 2898, 1602, 1510 
(C=C), 1440, 1294 (S=O); HRMS (ESI): C20H30FN2O3S [M+H
+]: calculated 397.1956, found 
397.1956. 
 
(1S,2R,4R,5S,6R)-N-(Cyclopropylmethyl)-4-(4-fluorophenyl)-8-methyl-6-(methylsulfonyl)-
8-azabicyclo[3.2.1]octan-2-amine (283 major) 
 (1S*,2S* 4R*,5S*,6R*)-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-8-methyl-6-
(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-amine (283 minor) 
 
 
3:2 mixture of diastereosiomers 
 
General procedure X was followed using ketone 273 (174 mg, 0.56 mmol), titanium 
isopropoxide (0.4 mL, 1.4 mmol), cyclopropanemethylamine (0.5 mL, 5.6 mmol) and NaBH4 
(42 mg, 1.12 mmol). Purification by automated reversed-phase flash chromatography eluting 
with  MeCN/H2O 1% formic acid gave title compound 283 (37 mg, 0.10 mmol, 18%) as a 
brown oil as an inseparable 3:2 mixture of diastereomers; δH (400 MHz, Chloroform-d) 7.27 
– 7.21 (2H, m, ArH), 7.21 – 7.16 (2H, m ArH minor), 6.86 (2H, t, J 8.5, ArH), 6.78 (2H, t, J 8.5, 
ArH minor), 4.03 (1H, s, 5-CH), 3.65 (1H, s, 5-CHminor), 3.56 – 3.49 (2H, m, 6-CH, 1-CH), 3.44 
– 3.30 (2H, m, 6-CH minor, 1-CH minor), 3.15 (1H, s, 2-CH minor), 2.97 (1H, s, 2-CH), 2.78 (4H, 
s, SO2Me, 4-CH minor), 2.76 (3H, s, SO2Me minor), 2.73 – 2.64 (1H, m, 4-CH), 2.53 – 2.29 (12H, 
m, NMe minor, NMe, NCH2, NCH2 minor, 7-CH2, 7-CH2 minor), 2.14 – 2.05 (1H, m, 7-CH2 minor), 
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2.05 – 1.94 (1H, m, 7-CH2), 1.93 – 1.77 (3H, m, 3-CH2, 3-CH2 minor), 1.71 (1H, d, J 8.3, NCH2 
minor), 1.68 (1H, d, J 8.3, NCH2), 1.65 – 1.50 (1H, m, 3-CH2 minor), 0.79 (1H, s, CH minor), 0.54 
(1H, dq, J 14.4, 6.0, 5.1, CH), 0.36 (1H, d, J 7.2, CH2 minor ), 0.25 – 0.16 (2H, m, CH2, CH2 
minor), 0.14 – 0.05 (2H, m, CH2, CH2 minor), 0.03 – -0.04 (1H, m, CH2), -0.27 (1H, dq, J 9.9, 5.0, 
CH2), -0.81 (1H, dq, J 10.0, 5.0, CH2); δC (101 MHz, Chloroform-d) 161.5 (d, J 247.0, ArF), 
161.4 (d, J 244.8, ArF), 139.4 (d, J 3.1, Ar), 138.8 (d, J 3.3, Ar), 129.6 (d, J 7.7, ArH), 129.1 
(d, J 7.7, ArH), 115.7 (d, J 21.1, ArH), 114.9 (d, J 20.9, ArH), 69.2 (6-C), 69.1 (6-C), 67.3 (5-
C), 65.8 (1-C), 65.7 (5-C), 65.4 (1-C), 56.0 (2-C), 54.8 (2-C), 51.2 (NCH2), 50.0 (NCH2), 45.4 
(4-C), 42.8 (4-CH), 41.7 (Me), 41.6 (Me), 40.9 (NMe), 40.7 (NMe), 28.9 (3-CH2), 28.4 (3-
CH2), 25.2 (7-CH2), 25.0 (7-CH2), 9.6 (CH), 8.4 (CH), 3.8 (CH2), 4.1 (CH2), 3.8 (CH2), 3.3 
(CH2); IR νmax (neat)/cm-1: 3404 (NH), 3079 (CH), 3007, 2937, 2847, 1508 (C=C), 1463, 1293 
(S=O); HRMS: C19H28FN2O2S [M+H
+]: calculated 367.1850, found 367.1858. 
 
4-((((1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-yl)oxy)methyl)benzonitrile (284) 
 
General procedure R was followed using alcohol 278a (140 mg, 0.48 mmol), NaH (30 mg, 
0.72 mmol) and 4-(bromomethyl)benzonitrile (188 mg, 0.96 mmol, 2.0 eq.). Purification by 
MDAP afforded title compound 284 (24 mg, 0.06 mmol, 12%) as a colourless oil; δH (400 
MHz, DMSO-d6) 7.90 – 7.79 (2H, m, ArH), 7.76 – 7.61 (2H, m, ArH), 7.49 (2H, d, J 8.5, 
ArH), 7.04 (2H, t, J 8.5, ArH), 4.77 (1H, s, 2-CH), 4.63 (1H, d, J 13.7, NCH2), 4.57 (1H, d, J 
13.7, NCH2), 4.00 (1H, t, J 8.4, 6-CH), 3.51 (1H, s, 5-CH), 3.50 – 3.42 (1H, m, 1-CH), 3.06 
(3H, s, Me), 2.95 – 2.85 (1H, m, 4-CH), 2.31 (1H, dq, J 13.7, 6.9, 7-CH2), 2.25 – 2.11 (4H, m, 
NMe, 3-CH2), 2.03 (1H, dd, J 13.7, 9.1, 7-CH2), 1.79 (1H, d, J 16.0, 3-CH2); 1 δC(101 MHz, 
DMSO-d6): 161.1 (d, J 241.4, Ar-F), 145.6 (Ar), 144.0 (Ar), 141.9 (d, J 3.0, Ar), 132.6 (ArH), 
131.2 (d, J 7.6, ArH), 130.7 (ArH), 128.1 (CN), 114.5 (d, J 20.5, ArH), 69.1 (2-C), 68.4 (5-C), 
67.8 (6-C), 66.1 (1-C), 45.5 (4-C), 42.1 (O-C), 40.9 (NMe), 33.1 (SO2Me), 27.8 (7-C), 26.9 (3-
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C); IR νmax (neat)/cm-1: 3037 (CH), 3014, 2951, 2894, 2228 (CN), 1506 (C=C), 1418, 1288 
(S=O); HRMS (ESI): [M+H+]: C23H26FN2O3S2 calculated 429.1643, found 429.1643. 
 
(1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-yl pyridin-3-ylcarbamate (291) 
 
General procedure Y was followed using alcohol 278a (150 mg, 0.48 mmol), NaHCO3 
(242 mg, 2.88 mmol) and 3-pyridyl isocyanate (144 mg, 1.20 mmol). Purification by MDAP 
afforded title compound 291 (23 mg, 0.05 mmol, 11%) as a colourless oil; δH(400 MHz, 
Methanol-d4): 8.62 (1H, s, ArH), 8.27 – 8.11 (1H, m, ArH), 8.01 (1H, s, ArH), 7.71 – 7.56 
(2H, m, ArH), 7.50 – 7.27 (1H, m, ArH), 7.13 – 6.85 (2H, m, ArH), 4.79 (1H, ad, J 8.3, 2-CH), 
4.01 (1H, t, J 8.0, 6-CH), 3.76 (1H, s, 5-CH), 3.57 (1H, d, J 8.6, 1-CH), 3.11 – 3.03 (3H, m, 
SO2Me), 3.02 – 2.91 (1H, m, 4-CH), 2.53 (1H, ddd, J 16.4, 9.0, 8.2, 7-CH2), 2.44 – 2.18 (5H, 
m, 3-CH2, 7-CH2, NMe), 2.03 – 1.94 (1H, m, 3-CH2); δC(101 MHz, Methanol-d4) δ 162.7 (Ar-
F), 160.3 (Ar-F), 153.9 (Ar), 142.7 (ArH), 140.9 (ArH), 130.2 (ArH), 129.5 (Ar), 126.4 (ArH), 
123.9 (ArH), 114.1 (ArH), 72.7 (2-C), 68.0 (5-C), 67.8 (6-C), 67.1 (1-C), 45.6 (4-C), 40.9 
(NMe), 39.5 (SO2Me), 27.7 (7-C), 26.5 (3-C); HRMS (ESI): C21H25FN3O4S [M+H
+]: 
calculated 434.1544, found 434.1546. 
 
(3aR*,4S*,5R*,7S*,8S*,8aS*)-9-(4-Fluorobenzyl)-5-(methylsulfonyl)-2-(thiazol-2-
yl)decahydro-4,7-epiminocyclohepta[c]pyrrol-8-ol (311) 
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General procedure R was followed using amine hydrochloride 306 (140 mg, 0.36 mmol), 
DIPEA (95 L, 0.54 mmol) and 2-bromothiazole (50 L, 0.54 mmol). Purification by 
automated reversed-phase flash chromatography eluting with  MeCN/H2O 1% formic acid 
gave title compound 311 (7 mg, 0.02 mmol, 4%) as a colourless oil; 1H NMR (400 MHz, 
Methanol-d4): 7.41 (2H, dd, J 8.5, 5.6, ArH), 7.14 (1H, d, J 3.7, ArH), 7.04 (2H, t, J 8.8, ArH), 
6.65 (1H, d, J 3.7, ArH), 3.91 (1H, t, J 8.2, 7-CH), 3.84 (1H, d, J 13.3, NBn), 3.77 (1H, s, 8-
CH), 3.75 – 3.67 (2H, m, NBn, 1-CH2), 3.62 (1H, d, J 10.3, 3-CH2), 3.54 – 3.46 (2H, m, 4-CH, 
3-CH2), 3.44 – 3.34 (2H, m, 1-CH2, 5-CH), 3.06 (4H, s, Me), 2.67 – 2.57 (1H, m, 8a-CH), 2.47 
(1H, dd, J 13.8, 9.3, 6-CH2), 2.36 (1H, dt, J 13.8, 6.9, 6-CH2), 2.15 (1H, dt, J 9.2, 6.3, 3a-CH); 
δC(101 MHz, Methanol-d4,): 169.0 (Ar), 162.0 (d, J 243.4, ArF), 138.4 (ArH), 135.6 (Ar), 
130.5 (d, J 8.0, ArH), 114.5 (d, J 21.4, ArH), 105.9 (ArH), 71.3 (4-C), 68.4 (7-C), 66.8 (5-C), 
60.6 (8-C), 55.7 (N-CH2), 53.4 (3-CH2), 50.9 (1-CH2), 46.1 (8a-C), 41.3 (3a-C), 39.3 (Me), 
23.8 (6-CH2); HRMS (ESI): [M+H
+]: C20H25FN3O3S2 calculated 438.1316, found 438.1311. 
 
1-((3aR*,4S*,5R*,7S*,8S*,8aS*)-9-(4-Fluorobenzyl)-8-hydroxy-5-
(methylsulfonyl)octahydro-4,7-epiminocyclohepta[c]pyrrol-2(1H)-yl)-2-methylpropan-1-one 
(310) 
 
General procedure V was followed using amine 306 (120 mg, 0.363mmol) and isobutyryl 
chloride (300 l, 2.64 mmol) and pyridine (120 l, 1.32 mmol). Purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O 1% formic acid. Crystallisation 
from ethanol gave title compound 310 (10 mg, 0.02 mmol, 7%) as a colourless solid as a 1:1 
ratio of rotamers; M.pt. 223.8 – 224.8 oC; 1H NMR (501 MHz, Methanol-d4, 333K): 7.33 – 
7.17 (4H, m, ArH, ArH), 7.02 – 6.79 (4H, m, ArH, ArH), 3.96 – 3.60 (10H, m, 1-CH2, 8-CH, 
8-CH, NCH2, NCH2, 7-CH, 7-CH), 3.60 – 3.51 (2H, m, 1-CH2), 3.48 – 3.33 (6H, m, 3-CH2, 5-
CH, 5-CH, 4-CH, 4-CH), 3.24 (2H, t, J 5.8, 3-CH2), 2.92 (3H, s, SO2Me), 2.92 (3H, s, SO2Me), 
2.71 – 2.55 (2H, m, CH(Me)2, CH(Me)2), 2.44 – 2.37 (1H, m, 8a-CH), 2.37 – 2.28 (3H, m, 6-
CH2, 6-CH2), 2.28 – 2.20 (2H, m, 6-CH2, 8a-CH), 1.98 – 1.91 (1H, m 3a-CH), 1.90 – 1.85 (1H, 
m, 3a-CH), 1.05 (3H, d, J 6.7, Me), 1.03 (3H, d, J 6.7, Me), 1.00 (3H, d, J 4.6, Me), 0.99 (3H, 
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d, J 4.6, Me); δC(101 MHz, Methanol-d4): 177.3 (C=O), 177.1 (C=O), 162.1 (d, J 243.0, ArF), 
162.1 (d, J 243.0, ArF), 135.7 (d, J 3.0, Ar), 135.6 (d, J 3.0, Ar), 130.5 (d, J 7.9, ArH), 130.5 
(d, J 7.9, ArH), 114.5 (d, J 21.4, ArH), 114.5 (d, J 21.4, ArH), 71.0 (4-C), 70.7 (4-C), 68.5 (7-
C), 68.3 (7-C), 66.8 (5-C), 66.7 (5-C), 60.6 (8-C), 60.5 (8-C), 55.7 (N-CH2), 55.7 (N-CH2), 
50.0 (3-CH2), 49.3 (3-CH2), 47.6 (1-CH2), 47.2 (1-CH2), 46.1 (8a-C), 44.5 (8a-C), 41.3 (3a-C), 
39.5 (3a-C), 39.3 (SO2Me), 39.2 (SO2Me), 32.1 (CH(Me)2), 31.8 (CH(Me)2), 23.9 (6-CH2), 
23.7 (6-CH2), 18.1 (Me), 18.1 (Me), 17.7 (Me), 17.6 (Me); IR νmax (neat)/cm-1: 3433 (OH), 
2961 (CH), 2936, 2919, 2886, 1620 (C=O), 1509 (C=C), 1328 (S=O); HRMS (ESI): 
C21H30FN2O4S [M+H
+]: calculated 425.1905, found 425.1902. 
 
(3aR*,4S*,5R*,7S*,8S*,8aS*)-9-Methyl-5-(methylsulfonyl)-2-(pyridin-2-yl)decahydro-4,7-
epiminocyclohepta[c]pyrrol-8-ol (313) 
 
General procedure R was followed using free amine 307 (120 mg, 0.46 mmol), DIPEA (121 
L, 0.69 mmol, 1.5 eq.) and 2-fluoropyridine (60 L, 0.69 mmol, 1.5 eq.) in DMF (2.3 mL). 
Purification by automated reversed-phase flash chromatography eluting with  MeCN/H2O/1% 
formic acid gave title compound 313 (24 mg, 0.07 mmol, 15%) as a brown solid as a ratio of 
1:6 isomers. Only the major isomer was assigned. 
 δH (400 MHz, Chloroform-d): 8.10 (1H, dd, J 7.0, 1.8, ArH), 7.63 (1H, ddd, J 8.8, 7.0, 1.8, 
ArH), 6.68 (1H, t, J 7.0, ArH), 6.57 (1H, d, J 8.8, ArH), 4.00 (1H, s, OH), 3.82 – 3.74 (2H, m, 
7-CH, 1-CH2), 3.65 – 3.59 (2H, m, 3-CH2, 4-CH), 3.56 – 3.40 (3H, m 3-CH2,1-CH2, 8-CH), 
3.33 (1H, t, J 5.6, 5-CH), 3.00 – 2.96 (3H, m, SO2Me), 2.61 – 2.51 (1H, m, 8a-CH), 2.52 – 2.38 
(4H, m, NMe, 6-CH2), 2.37 – 2.26 (1H, m, 6-CH2), 2.14 – 2.05 (1H, m, 3a-CH2); δC NMR 
(101 MHz, Chloroform-d): 165.5 (ArH), 142.9(Ar), 140.0(ArH), 111.5(ArH), 109.3 (ArH), 
70.9 (7-C), 69.3 (5-C), 68.9 (4-C), 63.1 (3-C), 51.5 (1-C), 49.3 (SO2Me), 46.0 9 (Me), 41.6 (8-
C), 41.1 (8a-C), 40.7 (3a-C), 24.5 (6-C); IR νmax (neat)/cm-1: 3387 (OH), 3013, 2940 (CH), 
2894, 2824, 1556 (C=C), 1475, 1285 (S=O); HRMS (ESI): C16H24N3O3S [M+H
+]: calculated 
338.1533, found 338.1530. 
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(3aR*,4S*,5R*,7S*,8S*,8aS*)-9-(4-Fluorobenzyl)-5-(methylsulfonyl)-2-(oxetan-3-
yl)decahydro-4,7-epiminocyclohepta[c]pyrrol-8-ol (309) 
 
General procedure W was followed using amine hydrochloride 306 (140 mg, 0.36 mmol) and 
cyclobutanone (113 L, 1.8 mmol), NaBH4 (40 mg, 3.0 eq.). Purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave title 
compound 309 (14 mg, 0.03 mmol, 9%) as a brown oil.  
δH (400 MHz, DMSO-d6): 7.38 (2H, dt, J 8.5, 6.2, ArH), 7.18 – 7.09 (2H, m, ArH), 4.60 – 
4.54 (2H, m, CH2), 4.48 – 4.41 (2H, m, CH2), 3.77 (1H, t, J 8.5, 7-CH), 3.74 – 3.68 (1H, m, 3-
CH), 3.65 (1H, d, J 13.3, NBn), 3.61 – 3.52 (1H, m, 3-CH), 3.47 (1H, s, 4-CH), 3.44 – 3.36 
(1H, m, NBn), 3.33 (1H, t, J 5.5, 1-CH), 3.20 – 3.12 (1H, m, 5-CH), 3.01 (3H, s, Me), 2.75 
(1H, t, J 7.8, 1-CH), 2.69 – 2.63 (1H, m, 8-CH), 2.39 – 2.05 (4H, m, 6-CH2, 8a-CH, CH), 1.83 
– 1.75 (1H, m, 3a-CH); δC (101 MHz, DMSO-d6): 163.9 (d, J 242.1, Ar-F), 136.9 (d, J 3.3, 
Ar), 130.8 (d, J 8.0, ArH), 115.3 (d, J 21.0, ArH), 75.5 (CH2), 75.2 (CH2), 71.7 (4-C), 66.3 (7-
C), 61.9 (5-C), 57.4 (8-C), 55.8 (NBn), 54.7 (3-C), 51.3 (1-C), 46.2 (8a-C), 42.4 (3a-C), 41.1 
(Me), 24.0 (6-C). IR νmax (neat)/cm-1: 3364 (OH), 3011 (CH), 2923, 2874, 1602, 1507 (C=C), 
1417, 1284 (S=O); HRMS (ESI): C20H28FN2O4S [M+H
+]: calculated 411.1748, found 
411.1746. 
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(1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-2-(pyridin-2-
yloxy)-8-azabicyclo[3.2.1]octane (290) 
 
 
 
General procedure R was followed using alcohol 278a (147 mg, 0.47 mmol), NaH (17 mg, 
0.71 mmol) and 2-fluoropyridine (81 L, 0.94 mmol, 2.0 eq.). Purification by MDAP afforded 
title compound 290 (16 mg, 0.04 mmol, 9%) as a brown oil;  
δH(501 MHz, Methanol-d4): 8.02 (1H, ddd, J 5.1, 2.0, 0.9, Pyr-H), 7.55 (1H, ddd, J 8.3, 7.1, 
2.0, Pyr-H), 7.47 – 7.39 (2H, m, ArH), 7.01 – 6.89 (2H, m, ArH), 6.82 (1H, ddd, J 7.1, 5.1, 1.0, 
Pyr-H), 6.65 (1H, dt, J 8.3, 0.9, Pyr-H), 5.36 (1H, ddd, J 10.9, 6.6, 4.2, 2-CH), 3.89 (1H, t, J 
8.2, 5-CH), 3.68 – 3.65 (1H, m, 6-CH), 3.27 – 3.18 (1H, m, 4-CH), 3.06 – 2.90 (3H, m, SO2Me), 
2.43 (1H, dd, J 13.7, 9.3, 7-CH2), 2.31 – 2.11 (5H, m, NMe, 3-CH2, 7-CH2), 1.82 (1H, ddd, J 
14.5, 10.9, 7.7, 3-CH2); δC (126 MHz, Methanol-d4): 162.7 (Ar), 161.2 (d, J 242.9, ArF), 146.4 
(ArH), 139.7 (d, J 3.1, Ar), 138.8 (ArH), 129.5 (d, J 7.6, ArH), 116.7 (ArH), 114.0 (d, J 21.0, 
ArH), 110.9 (ArH), 69.9 (2-C), 68.1 (6-C), 68.1 (5-C), 65.8 (1-C), 45.9 (4-C), 40.5 (NMe), 39.2 
(SO2Me), 27.3 (3-C), 24.5 (7-C); IR νmax (neat)/cm-1: 3063, 3013 (CH), 2948, 2898, 1595, 1510 
(C=C), 1433, 1288 (S=O); HRMS (ESI): [M+H+]: C20H24FN2O3S calculated 391.1486, found 
391.2219. 
 
(1S*,2R*,5S*,6R*)-8-Isopropyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-ol (178) 
 
General procedure F was followed using compound 117 (1.50 g, 5.15 mmol) and 10% Pd/C 
(250 mg, 10% weight) in MeOH/Acetone (30 mL) at rt. The title compound 178 (1.25 g, 5.05 
mmol, 99%) as a yellow oil;  
δH (400 MHz, Chloroform-d): 3.94 (1H, ddd, J 10.1, 5.7, 3.4, 5-CH), 3.78 (1H, d, J 3.0, 2-
CH), 3.47 (1H, dd, J 7.0, 3.5, 6-CH), 3.15 (1H, dd, J 9.8, 5.5, 1-CH), 3.05 (1H, p, J 6.1, 8-CH), 
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2.82 (3H, s, Me), 2.35 (1H, dd, J 14.5, 9.8, 7-CH2), 2.06 – 1.97 (1H, m, 7-CH2), 1.95 – 1.81 
(2H, m, 3-CH2, 4-CH2), 1.39 (1H, ddd, J 14.2, 6.1, 2.5, 3-CH2), 1.32 – 1.14 (1H, m, 4-CH2), 
1.05 (3H, d, J 6.1, Me), 0.98 (3H, d, J 6.1, Me). δC (101 MHz, Chloroform-d): 67.1 (1-C), 
63.1 (5-C), 59.7 (6-C), 55.3 (2-C), 44.1 (Me), 37.5 (8-C), 26.8 (7-C), 26.4 (3-C), 24.0 (4-C), 
21.9 (Me), 21.9 (Me); IR νmax (neat)/cm-1: 3473 (OH), 3120, 3102 (CH), 3047, 2967, 2944, 
2874, 1288 (S=O); HRMS (ESI): C11H22NO3S [M+H
+]: calculated 248.1315, found 248.1314. 
 
 
(1S*,2R*,5S*,6R*)-8-isopropyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-yl (4-
methoxyphenyl)carbamate) (317) 
 
General procedure Y was followed using compound 178 (100 mg, 0.4 mmol) in DMF (1mL), 
NaH (65 mg, 1.62 mmol, 4.0 eq.) and 4-methoxyphenylisocyanate (0.2 mL, 1.62 mmol, 4.0 
eq.). The reaction mixture was concentrated in vacuo and purification by automated reversed-
phase flash chromatography eluting with  eluting with MeCN/H2O/1% formic acid gave the 
title compound 317 (37.6 mg, 0.09 mmol, 24 %) as a brown oil; δH(400 MHz, Chloroform-d) 
7.35 (2H, d, J 8.7, ArH), 6.85 (2H, d, J 8.7 , ArH), 4.89 – 4.77 (1H, m, 5-CH), 3.73 (1H, s, 2-
CH), 3.70 (3H, s, Me), 3.67 – 3.60 (2H, m, 1-CH, 6-CH), 3.11 (1H, q, J 6.0, 8-CH), 2.90 (3H, 
s, Me), 2.19 (1H, dd, J 14.0, 9.5, 7-CH2), 2.08 (1H, dd, J 14.0, 6.2, 7-CH2), 1.95 – 1.84 (2H, 
m, 4-CH2, 3-CH2), 1.57 (1H, qd, J 14.2, 12.3, 7.6, 4-CH2), 1.42 (1H, dt, J 14.2, 4.3, 3-CH2), 
1.11 (3H, d, J 6.0, Me), 1.00 (3H, d, J 6.0, Me);δC (101 MHz, Chloroform-d) 155.2 (Ar), 153.5 
(C=O), 132.5 (Ar), 120.3 (Ar-H), 114.4 (Ar-H), 67.1 (5-C), 65.8 (6-C), 57.5 (2-C), 55.6 (Me), 
55.3 (1-C), 44.3 (8-C), 38.3(Me), 26.6 (7-C), 24.6 (3-C), 23.3 (4-C), 22.2 (Me), 22.1 (Me); IR 
νmax (neat)/cm-1: 3372 (NH), 3047 (CH), 2953 2851, 1684 (C=O), 1656, 1515 (C=C), 1222 
(S=O); HRMS (ESI): C19H29N2O5S [M+H
+]: calculated 397.1792, found 397.1786. 
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(1S*,2R*,5S*,6R*)-8-Isopropyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-yl (4-
fluorophenyl)carbamate (314) 
 
General procedure Y was followed using compound 178 (100 mg, 0.4 mmol) in DMF (1mL), 
NaH (65 mg, 1.62 mmol, 4.0 eq.), and 3-fluorophenylisocyanate (0.2 mL, 1.62 mmol, 4.0 eq.). 
The reaction mixture was concentrated in vacuo and purification by automated reversed-phase 
flash chromatography eluting with MeCN/H2O/1% formic acid gave the title compound 314 
(22.6 mg, 0.06 mmol, 16%) as a colourless solid; 
δH(400 MHz, Chloroform-d) 7.30 – 7.15 (1H, m, ArH), 6.98 – 6.90 (1H, m, ArH), 6.70 (1H, 
tdd, J 8.3, 2.5, 0.9, ArH), 6.61 (1H, s, ArH), 5.00 (1H, ddd, J 9.8, 5.9, 3.3, 5-CH), 3.79 (1H, s, 
1-CH), 3.67 (1H, dd, J 6.9, 3.3, 6-CH), 3.22 – 3.09 (2H, m, 8-CH, 2-CH), 2.82 (3H, s, Me), 
2.32 (1H, dd, J 14.6, 9.8, 3-CH2), 2.13 – 1.96 (3H, m, 3-CH2, 7-CH2, 4-CH2), 1.54 – 1.37 (2H, 
m, 4-CH2, 7-CH2), 1.14 (3H, d, J 6.1, Me), 1.01 (3H, d, J 6.0, Me); δC (101 MHz, Chloroform-
d) 163.2 (d, J 245.0, Ar), 152.4 (C=O), 139.2 (d, J 10.8, ArH), 130.2 (d, J 9.5, ArH), 113.9 
(ArH), 110.3 (d, J 21.4, ArH), 106.1 (d, J 28.6, Ar), 67.0 (5-C), 66.7 (2-C), 56.7 (6-C), 55.3 (1-
C), 44.0 (8-C), 37.1 (Me), 27.3 (3-C), 23.4 (7-C), 23.1 (4-C), 21.9 (Me), 21.8 (Me); IR νmax 
(neat)/cm-1: 3317 (NH), 3090 (CH), 3011, 2847, 1659 (C=O), 1542 (C=C), 1470, 1292 (S=O); 
HRMS (ESI): C18H26FN2O4S [M+H
+]: calculated 385.1592, found 385.1599. 
 
(1S*,2R*,5S*,6R*)-2-((4-Fluorobenzyl)oxy)-8-isopropyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octane (318) 
 
General procedure R was followed using compound 178 (100 mg, 0.4 mmol) in DMF (1mL), 
NaH (65 mg, 1.62 mmol, 4.0 eq.) and 4-fluorobenzyl bromide (0.2 mL, 1.62 mmol, 4.0 eq.). 
The reaction mixture was concentrated in vacuo and purification by automated reversed-phase 
flash chromatography eluting with  MeCN/H2O/1% formic acid gave the title compound 318 
(22.6 mg, 0.06 mmol, 16%) as a colourless oil; 
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δH (400 MHz, Methanol-d4) 7.38 (2H, dd, J 8.5, 5.6, ArH), 7.09 (2H, t, J 8.8, ArH), 4.57 (1H, 
d, J 11.9, NCH2), 4.53 (1H, d, J 11.8, NCH2), 3.99 (1H, s, 2-CH), 3.85 – 3.68 (2H, m, 5-CH, 
6-CH), 3.59 (1H, dd, J 9.9, 5.8, 1-CH), 3.18 (1H, p, J 6.1, 8-CH), 2.96 (3H, s, Me), 2.44 (1H, 
dd, J 14.2, 9.8, 7-CH2), 2.21 – 2.11 (1H, m, 7-CH2), 2.11 – 2.02 (1H, m, 4-CH2), 2.03 – 1.88 
(1H, m, 3-CH2), 1.64 – 1.38 (2H, m, 4-CH2, 3-CH2), 1.11 (6H, at, J 5.8, Me); δC (101 MHz, 
Methanol-d4) 162.36 (d, J 244.2, Ar-F), 134.7 (d, J 3.1, Ar), 129.4 (d, J 8.2, ArH), 114.6 (d, J 
21.7, ArH), 71.0 (5-C), 69.2 (N-C), 65.8 (1-C), 58.5 (6-C), 56.4 (2-C), 45.7 (Me), 37.5 (8-C), 
25.6 (7-C), 25.0 (3-C), 23.6 (4-C), 20.3 (Me); IR νmax (neat)/cm-1: 2964 (CH), 2944, 2928, 
1769 (C=O), 1656, 1459 (C=C), 1410, 1293 (S=O); HRMS (ESI): C18H27FNO3S [M+H
+]: 
calculated 356.1690, found 356.1689. 
 
 
2-(((1S*,2R*,5S*,6R*)-8-Isopropyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-
yl)oxy)benzo[d]oxazole (319) 
 
General procedure R was followed using compound 178 (100 mg, 0.4 mmol) in DMF (1mL), 
NaH (65 mg, 1.62 mmol, 4.0 eq.) and 2-chlorobenzoxazole (250 mg, 1.62 mmol, 4.0 eq.). The 
reaction mixture was concentrated in vacuo and purification by automated reversed-phase flash 
chromatography eluting with  MeCN/H2O/1% formic acid gave the title compound 319 (9.7 
mg, 0.03 mmol, 7%) as a brown oil;  
δH (400 MHz, DMSO-d6) 7.49 (1H, dd, J 8.0, 1.1, ArH), 7.35 (1H, dd, J 8.0, 1.1, ArH), 7.24 
(1H, td, J 8.0, 1.1, ArH), 7.15 (1H, td, J 8.0, 1.1, ArH), 4.45 (1H, ddd, J 12.8, 5.4, 2.7, 5-CH), 
3.88 (1H, dd, J 9.5, 5.9, 2-CH), 3.82 (1H, s, 1-CH), 3.68 (1H, d, J 6.5, 2.4, 6-CH), 3.24 (1H, p, 
J 6.1, 8-CH), 2.91 (3H, s, Me), 2.81 (1H, qd, J 12.4, 5.7, 4-CH2), 2.44 (1H, dd, J 14.1, 9.5, 3-
CH2), 2.16 – 2.08 (1H, m, 3-CH2), 2.06 – 1.87 (2H, m, 4-CH2, 7-CH2), 1.60 – 1.50 (1H, m, 7-
CH2), 1.13 (3H, d, J 6.0, Me), 1.05 (3H, d, J 6.0, Me); δC (101 MHz, DMSO-d6) 154.0 (Ar), 
142.4 (Ar), 131.5 (Ar), 124.3 (ArH), 122.6 (ArH), 110.3 (ArH), 110.3 (ArH), 65.5 (2-C), 58.7 
(6-C), 55.5 (1-C), 51.0 (5-C), 44.3 (8-C), 38.4 (Me), 28.4 (3-C), 25.0 (7-C), 22.2 (4-C), 19.6 
(Me); IR νmax (neat)/cm-1: 3014 (CH), 2997, 2878, 2807, 1591 (C=C), 1512, 1445, 1229 (S=O); 
HRMS (ESI): C18H25N2O4S [M+H
+]: calculated 365.1530, found 365.1527. 
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3-((((1S*,2R*,5S*,6R*)-8-Isopropyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-
yl)oxy)methyl)benzonitrile (315) 
 
General procedure R was followed using compound 178 (100 mg, 0.4 mmol) in DMF (1mL), 
NaH (65 mg, 1.62 mmol, 4.0 eq.), and 3-(bromomethyl)benzonitrile (317 mg, 1.62 mmol, 4.0 
eq.). The reaction mixture was concentrated in vacuo and purification by automated reversed-
phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave the title compound 
315 (14.2 mg, 0.04 mmol, 10%) as a colourless solid;  
δH (400 MHz, DMSO-d6) 7.79 – 7.72 (2H, m, ArH, ArH), 7.68 (1H, dd, J 8.0, 1.6, ArH), 7.58 
(1H, t, J 7.7, ArH), 4.56 (2H, s, NCH2), 3.72 (1H, s, 2-CH), 3.65 – 3.58 (2H, m, 5-CH, 6-CH), 
3.55 (1H, dd, J 9.7, 5.8, 1-CH), 3.00 – 2.94 (1H, m, 8-CH), 2.90 (3H, s, Me), 2.21 (1H, dd, J 
13.9, 9.7, 7-CH2), 2.03 – 1.88 (2H, m, 7-CH2, 4-CH2), 1.86 – 1.69 (1H, m, 3-CH2), 1.45 – 1.28 
(2H, m, 3-CH2, 4-CH2), 0.97 (6H, at, J 6.5, Me); δC (101 MHz, DMSO-d6) 141.3 (Ar), 132.6 
(ArH), 131.6 (ArH), 131.1 (ArH), 130.0 (ArH), 119.3 (CN), 111.7 (Ar), 71.8 (5-C), 68.4 (N-
C), 66.1 (1-C), 58.0 (6-C), 55.7 (2-C), 44.7 (8-C), 38.7 (Me), 26.4 (2-C), 25.7 (3-C), 24.2 (4-
C), 22.3 (Me), 22.2 (Me);IR νmax (neat)/cm-1: 3022 (CH), 2963, 2944, 2257 (CN), 1595 (C=C), 
1409, 1330, 1289 (S=O); HRMS (ESI): C19H27N2O3S [M+H
+]: calculated 363.1737, found 
363.1732. 
 
(1S*,2R*,5S*,6R*)-8-Isopropyl-6-(methylsulfonyl)-2-(pyrimidin-4-yloxy)-8-
azabicyclo[3.2.1]octane (320) 
 
General procedure R was followed using compound 178 (100 mg, 0.4 mmol) in DMF (1mL), 
NaH (65 mg, 1.62 mmol, 4.0 eq.) and 2-chloropyrazine (186 mg, 1.62 mmol, 4.0 eq.). The 
reaction mixture was concentrated in vacuo and purification by automated reversed-phase flash 
chromatography eluting with MeCN/H2O/1% formic acid gave the title compound 315 (85.1 
mg, 0.26 mmol, 65%) as a brown solid;  
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δH (300 MHz, Methanol-d4) 8.15 – 7.91 (3H, m, ArH), 5.35 – 5.24 (1H, m, 5-CH), 3.90 (1H, 
s, 1-CH), 3.86 (1H, dd, J 6.7, 3.4, 6-CH), 3.55 (1H, dd, J 9.8, 5.7, 2-CH), 3.28 – 3.08 (1H, m, 
8-CH), 2.87 (3H, s, Me), 2.41 (1H, dd, J 14.3, 9.8, 3-CH2), 2.23 – 1.97 (3H, m, 3-CH2, 7-CH2), 
1.73 – 1.62 (1H, m, 4-CH2), 1.59 – 1.43 (1H, m, 4-CH2), 1.17 (3H, d, J 6.1, Me), 1.04 (3H, d, 
J 6.1, Me); δC (101 MHz, Methanol-d4) 159.7 (Ar), 140.9 (ArH), 136.1 (ArH), 135.4 (ArH), 
68.3 (5-C), 66.0 (2-C) , 57.2 (6-C), 55.9 (1-C), 45.1 (8-C), 37.2 (Me), 26.0 (3-CH2), 24.3 (7-
CH2), 22.7 (4-CH2), 20.6 (Me); IR νmax (neat)/cm-1: 3011 (CH), 2942, 2879, 1650 (C=C), 1600, 
1530, 1472 1285 (S=O); HRMS (ESI): C15H24N3O3S [M+H
+]: calculated 326.1533, found 
326.1529. 
 
 
(1S*,2R*,5S*,6R*)-8-Isopropyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-yl pyridin-3-
ylcarbamate (317) 
 
General procedure Y was followed using compound 178 (100 mg, 0.4 mmol) in DMF (1mL), 
NaH (65 mg, 1.62 mmol, 4.0 eq.) and 3-pyridineisocynate (200 mg, 1.62 mmol, 4.0 eq.). The 
reaction mixture was concentrated in vacuo and purification by automated reversed-phase flash 
chromatography eluting with MeCN/H2O/1% formic acid gave the title compound 317 (30.9 
mg, 0.08 mmol, 21%) as a colourless solid;  
δH (400 MHz, DMSO-d6) 9.86 (1H, s, NH), 8.63 (1H, s, ArH), 8.22 – 8.18 (1H, m, ArH), 
8.17 (1H, s, ArH), 7.48 – 7.22 (1H, m, ArH), 4.90 (1H, ddd, J 11.4, 5.7, 3.3, 5-CH), 3.74 (1H, 
d, J 3.0, 1-CH), 3.70 – 3.62 (2H, m, 2-CH, 8-CH), 3.11 (1H, dq, J 10.0, 5.0, 4.0, 8-CH), 2.91 
(3H, s, Me), 2.20 (1H, dd, J 13.8, 9.6, 3-CH2), 2.10 (1H, dt, J 13.8, 6.1, 3-CH2), 2.00 – 1.87 
(2H, m, 4-CH2, 7-CH2), 1.70 – 1.51 (1H, m, 4-CH2), 1.43 (1H, ddd, J 12.7, 6.3, 2.3, 7-CH2), 
1.11 (3H, d, J 6.0, Me), 1.01 (3H, d, J 6.0, Me); δC (101 MHz, DMSO-d6) 153.5 (C=O), 143.6 
(ArH), 140.7 (ArH), 136.7 (Ar), 125.9 (ArH), 124.1 (ArH), 67.9 (5-C), 65.8 (2-C), 57.4 (6-C), 
55.3(1-C), 44.3(8-C), 38.3 (Me), 26.6 (3-C), 24.6 (7-C), 23.3 (4-C), 22.2 (Me), 22.1 (Me); IR 
νmax (neat)/cm-1: 3384 (NH), 3011 (CH), 2942, 2879, 1650( C=O), 1531 (C=C), 1472, 1285 
(S=O); HRMS (ESI): C17H26N3O4S
 [M+H+]: calculated 368.1639, found 368.1638. 
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 (1S*,2R*,5S*,6R*)-N,8-dibenzyl-N-methyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]octan-2-
amine (223) 
 (1S*,2S*,5S*,6R*)-N,8-dibenzyl-N-methyl-6-(phenylsulfonyl)-8-azabicyclo[3.2.1]octan-2-
amine (224) 
 
 
2:1 regioisomers  
General procedure X was followed using ketone 174 (100 mg, 0.28 mmol, 1.0 eq.), N- 
 
benzylmethylamine (0.37 mL, 2.81 mmol, 10 eq.), Ti(OiPr)4 (0.17 mL, 0.36 mmol, 2.0 eq.) in 
MeOH (100 mL) and NaBH4 (16 mg, 0.42 mmol, 1.5 eq.). Purification by flash 
chromatography on silica gel, eluting with a gradient of 20% EtOAc in hexane afforded a 1:2 
mixture of the amine diastereoisomers: 223 (35 mg, 0.08 mmol, 27%) as a colourless oil; Rf 
= 0.06 (30% EtOAc in hexane) and 224 (33 mg, 0.07 mmol, 26%) as a colourless oil; Rf = 0.66 
(30% EtOAc in hexane).  
 
Compound 223: 
1H NMR
 
(400 MHz, CDCl3) 7.98 – 7.87 (2H, m, ArH), 7.69 – 7.58 (1H, m, ArH), 7.63 – 7.49 
(2H, m, ArH), 7.38 – 7.09 (10H, m, ArH), 3.99 (1H, d, J 14.0, 8-NCH2), 3.86 – 3.77 (2H, m, 
8-NCH2, 2-CH), 3.56 (1H, d, J 3.5, 6-CH), 3.48 (1H, t, J 8.0, 1-CH), 3.40 (2H, s, NMeCH2), 
2.53 (1H, ddd, J 11.3, 5.2, 3.2, 5-CH), 2.38 – 2.20 (2H, m, 7-CH2), 1.99 (3H, s, Me), 2.00 – 
1.84 (2H, m, 4- CH2, 3-CH2), 1.51 – 1.36 (1H, m, 3- CH2), 1.33 – 1.13 (1H, m, 4- CH2). 13C 
NMR (101 MHz, CDCl3): 139.7 (Ar), 139.6 (Ar), 193.4 (Ar), 133.4 (ArH), 129.3 (ArH), 128.7 
(ArH), 128.5 (ArH), 128.4 (ArH), 128.2 (ArH), 128.2 (ArH), 126.8 (ArH), 126.8 (ArH), 69.2 
(1-CH), 61.8 (6-CH), 60.3 (2-CH), 60.2 (5-CH), 58.2 (NMeCH2), 55.5 (NCH2), 38.8 (CH3), 
29.6 (3-CH2), 26.6 (7-CH2), 23.6 (4-CH2). IR νmax (neat)/cm-1: 3061, 3027, 2943 (CH), 2863, 
2785, 1814, 1446 (C=C), 1325 (S=O); HRMS (ESI): C28H33N2O2S [M+H
+]: calculated 
461.2267, found 461.2257. 
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Compound 224: 
1H NMR
 
(400 MHz, CDCl3) 7.94 – 7.85 (2H, m, ArH), 7.67 – 7.57 (1H, m, ArH), 7.59 – 
7.48 (2H, m, ArH), 7.48 – 7.40 (2H, m, ArH), 7.35 – 7.15 (8H, m, ArH), 4.03 (1H, d, J 13.3, 
8-NCH2), 3.89 (1H, d, J 13.3, NMeCH2), 3.80 (1H, dt, J 3.5, 1.9, 2-CH), 3.77 – 3.68 (2H, m, 
8-NCH2, 1-CH), 3.61 – 3.48 (2H, m, NMeCH2, 6-CH), 2.61 (1H, dt, J 13.6, 7.4, 7-CH), 2.41 
(1H, d, J 7.3, 5-CH), 2.26 (3H, s, Me), 2.12 – 1.98 (1H, m, 3-CH2), 1.88 – 1.77 (1H, m, 4-
CH2), 1.74 (1H, dd, J 13.6, 9.0, 7- CH2), 1.55 (1H, ddt, J 15.1, 12.0, 7.3, 4-CH2), 1.43 – 1.32 
(1H, m, 3-CH2). 
13C NMR (101 MHz, CDCl3): 140.4, (C), 140.1, (C), 139.6 (C), 133.4 
(ArH), 129.5 (ArH), 129.3 (ArH), 128.6 (ArH), 128.2 (ArH), 128.2 (ArH), 128.0 (ArH), 126.9 
(ArH), 126.7 (ArH), 69.5 (6-CH), 65.0 (1-CH), 61.9 (5-CH), 60.9 (2-CH), 58.9 (NMeCH2), 
57.3 (8-NCH2), 39.8 (CH3), 32.0 (3-CH2), 31.2 (7-CH2), 18.7 (4-CH2); IR νmax (neat)/cm-1: 
3061, 3027, 2947 (CH), 2847, 2787, 1813, 1446 (C=C), 1367 (S=O); HRMS (ESI): 
C28H33N2O2S [M+H
+]: calculated 461.2267, found 461.2279. 
 
(1S*,2R*,5S*,6R*)-N,8-Dimethyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-amine 
(324) 
 
General procedure X was followed using compound 176 (1.00 g, 4.60 mmol, 1.0 eq.), 
methylamine (2M MeOH) (23 mL, 2.5 eq.), Ti(OiPr)4 (2.8 mL, 9.2 mmol, 2.0 eq.), NaBH4 (262 
mg, 6.9 mmol, 1.5 eq.). Purification by SCX SPE (strong cation exchange solid phase 
extraction) afforded the title compound 324 (595 mg, 2.56 mmol, 41%) as a yellow oil; δH (400 
MHz, Chloroform-d): 3.97 (1H, t, 8.3, 6-CH), 3.78 (1H, dt, J 3.7, 1.9, 5-CH), 3.56 – 3.50 
(1H, m, 1-CH), 3.14 (3H, s, Me), 2.84 (3H, s, Me), 2.66 – 2.56 (2H, m, 7-CH2), 2.20 (1H, dd, 
J 13.8, 9.3, 7-CH2), 2.17 (1H, m, 2-CH), 2.06 (3H, s, Me), 1.83 – 1.72 (2H, m, 3-CH2), 1.66 – 
1.55 (2H, m, 4-CH2); δC (101 MHz, Chloroform-d): 70.2 (6-C), 70.0 (1-C), 67.3 (2-C), 61.7 
(5-C), 45.5(Me), 43.7 (Me), 35.7 (Me), 33.1 (7-C), 32.3 (3-C), 23.4 (4-C); IR νmax (neat)/cm-1: 
3336 (NH), 3229, 3100 (CH), 3049, 2941, 1471, 1286 (S=O), 1127; HRMS (ESI): 
C10H21N2O2S [M+H
+]: calculated 233.1318, found 233.1324. 
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(1S*,2R*,5S*,6R*)-N,8-Dimethyl-6-(methylsulfonyl)-N-(4-(trifluoromethoxy)benzyl)-8-
azabicyclo[3.2.1]octan-2-amine (327) 
 
 
General procedure W was followed using compound 324 (99 mg, 0.43 mmol) in DMF (2.2 
mL), 4-(trifluoromethoxy)benzaldehyde (0.3 mL, 2.15 mmol, 5.0 eq.) NaBH4 (49 mg, 1.29 
mmol, 3.0 eq.) at 60 oC for 16 h. The reaction mixture was cooled and concentrated in vacuo, 
then purification by automated reversed-phase flash chromatography eluting with 
MeCN/H2O/1% formic acid gave the title compound 327 (13.6 mg, 0.03 mmol, 8%) as a 
colourless solid; δH(400 MHz, Chloroform-d) 7.31 (2H, d, J 8.6, ArH), 7.15 – 7.05 (2H, m, 
ArH), 3.99 (1H, d, J 13.6, NCH2), 3.78 – 3.71 (1H, m, 5-CH), 3.61 (1H, d, J 7.3, 6-CH), 3.57 
(1H, d, J 13.6, NCH2), 3.40 (1H, t, J 8.2, 1-CH), 2.90 – 2.77 (3H, m, Me), 2.52 – 2.41 (2H, m, 
7-CH2, 2-CH), 2.40 (3H, s, Me), 2.32 (3H, s, Me), 2.19 – 2.07 (1H, m, 4-CH2), 1.91 – 1.83 (2H, 
m, 3-CH2, 7-CH2), 1.62 – 1.43 (2H, m, 3-CH2, 4-CH2); δC (101 MHz, Chloroform-d) ; 148.4 
(Ar), 136.9 (Ar), 131.3 (OC3)130.4 (ArH), 120.9 (ArH), 67.5 (1-C), 65.3 (6-C), 63.0 (5-C), 61.5 
(2-C), 58.3 (N-C), 41.1 (Me), 40.4 (Me), 39.3 (Me), 30.4 (7-C), 30.3 (3-C), 18.2 (4-C); IR νmax 
(neat)/cm-1: 3077, 2956 (CH), 2866, 2827, 2787, 1593 (C=C), 1507, 1259 (S=O); HRMS 
(ESI): C18H26F3N2O3S
 [M+H+]: calculated 407.1611, found 407.1606. 
 
((1S*,2R*,5S*,6R*)-N,1-Dimethyl-N8-methyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-
2-yl)-1H-imidazole-2-sulfonamide (329) 
 
General procedure Q was followed using compound 324 (99 mg, 0.43 mmol) in DMF (2.2 
mL), NaHCO3 (217 mg, 2.88 mmol, 6.0 eq.) and 1-methylimidazole-2-sulfonyl chloride (311 
mg, 1.72 mmol, 4.0 eq.). The reaction mixture was concentrated in vacuo and purification by 
automated reversed-phase flash chromatography eluting with MeCN/H2O/1% formic acid gave 
the title compound 329 (32.6 mg, 0.09 mmol, 21%) as a colourless solid; 
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δH (400 MHz, DMSO-d6) 7.43 (1H, d, J 1.0, ArH), 7.06 (1H, d, J 1.0, ArH), 3.84 (3H, s, Me), 
3.79 (1H, t, J 8.4, 1-CH), 3.72 – 3.66 (1H, m, 5-CH), 3.62 (1H, s, 2-CH), 3.35 (1H, d, J 7.1, 6-
CH), 3.22 (3H, s, Me), 2.99 (3H, s, Me), 2.34 – 2.26 (1H, m, 7-CH2), 2.24 (3H, s, Me), 2.05 – 
1.96 (2H, m, 7-CH2, 3-CH2), 1.90 – 1.77 (1H, m, 4-CH2), 1.71 (1H, dd, J 16.0, 6.5, 4-CH2), 
1.48 (1H, ddd, J 12.9, 6.2, 2.8, 3-CH2); δC (101 MHz, DMSO-d6) 142.9 (Ar), 128.0 (ArH), 
126.4 (ArH), 70.1 (6-C), 66.3 (1-C), 62.8 (2-C), 55.9 (5-C), 41.9 (Me), 40.8 (Me), 34.9 (Me), 
33.4 (Me), 31.3 (3-C), 28.9 (7-C), 18.9 (4-C); IR νmax (neat)/cm-1: 3488, 3112 (CH), 2993, 
2941, 1651(C=C), 1458, 1288 (S=O), 1132; HRMS (ESI): C14H25N4O4S2 [M+H
+]: calculated 
377.1312, found 377.1308. 
 
((1S*, 2R*, 5S*, 6R*)-3-(3-Cyanophenyl)-1-methyl-18-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-yl)urea (328) 
 
 
General procedure Y was followed using compound 324 (99 mg, 0.43 mmol) in DMF (2.2 
mL), 3-isocyanatobenzonitrile (151 mg, 1.08 mmol) and NaHCO3 (216 mg, 2.58 mml). The 
reaction mixture was concentrated in vacuo and purification by automated reversed-phase flash 
chromatography eluting with MeCN/H2O/1% formic acid gave the title compound 328 (57 mg, 
0.15 mmol, 35%) as a colourless solid;  
δH (400 MHz, Methanol-d4) 8.30 (1H, s, NH), 7.93 (1H, t, J 1.9, ArH), 7.65 (1H, ddd, J 8.0, 
2.3, 1.1, ArH), 7.46 (1H, t, J 8.0, ArH), 7.37 (1H, dt, J 8.0, 1.3, ArH), 4.08 (1H, s, 2-CH), 4.02 
(1H, t, J 8.5, 1-CH), 3.82 (1H, d, J 7.3, 5-CH), 3.77 (1H, d, J 7.3, 6-CH), 3.23 (3H, s, Me), 3.07 
(3H, s, Me), 2.79 – 2.57 (4H, m, 4-CH2, Me), 2.51 – 2.41 (1H, m, 3-CH2), 2.36 (1H, dd, J 14.2, 
9.4, 7-CH2), 2.29 – 2.17 (1H, m, 4-CH2), 1.87 – 1.71 (2H, m, 4-CH2, 3-CH2); δC (101 MHz, 
Methanol-d4) 157.5 (C=O), 140.8 (Ar), 129.5 (ArH), 125.8 (ArH), 124.5 (ArH), 123.2 (ArH), 
118.4 (CN), 112.1 (Ar), 68.8 (6-C), 64.9 (1-C), 63.0 (2-C), 58.1 (5-C), 39.9 (Me), 39.3 (Me), 
34.7 (Me), 30.1 (3-C), 28.8 (7-C), 19.6 (4-C); IR νmax (neat)/cm-1: 3385 (NH), 2896 (CH), 
2786, 2257 (CN), 1653 (C=O), 1456 (C=C), 1386, 1295 (S=O); HRMS (ESI): C18H25N4O3S 
[M+H+]: calculated 377.1642, found 377.1641. 
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6.3.1 Chapter 2 compounds  
1-(2-Ethoxy-2-oxoethyl)-3-hydroxypyridin-1-ium bromide (351) 
 
 
General procedure A was followed using 3-hydroxypyridine 86 (1.00 g, 10.52 mmol) and 
ethyl bromoacetate (1.30 mL, 11.57 mmol) in MeCN (22 mL). Title compound 351 (2.7 g, 
10.3 mmol, 98%) was obtained as a colourless solid; δH (300 MHz, DMSO-d6): 8.68 – 8.63 
(1H, m, ArH), 8.59 (1H, dt, J 5.7, 1.3, ArH), 8.13 – 8.07 (1H, m, ArH), 8.04 (1H, dd, J 8.7, 
5.6, ArH), 5.66 (2H, s, CH2), 4.23 (2H, q, J 7.1, OCH2), 1.25 (3H, t, J 7.1, CH2); δC (75 
MHz, DMSO d6): 166.3 (C=O), 156.5 (ArH), 137.2 (ArH), 134.3 (Ar), 132.5 (ArH), 128.3 
(ArH), 62.2 (CH2) , 60.2 (CH2) , 13.9 (Me); IR νmax (neat)/cm-1:  3045, 2880, (CH), 2852, 
1707 (C=O), 1456 (C=C), 1401, 1360, 1216, HRMS (ESI): C9H12NO3  [M-H]: calculated 
182.0812, found 182.0811. 
 
1-(3-Cyanobenzyl)-3-hydroxypyridin-1-ium bromide (352) 
 
General procedure A was followed using 3-hydroxypyridine 86 (2.50 g, 26.3 mmol) and 3-
(bromomethyl)benzonitrile  (2.55 mL, 26.3 mmol) in IPA (50 mL). Title compound 352  
(7.65g, 23.4 mmol, 99%) was obtained as a colourless solid; δH (600 MHz, DMSO-d6): 8.76 
– 8.69 (2H, m, ArH), 8.07 (1H, s, ArH), 8.00 – 7.92 (2H, m, ArH), 7.91 – 7.85 (2H, m, ArH), 
7.61 (1H, d, J 8.4, ArH), 5.86 (2H, s, NCH2); δc (151 MHz, DMSO-D6): 157.7 (Ar), 136.4 
(Ar), 136.2 (ArH), 134.3 (ArH), 133.5 (ArH), 133.2 (ArH), 132.5 (ArH), 130.9 (ArH), 129.5 
(ArH), 118.8 (Ar), 112.4 (CN), 62.5 (CH2); IR νmax (neat)/cm-1: 3341 (OH), 3003 (CH), 2980, 
2853, 2212 (CN), 1585 (C=C), 1488, 1452; HRMS (ESI): C13H10N2O [M-H]: calculated 
211.2387, found 211.0879. 
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1-(Cyclopropylmethyl)-3-hydroxypyridin-1-ium bromide (353) 
 
General procedure A was followed using 3-hydroxypyridine 86 (2.30 g, 26.3 mmol) and 
(bromomethyl)cyclopropane (2.55 mL, 26.3 mmol) in IPA (50 mL). Title compound 353 
(6.00g, 26.1 mmol, 99%) was obtained as a colourless solid. 
δH (600 MHz, DMSO-d6): 8.68 (1H, s, ArH), 8.66 – 8.63 (1H, m, ArH), 7.98 (1H, d, J 8.9, 
ArH), 7.96 – 7.90 (1H, m, ArH), 4.45 (2H, d, J 7.6, CH2), 1.43 – 1.32 (1H, m, cyp), 1.02 – 0.94 
(1H, m, cyp), 0.67 – 0.44 (3H, m, cyp); δc (151 MHz, DMSO-d6): 157.3 (Ar), 136.0 (ArH), 
133.1 (ArH), 131.9 (ArH), 129.1 (ArH), 65.0 (CH2), 25.9 (cyp), 12.6 (cyp), 4.4 (CH). IR νmax 
(neat)/cm-1: 3341 (OH), 3002 (CH), 2980, 2950, 2729, 1584 (C=C), 1556, 1489; HRMS (ESI): 
C9H11NO [M-H]: calculated 150.0913, found 150.0909. 
 
3-(((1S*,5S*,6R*)-6-(Methylsulfonyl)-2-oxo-8-azabicyclo[3.2.1]oct-3-en-8-
yl)methyl)benzonitrile (354) 
 
 
General procedure B was followed using methyl vinyl sulfone (1.8 mL, 20.2 mmol) and benzyl 
salt 352 (7.65.0 g, 26.3 mmol), triethylamine (5.6 mL, 40.4 mmol). Purification by flash 
chromatography on silica gel, eluting with a gradient of 60-100% EtOAc in hexane afforded 
the major title compound 354 (1.89 g, 5.98 mmol, 29%) as a yellow solid; Rf = 0.47, (100% 
EtOAc in hexane); δH (400 MHz, Chloroform-d): 7.61 (1H, dt, J 7.4, 1.6, ArH), 7.54 (2H, d, 
J 11.6, ArH), 7.48 (1H, t, J 7.6, ArH), 7.06 (1H, dd, J 9.8, 5.0, 4-CH), 6.25 (1H, dd, J 9.8, 1.5, 
3-CH), 4.20 (1H, d, J 5.0, 5-CH), 3.88 (2H, s, NBn), 3.72 (1H, d, J 7.7, 6-CH), 3.49 (1H, dd, J 
9.4, 4.2, 1-CH), 2.93 (3H, s), 2.78 (1H, ddd, J 14.7, 7.7, 4.2, 7-CH2), 2.24 (1H, dd, J 14.7, 9.4, 
7-CH2); δc (126 MHz, Chloroform-d): 196.6 (C=O), 145.1 (4-C), 138.5 (Ar), 133.1 (ArH), 
132.0 (ArH), 131.7 (ArH), 129.7 (ArH), 129.2 (3-C), 118.5 (Ar), 112.9 (CN), 67.8 (6-C), 66.2 
(1-C), 58.2 (5-C), 51.2 (NBn), 38.8 (Me), 27.5 (7-CH2); IR νmax (neat)/cm-1: 3058, 3010, 2924 
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(CH), 2229 (CN), 1684 (C=O), 1573 (C=C), 1476, 1276 (S=O); HRMS (ESI): C16H17N2O3S 
[M+H+]: calculated 317.0954, found 317.0960. 
 
(1S*,5S*,6R*)-8-(Cyclopropylmethyl)-6-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-en-2-one 
(355) 
 
General procedure B was followed using methyl vinyl sulfone (2.55 mL, 20.2 mmol) and salt 
353 (6.0 g, 26.3 mmol), triethylamine (5.6 mL, 40.4 mmol). Purification by flash 
chromatography on silica gel, eluting with a gradient of 60-100% EtOAc in hexane afforded 
the major title compound 355 (1.13 g, 4.41 mmol, 22%) as a yellow solid; Rf = 0.32, (60% 
EtOAc in hexane); δH (400 MHz, Chloroform-d): 6.88 (1H, dd, J 9.8, 4.9, 4-CH), 6.02 (1H, 
dd, J 9.8, 1.5, 3-CH), 4.33 (1H, d, J 4.9, 5-CH), 3.73 (1H, dd, J 7.8, 1.5, 6-CH), 3.34 (1H, dd, 
J 9.5, 3.9, 1-CH), 2.63 (1H, ddd, J 15.0, 7.8, 3.9, 7-CH2), 2.52 (1H, dd, J 12.5, 6.5, CH2), 2.46 
(3H, s, SO2Me), 2.39 (1H, dd, J 12.5, 7.0, CH2), 2.14 (1H, dd, J 15.0, 9.5, 7-CH2), 0.80 – 0.68 
(1H, m, cyp), 0.52 – 0.40 (2H, m, cyp), 0.05 – -0.06 (2H, m, cyp); δc (126 MHz, Chloroform-
d): 197.4 (C=O), 144.5 (4-C), 128.9 (3-C), 67.8 (6-C), 66.5 (1-C), 58.1 (5-C), 51.9 (CH2), 38.1 
(Me), 27.7 (7-C), 9.8 (cyp), 3.9 (cyp), 3.4 (cyp); IR νmax (neat)/cm-1: 3075, 3005 (CH), 2949, 
2828, 1682 (C=O), 1458 (C=C), 1402, 1272 (S=O); HRMS (ESI): C12H18NO3S [M+H
+]: 
calculated 256.1002, found 256.1000. 
 
(1S*,4R*,5S*,6R*)-4-(3-Methoxyphenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-one (368) 
 
 
General procedure T was followed using cycloadduct 116 (1 g, 4.65 mmol), 3-
methoxyphenylboronic acid (2.12 g, 14.0 mmol, 3.0 eq.), chloro(1,5-
cyclooctadiene)rhodium(I) dimer (57 mg, 10 mol%), dioxane:H2O (6:1) (16 mL) and 
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triethylamine (0.7 mL, 4.65 mmol, 1.0 eq). Purification by flash chromatography on silica gel, 
eluting with a gradient of 50-100% EtOAc in hexane afforded the title compound 368  (1.1 g, 
3.40 mmol , 73%) as a colourless solid; Rf  = 0.54, (100% EtOAc in hexane); δH (501 MHz, 
Chloroform-d): 7.14 (1H, t, J 8.0, ArH), 6.87 – 6.80 (2H, m, ArH), 6.71 (1H, ddd, J 8.0, 2.6, 
1.0, ArH), 3.83 (1H, d, J 1.9, 5-CH), 3.71 (3H, s, OMe), 3.57 (1H, d, J 6.7, 6-CH), 3.51 (1H, t, 
J 7.6, 1-CH), 3.03 – 2.96 (1H, m, 4-CH), 2.88 (3H, s, SO2Me ), 2.63 (1H, dd, J 13.5, 6.7, 7-
CH2), 2.57 – 2.47 (2H, m, 3-CH2), 2.32 (3H, s, NMe), 2.21 (1H, dd, J 13.5, 8.9, 7-CH2); δC 
(126 MHz, Chloroform-d): 207.1 (C=O), 159.7 (Ar),  145.7 (Ar), 129.5 (ArH), 119.9 (ArH), 
113.4 (ArH), 112.1 (ArH), 73.8 (6-C), 69.0 (1-C), 68.6 (5-C), 55.2 (OMe), 47.2 (4-C), 40.5 
(NMe), 40.1 (SO2Me),  40.1 (3-C), 29.8 (7-C); IR νmax (neat)/cm-1: 3015, 2940 (CH), 2895, 
2873, 1603 (C=O), 1507 (C=C), 1462, 1267 (S=O); LCMS (ESI): C16H22NO4S [M+H
+]: 
calculated 324.1264, found 324.11. 
 
(1S*,4R*,5S*,6R*)-8-Methyl-6-(methylsulfonyl)-4-(4-(trifluoromethoxy)phenyl)-8-
azabicyclo[3.2.1]octan-2-one (367) 
 
 
General procedure T was followed using cycloadduct 116 (1 g, 4.65 mmol) and 4-
trifluoromethoxyphenyl boronic acid (2.87 g, 14.0 mmol, 3.0 eq.), chloro(1,5-
cyclooctadiene)rhodium(I) dimer (57 mg, 10 mol%), dioxane:H2O (6:1) (16 mL) and 
triethylamine (0.7 mL, 4.65 mmol, 1.0 eq). Purification by flash chromatography on silica gel, 
eluting with a gradient of 50-100% EtOAc in hexane afforded the title compound 367 (1.65g, 
4.38 mmol ,94%) as a colourless solid; Rf  = 0.57, (100% EtOAc in hexane); δH (501 MHz, 
Chloroform-d) 7.29 (2H, d, J 8.0), 7.07 (2H, d, J 8.0), 3.78 (1H, d, J 1.8, 5-CH), 3.62 – 3.52 
(2H, m, 6-CH, 1-CH), 3.08 (1H, ddd, J 7.9, 4.4, 1.6, 4-CH), 2.90 (3H, s, SO2Me), 2.59 – 2.49 
(3H, m, 3-CH2 7-CH2), 2.30 (3H, s, NMe), 2.23 (1H, dd, J 13.6, 8.9, 7-CH2); δC (126 MHz, 
Chloroform-d): 204.3 (C=O), 146.4 (Ar),  146.4 (OCF3), 140.9 (Ar), 127.3 (ArH), 119.2 
(ArH), 72.3 (6-C), 66.9 (1-C), 66.8 (5-C), 44.8 (4-C), 38.8 (NMe), 38.5 (SO2Me), 38.0 (3-C), 
28.1 (7-C); IR νmax (neat)/cm-1: 3059 (OH), 3009 (CH), 2972, 2946, 1682 (C=O), 1461 (C=C), 
1452, 1288 (S=O); LCMS (ESI): C16H19F3NO4S [M+H
+]: calculated 378.0981, found 378.15. 
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(1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-2-((4-
(trifluoromethoxy)benzyl)oxy)-8-azabicyclo[3.2.1]octane (380) 
 
 
 
General procedure R was followed using compound 278a (74 mg, 0.24 mmol) in DMF (1 mL), 
4-(trifluoromethoxy)benzyl bromide (100 L, 0.96 mmol, 4.0 eq.) and sodium hydride (20 mg, 
0.48 mmol, 2.0 eq.) at rt.  Purification by automated reversed-phase flash chromatography 
eluting with  MeCN/H2O/1%Formic acid gave title compound 380 (28 mg, 0.06  mmol, 24%) 
as a colourless oil; δH (600 MHz, DMSO-d6): 7.64 (2H, dd, J 8.7, 5.8, ArH), 7.36 (2H, d, J 
8.4, ArH), 7.31 – 7.25 (2H, m, ArH), 6.99 (2H, t, J 8.9, ArH), 4.50 (1H, d, J 12.4, O-CH2), 
4.45 (1H, d, J 12.4, O-CH2), 3.97 – 3.87 (1H, m, 6-CH), 3.48 – 3.42 (2H, m, 1-CH, 5-CH), 
3.41 – 3.39 (1H, m, 2-CH), 3.00 (3H, s, Me), 2.86 – 2.84 (1H, m, 4-CH), 2.27 (1H, dt, J 13.6, 
7.4, 7-CH2), 2.14 (3H, s, Me),  2.10 (1H, ddd, J 15.8, 8.3, 6.0, 3-CH2), 1.98 (1H, dd, J 13.5, 
9.2, 7-CH2), 1.74 (1H, dt, J 15.8, 1.4, 3-CH2); δC (151 MHz, DMSO-d6): 164.1 (Ar), 162.0 (d, 
J 242.7, Ar-F), 147.9 (d, J 2.9, Ar), 139.3 (Ar), 135.9 (O-CF3) 131.26 (d, J 7.9, ArH), 129.5 
(ArH), 121.3 (ArH), 114.5 (d, J 20.8, ArH), 77.0 (2-C), 69.1 (O-C), 68.4 (1-C), 67.9 (6-C), 66.3 
(5-C), 45.7 (4-C), 42.1 (Me), 41.0 (Me), 27.9 (7-C), 26.9 (3-C); IR νmax (neat)/cm-1: 3080, 3042, 
3008 (CH), 2944, 2869, 1600, 1509 (C=C), 1220 (S=O); HRMS (ESI): C23H26F4NO4S 
[M+H+]: calculated 488.1513, found 488.1540. 
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(1S*,2R*,4R*,5S*,6R*)-2-((4-Fluorobenzyl)oxy)-4-(4-fluorophenyl)-8-methyl-6-
(methylsulfonyl)-8-azabicyclo[3.2.1]octane (379) 
 
 
 
 
General procedure R was followed using compound 278a (74 mg, 0.24 mmol) in DMF (1 mL), 
4-fluorophenylmethyl bromide (130 L, 0.96 mmol, 4.0 eq.) and sodium hydride (20 mg, 0.48 
mmol, 2.0 eq.) at rt. Purification by automated reversed-phase flash chromatography eluting 
with MeCN/H2O/1% formic acid gave title compound 379 (32 mg, 0.08 mmol, 32%) as a 
colourless oil; 
δH (600 MHz, DMSO-d6): 7.64 (2H, dd, J 8.7, 5.8, ArH), 7.33 – 7.22 (2H, m, ArH), 7.12 (2H, 
t, J 8.9), 6.98 (2H, t, J 8.9, ArH), 4.45 (1H, d, J 11.6, OCH2), 4.41 (1H, d, J 11.6, OCH2), 3.99 
– 3.88 (1H, m, 6-CH), 3.48 – 3.39 (2H, m, 1-CH, 5-CH), 3.38 (1H, dt, J 5.7, 1.9, 2-CH), 3.00 
(3H, s, Me), 2.85 (1H, d, J 9.1, 4-CH), 2.32 – 2.21 (1H, m, 7-CH2), 2.14 (3H, s, Me), 2.14 – 
2.02 (1H, m, 3-CH2), 1.97 (1H, dd, J 13.5, 9.2, 7-CH2), 1.73 (1H, d, J 16.0, 3-CH2); δC (151 
MHz, DMSO-d6): 161.9 (d, J 242.7, Ar-F), 161.2 (d, J 241.7, Ar-F), 142.1 (d, J 2.9, Ar), 135.7 
(d, J 2.9, Ar), 131.3 (d, J 7.3, ArH), 129.8 (d, J 8.0, ArH), 115.5 (d, J 21.0, ArH), 114.5 (d, J 
20.2, ArH), 76.8 (2-C), 69.2 (O-C), 68.5 (1-C), 67.9 (6-C), 66.4 (5-C), 45.8 (4-C), 42.1 (NMe), 
41.0 (SO2Me), 27.9 (7-C), 26.8 (3-C); IR νmax (neat)/cm-1: 3064, 2961 (CH), 2921, 2880, 1624 
(C=C), 1497, 1418, 1240 (S=O); HRMS (ESI): C22H26F2NO3S [M+H
+]: calculated 422.1596, 
found 422.1616. 
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4-((((1S*,2R*,4R*,5S*,6R*)-8-Benzyl-4-(4-fluorophenyl)-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-yl)oxy)methyl)benzonitrile (375) 
 
 
General procedure R was followed using compound 281 (265 mg, 0.67 mmol) in DMF (3 mL), 
4-(bromomethyl)benzonitrile (450 mg, 2.35 mmol, 3.5 eq.) and sodium hydride (67 mg, 1.68 
mmol, 2.5 eq.) at rt. Purification by automated reversed-phase flash chromatography eluting 
with MeCN/H2O/1% formic acid gave title compound 379 (97mg, 0.19 mmol, 29%) as a 
colourless solid; δH (501 MHz, Chloroform-d): 7.60 – 7.56 (2H, m, ArH), 7.56 – 7.51 (2H, 
m, ArH), 7.23 – 7.18 (2H, m, ArH), 7.15 – 7.11 (2H, m, ArH), 7.08 – 6.99 (3H, m, ArH), 6.88 
– 6.82 (2H, m, ArH), 4.31 (1H, d, J 13.0, NBn), 4.23 (1H, d, J 13.0, NBn), 3.87 (1H, s, 5-CH), 
3.65 – 3.50 (3H, m, OCH2, 6-CH) 3.38 – 3.33 (1H, m, 1-CH), 2.97 – 2.87 (5H, m, Me, 2-CH), 
2.52 (1H, dt, J 14.6, 7.4, 7-CH2), 2.11 – 1.96 (3H, m, 7-CH2, 3-CH2); δC (126 MHz, 
Chloroform-d): 161.6 (d, J 244.4, ArF), 144.1 (Ar), 139.8 (d, J 3.2, Ar), 139.3 (Ar), 132.1 
(ArH), 130.8 (d, J 7.6, ArH), 129.0 (ArH), 127.9 (ArH), 127.2 (ArH), 126.8 (ArH), 118.9 (Ar), 
114.4 (d, J 20.8, ArH), 111.1 (CN), 76.9 (2-C), 69.2 (O-C), 69.0 (1-C), 67.6 (6-C), 62.8 (5-C), 
57.5 (NBn), 46.8 (4-C), 40.6 (Me), 28.4 (7-C), 27.4 (3-C); IR νmax (neat)/cm-1: 3061, 3008 
(CH), 2947, 2927, 2231 (CN), 1496 (C=C), 1455, 1290 (S=O); HRMS (ESI): C29H30FN2O3S 
[M+H+]: calculated 505.1956, found 505.1962. 
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(1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-2-((2-
(trifluoromethyl)benzyl)oxy)-8-azabicyclo[3.2.1]octane (381) 
 
 
General procedure R was followed using compound 278a (124 mg, 0.40 mmol) in DMF (2 
mL), 2-(trifluoromethyl)phenyl bromide (380 mg, 1.6 mmol, 4.0 eq.) and sodium hydride (31 
mg, 0.8 mmol, 2.0 eq.) at rt. Purification by automated reversed-phase flash chromatography 
eluting with  MeCN/H2O/1% formic acid gave title compound 381 (47 mg, 0.1 mmol, 25%) as 
a colourless oil; 
δH (600 MHz, DMSO-d6) 7.70 – 7.58 (4H, m, ArH), 7.48 – 7.43 (2H, m, ArH), 7.00 – 6.94 
(2H, m, ArH). 4.63 (1H, d, J 13.1, OCH2), 4.57 (1H, d, J 13.1, OCH2), 3.94 (1H, t, J 8.4, 6-
CH), 3.49 (1H, s, 5-CH), 3.47 – 3.44 (2H, m, 2-CH, 1-CH), 3.01 (3H, s, Me), 2.86 (1H, d, J 
8.5, 4-CH), 2.29 (1H, dt, J 14.0, 7.2, 7-CH2), 2.18 – 2.09 (4H, m, Me, 3-CH2), 2.00 (1H, dd, J 
13.6, 9.2, 7-CH2), 1.75 (1H, d, J 15.9, 3-CH2); δC (151 MHz, DMSO-d6) 161.1 (d, J 241.0, 
Ar-F), 142.0 (d, J 2.9, Ar), 137.9 (Ar), 133.1 (ArH), 131.2 (d, J 7.9, ArH), 129.9 (ArH), 128.3 
(ArH), 126.8 (CF3), 126.1 (ArH), 124.2 (Ar), 114.5 (d, J 20.8, ArH), 77.5 (2-C), 68.3 (1-C), 
67.9 (6-C), 66.5(O-C), 66.2 (5-C), 45.5 (4-C), 42.1 (Me), 41.0 (Me), 27.9 (7-C), 27.1 (3-C). 
IR νmax (neat)/cm-1: 3080, 3013 (CH), 2945, 2874, 1509 (C=C), 1457, 1313, 1219 (S=O); 
HRMS (ESI): C23H26F4NO3S [M+H
+]: calculated 472.1564, found 472.1579. 
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(1S*,2R*,4R*,5S*,6R*)-2-(Benzyloxy)-4-(4-fluorophenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octane (378) 
 
General procedure R was followed using compound 278a (124 mg, 0.40 mmol) in DMF (2 
mL), benzyl bromide (190 L, 1.6 mmol, 4.0 eq.) and sodium hydride (31 mg, 0.8 mmol, 2.0 
eq.) at rt. Purification by automated reversed-phase flash chromatography eluting with  
MeCN/H2O/1% formic acid gave title compound 378 (60 mg, 0.15 mmol , 37%) as a colourless 
oil; 
δH (600 MHz, DMSO-d6): 7.66 (2H, dd, J 8.4, 5.7, ArH), 7.30 (2H, t, J 7.7, ArH), 7.27 – 7.21 
(3H, m, ArH), 7.00 – 6.95 (2H, m, ArH), 4.47 (1H, d, J 12.2, O-CH2), 4.43 (1H, d, J 12.2, O-
CH2), 3.93 (1H, t, J 8.3, 6-CH), 3.48 – 3.41 (2H, m, 1-CH, 5-CH), 3.38 (1H, d, J 6.0, 2-CH), 
3.00 (3H, s, Me), 2.85 (1H, d, J 8.0, 4-CH), 2.27 (1H, dt, J 14.1, 7.3, 7-CH2), 2.14 (3H, s, Me), 
2.15 – 2.01 (1H, m, 3-CH2), 1.97 (1H, dd, J 13.5, 9.1, 7-CH2), 1.74 (1H, dt, J 15.8, 1.4, 3-CH2); 
δC (151 MHz, DMSO-d6): 161.2 (d,; J 241.3, Ar-F), 142.1 (d, J 2.9, Ar), 139.5 (Ar) 131.3 (d, 
J 7.9, ArH),  128.7 (ArH), 127.8 (ArH), 127.7 (ArH), 114.5 (d, J 20.4, ArH), 76.8 (2-C), 70.0 
(O-C), 68.5 (1-C), 68.0 (6-C), 66.4 (5-C), 45.8 (4-C), 42.1(Me), 41.0 (Me), 28.0 (7-C), 26.8 (3-
C); IR νmax (neat)/cm-1: 3064, 3030 (CH), 2943, 2867, 1509 (C=C), 1491, 1456, 1267 (S=O); 
HRMS (ESI): C22H27FNO3S [M+H
+]: calculated 404.1690, found 404.1712. 
 
3-((((1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(methylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-yl)oxy)methyl)benzonitrile (376) 
 
 
General procedure R was followed using compound 278a (124 mg, 0.40 mmol) in DMF (2 
mL), 3-(bromomethyl)benzonitrile bromide (313 mg, 1.6 mmol, 4.0 eq.) and sodium hydride 
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(31 mg, 0.8 mmol, 2.0 eq.) at rt. Purification by automated reversed-phase flash 
chromatography eluting with  MeCN/H2O/1% formic acid gave title compound 376 (32 mg, 
0.07 mmol , 19%) as a colourless oil; 
δH (600 MHz, DMSO-d6): 7.70 – 7.68 (1H, m), 7.67 – 7.62 (3H, m), 7.58 – 7.55 (1H, m), 7.51 
(1H, t, J 7.6), 7.01 – 6.96 (2H, m), 4.53 (1H, d, J 12.8, OCH2), 4.48 (1H, d, J 12.8, OCH2), 
3.99 – 3.90 (1H, m, 6-CH), 3.50 (1H, d, J 2.1, 5-CH), 3.45 (1H, d, J 7.4, 2-CH), 3.42 – 3.41 
(1H, m, 1-CH), 3.01 (3H, s, Me), 2.89 – 2.84 (1H, m, 4-CH), 2.28 (1H, dt, J 14.1, 7.3, 7-CH2), 
2.16 – 2.07 (4H, m, 3-CH2), 1.99 (1H, dd, J 13.5, 9.2, 7-CH2), 1.76 (1H, d, J 16.0, 3-CH2); δC 
(151 MHz, DMSO-d6): 161.1 (d, J 241.9, Ar-F), 142.0 (d, J 3.0, Ar), 141.4 (Ar), 132.3 (ArH), 
131.4 (ArH), 131.2 (d, J 7.3, ArH), 131.0 (ArH), 129.9 (ArH), 119.3 (Ar),  114.5 (d, J 20.2, 
ArH), 111.8 (CN), 77.1 (2-C), 68.8 (O-C), 68.3 (1-C), 67.9 (6-C), 66.1(5-C), 45.5 (4-C), 42.0 
(Me), 41.0 (Me), 27.9 (7-C), 27.1 (3-C); IR νmax (neat)/cm-1: 3078, 3013 (CH), 2944, 2870, 
2229 (CN), 1509 (C=C), 1484, 1293 (S=O); HRMS (ESI): C23H26FN2O3S [M+H
+]: calculated 
429.1643, found 429.1657. 
 
(1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-2-((3-methoxybenzyl)oxy)-8-methyl-6-
(methylsulfonyl)-8-azabicyclo[3.2.1]octane (377) 
 
 
General procedure R was followed using compound 278a (124 mg, 0.40 mmol) in DMF (2 
mL), 3-methoxybenzyl bromide (220 L, 1.6 mmol, 4.0 eq.) and sodium hydride (31 mg, 0.8 
mmol, 2.0 eq.) at rt. Purification by automated reversed-phase flash chromatography eluting 
with  MeCN/H2O/1% formic acid gave title compound 377 (37 mg, 0.09 mmol , 21%) as a 
colourless oil; 
δH (400 MHz, DMSO-d6) 7.81 – 7.64 (2H, m, ArH), 7.26 (1H, t, J 7.8, ArH), 7.11 – 6.96 (2H, 
m, ArH), 6.93 – 6.82 (3H, m, ArH), 4.52 – 4.40 (2H, m, OCH2), 3.99 (1H, t, J 8.3, 6-CH), 3.73 
(3H, s, Me), 3.51 – 3.44 (2H, m, 1-CH, 5-CH), 3.42 (1H, dd, J 5.0, 3.0, 2-CH), 3.06 (3H, s, 
Me), 2.94 – 2.85 (1H, m, 4-CH), 2.31 (1H, dt, J 14.0, 7.3, 7-CH2), 2.18 (4H, s, Me, 3-CH2), 
2.01 (1H, dd, J 14.0, 9.2, 7-CH2), 1.78 (1H, d, J 16.0, 3-CH2); 13C NMR (151 MHz, DMSO-
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D6) δ 161.2 (d, J 241.3), 159.8 (Ar), 142.1 (d, J 2.9, Ar),  141.2 (Ar), 131.3 (d, J 7.3),  129.8 
(ArH), 119.9 (ArH), 114.5 (d, J 20.9), 113.2 (ArH), 76.9 (2-C), 69.9 (O-C)), 68.5 (1-C), 68.0 
(6-C), 66.3 (5-C), 55.5 (Me), 45.8 (4-C), 42.1 (Me), 41.0 (Me), 27.9 (7-C), 26.9 (3-C); IR νmax 
(neat)/cm-1:  3077, 3008 (CH), 2943, 2869, 1586, 1509 (C=C), 1490, 1265 (S=O); HRMS 
(ESI): C23H29FNO4S [M+H
+]: calculated 434.1796, found 434.1809. 
 
4-((((1S*,2R*,4R*,5S*,6R*)-4-(4-Fluorophenyl)-8-methyl-6-(phenylsulfonyl)-8-
azabicyclo[3.2.1]octan-2-yl)oxy)methyl)benzonitrile (374) 
 
General procedure R was followed using alcohol 369 (203 mg, 0.54 mmol), NaH (54 mg, 1.35 
mmol) and 4-(bromomethyl)benzonitrile  (370 mg, 1.89 mmol, 3.5 eq.) in DMF (3 mL). 
Purification by flash chromatography on silica gel, eluting with a gradient of 10 - 40% EtOAc 
in hexane afforded the title compound 374 (68 mg, 0.14 mmol, 33%) as a colourless solid; Rf 
= 0.18, (30% in EtOAc); δH (600 MHz, DMSO-d6) 7.98 – 7.90 (1H, m, ArH), 7.85 – 7.70 (4H, 
m, ArH), 7.65 (2H, t, J 8.1, ArH), 7.48 (2H, dd, J 6.1, 2.60, ArH), 7.43 (2H, d, J 7.2, ArH), 
6.96 (2H, t, J 8.9, ArH), 4.55 (1H, d, J 13.5, OCH2), 4.50 (1H, d, J 13.5, OCH2), 4.04 (1H, t, J 
7.6, 6-CH), 3.45 (1H, d, J 6.6, 2-CH), 3.39 (1H, s, 5-CH), 3.38 – 3.29 (1H, m, 1-CH), 3.26 
(3H, s, Me), 2.71 (1H, d, J 4.9, 4-CH), 2.30 (1H, dt, J 13.4, 7.4, 7-CH2), 2.17 – 2.06 (1H, m, 3-
CH2), 1.79 (1H, dd, J 13.4, 9.0, 7-CH2), 1.65 (1H, d, J 16.0, 3-CH2); δC NMR (151 MHz, 
DMSO-d6)  161.2 (d, J 241.3, Ar-F), 145.6 (Ar), 142.0 (d, J 3.0, Ar), 140.1 (Ar),  134.3 (ArH),  
133.2 (ArH), 132.7 (ArH), 131.0 (d, J 8.1, ArH), 130.0 (ArH), 128.4 (ArH), 128.1 (CN), 114.7 
(d, J 20.3, ArH), 110.3 (Ar), 77.1 (2-C), 69.5 (5-C), 69.5 (6-C), 69.2 (1-C), 66.4 (4-C), 45.8 
(O-C), 42.3 (NMe), 28.0 (7-C), 26.9 (3-C); IR νmax (neat)/cm-1: 3018, 2967 (CH), 2940, 2896, 
2227 (CN), 1507 (C=C), 1462, 1268 (S=O); HRMS (ESI): C28H28FN2O3S [M+H
+]: calculated 
491.1799, found 491.1798. 
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(1S*,2R*,5S*,6R*)-8-Methyl-6-(methylsulfonyl)-N-(4-(trifluoromethoxy)benzyl)-8-
azabicyclo[3.2.1]octan-2-amine (384) 
 
 
General procedure W was followed using ketone 176 (1.03 g, 4.74 mmol), titanium 
isopropoxide (1.4 mL, 9.48 mmol), (3-(trifluoromethoxy)phenyl)methanamine (3 mL, 19.0 
mmol) and sodium borohydride (270 mg, 7.11 mmol, 1.5 eq.). Purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave title 
compound 384 (212 mg, 0.54 mmol, 11%) as a brown oil; 
δH (600 MHz, DMSO-d6): 7.60 – 7.56 (2H, m, ArH), 7.29 (2H, d, J 8.3, ArH), 4.01 (1H, d, J 
13.9, NCH2), 3.97 (1H, d, J 13.7, NCH2), 3.82 (1H, t, J 8.2, 6-CH), 3.57 (1H, s, 5-CH), 3.48 – 
3.43 (1H, m, 1-CH), 2.96 (3H, s, Me), 2.80 (1H, s, 2-CH),  2.33 – 2.23 (4H, m, Me, 7-CH2) 
2.00 – 1.93 (2H, m, 4-CH2, 7-CH2), 1.68 – 1.54 (2H, m, 3-CH2), 1.36 (1H, d, J 12.9, 3.7, 4-
CH2); δC (151 MHz, DMSO-d6): 165.9 (Ar), 148.5 (Ar), 131.7 (ArH), 129.6 (O-C), 121.3 
(ArH), 66.1 (1-C), 65.1 (6-C), 63.4 (5-C), 56.0 (2-C), 48.4 (N-C), 41.9 (Me), 40.9 (Me), 28.9 
(7-C), 28.4 (3-C), 19.3 (4-C); IR νmax (neat)/cm-1: 3287 (NH), 3006 (CH), 2840, 2787, 1557 
(C=C), 1510, 1343, 1149 (S=O); HRMS (ESI): C17H24F3N2O3 [M+H
+]: calculated 393.1454, 
found 383.1462. 
 
(1S*,2R*,5S*,6R*)-N,8-Dimethyl-6-(methylsulfonyl)-N-(2-(trifluoromethyl)benzyl)-8-
azabicyclo[3.2.1]octan-2-amine (386) 
 
 
General procedure Z was followed using compound 324 (142 mg, 0.7 mmol) in DMF (1.6 
mL), NaHCO3 (302 mg, 3.62 mmol, 6.0 eq.) and 2-(trifluoromethyl)benzyl bromide (574 mg, 
2.4 mmol, 4.0 eq.). The reaction mixture was concentrated in vacuo and purification by 
automated reversed-phase flash chromatography eluting with  MeCN/H2O 1% formic acid 
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gave the title compound 386 (25 mg, 0.06 mmol, 9%) as a brown solid; δH (300 MHz, 
DMSO-d6): 7.87 (1H, d, J 8.1, ArH), 7.66 (2H, td, J 5.9, 2.9, ArH), 7.42 (1H, t, J 7.6, ArH), 
4.12 (1H, d, J 15.1, NCH2), 3.82 (1H, t, J 8.3, 6-CH), 3.67 (1H, d, J 15.1, NCH2), 3.58 (1H, s, 
5-CH), 3.48 (1H, d, J 7.1, 1-CH), 2.98 (3H, s, Me), 2.41 (1H, t, J 2.4, 2-CH), 2.34 (1H, dd, J 
13.8, 7.0, 7-CH2), 2.26 (3H, s, Me), 2.22 (3H, s, Me), 1.88 (1H, dd, J 13.6, 9.2, 7-CH2), 1.69 
– 1.59 (2H, m, 3-CH2), 1.51 – 1.41 (2H, m, 4-CH2); δC (126 MHz, Methanol-d4): 139.7 
(ArH), 131.8 (ArH), 130.1 (ArH), 127.9 (Ar), 127.8 (Ar), 126.4 (ArH), 125.0 (d, J 5.9, CF3), 
66.2 (6-C), 63.1 (1-C), 62.6 (5-C), 40.5 (Me), 39.4 (Me), 39.1 (Me), 30.3 (7-C), 29.4 (3-C), 
18.0 (4-C); IR νmax (neat)/cm-1: 2999(CH), 2939, 2909, 1559, 1497 (C=C), 1464, 1214 
(S=O), 1154; HRMS (ESI): C18H26F3N2O2S [M+H
+]: calculated 391.1662, found 391.1671. 
 
4-((methyl((1S*,2R*,5S*,6R*)-8-Methyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-
yl)amino)methyl)benzonitrile (387) 
 
General procedure Z was followed using compound 324 (76 mg, 0.33 mmol) in DMF (1.6 mL), 
NaHCO3 (165 mg, 1.98 mmol, 6.0 eq.), and 4-(bromomethyl)benzonitrile  (258 mg, 1.32 mmol, 
4.0 eq.). The reaction mixture was concentrated in vacuo and purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O 1% formic acid gave the title 
compound 387 (52 mg, 0.15 mmol, 20%) as a brown solid.  
δH (501 MHz, DMSO-d6): 7.77 (2H, d, J 8.2, ArH), 7.52 (2H, d, J 8.2, ArH), 4.05 (1H, d, J 
14.6, NCH2), 3.82 (1H, t, J 8.3, 6-CH), 3.61 – 3.55 (2H, m, NCH2, 5-CH), 3.48 (1H, d, J 7.2, 
1-CH), 2.99 (3H, s, Me), 2.40 – 2.36 (1H, m, 2-CH), 2.36 – 2.29 (1H, m, 7-CH2), 2.27 (3H, s, 
Me), 2.19 (3H, s, Me), 2.03 – 1.93 (1H, m, 4-CH2), 1.88 (1H, dd, J 13.5, 9.2, 7-CH2), 1.70 – 
1.61 (2H, m, 3-CH2), 1.48 – 1.42 (1H, m, 4-CH2); δC (126 MHz, DMSO-d6): 147.7 (Ar), 132.6 
(ArH), 129.5 (ArH), 119.5 (Ar), 109.7 (CN), 66.6 (6-C), 66.3 (1-C), 62.8 (2-C), 61.9 (5-C), 
58.7 (Me), 41.5 (Me), 40.7 (Me), 40.7 (CH2), 30.9 (7-C), 29.8 (3-C), 18.4 (4-C); IR νmax 
(neat)/cm-1: 3097 (CH), 3006, 2975, 2932, 2889, 2280 (CN), 1558 (C=C), 1308 (S=O); HRMS  
(ESI): C18H26N3O2S [M+H
+]: calculated 348.1740, found 348.1784. 
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(1S*,2R*,5S*,6R*)-8-Benzyl-N-methyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-amine 
(325) 
 
General procedure W was followed using ketone 175 (383 mg, 1.3 mmol), titanium 
isopropoxide (373 L, 2.6 mmol, 2.0 eq.), methylamine (2M in MeOH) (20 mL, 20 mmol) and 
sodium borohydride (99 mg, 2.6 mmol, 2.0 eq.). Purification by automated reversed-phase 
flash chromatography eluting with  MeCN/H2O/1% formic acid gave title compound 325 (375 
mg, 1.22 mmol , 94%) as a brown oil; δH (400 MHz, Chloroform-d): 7.30 – 7.25 (2H, m, 
ArH), 7.24 – 7.18 (2H, m, ArH), 7.16 – 7.10 (1H, m, ArH), 3.75 – 3.69 (2H, m, NBn, 5-CH), 
3.54 – 3.45 (2H, m, NBn, 6-CH), 3.40 – 3.36 (1H, m, 1-CH), 2.45 (1H, dt, J 13.8, 7.0, 7-CH2), 
2.29 – 2.17 (1H, m, 2-CH), 2.03 (3H, s, Me), 1.98 – 1.88 (1H, m, 7-CH2), 1.88 – 1.79 (1H, m, 
4-CH2), 1.59 (1H, dd, J 14.9, 5.5, 3-CH2), 1.49 – 1.39 (1H, m, 3-CH2), 1.37 – 1.28 (1H, m, 4-
CH2); 13C NMR (101 MHz, CDCl3): 139.8 (Ar), 129.1 (ArH), 128.2 (ArH), 126.9 (ArH), 66.9 
(6-C), 63.5 (1-C), 61.4 (2-C), 58.0 (5-C), 57.4 (N-C), 40.5 (Me), 33.2 (Me), 29.8 (7-C), 29.5 
(3-C), 21.7 (4-C); IR νmax (neat)/cm-1: 3369 (NH), 3062, 3023 (CH), 2947, 2861, 1585 (C=C), 
1453, 1290 (S=O); HRMS (ESI): C16H25N2O2S [M+H
+]: calculated 309.1631, found 
309.1634. 
 
4-((((1S*,2R*,5S*,6R*)-8-Benzyl-6-(methylsulfonyl)-8-azabicyclo[3.2.1]octan-2-
yl)(methyl)amino)methyl)benzonitrile (392) 
 
General procedure Z was followed using compound 325 (125 mg, 0.41 mmol) in DMF (2 mL), 
NaHCO3 (200 mg, 2.46 mmol, 6.0 eq.) and 4-(bromomethyl)benzonitrile  (318 mg, 1.64 mmol, 
4.0 eq.). The reaction mixture was concentrated in vacuo and purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave the title 
compound 392 (15 mg, 0.04 mmol, 9%) as a brown solid; δH (400 MHz, DMSO-d6): 7.75 (2H, 
d, J 8.0, ArH), 7.42 (2H, d, J 8.0, ArH), 7.32 – 7.14 (5H, m, ArH), 4.08 (1H, d, J 14.4, NCH2), 
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3.88 (1H, t, J 8.4, 6-CH), 3.76 (1H, d, J 13.3, NCH2), 3.66 (1H, d, J 7.0, 1-CH), 3.63 – 3.53 
(3H, m, 5-CH, NCH2, NCH2), 3.00 (3H, s, Me), 2.48 – 2.44 (1H, m, 2-CH), 2.40 (1H, dd, J 
13.9, 7.1, 7-CH2), 2.14 (3H, s, Me), 2.03 – 1.87 (2H, m, 7-CH2, 3-CH2), 1.78 – 1.66 (2H, m, 3-
CH2, 4-CH2), 1.52 – 1.41 (1H, m, 4-CH2); δc (126 MHz, MeOD): 146.5 (Ar), 139.6 (Ar), 132.5 
(ArH), 129.5 (ArH), 129.4 (ArH), 128.5 (ArH), 127.1 (ArH), 118.5 (CN), 110.0 (Ar), 66.4 (6-
C), 65.1 (1-C), 62.0 (2-C), 60.3 (5-C), 40.9 (Me), 40.7 (Me), 58.2 (N-C), 57.0 (N-C), 31.4 (7-
C), 30.6 (3-C), 18.5 (4-C); IR νmax (neat)/cm-1: 3060, 3025, 2941 (CH), 2862, 2225 (CN) 1507 
(C=C), 1472, 1290 (S=O); HRMS (ESI): C24H30N3O2S [M+H
+]: calculated 424.2053, found 
424.2061 
 
 
(1S*,2R*,5S*,6R*)-8-Benzyl-N-methyl-6-(methylsulfonyl)-N-(4-(trifluoromethoxy)benzyl)-
8-azabicyclo[3.2.1]octan-2-amine (393) 
 
General procedure Z was followed using compound 325 (125 mg, 0.41 mmol) in DMF (2 mL), 
NaHCO3 (200 mg, 2.46 mmol, 6.0 eq.) and 4-(trifluoromethoxy)benzyl bromide (204 mg, 1.64 
mmol, 4.0 eq.). The reaction mixture was concentrated in vacuo and purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave the title 
compound 393 (97 mg, 0.20 mmol, 49%) as a colourless solid.  
δH (501 MHz, Chloroform-d) 7.40 – 7.37 (2H, m, ArH), 7.35 – 7.27 (5H, m, ArH), 7.17 (2H, 
d, J 8.1, ArH), 4.03 (1H, d, J 13.4, NCH2), 3.94 – 3.85 (3H, m, NCH2, 5-CH, 6-CH), 3.73 (1H, 
d, J 13.1, NCH2), 3.63 (1H, d, J 13.4, NCH2), 3.55 (1H, t, J 8.3, 6-CH), 2.94 (3H, s, Me), 2.75 
(1H, d, J 7.0, 5-CH), 2.68 – 2.60 (1H, m, 1-CH), 2.35 (3H, s, Me), 2.21 – 2.11 (1H, m, 4-CH2), 
2.11 – 2.00 (2H, m, 3-CH2, 7-CH2), 1.87 – 1.72 (1H, m, 3-CH2), 1.68 – 1.57 (1H, m, 4-CH2); 
δC (126 MHz, Chloroform-d) ; 148.6 (Ar), 148.6 (Ar), 139.1 (Ar), 135.9 (O-C), 130.6 (ArH), 
129.6 (ArH), 128.4 (ArH), 127.3 (ArH), 120.9 (ArH), 67.4 (1-C), 63.1 (6-C), 61.6 (5-C), 60.8 
(2-C), 57.4 (N-C), 57.3 (N-C), 40.6 (Me), 39.0 (Me), 31.2 (7-C), 30.8 (3-C), 18.5 (4-C); IR 
νmax (neat)/cm-1: 3012, 2999 (CH), 2965, 2891, 2201 (CN), 1558 (C=C), 1447, 1281 (S=O); 
HRMS (ESI): C24H30F3N2O3S [M+H
+]: calculated 483.1924, found 483.1948 
  219 
 
 
 
 
(3S*,3aS*,4S*,5R*,7S*)-Ethyl 9-methyl-5-(methylsulfonyl)-8-oxo-2,3,3a,4,5,6,7,8-
octahydro-4,7-epiminocyclohepta[c]pyrazole-3-carboxylate (356) 
 
General procedure M was followed using cycloadduct 116 (1.35 g, 6.27 mmol) and ethyl 
diazoacetate (contains  13 wt. % DCM) (1.8 mL, 15.68 mmol, 2.5 eq.) in THF (30 mL). The 
reaction mixture was concentrated in vacuo and purification by automated reversed-phase flash 
chromatography eluting with  MeCN/H2O/1% formic acid gave the title compound 356 (1.74 
g, 5.29 mmol, 84%) as a colourless oil; 
δH (501 MHz, Chloroform-d): 6.81 (1H, s, NH), 4.73 (1H, s, 4-CH), 4.32 – 4.23 (2H, m, OEt), 
4.12 (1H, d, J 11.3, 3-CH), 3.59 (1H, d, J 11.5, 5-CH), 3.54 – 3.45 (2H, m, 7-CH, 3a-CH), 2.93 
(3H, s, Me), 2.67 (1H, dt, J 14.7, 7.1, 6-CH2), 2.43 (3H, s, Me), 2.26 (1H, dd, J 14.7, 9.4, 6-
CH2), 1.31 (3H, t, J 7.1, OEt); δc (126 MHz, Chloroform-d): 203.1 (C=O), 161.9 (C=O), 142.7 
(C), 70.0 (5-C), 67.9 (7-C), 63.4 (3-C), 61.6 (OCH2), 61.1 (4-C), 53.4 (3a-C), 39.7 (Me), 38.4 
(SO2Me), 27.8 (6-CH2), 14.2(CH3); IR νmax (neat)/cm-1: 3329 (NH), 3010 (CH), 2982, 2940, 
1684 (C=O), 1497 (C=C), 1436, 1272 (S=O); HRMS (ESI): C13H20N3O5S [M+H
+]: calculated 
330.1118, found 330.1122. 
 
(4S*,5R*,7S*)-9-(4-Fluorobenzyl)-5-(methylsulfonyl)-8-oxo-2,4,5,6,7,8-hexahydro-4,7-
epiminocyclohepta[c]pyrazole-3-carboxylic acid (359) 
 
 
General procedure M was followed using cycloadduct 136 (200 mg, 0.64 mmol) and ethyl 
diazoacetate (contains  13 wt. % DCM) (185 L, 1.6 mmol, 2.5 eq.) in THF (3.2 mL). The 
reaction mixture was filtered through silica and the crude material taken to the next step. 
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General procedure N was then followed using compound x, NaOH (2M) (10 mL) and MeOH 
(5 mL). The reaction mixture was concentrated in vacuo and purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave the title 
compound 359 (21 mg, 0.05 mmol, 8%) as a brown solid; δH (400 MHz, DMSO-d6): 7.33 – 
7.17 (2H, m, ArH), 7.14 – 7.08 (2H, m, ArH), 4.98 (1H, s, 4-CH), 3.74 – 3.60 (4H, m, 7-CH, 
5-CH, NBn), 3.00 (3H, s, Me), 2.76 (1H, ddd, J 14.6, 8.1, 4.2, 6-CH2), 2.09 (1H, dd, J 14.6, 
9.7, 6-CH2); δC (101 MHz, DMSO-d6): 163.5 (C=O), 161.8 (d, J 242.5, ArF), 134.4 (d, J 2.9, 
Ar), 130.7 (d, J 7.9, Ar), 115.5 (d, J 21.2, Ar), 67.6 (5-C), 66.6 (7-C), 56.6 (4-C), 50.4 (NBn), 
40.9 (Me), 26.9 (6-C); IR νmax (neat)/cm-1: 3322 (NH), 3011 (CH), 2983, 2955, 1717 (C=O), 
1616 (C=C), 1457, 1297 (S=O); HRMS (ESI): C17H17FN3O5S [M+H
+]: calculated 394.0867, 
found 394.0869. 
 
(4S*,5R*,7S*)-9-Methyl-5-(methylsulfonyl)-8-oxo-2,4,5,6,7,8-hexahydro-4,7-
epiminocyclohepta[c]pyrazole-3-carboxylic acid (357) 
 
 
General procedure M was followed using cycloadduct 116 (1.35 g, 6.27 mmol) and ethyl 
diazoacetate (contains  13 wt. % DCM) (1.8 mL, 15.68 mmol, 2.5 eq.) in THF (30 mL). The 
reaction mixture was filtered through silica and the crude material taken to the next step. 
General procedure N was followed using intermediate compound, NaOH (4M) (15 mL) and 
MeOH (10 mL). The reaction mixture was concentrated in vacuo and purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave the title 
compound 357 (64 mg, 0.21 mmol, 3%) as a colourless oil; δH (400 MHz, Chloroform-d): 
8.13 (1H, OH), 5.38 (1H, s, 4-CH), 4.12 – 4.03 (2H, m, 5-CH, 7-CH), 3.44 (3H, s, Me), 3.14 
(1H, ddd, J 14.7, 8.1, 4.3, 6-CH2), 2.70 (3H, s, Me), 2.46 (1H, dd, J 14.7, 9.6, 6-CH2); δc (101 
MHz, Chloroform-d): 163.5 (C=O), 69.4 (5-C), 67.1 (7-C), 58.7 (4-C), 39.4 (Me), 34.5 (Me), 
27.2 (6-C); IR νmax (neat)/cm-1: 3293 (NH), 3003 (CH), 2919, 2845, 1698 (C=O), 1521, 1489 
(C=C), 1297 (S=O); LCMS (ESI): C11H14N3O5S [M+H
+]: calculated 300.0649, found 299.97. 
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(4S*,5R*,7S*)-9-Benzyl-8-oxo-5-(phenylsulfonyl)-2,4,5,6,7,8-hexahydro-4,7-
epiminocyclohepta[c]pyrazole-3-carboxylic acid (360) 
 
 
General procedure M was followed using cycloadduct 89 (3.14 g, 8.87 mmol) and ethyl 
diazoacetate (contains  13 wt. % DCM) (2.5 mL, 22.2 mmol, 2.5 eq.) in THF (45 mL). The 
reaction mixture was filtered through silica and the crude material taken to the next step. 
General procedure N was followed using intermediate compound, NaOH (8M) (20 mL) and 
MeOH (20 mL). The reaction mixture was concentrated in vacuo and purification by automated 
reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid gave the title 
compound 360 (426 mg, 0.97 mmol, 11%) as a brown solid; 
δH (400 MHz, DMSO-d6): 7.88 (2H, d, J 7.7, ArH), 7.75 (1H, t, J 7.7, ArH), 7.62 (2H, t, J 7.7, 
ArH), 7.31 – 7.16 (3H, m, ArH), 7.06 – 6.99 (2H, m, ArH), 4.94 (1H, s, 4-CH), 3.97 (1H, dd, 
J 9.3, 4.2, 7-CH), 3.66 – 3.57 (2H, m, NBn, 5-CH), 3.49 (1H, d, J 13.8, NBn), 2.79 (1H, ddd, 
J 14.5, 8.2, 4.2, 6-CH2), 2.13 – 2.02 (1H, m, 6-CH2), δC (101 MHz, DMSO-d6): 161.4 (C=O), 
161.4 (C=O), 136.5 (Ar), 135.8 (Ar), 132.3 (ArH), 127.7 (ArH), 126.8 (ArH), 126.5 (ArH), 
126.4 (Ar), 126.4 (ArH), 125.4 (ArH), 116.3 (Ar), 65.6 (5-C), 65.6 (7-C), 54.4 (4-C), 49.0 
(NBn), 24.9 (6-C); IR νmax (neat)/cm-1: 3448 (NH), 3063 (CH), 3004, 2949, 2845, 1700 (C=O), 
1582 (C=C), 1304 (S=O); HRMS (ESI): C22H20N3O5S [M+H
+]: calculated 438.1118, found 
438.1135. 
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(4S*,5R*,7S*)-9-Benzyl-1-methyl-5-(methylsulfonyl)-8-oxo-1,4,5,6,7,8-hexahydro-4,7-
epiminocyclohepta[c]pyrazole-3-carboxylic acid (362a) 
(4S*,5R*,7S*)-9-Benzyl-2-methyl-5-(methylsulfonyl)-8-oxo-2,4,5,6,7,8-hexahydro-4,7-
epiminocyclohepta[c]pyrazole-3-carboxylic acid (362b) 
 
 
3:2 mixture of regioisomers 
General procedure  was followed using pyrazole 170 (60 mg, 0.16 mmol), KOH (20 mg, 0.37 
mmol, 2.3 eq.), MeI (13 L, 0.21 mmol, 1.3 eq.) and DMF (0.8 mL). The reaction mixture was 
heated at 60 oC for 16 h. Purification by automated reversed-phase flash chromatography 
eluting with  MeCN/H2O/1% formic acid gave title compound 362 (52 mg, 0.13 mmol, 52%) 
as a colourless oil as a 3:2 mixture of reogioisomers. 
δH (400 MHz, DMSO-d6): 7.39 – 7.18 (10H, m, ArH, ArHmin), 5.02 (1H, s, 4-CH), 4.99 (1H, 
s, 4-CHmin), 4.21 (3H, s, Memin), 4.14 (3H, s, Me), 3.74 – 3.61 (8H, m, NBn, 5-CH, 7-CH-, 
NBnminor, 5-CHminor, 7-CHminor), 3.00 (3H, s, Me), 2.98 (3H, s, Memin), 2.82 – 2.71 (2H, m, 6-
CH2-, 6-CH2minor), 2.16 – 2.04 (2H, m, 6-CH2, 6-CH2minor); δc (101 MHz, DMSO-d6): 193.1 
(C=O-), 190.4 (C=Ominor), 162.6 (C=O-), 160.5 (C=Ominor), 142.2 (Arminor), 138.4 (Ar-), 138.1 
(Arminor), 138.1 (Ar-), 134.1 (Ar-), 130.5 (Arminor), 129.2 (Ar- and min), 128.9 (ArH- and min), 128.8 
(ArH- and min), 127.7 (ArH- and min), 67.7 (7-Cmin), 67.5 (7-C), 66.8 (5-Cmin), 66.5 (5-C), 57.2 (4-
C), 57.1 (4-Cmin), 51.3 (NBnmin), 51.1 (NBn), 41.1 (Memin), 40.9 (Me), 39.3 (Me), 39.2 (Memin), 
27.1 (6-Cmin), 26.9 (6-C); IR νmax (neat)/cm-1: 3032 (CH), 2978, 2904, 1639 (C=O), 1482 
(C=C), 1420, 1270 (S=O), 1024; HRMS (ESI): C18H20N3O5S [M+H
+]: calculated 390.1118, 
found 390.1135. 
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(4S*,5R*,7S*)-9-Benzyl-1-(4-cyanobenzyl)-5-(methylsulfonyl)-8-oxo-1,4,5,6,7,8-hexahydro-
4,7-epiminocyclohepta[c]pyrazole-3-carboxylic acid (363a) 
(4S*,5R*,7S*)-9-Benzyl-2-(4-cyanobenzyl)-5-(methylsulfonyl)-8-oxo-2,4,5,6,7,8-hexahydro-
4,7-epiminocyclohepta[c]pyrazole-3-carboxylic acid (363b) 
 
 
3:2 mixture of regioisomers 
General procedure  was followed using pyrazole 170 (60 mg, 0.16 mmol), KOH (20 mg,0.37 
mmol, 2.3 eq.), 4-(bromomethyl)benzonitrile (41 mg, 0.21 mmol, 1.3 eq.) and DMF (0.8 mL). 
Purification by automated reversed-phase flash chromatography eluting with MeCN/H2O/1% 
formic acid gave title compound 363 (66 mg, 0.15 mmol, 41%) as a colourless oil as a 3:2 
mixture of regioisomers. 
δH (501 MHz, Chloroform-d): 7.57 (2H, d, J 8.2, ArH), 7.53 (2H, d, J 8.2, ArHmin), 7.44 (2H, 
d, J 8.2, ArHmin), 7.39 (2H, d, J 8.1, ArH), 7.24 – 7.13 (6H, m, ArH and min), 7.04 (2H, dd, J 6.8, 
1.7, ArHmin), 7.02 – 6.95 (2H, m, ArH), 5.92 – 5.80 (2H, m, NCH2minor), 5.76 – 5.60 (2H, m, 
NCH2-),  5.12 (2H, s, 4-CH and min), 3.76 (1H, d, J 8.1, 5-CHmin), 3.69 (1H, d, J 8.0, 5-CH), 3.66 
– 3.58 (2H, m, NBnminor), 3.59 (1H, d, J 13.0, NBn-), 3.50 (1H, d, J 13.0, NBn-), 3.45 – 3.40 
(1H, m, 7-CH), 3.37 (1H, dd, J 9.5, 3.8, 7-CHmin), 2.84 (3H, s, Me-), 2.82 (3H, s, Meminor), 2.74 
– 2.66 (1H, m, 6-CH2-), 2.66 – 2.60 (1H, m, 6-CH2minor), 2.18 (1H, dd, J 15.4, 9.7, 6-CH2minor), 
2.10 – 2.00 (1H, m, 6-CH2-); δC (126 MHz, Chloroform-d): 192.5 (C=O ), 189.4 (C=O min), 
163.2 (C=O ), 163.1 (C=O min), 143.0 (Ar), 140.7 (Armin), 139.9 (Ar), 136.6 (Armin), 136.2 (Ar), 
133.6 (Armin), 132.8 (ArH), 132.6 (Ar), 132.6 (ArHmin), 131.2 (Armin),129.8 (Ar), 129.2 
(ArHmin), 129.1 (Armin),  128.9 (ArH), 128.8 (ArHmin), 128.8 (ArH), 128.8 (ArHmin), 128.7 
(ArH), 128.1 (Ar), 127.9 (Armin), 118.5 (Armin), 118.2 (Ar), 112.8 (CNmin), 112.2 (CNmin), 67.9 
(7-Cmin), 67.2 (7-Cmin), 67.1 (5-C), 67.0 (5-C), 57.6 (4-Cmin), 57.5 (4-C), 55.6 (NBnmin), 55.5 
(NBn), 52.1 (NBnmin), 52.0 (NBn), 38.5 (Me-C), 38.2 (Me-Cmin), 28.0 (6-Cmin), 27.5 (6-C). IR 
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νmax (neat)/cm-1: 3061, 3029, 3019 (CH), 2945, 2361 (CN), 1761 (C=O), 1558 (C=C), 1257 
(S=O); HRMS (ESI): C25H23N4O5S [M+H
+]: calculated 491.1384, found 491.1390. 
 
(4S*,5R*,7S*)-9-Benzyl-1-(methoxymethyl)-5-(methylsulfonyl)-8-oxo-1,4,5,6,7,8-
hexahydro-4,7-epiminocyclohepta[c]pyrazole-3-carboxylic acid (364a) 
 
General procedure  was followed using pyrazole 170 (62 mg, 0.16 mmol), KOH (19 mg,0.37 
mmol, 2.3 eq.), MOM-Cl (45 L, 0.47 mmol, 3.0 eq.) and DMF (0.8 mL). Purification by 
automated reversed-phase flash chromatography eluting with  MeCN/H2O/1% formic acid 
gave title compound 364a (22 mg, 0.05 mmol, 33%) as a colourless oil; δH (501 MHz, 
Methanol-d4): 7.23 – 7.08 (5H, m, ArH), 5.69 (1H, d, J 10.4, OCH2), 5.63 (1H, d, J 10.4, 
OCH2), 5.05 (1H, s, 4-CH), 3.74 – 3.66 (2H, m, NBn, 5-CH), 3.64 – 3.58 (2H, m, 7-CH, NBn), 
3.30 (3H, s, Me), 2.95 – 2.90 (3H, m, Me), 2.78 (1H, ddd, J 14.9, 8.2, 4.3, 6-CH2), 2.12 – 2.04 
(1H, m, 6-CH2); δc (126 MHz, Methanol-d4): 189.7 (C=O), 163.0 (C=O), 140.7 (Ar), 137.2 
(Ar), 129.3 (Ar), 128.5 (ArH), 128.1 (ArH), 127.2 (ArH), 81.2 (Me), 67.6 (7-C), 66.3 (5-C), 
57.1 (4-C), 56.2 (OBn), 51.2 (NBn), 38.3 (Me), 26.2 (6-C); IR νmax (neat)/cm-1: 3028, 3007 
(CH), 2935, 2839, 1697 (C=O), 1508 (C=C), 1496, 1246 (S=O); HRMS (ESI): C19H22N3O6S 
[M+H+]: calculated 420.1224, found 420.1251. 
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7.0 Appendix 
7.1 Listed decoration reactions 
7.1.1 Listed decoration reactions for section 3.1.1 
Starting material Conditions Product Outcome 
 
 
 
278 
 
 
 
404, (2.0 eq.) 
 
TBTU ( 2.0 eq.) 
DIPEA (4.0 eq.) 
DMA, rt, 36h 
 
 
405 
 
 
 
Complex 
mixture 
 
282 
 
406, (3.0 eq.) 
DMA (0.2M), 
NaHCO3 (6 eq.) 
16 h, 80 oC 
 
407 
 
Complex 
mixture 
 
278 
 
408 (2.0 
eq.) 
NaH (1.5 eq.), 
DMF (0.5M), 
0 oC - rt, 
16 h 
 
290 
Yield: 9% 
Only major 
isolated 
 
278a 
 
 
DMA (0.2M), 
NaHCO3 (6 eq.) 
16 h, rt 
 
409 (2.5 eq.) 
 
 
410 
 
 
Trouble 
purifying 
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278a 
 
 
 
411 (3.0 eq.) 
NaH (1.5 eq.), 
DMF (0.5M), 
0 - 50 oC , 
16 h 
 
 
412 
 
Complex 
mixture 
 
278a 
 
 
413, (2.0 eq.) 
NaH (1.5 eq.), 
DMF (0.5M), 
0 oC - rt, 16 h 
 
288 
 
Yield: 2% 
Only major 
isolated 
 
278a 
 
 
414 (2.0 eq.) 
NaH (1.5 eq.), 
DMF (0.5M), 
0 oC - rt, 
16 h 
 
 
286 
 
 
 
Yield: 11% 
Only major 
isolated 
 
278a 
 
 
415 (2.5 eq.) 
DMA (0.2M), 
NaHCO3 (6 eq.) 
16 h, rt 
 
 
291 
 
11% 
 
282b 
 
 
 
416 (3 eq.) 
STAB (2 eq.) 
DMA (1.13M), 80 oC, 
16 h 
 
417 
 
 
Starting 
material 
  227 
 
 
 
282b 
 
 
418 (3 eq.) 
Stab (2 eq.) 
DMA (1.13M), 
80 oC, 16 h 
 
419 
 
Purification 
problems 
 
282b 
 
 
i)  
420 6.0 eq.) 
DMA (0.15M) 
Pyridine (8.0 eq.), 
16 h, rt 
ii) NaOH, H2O, 
MeOH, 16 h, rt 
 
 
289 
 
 
 
 
Yield: 1% 
 
 
282b 
 
 
421 (3.0 eq.) 
Pyiridne (4.0 eq.) 
DMA (0.15M), 16 h, 
rt 
 
422 
 
 
Complex 
mixture 
 
282b 
 
i)  
423 (3.0 eq.) 
DIPEA (6.0 eq.) 
TBTU (6.0 eq.) 
DMA (0.15M), 16 h, 
rt 
ii) NaOH, H2O, 
MeOH, 16 h, rt 
 
424 
 
Trouble 
purifying 
 
 
282b 
 
i)  
425 (6 eq.) 
pyridine (4.0 eq.) 
DMA (0.15M), 16 h, 
rt 
ii) NaOH, H2O, 
MeOH, 16 h, rt 
 
285 
 
 
 
 
 
Yield: 16% 
 
  228 
 
 
 
282b 
 
 
426 (5.0 eq.) 
DMA (0.2M), 
DIPEA (5eq.) 
80 oC, 16 h 
 
 
427 
 
Complex 
mixture 
 
273 
 
Cyclopropanemethyl 
amine 
Ti(OiPr)4 (2.0 eq.) 
MeOH (0.2M), 
8 h, rt, 4Å MS 
 
(ii) NaBH4 (1.5 eq.), 
0 oC - rt, 4h 
 
 
283 
 
 
 
2:1 mixture 
18% 
 
 
 
 
273 
 
1i) Morpholine (20 
eq.), 4Å MS, 
AcOH (0.2 eq.), 16 h, 
rt 
ii) STAB (3 eq.), 0 oC 
- rt, 16 h 
 
2i) Morpholine (20 
eq.) 
Ti(OiPr)4 (2.0 eq.) 
MeOH (0.2M), 
8 h 
(ii) NaBH4 (1.5 eq.), 
0 oC - rt, 4 h 
 
 
 
 
 
 
 
428 
 
 
1) Starting 
material 
 
 
 
2) Starting 
material and 
reduced 
alcohol 
compound 
 
278a 
 
NaHCO3 (6.0 eq.) 
 
429 , (8.0 eq.) 
Heat 80oC, 16 h 
 
 
430 
 
Complex 
mixture 
  229 
 
 
 
278a 
 
 
NaH (1.5 eq.) 
DMF (0.5 M), 0 oC 
 
 
373 
(2.0 eq.), 16 h, rt 
 
284 
 
 
 
 
12% 
 
 
278a 
 
 
 
 
NaH (1.5 eq.) 
 
431 (2.0 eq.), 16 h, rt 
 
 
 
 
 
 
432 
 
 
Complex 
mixture 
 
 
282b 
 
 
433 (3.0 eq.) 
DMA (0.2M), 
pyridine (4 eq.) 
16 h, 80oC 
 
 
287 
 
 
 
6% 
 
 
282b 
 
i)  
434 (10 eq.) 
Pyridine (4 eq.) 
DMA (0.15M), 16 h, 
rt 
ii) NaOH, H2O, 
MeOH, 16 h, rt 
 
435 
 
 
 
Human 
error 
Table 40. A table showing the decoration reactions for the 1,4 addition series of compounds. 
7.1.2 Listed decoration reactions for section 3.1.2 
Starting material Conditions Product Outcome 
  230 
 
 
 
306 
 
 
421 (8.0 eq.) 
Pyiridne (4.0 eq.) 
DCM (0.2M), 16 h, 
rt 
ii) NaOH, H2O, 
MeOH, 16 h, rt 
 
436 
 
 
Complex 
mixture 
 
 
306 
 
i)  
437 (8 eq.) 
Pyridine (4.0 eq.) 
DCM (0.2M), 
16 h, rt 
ii) NaOH, H2O, 
MeOH, 16 h, rt 
 
310 
 
 
 
 
7% 
 
306 
 
437 (8.0 eq.) 
DMA (0.2M), 
pyridine (4 eq.) 
16 h, 80 oC 
  
438 
Complex 
mixture 
 
306 
 
i)  
418 (5 eq.) 
4Å MS, DMF 
(1.15M), 16 h 
ii) NaBH4 (3 eq.) 
0 - 80 oC, 16 h 
 
 
439 
Complex 
mixture 
 
306 
 
i)  
416 (5 eq.) 
4Å MS, DMF 
(1.15M), 16 h, rt 
ii) NaBH4 (3 eq.) 
0 - 80 oC, 16 h 
 
309 
 
 
 
9% 
  231 
 
 
 
306 
 
 
 
 440 (8.0 eq.) 
DMF (0.2M), 
DIPEA (4 eq.) 
16 h, rt 
 
 
441 
Complex 
mixture 
 
306 
 
 
442 (1.5 eq.) at 0oC 
DMF (0.2M), 
DIPEA (1.5 eq.) 
16 h, rt 
  
311 
 
 
 
 
4% 
 
306 
 
i)  
443 (5 eq.) 
4Å MS, DMF 
(1.15M), 
ii) NaBH4 (3 eq.) 
0 - 80 oC, 16 h  
312 
 
 
 
41% 
 
306 
 
 
444 (10 eq.), 
4Å MS, DMF 
(1.15M), 
ii) NaBH4 (3 eq.) 
0 - 80 oC, 16 h  
308 
 
31% 
Table 41. A table showing the decoration reactions for the pyrrolidine series of compounds 
 
7.1.3 Listed decoration reactions for section 3.1.3 
Starting material Conditions Product Outcome 
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178 
 
 
 445 (4.0 eq.) 
DMF (0.5M), NaH 
(4.0 eq.), 16 h, rt 
 
 
314 
 
 
 
16% 
 
178 
 
446 (4.0 eq.) 
DMF (0.5M), NaH 
(4.0 eq.), 16 h, rt 
 
315 
 
10% 
 
178  
447 (4.0 eq.) 
DMF (0.5M), NaH 
(4.0 eq.), 16 h, rt 
 
316 
 
 
24% 
 
178 
 
448 (4.0 eq.) 
DMF (0.5M), NaH 
(4.0 eq.) 
 
317 
 
 
21% 
 
178 
 
449 (4.0 eq.) 
DMF (0.5M), NaH 
(4.0 eq.), 16 h, rt 
 
319 
 
 
7% 
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178 
 
450 (4.0 eq.) 
DMF (0.5M), NaH 
(4.0 eq.), 16 h, rt 
 
320 
 
 
65% 
 
178 
 
451 (4.0 eq.) 
DMF (0.5M), NaH 
(4.0 eq.), 16 h, rt 
 
318 
 
 
16% 
 
7.1.4 Listed decoration reactions for section 3.1.4 
Starting material Conditions Product Outcome 
 
 
327 
 
 
452 (5.0 eq.) 
DMF (0.5M), 
NaBH4 (3.0 eq.) 60 
oC for 16 h 
 
 
 
 
 
8% 
 
327 
 
 
453 (4.0 eq.) 
 
DMF (0.5M), 
NaHCO3 (6.0 eq.), 
16 h 
 
328 
 
35% 
 
327 
 
433 (4.0 eq.), 
NaHCO3 (6.0 eq.), 
DMF (0.5M), 
16h 
 
329 
 
21% 
  234 
 
 
 
327 
 
 
408 (4.0 eq.), NaH 
(4.0 eq.) 
DMF (0.5M), 0 oC - 
rt 
 
454 
Complex 
mixture 
 
7.1.5 Listed decoration reactions for section 3.1.5 
Starting material Conditions Product Outcome 
 
 
189 
 
 
451 (4.0 eq), NaH 
(1.5 eq.), DMF 
(0.5M), 
0-60 oC, 16 h 
 
 
 
455 
 
 
 
 
Complex 
mixture 
 
188 
 
437 (6.0 eq), NaH 
(1.5 eq.), DMF 
(0.5M), 
0-60 oC, 3 d  
336 
 
 
11% 
 
188 
 
411  
(7.0 eq), NaH (1.5 
eq.), DMF (0.5M), 
0-90 oC, 3 d 
 
337 
 
19% 
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7.2 Assay descriptions 
7.2.1 Autophagy modulator assay description 
MCF7-LC3 (4000 cells/ well) cells were seeded in 384 well plates (Greiner). The next day 
cells were washed three times with 1x PBS using plate washer ELX405 (Biotek). After that, 
10 µM of compound was added using Echo dispenser (Labcyte) along with EBSS (starvation 
medium) and Chloroquine (50 µM) or Rapamycin (100 nM) and Chloroquine (50 µM). Three 
hours after incubation at 37°C cells were fixed by addition of 25 µl formaldehyde in 1 x PBS 
(4.6% final concentration) and simultaneously staining the nucleus with 1:500 Hoechst (Stock 
1 mg/ml) for 20 min at RT. Fixed cells were washed thrice with 1x PBS using plate washer 
ELX405 (Biotek). For visualization 4 pictures/well were acquired using ImageXpress Micro 
XL (Molecular Devices) at 20x and analysed with the granularity algorithm of MetaXpress 
Software (Molecular Devices).  
Dose-response analysis was carried out starting from 10 µM using a three-fold dilution curve 
over eight steps. IC50 calculations were done using Quattro Workflow software (Quattro 
Research GmbH).  
7.2.2 Hedgehog pathway assay description 
 
For assaying signal transduction through the Hh pathway, mouse embryonic mesoderm 
fibroblast C3H10T1/2 cells were used. These multipotent mesenchymal progenitor cells 
differentiate into osteoblasts upon treatment with the SMO agonist Purmorphamine. During 
differentiation osteoblast specific genes such as alkaline phosphatase (ALK), which plays an 
essential role in bone formation, are highly expressed. Activity of ALK can directly be 
monitored by following substrate hydrolysis yielding a highly luminescent product. Inhibition 
of the pathway results in reduction of luminescence. 
The screening for small molecule inhibitors of the Hh pathway was carried out in 384 well 
format. Shortly, 800 cells per well were seeded and allowed to grow overnight. The next day, 
compounds were added to a final concentration of 10 µM using the acoustic nanoliter dispenser 
ECHO 520. After one hour, Purmorphamine was added to a final concentration of 1.5 µM; 
control cells did not receive Purmorphamine. After four days, the cell culture medium was 
aspirated and a commercial luminogenic ALK substrate (CDP-Star, Roche) was added. After 
one hour, luminescence was read. To identify and exclude toxic compounds that also lead to a 
reduction in the luminescent signal, cell viability measurements were carried out in parallel.  
The cell viability assay followed the same workflow as the HH assay, except that only 200 
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cells per well were seeded. Cell culture medium alone served as control for the cell viability 
assay. For the measurement of cell viability, Cell Titer Glo reagent (Promega) which 
determines the cellular ATP content was used. Hits were scored as showing at least a 50% 
reduction in the luminescent signal in the HH assay, and a minimum of 80% cell viability. 
Dose-response analysis for hit compounds was done using a three-fold dilution curve starting 
from 10 µM.  IC50 values were calculated using the Quattro software suite (Quattro Research 
GmbH).   
 
 
 
7.2.3 DNA binding motif assay description 
The initial screen was done using 2 µM TO, 1 µM DAP and 250 µM fragment, in 10 mM 
sodium cacodylate at pH 7 (without KCl). Follow up screen was performed on the top 10 
ligands (roughly ≥15% displacement within error), each screened hTeloG and DS: 2 µM TO, 
1 µM DNA and 250 µM fragment in 10 mM sodium cacodylate with 100 mM KCl at pH 7. 
The repeated screen of the top 10 against DAP in 10 mM sodium cacodylate with 100 mM 
KCl at pH 7. Some of the fragments’ interactions with the DAP i-motif were dramatically 
affected by the addition of the KCl.  
 
FID ASSAY TO was diluted to 2 µM in buffer at pH 5.5 and hTeloC i-motif was diluted to 50 
µM. The tested ligands were diluted to 50 µM in buffer at pH 5.5. 196 µL of the TO solution 
was excited at 430 nm and the background fluorescence recorded from 450 to 650 nm. The 
background fluorescence emission intensity at 450 nm was normalised as 0%. Then 4 µL of 
hTeloC was added, mixed, allowed to equilibrate for 5 minutes and a second background 
fluorescence spectrum was taken when the sample was excited at 430 nm. The fluorescence 
emission intensity at 450 nm was normalized as 100% fluorescence. Then 1 µL aliquots of 
ligand were titrated into the sample and a spectrum measured. TO displacement was calculated 
using Equation S1 and plotted against concentration to calculate the DC50.  
 
Equation S1 𝐷𝑥 = 1 ‒ 𝐹𝑥 𝐹0 = 1 ‒ 𝐹𝑟𝑒𝑎𝑑 ‒ 𝐹𝑐0 𝐹𝑟𝑒𝑓𝑒𝑟𝑒𝑒𝑛𝑐𝑒 ‒ 𝐹𝑐0  
 
The IM-FID assay was conducted using 384-well microplates (Corning® Low Volume 384 
well Black Flat Bottom Polystryrene NBS TM Microplate) at 25°C. Microplate wells were 
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filled with 40 μL of a testing solution consisting of hTeloC (0.5 μM) and TO (1.0 μM) in buffer 
at pH 5.5. Then 0.5 μL of library compound solution (1 mM in DMSO) was added into each 
well. Each plate had three control wells of DNA in buffer and another three reference wells of 
DNA and TO in buffer without ligand. After mixing, plates were read on a BMG CLARIOstar 
using an excitation filter from 400 to 430 nm and an emission filter from 460 to 480 nm. Each 
scan was performed three times. The basal fluorescence signal (Fc0) were assigned as the 
average fluorescence intensity read from the control wells. The 100% fluorescence intensity 
read (Freference) was assigned as the average fluorescence intensity read from reference wells. 
The DC50 for each compound was calculated using the average of three reads (Fread) using 
Equation 1. Hit compounds were ranked according to DC50 (Supporting information). 
7.2.4 Plasmodium falciparum NF54 assay description 
The compounds were tested in triplicate on two separate occasions against the drug-sensitive 
strain of P. falciparum. The assay was carried out using activity of the parasite lactate 
dehydrogenase enzyme as a marker for parasite activity and thus survival.130 Compounds were 
tested at 10 different concentrations from a starting concentration of 6000nM down to 
approximately 12nM.144 Conditions of the assay were 2% parasitized erythrocytes at a 1% 
overall haematocrit in a total volume of 200µL. Cells were incubated in a specialised gaseous 
environment for 72h at 37C.145 Three controls, comprising of compounds with known and 
significant anitplasmodial activity, were used to validate the experiment. The IC50-values were 
obtained using regression analysis of a non-linear dose-response curve fitted using GraphPad 
Prism v.4.0 software. 
Of the 52 compounds tested, none showed significant activity against the human malaria 
parasite in vitro. For 48 of the compounds, no growth inhibition was observed at the highest 
starting concentration of 6000nM. The remaining 4 compounds were weakly active, with mean 
IC50 values from the two occasions of between 5µM and 6µM (highlighted in accompanying 
chart). In contrast, the reference compounds chloroquine, artesunate, and H3D-4060, all 
showed antiplasmodial activity between 5 and 35nM as expected. 
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7.3 Key NOESY interactions  
224 
223 
168 
  239 
 
 
163 
207 
89 
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 228 
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